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ABSTRACT 
 
Investigations of the Biological Roles of Substituted Cyclohexadienes   
 (December 2009) 
Bennie John Bench, B.S., Southeastern Oklahoma State University 
Chair of Advisory Committee:  Dr. Coran M. H. Watanabe 
 
In recent years there have been two cycloterpenals, molecules consisting of a 
cyclohexadienal core, isolated from nature.  Cyclocitral, the condensation product of 
citral, has been isolated from the North Sea bryozoans Flustra foliacea.  In the human 
eyes, cycloretinal has been isolated and is a toxic by product of the vision cycle.  This 
retinal dimer is believed to contribute to age related macular degeneration, the leading 
cause of blindness in the elderly.  In 1992, it was discovered that if β-
ionylideneacetaldehyde was incubated with beta-lactoglobulin (β-LG), the principal 
whey protein in dairy milk, that it would mediate the formation of cyclo-β-ional.  No 
follow up studies were performed on this protein mediated reaction or what biological 
activities these cycloterpenals may possess. 
This dissertation investigates the biological roles of substituted 
cyclohexadienes including cycloterpenals and cyclohexadiene enaminonitriles.  To 
mimic the protein mediated reaction, we developed a synthetic procedure to produce a 
wide array of cycloterpenal by utilizing L-proline.  Over 100 cycloterpenals were 
synthesized and screened for their biological activities against an array of cell based 
screens.  The phenotypic effects of these cycloterpenals were screened against a PC12 
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assay where dramatic effects were observed on neurite outgrowth.  During the 
synthesis of starting materials for the production of our cycloterpenal library, it was 
discovered that if excess base was added to the Horner-Wadsworth-Emmons reaction 
between a methyl-ketone and diethyl-(cyanomethyl)-phosphonate, conversion of the 
α-β-unsaturated nitrile into an enaminonitrile was observed.  This new synthetic 
procedure was optimized to generate a library of enaminonitriles as well as their 
quinazoline derivatives.   
The work within also includes the investigation of the β-LG mediated reaction 
formation of cycloterpenals with natural and unnatural β-methyl aldehydes.  We were 
able to demonstrate that β-LG could mediate the conversion of α,β-unsaturated 
aldehydes into their corresponding cycloterpenal.  In vitro analysis was also 
performed with store bought milks and the β-LG present was able to mediate the 
formation of cyclocitral.  An in vivo experiment was also performed by utilizing New 
Zealand White rabbits to demonstrate the formation of cycloretinal within the blood 
stream by feeding a source of β-LG with retinal.   
Interestingly,  in  human blood,  β-LG  is  present  at  concentrations  of 0.7-1.2 
g/dL.   The protein  has been i dentified within drusen pigments and lipofuscin granules 
that  accumulate  in   the  retina of macular  degeneration  patients.   As humans  do  not 
produce  beta-lactoglobulin,  the source  of  this  protein is  from milk and milk products.  
With  these experiments,  we clearly demonstrate  that under  the  appropriate conditions, 
cycloretinal  can  be  produced with  β-LG.   We have  clearly  established  a  direct  link 
between β-LG chemistry and age-related macular degeneration.  
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CHAPTER I 
INTRODUCTION 
INTRODUCTION 
 Nature is a masterful synthetic chemist, producing compounds with diverse 
architecture and functionality.  Natural resources have been used since antiquity for their 
pharmacological benefits.  The sources of medicinal drugs range from terrestrial plants, 
marine organisms, and various microorganisms.  To date, over 100,000 different 
molecules have been isolated and identified with many possessing biological activities.1  
These metabolites have significantly impacted the pharmaceutical market in the United 
States.  Over the past 25 years, 47% of pharmaceuticals in the U.S. were comprised of 
natural products or their isolated derivatives.  Furthermore, 73% of new drugs were 
synthetic derivatives or were built upon the basic molecular scaffold of natural products 
previously identified (Figure 1).2,3   
 
  
Figure 1.  Graphical representation of drugs developed in the U.S. 1 
 
This dissertation follows the style of the Journal of Organic Chemistry. 
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Terpenoids 
Among the classes of natural products, almost one-half of these molecules are 
isoprenoids , also referred to as terpenoids.  The terpenoids are the oldest known 
biomolecules possessing many biological functions.4,5  Examples of terpenoids in nature 
include the quinines in electron transport chains, components of membranes, plant 
defense, as hormones, and as photosynthetic pigments such as carotenoids and side 
chains of chlorophyll.6  Terpenoids are synthesized in many species within the realms of 
eubacteria, archaebacteria, and eukaryotes via the condensation of isopentenyl 
pyrophosphate (IPP) 1 and its isomer dimethylallyl pyrophosphate (DMAPP) 2 (Scheme 
1).  These compounds are biosynthesized by two different routes.  The pathway to IPP 1 
in mammals and yeast begins with acetyl-CoA 3 with two other units being  
 
Scheme 1.  Building blocks of terpenoids.  After 7 
 
 
 
activated to the thioester and condensed in several steps to form hydroxymethylglutaryl-
CoA (HMG-CoA) 4.  HMG-CoA 4 then undergoes dehydration, reduction, 
decarboxylation, and phosphorylation in multiple steps to produce IPP (Scheme 2).8,9    
The second pathway, termed the non-mavalonate pathway, was discovered in 1993 and 
many of the mechanistic details are still not well understood. It begins with the  
1 2
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Scheme 2.  Malvonate biosynthesis of isopentenyl pyrophosphate. After 7 
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condensation of one unit of pyruvate 5 and one unit of glyceraldehydes-3-phosphate 6 to 
give 1-deoxy-D-xyulose-5-phosphate 7 (Scheme 3). Scheme 3 demonstrates that 1-
deoxy-D-xyulose-5-phosphate 7 undergoes several reductions and rearrangements to 
produce IPP 1.10,11 
 
Scheme 3.  The deoxyxylulose phosphate pathway for IPP.  After 7 
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 The production of terpenoids starts with the isomerization of IPP 1 to DMAPP 2 
by IPP isomerase (Scheme 1).12,13  The enzyme farnesyl diphosphate synthase catalyzes 
the coupling of the two substrates (IPP and DMAPP) giving geranyl diphospate (GPP).  
This is performed in a head-to-tail fashion.  First off, the reaction begins with a catalyzed 
ionization of the allyl pyrophosphate producing a carbocation intermediate.  This carbon 
is attacked by the alkene of IPP to produce a tertiary carbocation.  This intermediate is 
then deprotonated with the loss of the pro-R hydrogen (Scheme 4).13  This enzyme can 
also add another C-5 unit to produce the sesquiterpene, farnsenal (C15).    This process 
can continue to give terpenes up to 25 carbons long.  Triterpenes (C30) and tetraterpenes 
(C40) can also be generated by the coupling of C15 and C20 units. 
 
 
Scheme 4.  Head-to-tail condensation of IPP and DMAPP to produce GPP.  After 7 
 
 
 
 IPP and DMAPP can also be condensed in a tail-to-tail fashion which leads to the 
terpenoids, squalene and phytoene.14-16  There are two pathways in which these 
molecules are made.  The first is a reductive pathway which results in two saturated 
methylene units at the connection point.  This particular pathway leads to squalene 
which undergoes further metabolism to produce many compounds including steroids.  
The second pathway is a non-reductive pathway involving the formation of the triene 
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carotenoids, such as lycopene.  This is due to the carbon-carbon bond forming from the 
two allylic alcohol positions.   
 
Scheme 5.  Tail-to-tail condensation of geranylgeranyl pyrophosphate.  After 7 
 
 
 
Carotenoids 
The carotenoids form an important class of biologically active terpenoids and play a 
critical role in energy transfer processes such as photosynthesis or photoprotection.  
Carotenoids, such as lycopene 8 (Figure 2), act as a class of anti-oxidants which are 
responsible for the scavenging of free radicals within the human body.17  For instance, 8 
is 100 times more effective in singlet-oxygen quenching than vitamin E 9.18  Lycopene 
also acts as an important intermediate in the biosynthesis of β-carotene.  β-carotene 10, 
can be enzymatically cleaved by a β-carotene 15,15’-monooxygenase to form two 
retinals 11.19-21  Retinal 11 is important as it serves as the chromophore for the visual 
transduction cycle.22  Retinal 11 can easily be oxidized to form retinol 12, which is better 
known as vitamin A.  Another key retinoid, retinoic acid 13, can be made from retinal 
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via a retinal oxidase. 23-26  Retinol 12 and retinoic acid 13 (Figure 3) exhibit a variety of 
biological activities and are potent modulators of growth and differentiation.27-29  
Interestingly, 13 has been shown to differentiate embryonic stem cells into a neuron-like 
phenotype.30   It has also been employed as a chemotherapeutic agent in the treatment of 
promyelocytic leukemia by causing terminal differentiation of the tumor cells.   
 
O
HO
 
Figure 2.   Structures of carotenoids lycopene, vitamin E, and β-carotene. 
 
 
 
Figure 3.  Biologically relevant retinoids.   
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Cycloterpenals in Nature 
An understudied subclass of the carotenoids is the cycloterpenals.31,32  In nature, 
only two cycloterpenals (with a cyclohexadienal structural core) have been discovered.  
Interestingly, condensation of all-trans-retinal gives a C-40 ring-fused dimer 14 which is 
also known as cycloretinal (Figure 4).  This molecule, along with other bisretinoids, is 
believed to act as a contributor of age-related macular degeneration, the leading cause of 
blindness in the elderly.33,34  Since the isolation and identification of cycloretinal from 
the human eye in 2004, the formation of this metabolite has been under scrutiny. 27  In 
2005, Nakanishi proposed that the C-40 dimer was formed with a protonated Schiff base 
conjugate with phosphatidylethanolamine (PE) (Scheme 6) supplied within retinal 
pigment epithelium (RPE) cells.  The Schiff base then tautomerizes to react with free 
retinal via a Michael-type addition.  After ring closure and elimination of the amino 
group of PE, the all-trans retinal dimer 14 is formed. 28   
The self-dimerization of citral has been suspected since the late 1890’s.35,36  The 
1,2,4-trisubstituted structure 15 (Figure 4) was definitively ascribed in 1932.37  
Recently, citral dimer (cyclocitral) 15 was isolated from the North Sea bryozoan Flustra 
foliacea38,39 and shown to exhibit antibacterial activity against Roseobacter sp. and 
Sulfitobacter sp. in an agar diffusion assay (100 µg resulted in a 0.5 and 1.0 cm zone of 
inhibition respectively).  The formation of this metabolite in the bryozoans is unknown 
but it is speculated that a base catalyzed reaction is taking place as citral is also isolated 
from the bryozoans in substantial amounts. 38,39 
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Figure 4.  Structures of cycloretinal, cyclocitral, and C-30 dimer.   
 
 
Scheme 6.  Nakanishi’s proposed formation of all-trans-retinal C-40 dimer.28 
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β-LG Promotes Biosynthesis of Cycloterpenals 
Incubation of the principal milk protein β-lactoglobulin (β-LG) with β-
ionylideneacetaldehyde has been shown to result in cyclohexadienal formation of its 
corresponding C-30 homodimer, cyclo-β-ional 16 (Figure 4).40,41  This protein mediated 
reaction was detected by UV-Vis and circular dichroism analyses with no further 
research being done to explore the phenomenon along with no follow up studies on the 
probable biological roles of these cycloterpenals.  This is intriguing as β-LG is the 
principal whey protein in dairy milk.  Protein analysis of blood samples reveal that levels 
of β-LG in the blood stream are on average between 0.7 to 1.2 g/dL.  As humans do not 
possess a β-LG homolog, the source of this protein must be dietary.  The lipocalin 
closest to β-LG in humans is glycodelin (also known as PP14 or pregnancy-associated 
endometrial glycoprotein).  This protein is associated in the first trimester of 
pregnancy.42  The exact function of glycodelin is also unknown. 
   
Beta-Lactoglobulin 
Beta-lactoglobulin (β-LG) is the principal whey protein of ruminant species and 
is also present in many other species.43  Based on its amino acid sequence and 3-
dimensional structure, the protein is classified as a member of the lipocalin family.  The 
lipocalin family is a large and diverse family of proteins with various functionalities 
ranging from insect camouflage to small hydrophobic molecule transport exemplified by 
the serum retinol-binding protein.44  β-LG is the major whey protein in milk constituting 
50-55% of the protein volume.43  The protein has been studied extensively for its 
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physical and biochemical properties for over 70 years now because of its size, stability, 
and convenience (~3 g/liter of milk).43,45-47   
To date, the biological function of β-LG is unknown.  While β-LG may serve as a 
nutritional supplement,48 the structural similarity to retinol-binding protein and fatty 
acid-binding protein suggests that it has a transport role for ligands such as retinoids and 
various fatty acids.44,49-52  Binding studies have been performed with hydrophobic 
ligands examining a probable role in transport similar to that of other lipocalins with 
dissociation constants ranging from 10-4 to 10-9 M.  Some examples can be seen for the 
binding of various fatty acids, retinoids, and steroids in Table 1. 
  β-LG may also play a role in digestion of milk fats as ruminant β-LG has been 
isolated with fatty acids bound.54  Not all β-LGs have the same properties.  It has been 
shown that this is not the case for all β-LGs as mares and sows do not exhibit significant 
fatty acid binding. However, β-LG from all species bind retinol just as serum albumin 
and α-lactalbumin, indicating that it is not highly specific.55  
β-LG is comprised of 162 amino acids with a molecular weight of ~18,400 
Daltons.56  The protein, with a predominant β-sheet configuration, contains nine anti-
parallel β-strands (A-I) with one α-helix.  The calyx is comprised of two surfaces with β-
strands A-D forming one side and strands E-H forming the other.  β-strand I is located 
on the outer surface of the calyx (Figure 5 and Figure 6).57-60The retinoid binding site 
for β-LG has been well established and lies inside the calyx of the protein.61  Fatty acids 
and vitamin D have also been shown to bind directly to the calyx.60,62-64  Recently, others 
have speculated upon the existence of other hydrophobic pockets within 
11 
 
Table 1.  Selected ligand binding data for bovine β-lactoglobulin. 
 
 
Ligand Kd (M) 
Lauric  7.0 x 10-7 
Palmitate 1.0 x 10-7 
Retinoic Acid 2.0 x 10-7 
Retinol 2.0 x 10-8 
Vitamin D2 4.91 x 10-9 
Stearate 1.2 x 10-7 
Cholesterol 3.49 x 10-8 
 
 
the protein.  Biochemical binding assays performed with vitamin D showed uptake at a 
secondary binding site remote from the calyx.65-69  In 2008, a crystal structure was 
obtained with vitamin D3 binding within a secondary hydrophobic site of β-LG (residues 
136-149),70 while others have also speculated about other potential binding pockets 
within β-LG.71-73   
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Figure 5.  Native BLG crystal structure.49   
The diagram was prepared with VMB. 
 
 
Figure 6.  The dimer interface viewed perpendicular to strand I.57 
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Macular Degeneration and A2E 
 Age-related macular degeneration affects 10-20% of people over the age of 65 in 
which the macula,74,75 the inner lining of the eye, suffers thinning or atrophy.  These 
events lead to the loss of central vision (Figure 7).   AMD is defined as either “dry” or 
“wet”.  Dry macular degeneration is the most common form of all AMD.  A build-up  
 
  
Figure 7.  Macular degeneration affects central vision.74   
Photos courtesy of NIH National Eye Institute. 
 
over time of drusen leads to small lesions within the central region of the macula.  
Drusen are tiny or white accumulations of extracellular material that build up in the 
Bruch’s membrane of the eye (Figure 8).76,77    Wet macular degeneration is less 
common accounting for 10% of all AMD cases.  This form is characterized by choroidal 
neovascularization.  This is the development of abnormal blood vessels under the retinal 
pigment epithelium (RPE) layer of the retina.  This leads to intense scarring of the 
macula as these vessels continuously hemorrhage and bleed.78  The overall progression 
of AMD is very slow.  There are many influences on the disease ranging from genetic 
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benefactors to environmental risks including diet, cigarette smoking, and exposure to 
light.79 
 
 
Figure 8.  Tunneling electron microscopy representation of drusen build-up.77  
Photo courtesy of The Center for the Study of Macular Degeneration Neuroscience 
Research Institute, University of California Santa Barbara. 
 
 
 AMD can also be associated with the build-up of retinal lipofuscin (RLF) 
granules (Figure 9).  These granules begin to accumulate around the age of 20 and by 
the age of 80 they may constitute up to 20% of the cell volume.80  These granules 
contain a mixture of proteins, lipids, and fluorescent bis-retinoid compounds.  Proteomic 
studies were performed demonstrating that 41 different proteins including β-
lactoglobulin were present within the granules.81  Fluorescent compounds including 
cycloretinal and the bis-retinoid A2E 17 along with its isoform iso-A2E 18 (Scheme 7) 
have been isolated and characterized from RLF.81-83  Evidence suggests that these toxic 
vision byproducts that accumulate in RLF contribute to the death of RPE eventually 
leading to the visual impairment of the individual through the oxidation of the 
15 
 
conjugated double bonds resulting in highly reactive epoxides 19 which lead to 
pathogenesis (Scheme 7).84-86   
 
 
Figure 9.  Atomic force micrograph of RLF granules.81 
 
 
Scheme 7.  A2E and iso-A2E form highly reactive epoxides. 84-86   
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 After 70 years of extensive research, the biological function of β-LG is still 
unknown.  With experiments showing that it might be involved in the transport of 
essential metabolites, the possibility of other functions cannot be ruled out.  The 
discovery of the β-LG meditated self-condensation of natural aldehydes in 1992 
indicated that the protein might possess another biological role.  With the generation of 
cycloterpenals from this reaction, it can be hypothesized that β-LG might play a role in 
developmental processes such as neuronal development or cellular differentiation.  The 
isolation of cyclocitral and cycloretinal from nature provides evidence that this 
understudied class of cycloterpenals may play an essential role in nature as they may 
possess many biological attributes.  In order to elucidate the functions of β-LG and 
cycloterpenals, a scheme must be designed to mimic the formation of cycloterpenals 
with β-LG to develop new compounds based on this cyclohexadienal motif.  This is 
currently in development in Dr. Coran Watanabe’s group to investigate the biological 
roles of cycloterpenals and thus elucidate another function of β-LG.    
 
STATEMENT OF PURPOSE 
 Natural products have become a staple in the everyday lives of humans.  The 
carotenoids play an essential role in many biological functions and the recently 
discovered cycloterpenal class may possess unheard biological activities.  The isolation 
of cycloretinal from the human eye in recent years has brought these cyclohexadiene 
core molecules to the attention of many scientists as this molecule along with other bis-
retinoids from the human eye lead to the development of macular degeneration.  With 
the ability of β-LG to condense natural β-methyl aldehydes such as retinal into 
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cycloretinal, one would have to believe that this protein mediated reaction can occur 
with other natural aldehydes that we consume on a daily bases, especially if one has a 
high intake of dairy products.  Further analysis of this reaction could lead to the 
understanding of β-LGs biological roles as well as a better understanding as to the role 
the cycloterpenals play in nature.   
18 
 
CHAPTER II 
INVESTIGATIONS OF THE BIOLOGICAL ROLES OF β-LACTOGLOBULIN 
INTRODUCTION 
The lipocalin family is a large and diverse family of proteins with various 
functionalities ranging from insect camouflage to small hydrophobic molecule transport 
exemplified by the serum retinol-binding protein.44  Bovine β-lactoglobulin (β-LG), a 
typical lipocalin, is a major whey protein in milk constituting 50-55% of the protein 
volume.43  β-LG has been studied extensively for its physical and biochemical properties 
for over 70 years now because of its size, stability, and convenience (~3 g/liter of 
milk).43,45-47  To date, the biological function of β-LG is unknown.  While β-LG may 
serve as a nutritional supplement,48 the structural similarity to retinol-binding protein 
and fatty acid-binding protein suggests that it has a transport role for ligands such as 
retinoids and various fatty acids.44,49-52  Binding studies have been performed with 
ligands that are hydrophobic which in turn exemplifies a probable role in transport 
similar to that of other lipocalins with dissociation constants ranging from 10-4 to 10-9 
M.53  β-LG may also play a role in digestion of milk fats as ruminant β-LG has been 
isolated with fatty acids bound.54  It has been shown this is not the case for all β-LGs as 
mares and sows do not exhibit significant fatty acid binding.  However, β-LG from all 
species binds retinol just as serum albumin and α-lactalbumin, indicating that it is not 
highly specific. 55  
β-LG is comprised of 162 amino acids with a molecular weight of ~18,400 
Daltons.56  The protein, with a predominant β-sheet configuration, contains nine anti-
parallel β-strands (A-I) with one α-helix.  The protein is a dimeric structure comprised of 
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two surfaces with β-strands A-D forming one side of the calyx while strands E-H form 
the other.  β-strand I is located on the outer surface of the calyx.57-60  The retinoid 
binding site for β-LG has been well established and lies inside the calyx of the protein.61  
Fatty acids and vitamin D have also been shown to bind directly to the calyx.60,62-64  
Recently, there has been controversy towards the existence of other hydrophobic pockets 
within the protein.  Biochemical binding assays performed with vitamin D showed 
uptake at a secondary binding site remote from the calyx.65-69  In 2008, a crystal structure 
was obtained with vitamin D3 binding within a secondary hydrophobic site of β-LG 
(residues 136-149).70  Still, there are speculations of other potential binding pockets 
within β-LG.71-73   
 In the early 1990’s, incubation of β-LG with β-ionylideneacetaldehyde resulted 
in cyclohexadienal formation of its corresponding C-30 homodimer, cyclo-β-ional (16) 
(Figure 10).41,87  This protein mediated reaction was detected by UV-Vis and circular 
dichroism analyses with no further studies performed to explain the phenomenon along 
with no follow up studies on the probable biological roles these cycloterpenals may 
possess. In our laboratory, we have developed synthetic strategies to make a vast library 
of molecules and investigated the probable biological roles of these cycloterpenals.31,32  
We broadly speculated that these molecules could be important in developmental 
processes such as neurite outgrowth.  When our library was screened against PC12 cells, 
we observed the reduction of  the cancerous proliferation as the cells began to 
differentiate into neurons.32 
 To date, there have only been two cycloterpenals discovered in nature.  
Cyclocitral (15), was recently isolated from the North Sea bryozoans Flustra foliacea 
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and shown to exhibit antibacterial activity.39,88,89  Cycloretinal (15), condensation 
product of all-trans-retinal, has been isolated and characterized from the human eye 
(Figure 10).33,34  Cycloretinal along with other bis-retinoids, A2E and its minor isomers, 
are believed to play a major role in death of retinal pigment epithelial (RPE) cells.90  
Accumulation of these toxic molecules occurs slowly over time in granules termed 
lipofuscin.  These retinal lipofuscin (RLF) granules begin building up around the age of 
20 and by 80 years constitutes up to 20% of the cell volume in RPE cells.80  Evidence 
suggests that the toxic vision byproducts that accumulate in RLF contribute to the death 
of RPE eventually leading to the visual impairment of the individual.84-86  How these 
toxic byproducts of the vision cycle are being formed is still a mystery.  It has been 
shown that at high concentrations of all-trans-retinal, a fluorescent bis-retinoid adduct 
can form on lysine residues of rhodopsin in the rod outer segments.91  This could be one 
possible way for these toxic molecules to form, but interestingly, the protein β-LG has 
been characterized within the human eye, particularly within the RLF granules that 
house these toxic molecules.81-83  In this report, we demonstrate that β-LG mediates the 
formation of the toxic byproduct cycloretinal not only in vitro but also in vivo in a rabbit 
model where the metabolite was isolated in the blood.  Other cycloterpenals can also be 
synthesized utilizing β-LG under optimal conditions. 
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Figure 10.  Chemical structures of cyclo-β-ional, cyclocitral, and cycloretinal. 
 
RESULTS AND DISCUSSION 
Optimization of β-LG Mediated Synthesis of Cycloterpenals 
In 1990, it was reported that the incubation of β-LG with β-
ionylideneacetaldehyde resulted in the formation of cyclo-β-ional 16.41,87  This reaction 
was monitored with UV-Vis and circular dichroism spectroscopy with no further 
investigations to fully evaluate this protein mediated reaction, i.e. the scope of the 
reaction and mechanism of its formation (Scheme 8).  
 
Scheme 8.  β-LG mediated formation of cycloterpenals from β-methyl aldehydes.  
 
 
 
 To optimize the reaction, we followed the general conditions set forth by Li et. 
al. by utilizing a 0.2% solution of β-LG allowing the reaction to go overnight, incubating 
the protein solution at room temperature (with shaking) with β-ionylideneacetaldehyde 
O
OO
16 15 
14 
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using a 1:2 protein to substrate molar ratio.41  We scaled up the reaction in hopes of 
visualizing the homodimer by NMR and to our surprise after one day we saw trace 
amounts of 16 (Figure 11).  The successful detection of the dimer product by NMR led 
us to further optimize the reaction by treating various  
 
 
Figure 11.  1H-NMR of aldehyde region for cyclo-β-ional formation. 
 
solutions of β-LG (0.2%-1.0%) with citral.  These reactions were performed at room 
temperature over three days as seen in Figure 12.  The production of cyclocitral 
increased with elevated concentrations with 1.0% giving the best production with an 
isolated yield of 29.1%.  The yields for protein concentrations of 0.2%, 0.4%, 0.6%, and 
0.8% were 8.2%, 13.4%, 17.9%, and 22.6%, respectively.   
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Figure 12.  Various concentrations of β-LG observing cyclocitral production versus 
citral starting material. 
 
Varying the protein to substrate ratio from 1:3 to 1:10 revealed that a protein to 
substrate concentration of 1:3 was optimal with an isolated yield of 58%.  This is a 
dramatic improvement in yield as compared to product obtained with a 1:2 ratio, but 
when the ratio was increased to 1:4, the isolated yield was similar to that of 1:3.  This 
was also the case for higher equivalents of substrate used.   This is suggestive that the 
protein mediated reaction is a single turnover reaction resulting in dead protein after one 
reaction.  Also, this indicates that there is another binding pocket available for the 
reaction to proceed.  If the reaction was taking place within the central calyx, then only 2 
equivalents would be necessary for production of the dimer.  Worthy of note, the protein 
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remains yellow even after organic extraction which we believe to be the calyx bound 
substrate.  Denaturation of the protein after reaction by boiling led to the recovery of the 
reminder of the starting material. 
To further optimize this reaction, we looked at a comparison of the reaction 
carried out at room temperature (25°C) versus that of body temperature (37°C) since the 
protein is a component of the milk we drink.  The production of cyclocitral was greater 
and faster at the higher temperature as shown in Figure 13.  Evaluation of the reaction 
 
 
Figure 13.  Temperature optimization at room temperature (25°C) (left) versus body 
temperature (37°C) (right). 
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 progression revealed that the reaction was complete within a 4-day period, producing a 
58% yield.  The yields for days one thru three were 12.3%, 22.4%, and 36.2%, 
respectively.  The reaction yield at five days was equivalent to that obtained at 4-days 
(58%). 
Our next step in optimizing the reaction was to investigate the behavior of the 
reaction at various pHs.  A pH profile (Figure 14) was carried out to observe the effects 
on the dimerization of citral.  Yields diminished at pH values of 1.0 and 11.0 while pH 
7.0 was found to be the optimal pH for the reaction.  The equilibrium shifts at lower and 
higher pH values as the protonation state of the amine is affected.  At pH 7.0, a yield of 
58% was obtained while at pH values of 5.0 and 9.0 yields of 14% and 28% were 
isolated (Table 2).  There was also a distinct color change at various pHs.  At pH 7, the 
normal yellow color was observed with the uptake of citral.  However, at acidic pHs, the 
color changes ranged from milky, pH 5, to clear as the pH was decreased.  At basic 
conditions, and intense orange color was seen at pH 9, giving a slightly less intense color 
at pH 11 (Figure 15).  The yield of cyclocitral was greater at pH 9 than that of pH 11 
which would indicate a greater uptake at pH 9.   
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Table 2.  Yields at various pHs.   
 
pH 
Percent 
Yield 
1 0 
3 9.8 
5 13.6 
7 50.7 
9 27.9 
11 0 
 
 
 
Figure 14.  pH effects on the self-condensation of BLG with citral. 
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Figure 15.  pH profile color changes. 
 
Bovine Serum Albumin Control 
In order to determine specificity of the dimerization reaction to β-LG, we looked 
at one the most studied proteins in the world, bovine serum albumin (BSA).  BSA 
contains 60 lysine residues.  Various concentrations of BSA (0.2% to 1.0%) were treated 
with an excess amount of citral and cyclocitral formation followed.  We allowed these 
reactions to go for four days before extraction.  Interestingly in all cases, there was no 
dimerization observed as only unreacted citral was isolated.   
 
Microbial and RPE Controls 
 Protein lysates from bacterias E. coli, B. subtilis, and yeast S. cerevisiae were 
screened for cyclocitral production, incubating each with excess citral.  The lysates only 
yielded citral and no dimerization product was obtained.  As control reactions, the 
lysates with no substrate present were extracted with ethyl acetate screened to ensure 
that no metabolites peaks would appear in the aldehyde region of interest (Figure 17).  It 
should be noted that there are over 4000 proteins in each microbe’s proteome. 
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Figure 16.  BSA control spectra indicating no cyclocitral formation. 
 
Cycloretinal has been isolated from retinal pigment epithelial (RPE) cells in 
human eyes,33,34 we examined whether the RPE cell protein lysate was capable of 
supporting dimer formation.  We grew 10 plates of RPE cells to 95% confluency and 
used a dounce homogenizer to lyse the cells.  A crude extract of the lysates indicated no 
presence of cycloretinal as well as A2E by 1H-NMR and mass spectrometry (MS).92  
After the RPE lysates were treated with citral for four days, there was no cyclocitral 
present via 1H-NMR and MS upon extraction.  While this experiment shows that the 
lysates of RPE cells cannot perform the dimerization reaction, one might also speculate 
that rhodopsin may act as a player in cycloretinal formation as studies have shown that 
when retinal is at high concentrations, three lysine residues are modified with the 
addition of bis-retinoid adducts (A2-rhodopsin).91  There is currently no evidence of 
cycloretinal adducts being attached to rhodopsin.   
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Figure 17.  E. coli control indicating no metabolites in region of interest and after citral 
treatment. 
  
Induced Protein Denaturation Experiments 
 To inactivate β-LG, we utilized two different sources for the denaturation of our 
protein.  The first experiment we performed was heat denaturation by taking 500 mL of 
a β-LG solution and boiling it for 10 minutes at 100 °C.  Once the solution was cooled, 
the reaction was set up under optimal conditions with citral as substrate, and allowed to 
stir for four days at 37 °C.  Upon extraction of the colorless solution, it was found that 
no cyclocitral was produced as only the starting material was isolated.       
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 The other inactivation experiment that we performed was urea-induced 
denaturation.  We treated β-LG with an excess amount of urea, to reduce the protein-
protein and protein-water contacts,93 over a two day period before we incubated the 
mixture with citral for an extra two days to observe cyclocitral formation.  After two day 
post citral addition, extraction of the mixture yielded no cyclocitral.      
 
Production of Self-condensation Products with Various Aldehydes   
With our conditions optimized, we next looked at the effects of various substrates 
ranging from small aromatics, bulky aromatics, and long chain alkyl substrates over a 
four day period.  We observed good conversion of the aldehyde to the dimer product. 
Percent conversion was monitored by 1H-NMR after extraction where percent yield was 
determined by product isolation.  With each of these reactions, β-LG would begin as a 
clear solution and darken overtime.  For example, when β-LG is incubated with citral, 
the protein changes from clear to yellow and with retinal, the protein changes to a 
reddish-orange color.  After extraction, boiling of the aqueous layer leads to isolation of 
the remaining substrate that remains bound to the protein following extraction.  If 100% 
conversion is not achieved, it can be speculated that binding site interactions that 
facilitate the reaction are not optimal for that particular substrate.  This was 
predominantly observed in the bulkier substrates and alkyl substrates.  The reaction that 
gave the greatest yield (Table 2) after four days was the thiophene aldehyde with an 
isolated yield of 60.3%.  The lowest isolated yield was the long alkyl chained farnesal at 
23.4%.  While the conversion of the naphthalene and biphenyl substrates after four days 
was fairly low, the overall yields (58.0% and 57.9% respectively) of the substrates 
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dimerized was significantly higher when compared to other substrates where their yields 
were actually lower.  This can be seen when looking at the phenyl substrate as 
conversion was 77.0% with a meager isolated yield of 32.4% (Table 3). 
 
Proposed Reaction Mechanism 
The β-LG mediated reaction is thought to ensue by nucleophilic attack of the 
aldehyde with a terminal amine of lysine residues, resulting in the formation of a Schiff 
base 20 (Figure 18).  Tautomerization, invoked by deprotonation of the β-methyl group 
of the imine, gives the β-methylenic lysine adduct 21 that can be visualized to dimerize 
with 20 following a Diels-Alder or Michael-like imine addition mechanism (pathway 
marked with green arrows).  With the Michael-like imine addition, intermediate 22 is 
generated which then undergoes cyclization into reaction intermediate 23 (direct 
intermediate from Diels-Alder mechanism).  From intermediate 23, the lysine attached at 
C-4 of the cyclohexene ring readily dissociates leaving the cyclohexadiene intermediate 
24.  Intermediate 24 then undergoes hydrolysis to give the 1,2,4-trisubstitued 
cyclohexadienal product 25. 
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Table 3.  Dimerization yields from one to four days.   
aMeasured by 1H-NMR.  bIsolated yield. 
 
 Day 1 Day 2 Day 3  Day 4  
R group 
% 
conv.a 
% 
yieldb
% 
conv.a
% 
yieldb
% 
conv.a
% 
yieldb 
% 
conv.a 
% 
yieldb
 
 
 
18.8 12.3 24.3 22.4 52.1 36.2 100.0 57.7 
 
 
 
24.6 11.1 47.3 11.5 51.0 16.3 100.0 23.6 
 
 
 
18.7 14.9 100.0 33.7 100.0 34.8 100.0 37.8 
 
 
 
2.4 15.6 30.1 30.5 100.0 54.9 100.0 55.3 
 
 
 
13.6 5.9 22.3 10.7 34.6 14.8 49.2 24.8 
 
 
 
19.5 23.6 17.5 31.9 19.7 43.1 20.0 44.2 
 44.5 8.3 55.7 22.4 67.3 25.7 77.9 32.4 
 
 
 
10.8 7.1 58.8 27.3 100.0 51.8 100.0 60.3 
 7.7 11.5 37.0 25.2 38.0 48.9 39.1 58.0 
 
 
 
34.9 8.4 45.1 27.5 44.1 38.9 52.5 57.9 
 
Me
S
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Heterodimer Formation Utilizing Β-LG  
 Since β-LG has been proven to form cycloterpenals from β-methyl aldehydes, we 
also wanted to demonstrate that the protein could mediate the condensation reaction with 
a β-methyl substrate and an α,β-unsaturated aldehyde.  We decided to observe the 
dimerization between citral and cinnamaldehyde (Scheme 9) since previous studies have 
shown that this particular reaction will give not only products due to a proton abstraction 
from the  β-methyl position (26) but also produce cis  and trans diasteriomers (27 and 28 
respectively)  from the proton abstraction of the γ-methylene position, along with 
  
 
Figure 18.  Proposed routes to the synthesis of 1,2,4-trisubstituted cyclohexadienals.  
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Scheme 9.  β-LG mediated reaction products between citral and cinnamaldehyde.  
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cyclocitral 15 itself.32  For the β-LG mediated reaction, we saw all four products 
produced. 
For this particular reaction, we incubated β-LG with cinnamaldehyde and citral 
simultaneously.  We were interested in observing the effects when the two substrates 
were at ratios of 1:1 or 1:2 to look at overall isolated yields of the various products 
shown in Table 4.  Isolated yields varied in each case as there is a competition for the 
binding of the substrates to the active lysine residues.  At both concentrations, the major 
product isolated was the cis-diasteriomer 27 with yields after three days of 19% and 
yields of 22.2% and 28.3% for 1:1 and 1:2, respectively after four days.  The other major 
product formed was cyclocitral with yields of 18% and 20% for 1:1 and slightly 
increasing to approximately 24% for time points at 1:2.  In the formation of the trans-
diasteriomer from day three to four, we saw a slight increase in production at 1:1, but in 
for 1:2 the isolated yield was slightly diminished as the cis product had slightly 
increased.   
15 
26 27 
28
35 
 
Table 4.  Reaction yields for citral/cinnamaldehyde β-LG reaction. 
Percent yields were determined by HPLC purification. 
 
1:1 Day 3 Day 4 1:2 Day 3 Day 4 
Compound % yield % yield Compound % yield % yield 
26 13.4 19.1 26 12.2 19.2 
27 19.1 22.2 27 19.2 28.3 
28 8.7 10.3 28 9.7 7.2 
15 18.3 20.1 15 23.7 24.3 
 
 
Rate of Β-LG Mediated Reaction 
 To determine the observed rate for the formation of cycloterpenals by β-LG, 
citral was used as a model substrate resulting in the formation of cyclocitral.  The rate 
was determined by comparing integrated peak areas to a calibration curve to determine 
the amount of cyclocitral injected onto the column versus the resulting integrated peak 
area.  Three different concentrations of citral were used to see if the increased amount of 
substrate had any effect on the rate of the formation of cyclocitral.  In other words, was 
the protein mediated reaction catalytic or a single turnover event.  Optimal substrate 
conditions were used (3x) as well as saturation conditions of 10X and 50X to that of the 
protein concentration.  Interestingly, the results were similar for each concentration 
(Figure 19).  This data corroborates well with previous experiments that indicated no 
increased yield when the protein was incubated with more than three equivalents of 
substrate.  The rate of the reaction for cyclocitral formation is 0.034 M/min.  To compare 
the rate of formation of cyclocitral to the other dimerization reactions, a comparison of 
the peak areas versus time was utilized.  It was found that the reactions involving 
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thiophene, naphthalene, retinal, 3-methyl-2-butenal, and biphenyl were greater than 
citral.  The other substrates were substantially less than that of the formation of 
cyclocitral.  
  
 
Figure 19.  Rate of formation for cyclocitral at various concentrations. 
 
KD Measurements 
We measured the dissociation constants (Kd) for each of the substrates mentioned 
above to determine how tightly the ligands bind to the main calyx of BLG.  These 
measurements were performed using a fluorescent titration of each ligand at pH 7.0 in 
phosphate buffer saline (PBS).  The Kd values (Error! Not a valid bookmark self-
reference.) obtained were all in the micromolar range (10-6) with the exception of 3-
methyl-2-butenal which displayed the highest affinity at 9.83 x 10-7 M. The values that 
we obtained for this series of β-methyl aldehydes is comparable to Kd values that have 
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been obtained for other molecules, ranging from 10-4 to 10-8 M by fluorescence 
microscopy.94 
Table 5.  Kd measurement for substrates used for dimerization observations. 
 
Substrate Kd Substrate Kd 
 
 
 
1.34 x 10-6  2.05 x 10-6 
 
 
 
2.88 x 10-6  1.15 x 10-6 
 
 
 
1.81 x 10-6  1.51 x 10-6 
 
 
 
1.35 x 10-6  1.63 x 10-6 
 
 
9.83 x 10-7  2.26 x 10-6 
 
Mass Spectrometric Evidence of Active Lysine Residues   
To gain an understanding of how β-LG is promoting this dimerization reaction, 
we decided perform a reductive amination with sodium cyano-borohydride (NaCNBH3) 
to crosslink citral to the protein.  Two different treatments were performed.  The first 
was to saturate the reaction with reductant and the second was to add the reductant after 
a small aliquot was taken from the reaction.  Time points that were analyzed were at 6, 
24, 48, 72, and 96 hours.  Both mixtures were passed through a spin-column fitted with 
Sephadex resin to remove small molecules and borate salts.  These samples were then 
O
O
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O
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concentrated and digested with trypsin and subsequently analyzed by mass spectroscopy 
for residues containing a mass shift with citral or cyclocitral bound.   
At the beginning of this investigation, we originally speculated that the reaction 
would take place in the central calyx of the protein (K60 and K69).  Thus far, 
experimentation has led us to believe that other lysines within the protein may be 
performing the dimerization reaction.  By our account, we found that 85% of the 15 
lysine residues had citral reduced to them with one containing the dimerization product 
intermediate with MASCOT ion scores above 20.  Lysines K8 and K142 were the only 
two not shown to display citral bound.   The reduction of citral to multiple lysines was 
expected as previous studies have shown reductions of various substrates to as high as 
95% of the 15 lysines.95-98  As shown in Figure 20, the modified lysines that were 
consistently detected in each sample were  from K77 and K91 (red) corresponding to the 
peptides TK*IPAVFK (yellow) (MASCOT score of 40)  and 
IDALNENK*VLVLDTDYKK (blue) (MASCOT score of 101) (Please note that these 
modified residues were also found in peptides with slightly different sequences due to 
multiple missed tryptic cleavage sites).  Modification of K77 was observed as fragment 
ions (M+citral) b3, b4, b5. b6. and b7 (Figure 21), while modification of K91 with citral 
gave mass ion fragments b8, b9, b10, b11, and b13 (Figure 22).   
 
1 MIVTQTMKGLDIQKVAGTWYSLAMAASDISLLDAQSAPLRVYVEELKPTPE  
52 GDLEILLQKWENGECAQKKIIAEKTKIPAVFKIDALNENKVLVLDTDYKK             
102 YLLFCMENSAEPEQSLACQCLVRTPEVDDEALEKFDKALKALPMHIRLSF 
153 NPTQLEEQCHI 
 
Figure 20.  β-LG sequence with fragments containing active lysine residues. 
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We were also able to observe the dimer intermediate 24 bout to K91 within 
peptide fragment IDALNENK**VLVLDTDYK (MASCOT score of 60).  This result 
might suggest that upon a substrate molecule binding the calyx allowing K77 and K91 to 
get in close enough proximity that K77, which is on a flexible loop can interact with 
K91.  To confirm this modification, mass fragment ions b8, b9, and b10 were observed 
(Figure 23).   
 
   
 
Figure 21.  TK*IPAVFK fragmentation pattern. 
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Figure 22.  IDALNENK*VLVLDTDYKK fragmentation pattern. 
 
 
Figure 23.  Dimer bound IDALNENK**VLVLDTKYK fragmentation pattern. 
 
 
b13 
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With this information, we looked at the crystal structures of native β-LG, with 
palmitate bound, and retinol bound to look at the changes of the K77 and K91 residues 
upon binding of a substrate.   In the native protein (Figure 24),49 the terminal amines of 
the lysines are 16.09 Å apart.  When a substrate is bound to the calyx, for instance 
palmitate,64 the lysines move to 12.60 Å, which is a difference of 3.49 Å  from the native 
protein (Figure 25).  When you look at the structural change with the binding of retinol 
to the calyx,62 the two lysine residues move within a distance of 12.10 Å of each other, a 
difference of 3.99 Å from the native protein (Figure 26). 
 
 
 
Figure 24.  Native β-LG crystal structure depicting K77 and K91.49 
The diagram was prepared with VMB. 
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Figure 25.  β-LG crystal structure depicting K77 and K91 with palmitate bound.64  
The diagram was prepared with VMB. 
 
 
 
Figure 26.  β-LG crystal structure depicting K77 and K91 with retinol bound.62 
The diagram was prepared with VMB. 
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Retinol/Β-ionone Uptake Before Addition of Substrate 
 So far, experimental evidence suggests that the dimerization reaction occurs in 
another location other than the primary active site of β-LG.  To further probe this 
mechanism, incubation of the protein with substrates other than β-methyl aldehydes for 
two days was utilized.  After the two day period, two equivalents of citral was added to 
see if the dimerization would still occur.  In this series of experiments, we probed the 
calyx binding with the substrates retinol and β-ionone which have Kd values of 1.5 x 10-7 
M and 6.0 x 10-7 M.94  In order to ensure that the substrate was bound to the calyx, β-LG 
was incubated with 2 equivalents of substrate and was stirred at 37 °C for two days prior 
to the addition of citral.  After two more days, the reaction mixture was extracted to find 
that the reaction had proceeded as normal.  For retinol, the isolated yield of cyclocitral 
was 19.3% and with β-ionone the overall yield for the reaction was 17.1%.  This data 
corroborates with that of the two day incubation with only citral and β-LG where the 
yield was 22%.  As a control, a β-LG solution was stirred for two days at 37 °C with no 
substrate.  After the two period, three equivalents of citral was added and the reaction 
was allowed to stir an additional two days.  The reaction yield was 21.5%. 
 
Sequence Comparison Amongst Similar Β-LGs 
 With the knowledge that K77 and K91 are likely responsible for the dimerization 
reaction, we looked at other β-LG sequences from other species to see if these two 
lysines were conserved.  A comparison of the amino acid sequences of 20 various β-LGs 
was performed by Sawyer et. al.46 in 2000 and based upon this only three other β-LGs 
had K77 and K91 conserved.  These included buffalo, goat, and sheep (Figure 27).  
44 
 
While bovine lactoglobulin is the smallest of these proteins, the homology to the other 
three is varied by only two amino acids.  The other proteins in the survey had amino acid 
substitutions at one of the sites or both amino acids modified.  These included β-LGs 
from cat, dog, horse, donkey, dolphin, pig, baboon, wallaby, kangaroo, and possum.46  
 
      Buffalo MKCLLLALGLALACGAQAIIVTQTMKGLDIQKVAGTWYSLAMAASDISLL 
      Cow B   ------------------MIVTQTMKGLDIQKVAGTWYSLAMAASDISLL 
      Goat    MKCLLLALGLALACGIQAIIVTQTMKGLDIQKVAGTWYSLAMAASDISLL 
      Sheep   MKCLLLALGLALACGVQAIIVTQTMKGLDIQKVAGTWHSLAMAASDISLL 
                                :******************:************ 
 
      Buffalo DAQSAPLRVYVEELKPTPEGDLEILLQKWENGECAQKKIIAEKTKIPAVF 
      Cow B   DAQSAPLRVYVEELKPTPEGDLEILLQKWENGECAQKKIIAEKTKIPAVF 
      Goat    DAQSAPLRVYVEELKPTPEGNLEILLQKWENGECAQKKIIAEKTKIPAVF 
      Sheep   DAQSAPLRVYVEELKPTPEGNLEILLQKWENGECAQKKIIAEKTKIPAVF 
              ********************:***************************** 
 
      Buffalo KIDALNENKVLVLDTDYKKYLLFCMENSAEPEQSLACQCLVRTPEVDDEA 
      Cow B   KIDALNENKVLVLDTDYKKYLLFCMENSAEPEQSLACQCLVRTPEVDDEA 
      Goat    KIDALNENKVLVLDTDYKKYLLFCMENSAEPEQSLACQCLVRTPEVDKEA 
      Sheep   KIDALNENKVLVLDTDYKKYLLFCMENSAEPEQSLACQCLVRTPEVDNEA 
              ***********************************************.** 
Figure 27.  Amino acid sequences for β-LGs from various species with conserved K77 
and K91. 
The SwissProt99 databank entries are: buffalo, P02755; cow, P02754; goat, P02756; sheep, 
P02757. 
   
 
Milk Promoted Biosynthesis of Cycloterpenals 
As previously mentioned, β-LG is able to survive the milk process even at 
elevated temperatures used during pasteurization (to kill bacteria).  We have clearly 
demonstrated that β-LG undergoes the self dimerization of β-methyl aldehydes to 
cycloterpenals, so why would not the milk we drink also perform this dimerization 
reaction?  In human blood, β-LG is present at concentrations of 0.7-1.2 g/dL.  For this 
experiment, we took store bought milks such as whole (also chocolate), 2%, skim, half 
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& half, buttermilk, and fresh cow’s milk and incubated it with excess citral for four days 
at 37 °C.  These milks were then treated with excess citral as the exact concentration of 
β-LG present in each could not be determined.  The color changes of the milks should be 
noted, especially in the case of skim milk, as it paralleled that seen with the β-LG 
solution (Figure 28).  The color of the milk changed from a normal milk white color to  
 
 
Figure 28.  Various milks incubated with citral for four days. 
From left to right: Fresh cow’s milk, skim, 2%, whole, chocolate, half & half, buttermilk. 
 
that of a dark yellow, possibly reflecting Schiff base formation.  The amount of fats, 
cholesterols, and sugars present in each milk sample could be affecting the amount of 
cyclocitral produced as the binding sites become occupied by small molecules.  The 
uptake of citral by other proteins present in the milks could also havd an effect on 
overall yields.  This is reflected in the isolated yields obtained for each of the milk 
reactions.    As seen in Figure 29, the reaction product was observed with skim, and 2%, 
whole milk.  Very little conversion was seen with buttermilk.  The highest yielding was 
that of skim milk with a calculated yield (based on the amount of citral added) of 14.4%.  
The 2% milk exhibited a yield of 7.3% while whole and buttermilk gave a 4.8% and 
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1.2% yield, respectively.  We were also able to detect cyclocitral in fresh cow’s milk but 
only when adding a larger excess of citral to the milk.  In the case of chocolate milk, the 
yield was comparable to that of whole milk with an isolated yield of 4.2%.  For half & 
half, no dimerization product was detected.   
 In order to ensure that no small metabolites were responsible for the dimerization 
of citral to cyclocitral, 200 mL of skim, 2%, whole, and buttermilk was passed through a 
Sephadex G25 column.  The flow through was then subjected to the exact same reaction 
conditions as used with the untreated milks.  The yields for each reaction were 
unchanged indicating that only β-LG in the milks were responsible for the formation of 
the cyclocitral product.     
 
 
Figure 29.  1H-NMR of cyclocitral being produced from store bought milk after four 
days.   
The two doublets at 9.85 and 9.95 correspond to citral and singlet at 9.38 is cyclocitral. 
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Synthesis of Retinal 
 In order to perform our in vivo rabbit study, we needed to secure a source of 
retinal.  We developed a synthetic scheme beginning with β-ionone with a five steps 
synthesis to generate all-trans-retinal (Scheme 10).  The first step was to generate a 
stock pile of β-ionylideneacetaldehyde (C-15 aldehyde), which is synthesized in two 
steps from β-ionone.  The C-15 aldehyde was then converted to all-trans-C-18 tetraene 
ketone 29 by utilizing an aldol condensation between acetone and β-
ionylideneacetaldehyde in the presence of 1.0 M sodium hydroxide.  This reaction gave 
us a yield of 92%.100  A Horner-Wadsworth-Emmons reaction was then performed on 
the methyl-ketone by treating it with an ylide solution generated by treatment of diethyl-
(cyanomethyl)-phosphonate with sodium hydride to give all-trans- C-20 β-methyl nitrile 
30 in an 88% yield.101,102  This C-20 nitrile was then reduced with diisobutylaluminum 
hydride to give all-trans-retinal 31 in an 86% yield.101,103-105 
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Scheme 10.  Synthetic route for retinal. 
 
 
In Vivo Study Utilizing New Zealand White Rabbits 
 We have demonstrated that cycloterpenal formation can occur with β-LG in vitro 
as demonstrated with isolated protein and the protein in various milks.  As cycloretinal 
has been isolated from the human eye,33,34 we set out to explore whether β-LG will form 
cycloretinal in vivo in a rabbit model.  It has been shown that intact β-LG readily passes 
through the intestinal transepithelium cells in the rabbit’s ileum.  The absorption of 
intact β-LG into the blood stream is through intracellular transfer.106,107  To do this, eight 
New Zealand White rabbits (2.5 kg) were randomly allocated to the control (basic diet) 
(n=1), β-LG/water control (n=1), skim milk control (n=1), retinal control (n=1), β-
LG/water + retinal (n=2), and skim milk + retinal (n=2).  Rabbits were fed twice daily 
for a period of one week their respective diets.  All of the rabbits had free access to a 
29 30 
31 
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standard rabbit diet and water.  β-LG/water was administered at 1.3 g/kg with the dosage 
of retinal being at 40 mg/kg for each feeding.  After seven days, the rabbits were 
exsanguinated and the blood was removed for subsequent analyses.  To probe for the 
formation of cycloretinal, the blood was extracted followed by characterization via 1H-
NMR and MS.  The control rabbit, with a normal diet, was used to ensure that no 
metabolites were in the aldehyde region of interest.  The positive control rabbits yielded 
no cycloretinal.  For the retinal feeding control, the substrate was absorbed into the 
blood stream with no cycloretinal present.  As for the feedings involving either a β-LG 
solution or skim milk with retinal, the opposite was observed.  We saw the in vivo 
formation of cycloretinal with each source.  We were also able to see to absorption of 
retinal into the blood stream of the rabbits as each extract contained isomers of retinal 
(Figure 30).   
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Figure 30.  1H-NMR overlay of rabbit feedings. 
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 To assess β-LG uptake in the blood of rabbits, we looked at the serum of bloods 
from the β-LG/water and skim milk controls and feedings against the negative control 
(standard diet).  A SDS-PAGE gel was ran with the serum (diluted 1:10) from each 
blood sample.  The gel (Figure 31) showed that the β-LG was readily absorbed into the 
blood stream of the rabbits as each sample contained a band corresponding to the β-LG 
control at approximately 18 kD.  However, the non-feeding control showed no traces of 
β-LG and looked like the other samples with the exception of the band at approximately 
18 kD. 
 
 
Figure 31.  SDS-PAGE gel of rabbit feedings. 
 
 
 With SDS-PAGE gel confirmation of β-LG uptake, we next proceeded to 
demonstrate that the protein in the blood could perform the reaction in vitro.  We took 
the β-LG/water control and the non-feeding control, 10 mL each, and incubated them 
with all-trans-retinal over a four day period at 37 °C.  After four days, the mixture was 
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extracted and assayed for cycloretinal production.  By 1H-NMR and MS, we observed β-
LG (isolated from blood) could still perform the reaction.  This experiment demonstrates 
the resiliency of β-LG.  It clearly survives the acid environment of the stomach and 
makes it into the blood stream of rabbits.  It leads one to speculate that it can survive in 
humans and make it way to eye where β-LG has been characterized in proteomic studies. 
 
 
 
Figure 32.  1H-NMR overlay of blood experiment. 
 
 
CONCLUSION 
The results in this chapter demonstrate that the major milk whey protein β-LG 
promotes the formation of cycloterpenals.  We have shown that the reaction is 
amendable to various β-methyl substrates with moderate yields.  The protein reaction 
was optimized and the mechanism of the reaction was probed with discovery of two 
lysines outside the central calyx of the protein being responsible for the dimerization.  In 
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vitro experiments were also carried out on store bought milks where the dimerization of 
citral into cyclocitral was observed in skim, 2%, whole, and buttermilk.  In vivo 
experiments were performed utilizing a rabbit model where the rabbits were fed sources 
of β-LG along with retinal which led to cycloretinal formation.  In order to prove that β-
LG can survive in the blood stream, the blood from the β-LG control rabbit was treated 
with retinal and cycloretinal was formed with the surviving protein.  With this in mind, 
β-LG has been characterized in the human eye along with cycloretinal.  The mechanism 
for this bis-retinoid formation has yet to be determined but it can be speculated that if β-
LG is present under the right conditions, then the formation of cycloretinal is possible. 
 
EXPERIMENTAL 
General 
Fresh THF was dried by passage through an MBRAUN solvent purification 
system and stored over molecular sieves.  All other solvents and reagents were 
purchased and used without further purification unless noted.  1H (300 MHz) and 13C (75 
MHz) spectra were recorded on a 300 MHz spectrometer.  Chemical shifts for 1H and 
13C NMR spectra are reported in ppm referenced to TMS (0 ppm) and coupling 
constants are reported in Hertz (Hz).  MS spectra were recorded on an API QSTAR 
PULSAR (ES) apparatus.  Chromatographic separations were achieved by flash silica 
chromatography (silica gel 60 mesh, EMD Biosciences).  Fluorescence measurements 
were recorded on a PTI QuantaMaster series spectrofluorometer.  HPLC separation were 
performed on a Varian ProStar system.  Retinal 31101,103,105 and intermediates 29100 and 
30101 have been previously synthesized and characterized.  Initial experiments were 
54 
 
carried out using β-LG from Sigma (L3908, St. Louis, MO, 90% β-LG).  The β-LG 
source that was used primarily for experimentation was obtained from Davisco Foods 
International, Inc. (JE-003-6-922, La Sueur, MN, 93.6% β-LG).  All cycloterpenals have 
been fully characterized previously.31,32 
 
Synthesis of Α,Β-Unsaturated Aldehydes 
α,β-unsaturated nitriles for the synthesis of the α,β-unsaturated aldehydes used to 
produce the cyclohexadienals were synthesized following literature protocols102 and 
purified by flash column chromatography (gradient of 2-10% ethyl acetate/hexanes).  
α,β-Unsaturated aldehydes were prepared by reduction of their corresponding nitriles 
and purified by flash column chromatography (2%-10% ethyl acetate/hexanes).104  
Farnesal was synthesized from farnesol.108  In each case, the all-trans isomer was 
utilized in the self-condensation reactions.   
 
Organisms 
Retinal Pigment Epithelium (RPE) cells (CRL-2302) and B. subtilis strain 6633 
were obtained from the American Type Culture Collection, Rockville, MD. The yeast S. 
cerevisiae wild-type strain [#404; BY4741; MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0] was 
obtained from Dr. Michael Kladde at the Department of Biochemistry, Texas A&M 
University. The E. coli strain DH10B was obtained from Prof. Dennis Gross, Texas 
A&M University, Department of Plant Pathology. 
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Media Conditions 
• LB (Luria-Bertani) medium contained the following components per liter:  Bacto-
peptone, 10g; Yeast extract, 5g; Sodium chloride, 5g; and deionized water. 
• YPD (Yeast Peptone Dextrose) medium contained the following components per 
liter:  Yeast extract, 5g; Bacto-peptone, 5g; Glucose, 20 g; and deionized water. 
• NB (Nutrient Broth) medium contained the following components per liter:  Beef 
extract, 3g; Peptone, 5g; and deionized water. 
Agar plates of the above media were prepared by adding 20 g/L bacto-agar.  All media 
were autoclaved at 121 °C for 20 minutes. 
 
RPE Cell Cultures 
A human adult RPE cell line (ARPE-19, ATCC) was maintained as stock cultures in BD 
Falcon (Catalog # 353003) 100 mm Cell Culture Dishes and was passaged weekly.  The 
medium used for cell propagation was an ATCC-formulated Dulbecco’s modified 
Eagles medium DMEM:F12 Medium (Catalog No. 30-2006) containg 10% fetal bovine 
serum (FBS, GIBCO, Catalog # 26140-079), propagated in a 5% carbon dioxide 
atmosphere at 37 °C.    
 
General Procedure for Β-LG Mediated Reactions 
 In a 1000 mL Erlenmeyer flask, 500 mL of a 1% β-LG solution (PBS, pH 7.0) 
and three equivalents of substrate (0.5 M in absolute ethanol, 1.630 mL) were mixed 
together.  This mixture was placed in a 37 °C shaker and stirred at 250 rpm for four 
days.  The β-LG mixture was removed and 500 mL of ethyl acetate was added along 
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with a magnetic stir bar and the mixture stirred for 30 minutes at room temperature to 
extract the product.  To avoid emulsions, the mixture was centrifuged at 9000 rpm at 4 
°C for 30 minutes.  The organic layer was collected, dried over anhydrous magnesium 
sulfate, and concentrated in vacuo.   
 
Heterodimer Formation Utilizing Β-LG  
In a 1000 mL Erlenmeyer flask, 500 mL of a 1% β-LG solution (PBS, pH 7.0) 
and one equivalent of citral and cinnamaldehyde (0.5 M in absolute ethanol, 0.543 mL 
each) were mixed together.  This mixture was placed in a 37 °C shaker and stirred at 250 
rpm for three and four days, respectively.  The β-LG mixture was removed and 500 mL 
of ethyl acetate was added along with a magnetic stir bar and the mixture stirred for 30 
minutes at room temperature to extract the product.  To avoid emulsions, the mixture 
was centrifuged at 9000 rpm at 4 °C for 30 minutes.  The organic layer was collected, 
dried over anhydrous magnesium sulfate, and concentrated in vacuo.  The crude material 
was subsequently purified via HPLC and products were characterized according to 
Bench et al.32 
 
PH Profile Experiment 
 To determine the optimal pH for the protein reaction, we looked at a range of 
pHs which included 1.0, 3.0, 5.0, 7.0, 9.0 and 11.0.  500 mL of PBS, pH 7.0, was either 
buffered with 1.0 M HCl or 1.0 NaOH to obtain the desired pHs using a Seven Easy pH 
meter (Mettler-Toledo, Switzerland, Product # Z654280).  Five grams of β-LG was then 
dissolved in each buffered PBS solution to give a 1% solution which was then treated 
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with three equivalents of citral (0.5 M in absolute ethanol, 1.630 mL).  This mixture was 
placed in a 37 °C shaker and stirred at 250 rpm for four days.  The β-LG mixture was 
removed, 500 mL of ethyl acetate was added along with a magnetic stir bar and the 
mixture was stirred for 30 minutes at room temperature to extract the product.  To avoid 
emulsions, the mixture was centrifuged at 9000 rpm at 4 °C for 30 minutes.  The organic 
layer was collected, dried over anhydrous magnesium sulfate, and concentrated in vacuo.   
 
Retinol/Β-ionone Competition Experiment 
 In a 1000 mL Erlenmeyer flask, 500 mL of a 1% β-LG solution (PBS, pH 7.0) 
and two equivalents of retinol or β-ionone (0.5 M in absolute ethanol, 1.086 mL) were 
mixed together.  This mixture was placed in a 37 °C shaker and stirred at 250 rpm for 48 
hours prior to the addition of two equivalents of citral (0.5 M in absolute ethanol, 1.086 
mL).  The reaction mixture was allowed to stir for the remaining two days.  The β-LG 
mixture was removed and 500 mL of ethyl acetate was added along with a magnetic stir 
bar and the mixture stirred for 30 minutes at room temperature to extract the product.  To 
avoid emulsions, the mixture was centrifuged at 9000 rpm at 4 °C for 30 minutes.  The 
organic layer was collected, dried over anhydrous magnesium sulfate, and concentrated 
in vacuo.   
 
Rate Determination of Β-LG 
 To ten 250 mL Erlenmeyer flasks, 100 mL of 1% β-LG (PBS, pH 7.0) was mixed 
with three equivalents of citral (0.5 M in absolute ethanol, 0.326 mL).  The solutions 
were placed in a 37 °C shaker at 250 rpm for 7, 12, 24, 48, 72, 97, 120, 149, 168, and 
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240 hours.  When each mixture was removed, 125 mL of ethyl acetate was added along 
with a magnetic stir bar and the mixture stirred for 30 minutes at room temperature to 
extract the product.  To avoid emulsions, the mixture was centrifuged at 9000 rpm at 4 
°C for 30 minutes.  The organic layer was collected, dried over anhydrous magnesium 
sulfate, and concentrated in vacuo.  All HPLC procedures used a Varian ProStar 230 
solvent delivery module.  Elution was monitored at 240 nm with a Varian ProStar 330 
Photodiode Array Detector.  Integrals were determined by using Star Workstation for the 
ProStar 330 diode array detector.  The stationary phase was a Phenomenex Luna 5µ 
silica column (250 x 10 mm, part # 00G-4274-N0, Torrance, CA).  The mobile phase 
was 100% dichloromethane at a flow rate of 3 mL/min.  Under this condition, cyclocitral 
eluted at 5.55 minutes.  The amount of cyclocitral was quantitated by comparing the 
integrated peak area to a calibration curve of the amount of pure cyclocitral injected onto 
the column versus the resulting integrated peak area.  This same procedure was 
performed for the addition of ten equivalents (1.087 mL) and fifty equivalents (5.435 
mL) of citral (0.5 M in absolute ethanol) to 100 mL of 1% β-LG. 
 
General Procedure for Heat Denaturation 
In a 1000 mL Erlenmeyer flask, 500 mL of a 1% β-LG solution (PBS, pH 7.0) 
was boiled for 10 minutes at 100 °C.  Once the solution was cooled to the touch, three 
equivalents of citral (0.5 M in absolute ethanol, 1.630 mL) was added to the protein 
solution.  This mixture was then placed in a 37 °C shaker and stirred at 250 rpm for four 
days.  The β-LG mixture was removed and 500 mL of ethyl acetate was added along 
with a magnetic stir bar and the mixture stirred for 30 minutes at room temperature to 
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extract the product.  To avoid emulsions, the mixture was centrifuged at 9000 rpm at 4 
°C for 30 minutes.  The organic layer was collected, dried over anhydrous magnesium 
sulfate, and concentrated in vacuo.   
 
General Procedure for Urea-Induced Denaturation 
In a 1000 mL Erlenmeyer flask, 500 mL of a 1% β-LG solution (PBS, pH 7.0) 
and ten equivalents of urea (0.5 M in absolute ethanol, 5.43 mL) were mixed together.  
This mixture was then placed in a 37 °C shaker and stirred at 250 rpm.  After two days 
of incubation, three equivalents of citral (0.5 M in absolute ethanol, 1.630 mL) was 
added to the protein solution and stirred for an additional four days. The β-LG mixture 
was then removed and 500 mL of ethyl acetate was added along with a magnetic stir bar 
and the mixture stirred for 30 minutes at room temperature to extract the product.  To 
avoid emulsions, the mixture was centrifuged at 9000 rpm at 4 °C for 30 minutes.  The 
organic layer was collected, dried over anhydrous magnesium sulfate, and concentrated 
in vacuo.   
 
General Procedure for Microbial Protein Controls 
Microbes were grown on their respective plates under appropriate conditions.  A 
single colony was picked and placed in a 3 mL culture and allowed to grow overnight 
before being transferred to a 500 mL culture.  After 24 hours, the culture was centrifuged 
and the cell pellet flash frozen with liquid nitrogen before being stored at -80 °C.  To 
lyse the cells, a Biospec Products Bead Beater (Biospec Products, Bartlesville, OK, 
Model 1107900) was utilized with 0.1 mm Glass Beads (Biospec Products, Bartlesville, 
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OK, Catalog # 11079101).  To the frozen cell pellets, PBS (pH 7.0) was added and ten 
30 second pulses with 1 minute intervals was performed to lyse the cells.  Prior to 
performing dimerization screens, a metabolite control was generated where 40 mL of the 
protein extract was extracted with 200 mL of ethyl acetate, dried with anhydrous 
MgSO4, and concentrated in vacuo.  A 1H-NMR spectrum was produced to ensure that 
there were no metabolites in the aldehydic region of interest.  Results were also 
confirmed by mass spectrometry.  Protein concentration was measured by Bradford 
assay (Biorad, Hercules, CA, Catalog # 26140-079) and diluted to a 1% solution with 
PBS buffer.  To establish whether crude protein extracts could support cycloterpenal 
formation, protein lysates were incubated with 0.5 M citral at 37 °C with shaking (250 
rpm) for 4 days.  As detailed previously, following incubation, the suspension was 
extracted with 300 mL of ethyl acetate, centrifuged, dried over anhydrous MgSO4, and 
concentrated in vacuo.   
 
RPE Cell Screen for Dimerization 
RPE cells were subcultured until a total of 10 plates (95% cell coverage) were 
obtained.  Cells were removed with 3 mL of a 0.05% (w/v) Trypsin- 0.53 mM EDTA 
solution (Gibco, Canada, Catalog # 25300-054) and placed in a 50 mL conical tube.  
Cells were pelleted for 20 minutes at 1000 rpm.  To remove traces of medium, the cells 
were washed twice with DPBS, 1X without calcium and magnesium (Cellgro, Catalog # 
21031187), and then resuspended in 10 mL of DPBS.  The cell suspension was then 
lysed utilizing a 50 mL dounce homogenizer.   Before a dimerization screen was 
performed, a metabolite control was performed where 5 mL of the protein lysate was 
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extracted with ethyl acetate (50 mL), dried with anhydrous MgSO4, and concentrated in 
vacuo.  A 1H-NMR was run to ensure that there were no metabolites in the aldehydic 
region of interest.  Protein concentration was measured by Bradford assay (Biorad, 
Hercules, CA, Catalog # 26140-079) and diluted to a 1% solution with PBS buffer.  To 
establish whether the crude protein extract could support cycloterpenal formation, 
protein lysates (10 mL) were incubated with 0.5 M citral at 37 °C with shaking (250 
rpm) for 4 days.  As detailed previously, following incubation, the suspension was 
extracted with 300 mL of ethyl acetate, centrifuged, dried over anhydrous MgSO4, and 
concentrated in vacuo.   
 
Dimerization Utilizing Store Bought Milks 
To demonstrate the dimerization with processed milks, skim milk, 2% milk, 
whole milk, buttermilk, and half and half were purchased.  We also looked at fresh 
cow’s milk.  The milks purchased contained approximately 8-9 grams of protein 
according to their labels.  Initial experiments were performed with 200 mL of milk taken 
from the carton and diluted with 300 mL of PBS (pH 7.0) with 2.20 mL (3.80 mL for 
fresh cow’s milk) of 0.5 M citral (in absolute ethanol) which was placed in a 37 °C 
shaker for 4 days being stirred at 250 rpm.  After this time, the solutions were extracted 
with 300 mL of ethyl acetate and stirred with a magnetic stirrer for 30 minutes.  The 
mixture was centrifuged for 30 minutes at 9000 rpm for 30 minutes at 4 °C.  The organic 
layer was removed, dried with anhydrous MgSO4, and concentrated in vacuo.   
To ensure that there were no small metabolites responsible for the dimerization, 
each milk was passed through a Sephadex G25 (GE Healthcare, Uppsala, Sweden, 
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Product # 17-0033-01) column by measuring out 20 g of the powder and suspending it in 
100 mL of PBS.  This slurry was then poured into a 5.08 cm x 60 cm column with 
porosity disc sealed in.  200 mL of milk was passed through the column by the addition 
of PBS until a total volume of 500 mL was obtained.  The filtered milk was retested 
using the same conditions as previously mentioned.  
 
In Vivo Study Utilizing New Zealand White Rabbits 
The following protocol (AUP#2008-70) was approved by the Texas A&M 
University Institutional Animal Care and Use Committee (IACUC).  Eight adult New 
Zealand White rabbits (2.5 kg, Myrtle’s Rabbitry, Thompsons Station, TN) were 
randomly allocated to the control (normal diet, n=1), β-LG/water control (n=1), skim 
milk control  (n=1), retinal control (n=1), β-LG/water + retinal (n=2), and skim milk + 
retinal (n=2).  All rabbits had free access to a standard rabbit diet and water.  The rabbits 
were housed separately in standard cages in the LARR facility at Texas A&M University 
and maintained under standard conditions.  Each day, the rabbits were provided the 
solutions by gavage twice daily for one week.  Each solution was administered in 50 mL 
volumes with the exception of the retinal feeding in which a volume of 1 mL was fed.  
The β-LG/water solutions were supplied at 1.3 g/kg in 50 mL of water.  The dosage of 
retinal used was 40 mg/kg dissolved in 150 µL of absolute ethanol.   
 After seven days, the rabbits were anesthetized with a solution containing 10 
mg/kg of ketamine with 3 mg/kg xylezine by intravenous injection allowing 5 minutes 
for the cocktail to take effect.  Depth of anesthesia was monitored prior to blood removal 
by squeezing the foot of the subject.  Cardiac blood was removed by opening the thorax 
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to visualize the heart before carrying out cardiac puncture, which also led to 
exsanguinition of the rabbit.  This process allowed us to obtain approximately 40-50 mL 
of blood from each subject.  The blood (40 mL) was then processed by extraction with 
ethyl acetate (300 mL) assisted by stirring with a magnetic stirrer for one hour.  This 
mixture was then centrifuged for 30 minutes at 9000 rpm for 30 minutes at 4 °C.  The 
organic layer was removed, dried with anhydrous MgSO4, and concentrated in vacuo.   
To assess β-LG content in the samples, bloods from the control (normal diet), β-
LG/water control, β-LG/water + retinal, skim milk control, and skim milk + retinal were 
centrifuged at 4000 rpm for 30 minutes at 4 °C to separate red blood cells from serum.  
After centrifugation, 1 µL of serum was diluted with 9 μl of PBS pH 8.0 and 10 μl of 2x 
SDS-PAGE Treatment Buffer (125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 0.2 mg/ml 
bromophenol blue, 0.2 mM DTT).  Samples were heated to 90°C for 10 min and 
electrophoresed on a 15% SDS-PAGE gel at 200V for 35 min.  Following 
electrophoresis, the gel was stained with Coomassie Blue to visualize protein bands.  
To see if the β-LG absorbed within the blood could perform the dimerization of 
retinal to cycloretinal, 10 mL of blood from the β-LG/water control and 10 mL of blood 
from the control were incubated at 37 °C with 400 mg (dissolved in 1 mL of absolute 
ethanol) of retinal for 4 days.  The blood was then processed by extraction with ethyl 
acetate (200 mL) where it was stirred with a magnetic stirrer for one hour.  This mixture 
was then centrifuged for 30 minutes at 9000 rpm for 30 minutes at 4 °C.  The organic 
layer was removed, dried with anhydrous MgSO4, and concentrated in vacuo.   
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KD Measurements 
 The Kd measurements were determined by utilizing the method set forth by Cho 
et al.61  Fluorescence was measured on a PTI QuantaMaster series spectrofluorometer.  
Substrate, 2 μL, (100 μM in absolute ethanol) portion was added to 2 mL of β-LG (1.2 
μM subunit concentration) in PBS (pH 7.0) and mixed for 30 seconds.  The tryptophan 
fluorescence was excited at 290 nm and was monitored at 334 nm at room temperature.  
The apparent dissociation constant, Kd’ of a single binding site was calculated by the 
Cogan et al. method.109  The following equation was utilized in the dissociation 
constants for our substrates. 
Poα = (Ro/n)(α/1-α) – Kd’/n 
where α is the fraction of free binding sites, Ro is the total substrate concentration, Po is 
the total protein concentration, and n is the apparent molar ratio of ligand to protein at 
saturation.  The value of α was calculated for every point on the titration curve using the 
following equation: 
α = (F  –  Fmin)/(Fo – Fmin) 
where F = (I/Io) represents the relative fluorescence intensity at a certain Ro, Fmin 
represents the fluorescence intensity upon saturation of all the apoprotein molecules 
(with a 3-fold molar excess of ligand), and Fo is the initial fluorescence intensity.  
Addition of more than 1 mole of substrate/mole of β-LG caused no further reduction in 
the tryptophan fluorescence.  
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Mass Spectroscopy for Reduction of Substrate to Β-LG 
Five reactions consisting of 1% β-LG (1 mL) were incubated with 4X citral (5.0 
x 10 -4 M, 4.35 µL)  and 10X NaCNBH3 (5.0 x 10-4 M, 10.9 µL) and placed in a 37 °C 
shaker (250 rpm) to give time points of 6, 24, 48, 72, and 96 hours.  At each time point, 
the mixture was removed and 2 x 75 µL passed through a Bio Rad Micro Bio-Spin P-30 
Tris chromatography column (Biorad, Hercules, CA, Catalog # 732-6233) to remove 
borate salts and excess substrate for a total volume of 150 µL.  Alternatively, another 
five reactions were setup but only incubated with 4X citral (5.0 x 10 -4 M, 4.35 µL).  At 
time points of 6, 24, 48, 72, and 96 hours, a 200 µL aliquot was removed and treated 
with 10X NaCNBH3 (5.0 x 10-4 M, 10.9 µL).  This mixture was heated at 50 °C for 30 
minutes prior to the removal of borate salts and excess substrate via a micro bio spin 
column.   
 β-LG was diluted to a final concentration of 0.1 mg/mL in 50 mM Ammonium 
Bicarbonate buffer.  This sample was reduced by adding dithiothreitol (DTT) to a final 
concentration of 5 mM followed by incubation at 60 ◦C for one hour.  Alkylation was 
performed by adding idoacetamide (20 mM final concentration) and the solution 
incubated at room temperature for ten minutes.  Trypsin was added at an enzyme to 
protein ratio of 1:50 (w/w) and digestion was carried out at 37 ◦C overnight.  A Hitachi 
High Technologies (Dallas, TX) NanoFrontier Liquid Chromatography Mass 
Spectrometer equipped with a nanoelectrospray ionization (nanoESI) source was used.  
200 ng of the resulting digest was loaded and Liquid chromatography (LC) separation 
was achieved using Grace Vydac C18 column (150 × 0.075 mm, 300 Å) (Deerfield, Il) 
at a flow rate of 200 nL min-1.  Peptides were eluted using a gradient of (A): 98% water, 
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2% acetonitrile, 0.1% formic acid versus (B): 98% acetonitrile, 2% water, 0.1% formic 
acid.  The gradient time table was as follows: 2% B for 5 min, 2-10% for 0.1 min, 10-
40% for 29.9 min, 40-60% for 10 min, 60-98% for 5 min, held at 98% for 6 min, 98-2% 
for 1 min, held at 2% for 13 min, for a total run time of 70 min.  The MS data was 
obtained on a linear quadrapole ion trap (LIT)-time-of-flight (TOF) mass spectrometer in 
positive ion mode (100-2000 Da) using a spray voltage of +2000 V and a micro channel 
plate (MCP) detector at +2100 V.  Mascot (www.matrixscience.com) was used to 
analyze the data.  Briefly, the raw data output was converted to a Mascot Generic File 
format and the data was searched against the Swiss Prot database with the following 
parameters.: 200 ppm peptide mass tolerance, +/- 0.5 Da fragment mass tolerance, 2 
missed cleavages allowed for, variable modifications of Carbamidomethyl, Citral on 
Lysine (266.20 Da residue mass), and cyclocitral (400.32 Da residue mass).  Tandem 
MS data was then interpreted manually using the NanoFrontier LD Data Processing 
program.  Figures were created by deconvoluting the observed masses to the +1 charge 
state and labeling b and y fragment ions. 
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CHAPTER III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF SELF-CONDENSATION 
CYCLOTERPENALS *              
INTRODUCTION 
 Carotenoids form an important class of biologically active molecules and play a 
critical role in energy transfer processes such as photosynthesis or photoprotection.  
Carotenoids, such as lycopene 8 (Figure 33), act as a class of anti-oxidants which are 
responsible for the scavenging of free radicals within the human body.17  For instance, 8 
is 100 times more effective in singlet-oxygen quenching than vitamin E 9.18  Lycopene 
also acts as in important intermediate in the biosynthesis of β-carotene.  β-carotene 10, 
another important carotenoid, can be enzymatically cleaved by a β-carotene 15,15’-
monooxygenase to form two retinals 11.19-21  Retinal 11 is important as it serves as the 
chromophore for the visual transduction cycle.22  11 can easily be oxidized to form 
retinol 12, which is better known as vitamin A.  The other important retinoid, retinoic 
acid 13, can be made from retinal 11 via a retinal oxidase. 23-26  These retinoids (Figure 
34) exhibit a variety of biological activities ranging from dermatological uses to cancer 
preventative agents, and are potent modulators of growth and differentiation.27-29  
Interestingly, 13 has been shown to differentiate embryonic stem cells into a neuron-like 
 
*Parts of this chapter are reprinted with permission from “Proline Promoted Synthesis of Ring-
Fused Homodimers:  Self-Condensation of α,β-Unsaturated Aldehydes.” Bench, B. J., Lui, C., 
Evett, C. R., Watanabe, C. M. H., 2006. Journal of Organic Chemistry, 71, 9458-9463, 
Copyright 2006 by American Chemical Society and from “Synthesis and Cellular Effects of 
Cycloterpenals:  Cyclohexadienal-Based Activators of Neurite Outgrowth.” Bench, B. J., Tichy, 
S. E., Perez, L. M., Benson, J., Watanabe, C. M. H., 2008. Bioorganic & Medicinal Chemistry, 
16, 7573-7581, Copyright 2008 by Elsevier Ltd. 
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Figure 33.   Structures of relevant carotenoids. 
 
phenotype.30   It has also been employed as a chemotherapeutic agent in the treatment of 
promyelocytic leukemia by causing terminal differentiation of the tumor cells.   
 
 
Figure 34.  Biologically active retinoids.   
 
Interestingly, condensation of all-E-retinal gives a C-40 ring-fused dimer 14 
(with a cyclohexadienal structural core) which is also known as cycloretinal.  This 
molecule, along with other bisretinoids, is believed to act as a contributor of age-related 
macular degeneration, the leading cause of blindness in the elderly.33,34  The self-
dimerization of citral has been suspected since the late 1890’s.35,36  The 1,2,4-
10 
9 
8 
11 
13 
12 
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trisubstituted structure 15 was definitively ascribed in 1932.37  Recently, citral dimer 
(cyclocitral) 15 was isolated from the North Sea bryozoans Flustra foliacea38,39 and  
 
 
O O O
 
Figure 35.  Structures of relevant homodimers.   
  
 
shown to exhibit antibacterial activity against Roseobacter sp. And Sulfitobacter sp. in 
an agar diffusion assay (100 µg resulted in a 0.5 and 1.0 cm zone of inhibition 
respectively).  Furthermore, incubation of the principal milk protein β-lactoglobulin with 
β-ionylideneacetaldehyde has been shown to result in cyclohexadienal formation of its 
corresponding C-30 homodimer 16 (Figure 35).40  While molecules with this structural 
scaffold are not unprecedented in nature, little is known regarding their biological 
function.   
 Over the past century, a variety of conditions have been used to develop facile 
synthetic routes to these self-condensation products.  The general synthetic strategy has 
involved the use of strongly basic conditions such as lithium diisopropyl amide 
(LDA),110 sodium hydride (NaH),111,112 potassium hydride (KH),33,34,36,113 potassium tert-
16 15 14 
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butoxide,113,114 and others.115-117  The problem with using these harsh basic conditions is 
that there is no degree of stereoselectivity.   
 Proline is a widely employed organocatalyst118,119 as it is readily available and 
inexpensive.120,121  It has been employed in a variety of asymmetric organic reactions 
including aldol,122-132 Diels-Alder,133-138 and Michael addition,126,139-144 among many 
others.120,121 
In this chapter, we fully investigate the use of L-proline as a chiral auxiliary to 
catalyze asymmetric self-condensation of a variety of α,β-unsaturated aldehydes.87  The 
scope of the reaction is investigated with 13 β-methyl substituted substrates (and 1 β-
ethyl substituted substrate (Figure 36).  Seven proline/proline-based catalysts and the 
reaction conditions were optimized.  NMR and MS analyses as well as reactions with 
various proline derivatives also provide mechanistic insight into the reaction.  In order to 
address the biological activity of this homodimer library, we tested it against PC12 cells 
where promising effects on neurite outgrowth were observed.  We also screened the 
library for cytotoxic effects with an array of assays including Jurkats (human T-cell 
leukemia), yeast (Saccharomyces cerevisiae), and two bacterial strains (Escherichia coli, 
Bacillus subtilis). 
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Figure 36.  Chemical structures of the homodimer cycloterpenals-based compound 
library. 
 
RESULTS AND DISCUSSION 
Optimization of Homodimer Synthesis 
 Initially, we optimized conditions for these reaction (varying the temperature and 
substrate to catalyst ratios), utilizing citral 15 as a model substrate and L-proline to 
implement the reaction (Scheme 11).  Reactions mediated with other amino acids (Trp, 
 
Scheme 11.  General reaction scheme for homodimer production.   
 
39 41 
35 
37 
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40 36 
38 
33 
32 
14 
16 15
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His, Arg, Gly, and Ile) either fail or proceed to a lesser extent than proline.87  Product 
yields were highest when the reactions were carried out at room temperature versus -20 
to 0 °C or 50-100 °C.  Cyclocitral (15) is typically isolated as the sole product in a 65% 
yield following 16-24 hours of incubation at room temperature using L-proline in 
ethanol (Table 6).  This is in contrast to treatment of citral with NaH, which gives a 
mixture of the desired cyclocitral (15) along with a tetra-substituted cyclohexadienal 
(15a) in a 5:95 product ratio (Figure 37).111  When the temperature is decreased (-20 to 
0 °C), the reaction is sluggish and yields diminish to less than 5%.  The majority of the 
starting  
 
O O
NaH
dry ether O+
 
Figure 37.  Products formed by treatment of citral with NaH. 
 
 
material remains as a Schiff base at 48 hours.  On the contrary, when the temperature is 
increased, many unidentified byproducts begin to form within 1 hour and cyclocitral is 
obtained in less than 10% yield at 16 hours.  Varying the substrate to auxiliary agent (L-
proline) ratios also had a dramatic effect on reaction yields.  We evaluated six different 
substrate-to-catalyst mol ratios:  1:0.5, 1:1, 1:1.25, 1:1.5, 1:1.75, and 1:2, respectively, 
whereby 1:1.5 molar concentrations exhibited the highest conversion rates (65%).  At 
1:0.5, 1:1, and 1:1.25 concentrations, the yields were <5%, 27%, and 42%, respectively.  
15 15a
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Likewise, at higher proline concentrations, yields were diminished to 37% (1:1.75) and 
35% (1:2). 
 
Synthesis of Homodimers Utilizing L-proline 
 Various substrates were tested utilizing these optimized conditions to investigate 
the generality of the reaction as illustrated in Table 6.  Product yields ranged from 42% 
to 89% and ee values from 26% to 62%.  Treatment of retinal (14) and β-
ionylideneacetaldehyde (16) with ethanolic proline gave correspondingly higher yields 
than those originally reported, and yields are provided for the reaction with 
senecioaldehyde (37) and citral (15) that were not previously provided.87  The new 
substrates examined included those of small aromatics such as thiophene (32), chloro-
thiophene (33), methyl-furan (34), and phenyl (35).  We also looked at starting materials 
that contained aliphatic alkyl substituents (36 and 38), as well as bulky substituents such 
as biphenyl (39), fluorene (40), and naphthalene (19).  Interestingly, the thiophene-
substituted aldehyde (33) gave an unexpectedly lower yield than the methyl-furan-
substituted (34) but gave a correspondingly higher ee.  When the halogenated chloro-
thiophene (33) was tested, the yield was slightly higher than that of 32 with relatively 
equivalent ee values.  The phenyl-substituted α,β-unsaturated aldehyde (35) gave a 
moderate yield of 50% and an ee of 56%.  Modest yields were obtained with the alkyl 
substituted 3-methyl-2-nonenal (36) and farnesal (38), presumably attributed to the 
flexibility of the groups versus the more rigid conjugated long chain  substituents (14 
and 16) where the highest yields were observed.  We expected the biphenyl (39),  
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Table 6.  Effects of various substrates on proline promoted homodimerization. 
 
 
Ra Number yield (%)b ee (%)c 
 
 
14 89 52 
 
 
15 65 50 
 
 
16 87 62 
 
 
32 47 40 
 
 
33 51 44 
 
 
34 60 26 
 
 
35 50 56 
 
 
36 73 54 
 
 37 42 51 
 
 
38 52 46 
 
 
39 62 46 
 
 
40 57 42 
 
 
41 66 40 
 
aReaction conditions: 1 equiv of aldehyde and 1.5 equivs of L-proline dissolved in 
ethanol and stirred at room temperature for 16-24 hours. bIsolated yield.  cDetermined by 
Pr(hfc)3 chiral shift reagent. 
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fluorene (40), and naphthalene (41) substituents to result in low transformation 
efficiencies due to steric hindrance which could be attributed to the bulkiness of the side 
chains.  However, product yields were remarkably good when compared to others with 
yields of 52%, 62%, and 57% respectively.  Circular dichroism (CD) analysis (Figure 
38) of the menthylhydrazone derivatives of the C-30 dimer (formed through 
dimerization of 16) suggests that the absolute configuration  of the major isomer formed 
in these L-proline mediated reactions is the S-configuration as determined by the 
quadrant rule (chiral excitation theory).145 
 
 
 
Figure 38.  CD spectra of menthylhydrazone derivatives. 
RS 
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Use of Proline Derivaties on Dimerization 
 Since the reaction appeared amenable to a variety of different substrates, we 
analyzed various proline derivatives to determine their effects on the enantioselectivity 
of the reaction.  Previous work has shown that the reaction can be promoted by trans-4-
hydroxy-L-proline, D-proline, and cis-4-hydroxy-D-proline.87  Citral (15) was reacted 
with six different proline derivatives including L-proline methylester (42),146 iso-propyl 
ester (43),146 benzyl ester, (44),146 prolinol (45),147 diethyl prolinol (46),147 and biphenyl  
 
Table 7.  Effect of proline derivatives on homodimerization. 
 
R groupa catalyst yield (%)b time (h) ee (%)c
 
42 38 5 n/a 
 
 
43 43 34 n/a 
 
44 72 33 n/a 
 
 
45 78 23 13.4 
 
46 57 18 15.5 
 
47 49 30 14.8 
aReaction conditions: 1 equiv of aldehyde and 1.5 equivs of L-proline dissolved in ethanol and 
stirred at room temperature for 16-24 hours. bIsolated yield.  cDetermined by Pr(hfc)3 chiral shift 
reagent. 
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prolinol (47) (Table 7).  To our disappointment no stereoselectivity was observed, which 
was the case for the esters (42-44) that were synthesized.  The highest selectivity was 
obtained with α,α-diethyl prolinol (46), which gave an enantiomeric excess of 15.5%  
Reaction yields were moderate with the exceptions of the benzyl ester (44) and prolinol 
(45), which generated yields similar to that of L-proline.  Solvent effects on citral 
dimerization were also examined with prolinol (45); THF, DMSO, DMF, and 2-propanol 
were each examined, but no improvement on enantiomeric selectivity was observed.  As 
with the proline-assisted reaction, ethanol generated the highest yield of 78%.  
Reaction Mechanism for Homodimerization 
 The proline promoted reaction is thought to commence by nucleophilic 
attack of the aldehyde with proline, resulting in the formation of a Schiff base 48 
(Figure 39).  Tautomerization, invoked by deprotonation of the β-methyl group, gives 
the β-methylenic proline adduct 49 that can be visualized to dimerize with 48 following 
a Diels-Alder or Michael-like imine addition mechanism (pathway marked with green 
arrows).  During the Michael-like imine addition, intermediate 50 is generated and 
undergoes cyclization into reaction intermediate 51 (direct intermediate from Diels-
Alder mechanism).  From the di-proline intermediate 51, the proline attached at C-4 of 
the cyclohexene ring readily dissociates leaving the cyclohexadiene intermediate 52.  
Intermediate 52 then undergoes hydrolysis to give the 1,2,4-trisubstitued 
cyclohexadienal product 53.    
78 
 
The need for 1.5 equivalents of chiral auxiliary (L-proline) in the reaction 
mixture is that is it is necessary to convert all of the starting aldehyde to that of the 
Schiff base (accounting for 1 equivalent of L-proline), while the additional 0.5  
 
 
 
Figure 39.  Proposed routes to the synthesis of 1,2,4-trisubstituted cyclohexadienals.  
 
equivalents is needed to deprotonate the β-methyl group.  In support of this mechanism, 
many of the proline derivatives listed in Table 7 were capable of catalyzing the reaction 
in similar yields to that of L-proline.  Therefore, proton abstraction is not an 
intramolecular process involving the proline carboxylate.  Additionally, while proline 
52 53 
50 51 
49 49 
48 48 
Diels Alder Imine Addition 
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derivatives have been reported to give modest improvements in enantioselectivity over 
proline itself.120,121 in our case no improvement was observed.  Hence, the reactive 
center might be too remote for these derivatized proline chiral auxiliary agents to impart 
much of an impact.  This in turn would suggest that the reaction likely proceeds through 
imine addition versus a Diels-Alder based mechanism.111,112,114-117  The Diels-Alder 
approach involves the enamine and γ-positions of the diene in a more concerted type 
mechanism generating reaction intermediate 51 (Figure 39).  On the contrary, the 
Michael-like imine addition involves only the γ-position, a remote carbon center of the 
cis-diene.  The effect of the chiral auxiliary should be quite pronounced if the reaction 
followed a Diels-Alder reaction pathway.  In further support of this notion, previous 
reports of proline-assisted Michael additions, where effects on ee values were observed, 
have involved addition by the α-position of the donor molecule (Figure 40).126,139-144  In 
our case, we are two carbon atoms removed (addition occurs with the γ-carbon of the 
donor molecule) and the chiral auxiliary is too far removed to elicit an effect. 
 
Detection of Reaction Intermediates 
 To provide additional experimental evidence for our proposed mechanism, we 
performed a time course analysis of this proline-assisted dimerization reaction by NMR 
and MS.  The two experiments that were performed were with retinal for detection of 
reaction intermediates during the formation of 14 (requires addition of triethylamine) 
and citral to detect the formation of 15 (readily deprotonates with excess L-proline).  The 
results for the dimerization of cycloretinal are provided here (Figure 41) while the 
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Figure 40.  Schematic diagram depicting Michael donor and acceptor interactions. 
 
 
results for citral can be found in the appendices for this chapter.  After retinal and proline 
were mixed in a NMR tube, an immediate scan (2 minutes) revealed formation of the 
Schiff base (54), giving both cis and trans isomers (α-carbon to the protonated imine) at 
8.90 and 8.80 ppm, respectively.148  After 9 minutes, two new pairs of peaks began to 
appear corresponding to cis/trans isomers at 9.01 and 9.11 ppm, respectively.  We 
thought that it might correspond to the di-proline intermediate 55 but the C-6 proline 
readily dissociates to give intermediate 56.  Reaction intermediate corresponds to the 
new doublets being formed after 9 minutes.  While full characterization of 56 could not 
be obtained due to convolution of the spectra, two additional pairs of doublets (7.25 and 
7.57 ppm) were detected, corresponding to the coupled cyclohexadiene ring protons.   
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Figure 41.  Time course analysis of retinal homodimerization by NMR. 
 
 
Coupling of the protons was confirmed by H,H-COSY.  Retinal was fully consumed by 
a time of 1 hour and 20 minutes postinduction with intermediates 54 and 56 remaining, 
providing evidence that the condensation reaction occurs between two proline adducts 
(Figure 39, condensation between 48 and 49) as opposed to one proline adduct and one 
free floating aldehyde.  After 3 hours, all of the retinal is consumed so triethylamine (1 
equivalent) was added to facilitate dimer formation.87  Traces of the cycloretinal product 
were apparent by 4 hours.  Mass spectral analysis of the reaction was performed at four 
time points (30 minutes, 1 hour 30 minutes, 2 hours 30 minutes, and 4 hours and 
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Scheme 12.  Reaction intermediates for the formation of cycloretinal. 
 
 
30 minutes).  The data points were consistent with the NMR results (Figure 42, reaction 
progression at 2 hours 30 minutes), showing detection of both the Schiff base 54 and 
intermediate 56 (Scheme 13).  In the case for citral, similar results are observed with the 
exception of triethylamine needing to be added in order to facilitate the dimer formation.  
Formation of Schiff base 57 was observed just as in retinal while the bi-proline 
Retinal 54 
56 
55 
14 
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intermediate 58 was not observed.  Reaction intermediate 59 was characterized just as in 
the retinal reaction leading to formation of cyclocitral 14.  NMR and MS experiments 
paralleled those observed with retinal. 
 
 
 
Figure 42.  Mass spectra of cycloretinal intermediates.   
Mass spectral peaks (M + Li) observed at 2h 30 min. post induction: (top) Schiff base 54 
(388.2812 amu) and (bottom) intermediate 56 (654.5181 amu). 
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Scheme 13.  Reaction intermediates for the formation of cyclocitral. 
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Deuterium Exchange Experiments for Kinetic Isotpe Effects 
 Additionally, we synthesized a benzylidene nitrile 60 which we then reduced to a 
β-methyl substituted benzylidene aldehyde 61 in deuterated form with the intent of 
measuring a kinetic isotope effect for the homodimerization reaction (Scheme 14).  
However, a deuterium exchange experiment revealed significant solvent exchange by the 
reaction.  Citral was reacted with L-proline in deuterated methanol and cyclocitral 15 
was examined by both MS and NMR.  MS analysis revealed the presence of cyclocitral 
15 labeled with at least one and up to a possible 10 deuteriums atoms being exchanged 
(Figure 43).   
57 
58
59
15 
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Scheme 14.  Synthesis of benzylidene aldehyde. 
 
O a
a) 1 equiv. C6H12NO3P, 1 equiv. NaH, RT
b) 1 equiv. DIBAL
bCN O
D D
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D D
D
D D
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Figure 43.  Citral mass spectra. 
Mass spectra (Top) of natural cyclocitral and (Bottom) of deuterated cyclocitral 15.  Each m/z is 
(M+Li). 
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NMR analysis/integration of the peaks numbering scheme (Figure 44) confirmed the 
incorporation of deuterium at the aldehyde position as well as at C-3, C-3’, C’3”, C-5, C-
7, C-1” (Table 8 and Table 9).  Two different sets of peaks were integrated with the 
percent deuterium incorporated values being relatively consistent.  For example, at C-3, 
a value of 43.30% is observed with the hydrogen’s on C-5’, 6’, 5”, and 6” being 
integrated with an integral of 1200 being used.  This value is used because we used an 
integral of 100 for each proton attached to the carbon (Table 8).  When we used an 
integral of 100 for the hydrogen on C-2, a percent deuterium incorporated value of 
43.06% was calculated (Table 9).  The significant exchange observed during the course 
of this reaction hinders our ability to measure a kinetic isotope effect. 
 
O1
2
34
5
6 71''
2''3''
4''5'' 6''
1'
2'
3'
4'
5'
6'
 
Figure 44.  Numerical notation of citral homodimer 15. 
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Table 8.  Hydrogen/Deuterium integrations for cyclocitral. 
Integrated at 1H 5', 6', 5", and 6" (Integral=1200). 
Carbon  1H (ppm) Deuterated (D) 
Natural 
(N) 
% total 
hydrogen 
((D/N)*100%) 
% 
deuterium 
incorporat
ed  (100-
%total 
hydrogen)
CHO 9.41  50.37 84.53 15.47 
1  42.58    
2 6.67 41.12 41.29 99.59 0.41 
3 5.92 31.99 56.42 56.70 43.30 
4      
5a 2.36 66.22 105.17 62.96 37.04 
5b 2.02 108.99 123.39 88.33 11.67 
6      
7 1.19 138.97 177.44 78.32 21.68 
1', 2' 2.18 263.62 267.32 98.62 1.38 
3',3" 5.04-5.09 196.45 224.49 87.51 12.49 
4'      
5', 6', 5", 6" 1.51-1.72 1200.00 1200.00 100.00 0.00 
1"a, 2"a, 2"b 1.74-1.94 228.27 286.27 79.74 20.26 
1"b 1.31-1.41 234.41 538.43 43.54 56.46 
4"      
 
Effects on Neurite Outgrowth and General Cytotoxicity 
 Given the demonstrated ability of retinoic acid and its analogs to modulate 
growth and cellular differentiation and the ability of a milk whey protein to generate 
cyclo-β-ional, the cycloterpenal-based library of compounds was evaluated for their 
ability to stimulate neurite outgrowth in a PC12 assay.  PC12 cells are a pluripotent cell 
line that was originally cloned in 1976 from a transplantable rat pheochromocytoma and 
exhibits the ability to differentiate into neurons.  The PC12 assay is a widely 
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implemented method of identifying compounds that promote neurite outgrowth or 
survival.149 
Table 9.  Hydrogen/Deuterium integrations for cyclocitral at proton 2.  
Integrated at 1H 2 (Integral=100). 
 
Carbon  1H (ppm) Deuterated (D) 
Natural 
(N) 
% total 
hydrogen 
((D/N)*100%) 
% 
deuterium 
incorporat
ed  (100-
%total 
hydrogen)
CHO 9.41 103.57 121.99 84.90 15.10 
1      
2 6.67 100 100.00 100.00 0.00 
3 5.92 77.8 136.63 56.94 43.06 
4      
5a 2.36 161.06 254.70 63.24 36.76 
5b 2.02 265.07 298.85 88.70 11.30 
6      
7 1.19 337.99 429.74 78.65 21.35 
1', 2' 2.18 641.14 647.38 99.04 0.96 
3',3" 5.04-5.09 477.79 543.68 87.88 12.12 
4'      
5', 6', 5", 6" 1.51-1.72 2918.47 2926.21 99.74 0.26 
1"a, 2"a, 2"b 1.74-1.94 555.16 693.29 80.08 19.92 
1"b 1.31-1.41 570.1 1304.00 43.72 56.28 
4"      
 
 
 The PC12 cells were plated onto collagen Type IV plates at 10,000 cells /well, 
allowed to adhere for 24 hours, followed by the addition of compound at concentrations 
of 100, 10, and 1 μg/mL, respectively.  The cells were monitored over a period of two 
weeks, where the most pronounced effects were observed at about one week of 
exposure.  From our library of cyclohexadienals, one homodimer (36) was able to 
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successfully stimulate neurite outgrowth (Figure 45).  Therefore, neurite outgrowth 
activity appears to be associated with hydrocarbon chains. 
To assess the degree to which stereochemistry dictates phenotype in the neurite 
outgrowth assay, the homodimer was derivatized into a  menthylhydrazone derivative150 
to allow separation of the stereoisomers by HPLC (Scheme 15).  Following HPLC 
purification, the compounds were each hydrolyzed giving each aldehyde in 
enantiomerically pure form.  Upon reanalysis in the PC12 assay, the R-configuration was 
shown to be responsible for neurite outgrowth activity while the S-configuration 
exhibited no activity (Figure 46).   
 
 
 
Figure 45.  Stimulation of neurite outgrowth. 
(A) Control, cells treated with absolute ethanol; (B) 3-Methyl-2-nonenal homodimer; 1 μg/mL at 
5 days.  
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Scheme 15.  Isolation of stereoisomers. 
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As cyclocitral 15 has been reported to possess antibiotic activity,39,88,151,152 we also 
surveyed our cyclohexadienal library of compounds against bacterial strains 
(Escherichia coli and Bacillus subtilis) and yeast (Saccharomyces cerevisiae).  All 
compounds were tested at three concentrations, 100, 10, and 1 µg/mL.  For the 
homodimer library, moderate to no inhibition was observed, where compounds exhibited 
MIC values >100 µg/mL.    Against Jurkats, a human T-cell Leukemia cell line, the 
effects were again moderate for the compounds tested. 
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Figure 46.  Stimulation of neurite outgrowth by homodimer stereoisomers. 
(A) Control, cells treated with absolute ethanol; (B) R-3-methyl-2-nonenal homodimer, 10 
μg/mL at 6 days; (C) S-3-methyl-2-nonenal homodimer, 10 μg/mL at 6 days;   
 
 
CONCLUSION 
The results in this chapter demonstrate the use of L-proline to promote asymmetric self-
condensation of α,β-unsaturated aldehydes to form trisubstituted cyclohexadiene 
products.  Reaction conditions are mild and yet amendable to a variety of different 
substrates, yielding molecules with complex scaffolds from simple precursors.  
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Mechanistic hypotheses are presented involving condensation between two proline 
adducts through either a Diels-Alder or Michael-like imine addition.  The progress of the 
reaction was monitored in time course analyses by NMR and MS, providing evidence 
for the intermediacy of Schiff base (48) and protonated imine (52).  Moreover, these 
experiments revealed the complete loss of starting aldehyde during the reaction in 
support of a two proline adduct-based mechanism.  Additionally, investigations with 
various proline derivatives gave similar yields to that of L-proline, suggesting that 
deprotonation and activation of the β-methyl group to give (49) is an intermolecular 
process and does not involve the proline carboxylate of the Schiff base (48).  The 
moderate ee values exhibited by these proline chiral auxiliaries suggest that the reaction 
likely proceeds through imine addition versus a Diels-Alder based mechanism since a 
Diels-Alder would involve two reaction centers, the enamine and γ-positions of the diene 
(Figure 39), while imine addition would only involve the γ-position, a remote carbon 
center, of the cis-diene.  The phenotypic effects of this library of homodimers were 
examined in a PC12 assay where dramatic effects were observed on neurite outgrowth.  
These results suggest that molecules with this cyclohexadienal motif might have 
applications in neurite regeneration, which plays a significant role in the treatment of 
neurodegenerative diseases or central nervous system injuries. 
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EXPERIMENTAL 
General 
Fresh THF was dried by passage through an MBRAUN solvent purification 
system and stored over molecular sieves.  All other solvents and reagents were 
purchased and used without further purification.  1H (300 MHz) and 13C (75 MHz) 
spectra were recorded on a 300 MHz spectrometer.  Chemical shifts for 1H and 13C 
NMR spectra are reported in ppm referenced to TMS (0 ppm) and coupling constants are 
reported in Hertz (Hz).  MS spectra were recorded on an API QSTAR PULSAR (ES) 
apparatus.  Infrared (IR) spectra were recorded with a FT-IR spectrometer.  
Chromatographic separations were achieved by flash silica chromatography (silica gel 
60 mesh, EMD Biosciences).  The nitrile, 3-phenyl-but-2-enenitrile, and aldehydes, 3-
phenyl-but-2-enal and farnesal have been reported previously.  All-trans retinal, citral, 
and senecioaldehyde used in preparation of dimers 14, 15, and 37 were each purchased 
from Aldrich. 
 
Organisms 
PC12 neuronal cells (CRL 1721) and B. subtilis strain 6633 were obtained from 
the American Type Culture Collection, Rockville, MD. The yeast S. cerevisiae wild-type 
strain [#404; BY4741; MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0] was obtained from Dr. 
Michael Kladde at the Department of Biochemistry, Texas A&M University. The E. coli 
strain DH10B was obtained from Prof. Dennis Gross, Texas A&M University, 
Department of Plant Pathology. 
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Media Conditions 
• LB (Luria-Bertani) medium contained the following components per liter:  Bacto-
peptone, 10g; Yeast extract, 5g; Sodium chloride, 5g; and deionized water. 
• YPD (Yeast Peptone Dextrose) medium contained the following components per 
liter:  Yeast extract, 5g; Bacto-peptone, 5g; Glucose, 20 g; and deionized water. 
• NB (Nutrient Broth) medium contained the following components per liter:  Beef 
extract, 3g; Peptone, 5g; and deionized water. 
Agar plates of the above media were prepared by adding 20 g/L bacto-agar.  All media 
were autoclaved at 121 °C for 20 minutes. 
 
Neurite Outgrowth Assay 
PC12 cells were maintained in 100 mm Collagen Type IV dishes at 37 ˚C in a 
5% CO2/air temperature.  The cell culture medium consisted of RPMI 1640, with 10% 
heat-inactivated horse serum and 5% fetal bovine serum in a 10 mL volume.  Cells were 
removed from the culture flasks by flushing with fresh culture medium.  Cells were then 
transferred to a 15 mL falcon tube and centrifuged for 15 min. at 1000 rpm.  The 
medium was removed and the cells were resuspended in fresh culture medium.  The cells 
were counted with a hemocytometer and replated in a 96 well Collagen Type IV plate at 
10,000 cells/well with enough fresh medium to bring the volume to 200 μL.  The cells 
were allowed to adhere for 24 h prior to the addition of compound.  Each 
cyclohexadienal compound was examined at three concentrations in duplicate, to give 
final concentrations of 100, 10 and 1 μg/mL respectively.  Each well was visually 
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monitored over a period of 2 weeks for neurite outgrowth and intercellular connections.  
Only fresh medium was added when necessary.  Photographs were taken with an 
Olympus SP-310 camera equipped with a modified lens piece that fits over the 
microscope eyepiece. 
 
Cytotoxicity Assay Against Jurkat Cell LIne 
Jurkat cells were maintained in 75 cm2 culture flasks at 37 ˚C under a 5% CO2 
atmosphere.  The cell culture medium consisted of RPMI 1640 with 10% fetal bovine 
serum.  Cells were harvested by centrifugation (20 min. at 1000 rpm), resuspended in 
fresh culture medium and counted on a hemocytometer.  The cells (1 mL) were arrayed 
(200,000 cells/well) in 48 well plates to which compound was added to give final 
concentrations of 100, 10 and 1 μg/mL respectively.  Cells were incubated for 24 h, 
transferred to 1.5 mL eppendorf tubes and centrifuged for 15 min. at 14,000 rpm.  The 
medium was removed and the cell pellet resuspended in 1 mL of phosphate buffer saline 
(PBS) to wash the cells.  The cells were again centrifuged for 15 min. at 14,000 rpm.  
The PBS was removed and the cell pellet resuspended in a lysis buffer (CyQuant Cell 
Proliferation Kit).  The stock solution, 20X, should be diluted to a final concentration    
1X with an 80 fold dilution of propidium iodide (Molecular Probes, P3566) in order to 
visualize 200,000 cells/well.  The total volume prepared should be enough for entire 
assay.  The lysed cells were then placed in a black 96 well plate and analyzed using a 
Bio-Tek fluorometer to measure relative fluorescence. 
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Anti-bacterial and Anti-fungal Assays 
Microbes (Saccharomyces cerevisiae, Escherichia coli, and Bacillus subtilis 
6633) were cultured and maintained on agar plates (see supplemental material for media 
conditions).  A single colony was used to inoculate 3 mL of culture medium and allowed 
to grow for 16 h.  The cells (500 μL) were diluted with 50 mL of fresh medium to an 
O.D. of 0.1 and aliquoted into a 96-well plate (100 µL/well).  The assays were set up in 
duplicate and the compounds tested to give final concentrations of 100, 10 and 1 μg/mL.  
Plates were incubated (E. coli and B. subtilis, 37 °C; yeast, 30 °C) and shaken (250 rpm) 
for 16 h and cell density (O.D.) measured with a Bio-Tek microplate reader.   
 
Synthesis of Α,Β-Unsaturated Nitriles 
Nitriles for the synthesis of the α,β-unsaturated aldehydes used to produce the 
cyclohexadienals were synthesized following literature protocols102 and purified by flash 
column chromatography (gradient of 2-10% ethyl acetate/hexanes).   
 
Characterization of Α,Β-Unsaturated Nitriles 
 
CN
3-Methyl-5-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2,4-
dienenitrile (62):153 Yield:  94%   
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1H NMR (300MHz, CDCl3, 25°C), δ:  6.54 (d, 1H, J = 16.2 Hz), 6.11 (d, 1H J = 16.2 Hz,), 
5.06 (s, 1H), 2.16 (d, 3H, J = 0.6 Hz,), 1.980-2.03 (m, 2H), 1.67 (d, 3H, J = 0.9 Hz,), 1.54-
1.62 (m, 2H), 1.41-1.46 (m, 2H), 1.01 (s, 6H). 
13C NMR (75 MHz, CDCl3, 25°C) δ: 157.1 (C), 136.1 (C), 135.6 (CH), 132.9 (CH), 130.2 
(C) 117.9 (C), 96.6 (CH), 39.6 (CH2), 34.3, (C), 33.3, (CH2), 29.0 (2 x CH3), 21.8 (CH2), 
19.2 (CH3), 16.5 (CH3) 
IR (neat) ν 2925, 2855,2210, 1738, 1614,1585, 1455, 1375, 1365, 1217, 966 cm-1  
HRMS (ESI) for C15H21NLi (M+Li)+: calcd 222.1834, found 222.1828. 
 
S CN
3-Thiophen-2-yl-but-2-enenitrile (63):154  Yield:  83% 
1H NMR (300MHz, CDCl3, 25°C), δ: 7.32 (dd, 1H, J = 1.2, 5.1 Hz), 7.22 (dd, J = 1.2, 1H 
3.6 Hz), 7.00 (dd, J = 3.9, 1H, 5.1 Hz), 5.5 (d, 1H, J = 1.2), 2.34 (d, 3H, J = 1.2 Hz). 
13C NMR (75 MHz, CDCl3, 25°C) δ: 152.27 (C), 142.03 (C), 128.83 (CH), 128.70 (CH), 
128.12 (CH), 117.82 (C), 93.01 (CH), 20.13 (CH3) 
IR (neat) ν 3054, 2925, 2852, 2212, 1736, 1596, 1425, 1265, 705, 703 cm-1  
HRMS (ESI) for C8H7NSLi (M+Li)+: calcd 156.0459, found 156.0479. 
 
S CN
Cl
3-(5-chlorothiophen-2-yl)-but-2-enenitrile (64):  
1H NMR (300 MHz, CDCl3, 25°C), δ-7.01, (d, J=3.9 Hz, 1H), 6.81 (d, J=3,9 Hz, 1H), 
5.39 (q, J=0.9 Hz, 1H), 2.31 (d, J=0.9 Hz, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ-151.3 (C), 140.4 (C), 133.4 (C), 127.9 (CH), 127.7 
(CH), 117.4 (C), 93.3 (CH), 19.5 (CH3) 
IR (neat) ν 3098, 3042, 2926, 2853, 2210, 1594, 1428, 1384, 989, 786 cm-1 
HRMS (ESI) for C8H6ClNSLi (M+Li)+: calcd 190.0070, found 190.0108. 
 
O CN
3-(5-Methyl-furan-2-yl)-but-2-enenitrile (65):  Yield:  70%, yellow oil 
1H NMR (300MHz, CDCl3, 25°C), δ: 6.48 (d, 1H, J = 3.3 Hz,), 6.04 (m, 1H), 5.54 (s, 1H), 
2.26 (s, 3H), 2.17 (d, 3H, J=0.9 Hz,) 
13C NMR (75 MHz, CDCl3, 25°C) δ: 155.8 (C), 150.8 (C), 146.1 (C), 118.3 (C), 114.2 
(CH), 109.2 (CH), 89.8 (CH), 17.0 (CH3), 13.9 (CH3) 
IR (neat) ν 3009, 2925, 2855, 2210, 1730, 1640, 1610, 1578, 1513, 1263, 703 cm-1 
HRMS (ESI) for C9H9NOLi (M+Li)+: calcd 154.0844, found 154.0844. 
 
CN
(E)-3-phenyl-but-2-enenitrile (66):155    
1H NMR (300MHz, CDCl3, 25°C), δ=7.36-7.44 (m, 5H), 5.56 (q, J=0.9, 2.1 Hz, 1H), 
2.39 (d, J=0.9 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=159.8 (C), 138.3 (C), 130.6 (CH), 129.1 (2 x CH), 
126.1 (2 x CH), 117.9 (C), 95.7 (CH), 20.3 (CH3) 
IR (neat) ν 3062, 2982, 2214, 1608, 1575, 1496, 1446, 1381, 1262, 1079, 1027, 921, 
825, 754, 690 cm-1  
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HRMS (ESI) for C10H9NLi (M+Li)+: calcd 150.0895, found 150.0884. 
 
CN3-Methyl-non-2-enenitrile (67):156  Yield:  92% 
1H NMR (300MHz, CDCl3, 25°C), δ: 5.05 (m, 1H), 2.12 (t, 2H, J=7.5), 1.98 (d, 3H, 
J=0.9), 1.28-1.50 (m, 11H)   
13C NMR (75 MHz, CDCl3, 25°C) δ: 165.4 (C), 117.1 (C), 94.9 (CH), 38.5 (CH2), 31.5 
(CH2), 28.7 (CH2), 27.0 (CH2), 22.5 (CH2), 20.8 (CH3), 14.1 (CH3) 
IR (neat) ν 3007, 2960, 2933, 2868, 2212, 1737, 1573, 1465, 738 cm-1  
HRMS (ESI) for C10H17OLi (M+Li)+: calcd 158.1521, found 158.1520. 
 
CN
3-Biphenyl-4-yl-but-2-enenitrile (68):157  Yield:  92% 
1H NMR (300MHz, CDCl3, 25°C), δ: 7.62-7.67 (m, 4H), 7.41-7.56 (m, 5H), 5.67 (d, 1H, J 
= 0.9 Hz), 2.50 (d, 3H, J=0.6 Hz) 
13C NMR (75 MHz, CDCl3, 25°C) δ: 159.3 (C), 143.3 (C), 140.1 (C), 137.1 (C), 129.3 (2 
x CH), 128.3 (CH), 127.7 (2 x CH), 127.3 (2 x CH), 126.64 (2 x CH), 118.04 (C), 95.48 
(CH), 20.33 (CH3)  
IR (neat) ν 3030, 2924, 2365, 2343, 2214, 2018, 1736, 1365, 1217, 811, 766, 690 cm-1  
HRMS (ESI) for C16H13NLi (M+Li)+: calcd 226.1208, found 226.1210. 
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CN
3-(9H-Fluoren-2-yl)-but-2-enenitrile (69):  Yield:  94%, green 
crystalline solid 
1H NMR (300MHz, CDCl3, 25°C), δ: 7.34-7.82 (m, 7H), 5.67 (d, 1H, J = 1.2 Hz), 3.90 (s, 
2H), 2.52 (d, J = 1.2 Hz, 3H)  
13C NMR (75 MHz, CDCl3, 25°C) δ: 160.0 (C), 144.2 (C), 144.0 (C), 143.9 (C), 140.9 
(C), 136.7 (C), 127.9 (CH), 127.3 (CH), 125.4 (CH), 125.1 (CH), 122.7 (CH), 120.7 (CH), 
120.2 (CH), 118.2 (C), 94.9 (CH), 37.1 (CH2), 20.6 (CH3)  
IR (neat) ν 3057, 2922, 2853, 2210, 1736, 1598, 1457, 1440, 1263, 814, 735 cm-1 
HRMS (ESI) for C17H13N (M+H)+: calcd 232.1126, found 232.1114. 
 
CN
3-naphthalen-2-yl-but-2-enenitrile (70):158  Yield 82%, white solid 
1H NMR (300MHz, CDCl3, 25°C), δ: 7.81-7.90 (m, 4H), 7.49-7.55 (m, 3H), 5.72 (q, 1H, 
J=0.9 Hz), 2.5 (d, 3H, J=0.9 Hz) 
13C NMR (75 MHz, CDCl3, 25°C) δ: 159.4 (C), 135.3 (C), 134.2 (C), 133.2 (C), 129.0 
(CH), 128.9 (CH), 127.9 (CH), 127.7 (CH), 127.2 (CH), 126.4 (CH), 123.0 (CH) 118.1 
(C), 95.9 (CH), 20.3 (CH3) 
IR (neat) ν 3060, 2981, 2211, 1607, 1435, 1440, 1380, 1133, 809, 750 cm-1 
LRMS (ESI) for C14H11N (M+H)+: calcd 194.1, found 194.0. 
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α,β-Unsaturated aldehydes were prepared by reduction of their corresponding 
nitriles and purified by flash column chromatography (2%-10% ethyl 
acetate/hexanes).104  Farnesal was synthesized from farnesol.108  In each case, the all-
trans isomer was utilized in the self-condensation reactions.   
O
 3-Methyl-5-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2,4-dienal  
(71):153  Yield:  97%   
1H NMR (300MHz, CDCl3, 25°C), δ: 10.09 (d, 1H, J= 8.1 Hz), 6.70 (d, 1H, J= 16.2 Hz,), 
6.17 (d, 1H,  J=15.9 Hz,), 5.89 (d, 1H, J=7.8 Hz,), 2.27 (s, 3H), 2.00 (t, 2H, J=6.0 Hz,),  
1.68 (s, 3H), 1.52- 1.62 (m, 2H), 1.42-1.45 (m, 2H), 1.00 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ: 191.1 (CH), 157.2, (C), 136.1 (C), 135.6 (CH), 132.8 
(CH), 132.5 (C), 130.2 (CH), 39.6 (CH2), 34.2 (C), 33.2 (CH2) 28.9 (2 x CH3), 21.7 (CH2), 
19.1 (CH3), 16.5 (CH3) 
IR (neat) ν 2930, 2865, 1738, 1665, 1606, 1448, 1376, 1364, 1216, 1206, 1116, 963, 764, 
749, 732 cm-1 
HRMS (ESI) for C15H22OLi (M+Li)+: calcd 225.1831, found 225.1835. 
 
S
O
 3-Thiophen-2yl-but-2-enal (72):159  Yield:  88%  
1H NMR (300MHz, CDCl3, 25°C), δ: 9.84 (d, 1H , J=7.5 Hz,),  7.13-7.20 (m, 1H), 7.04 
(dd, 1H, J=0.9, 3.9 Hz,), 6.80-6.85 (m, 1H), 6.17 (dd, 1H, J=1.2, 7.8 Hz,), 2.26 (d, 3H, 
J=1.2 Hz,)  
Synthesis of A,B-Unsaturated Aldehydes
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13C NMR (75 MHz, CDCl3, 25°C) δ: 190.3 (CH), 149.7 (C). 144.5 (C), 129.1 (CH), 128.6 
(CH), 128.2 (CH), 124.3 (CH), 15.9 (CH3)  
IR (neat) ν 3104, 3015, 2924, 2852, 2771, 2209, 1739, 1654, 1595, 1421, 1245, 1128, 745 
cm-1 
HRMS (ESI) for C8H8OSLi (M+Li)+: calcd 159.0456, found 159.0458. 
 
S
OCl
 (E)-3-(5-chlorothiophen-2-yl)but-2-enal (73):   
1H NMR (300MHz, CDCl3, 25°C), δ=  10.04 (d, J=7.8 Hz, 1H), 7.19, (d, J=3.9 Hz, 1H), 
6.88 (dd, J=0.6, 3.9 Hz, 1H), 6.24 (dd, J=1.2, 7.8 Hz, 1H), 2.47 (d, J=1.2, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=190.6 (CH), 149.1 (C), 143.0 (C), 132.3 (C), 127.9 
(CH), 127.8 (CH), 124.5 (CH), 15.6 (CH3) 
IR (neat) ν 3099, 2925, 2855, 1658, 1598, 1424, 1129, 1003, 909, 791, 730 cm-1 
HRMS (ESI) for C8H7ClOSLi (M+Li)+: calcd 193.0066, found 193.0065. 
 
O
O
3-(5-Methyl-furan-2-yl)-but-2-enal (74):160  Yield:  89% 
1H NMR (300MHz, CDCl3, 25°C), δ: 10.04 (d, 1H , J=8.1 Hz,), 6.68 (d, 1H, J=3.6 Hz,), 
6.43 (dd, 1H, J = 0.9, 8.1 Hz,), 6.08-6.10 (m, 1H), 2.35 (d, 3H , J=0. 9,), 2.31 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=190.96 (CH), 156.29 (C), 152.09 (C), 144.34 (C), 
121.33 (CH), 115.15 (CH), 109.40, (CH), 14.11 (CH3), 13.45 (CH3) 
IR (neat) ν 3010, 2924, 2853, 1649, 1608, 1578, 1513 
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HRMS (ESI) for C9H10O2Li (M+Li)+: calcd 157.0841, found 157.0817. 
O
(E)-3-phenyl-but-2-enal (75):161   
1H NMR (300MHz, CDCl3, 25°C), δ=10.12 (d, J=7.5 Hz, 1H), 7.48-7.52 (m, 5H), 6.33 
(dq, J=1.35, 7.75 Hz, 1H), 2.48 (d, J=1.2 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.4 (CH), 157.8 (C), 140.7 (C), 130.1 (CH), 
128.8 (2 x CH), 127.3 (2 x CH), 126.5 (CH), 16.5 (CH3) 
 HRMS (ESI) for C10H10OLi (M+Li)+: calcd 153.0892, found 153.0882. 
 
O3-Methyl-non-2-enal (76):162,163  Yield:  87% 
1H NMR (300MHz, CDCl3, 25°C), δ: 9.97 (d, 1H, J=8.4 Hz), 5.88 (dd, 1H, J=0.3, 8.1 
Hz,), 2.57 (t, 2H, J = 7.2 Hz,), 1.98 (d, 3H, J=1.2 Hz), 1.50-1.6 (m, 8H), 0.87-0.92 (m, 3H)  
13C NMR (75 MHz, CDCl3, 25°C) δ: 191.3 (CH), 164.5 (C), 127.3 (CH), 40.7 (CH2), 31.7 
(CH2), 29.0 (CH2), 27.2 (CH2), 22.6 (CH2), 17.5 (CH3), 14.1 (CH3) 
IR (neat) ν 3005, 2956, 2930, 2858, 1737, 1673, 1456, 1377, 1275, 1260, 1196, 764, 725 
cm-1  
HRMS (ESI) for C10H18OLi (M+Li)+: calcd 116.1518, found 161.1528. 
 
O (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienal 
(77):108  1H NMR (300MHz, CDCl3, 25°C), δ=9.85 (d, J=7.8 Hz, 1H), 5.74 (dd, J=1.4, 
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7.8 Hz, 1H), 4.97 (m, 2H), 2.10 (m, 4H), 2.05 (d, J=1.2 Hz, 3H), 1.93 (m, 2H), 1.85 (m, 
2H), 1.54 (s, 3H), 1.49 (s, 3H), 1.47 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.1 (CH), 163.8 (C), 136.5 (C), 131.4 (C), 127.5 
(CH), 124.3 (CH), 122.7 (CH), 40.7 (CH2), 39.8 (CH2), 26.7 (CH2), 26.6 (CH3), 25.8 
(CH2), 17.7 (CH3), 17.6 (CH3), 16.1 (CH3) 
IR (neat) ν 2966, 2918, 1673, 1634, 1445, 1382, 1194, 1119 cm-1 
HRMS (ESI) for C15H24OLi (M+Li)+: calcd 227.1987, found 227.1951. 
 
O
3-Biphenyl-4-yl-but-2-enal (78):164  Yield:  90% 
1H NMR (300MHz, CDCl3, 25°C), δ: 10.21 (d, 1H, J = 7.8 Hz), 7.58-7.72 (m, 4H) 7.37-
7.50 (m, 5H), 6.48 (dq, 1H, J = 1.2, 7.8 HH), 2.60 (d, 3H, J = 1.2 Hz) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.4 (CH), 157.2 (C), 143.2 (C), 140.2 (C), 139.4 
(C), 129.2 (2 x CH), 128.2 (CH), 127.6 (2 x CH), 127.3 (2 x CH), 127.24 (CH), 127.0 (2 x 
CH), 16.5 (CH3) 
IR (neat) ν 3033, 2969, 2285, 1737, 1649,1599,1487, 1245, 1137, 831, 690 cm-1  
HRMS (ESI) for C16H14OLi (M+Li)+: calcd 229.1205, found 229.0997. 
 
O
3-(9H-Fluoren-2-yl)-but-2-enal (79):  Yield:  83%; yellow solid 
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1H NMR (300MHz, CDCl3, 25°C), δ: 10.20 (d, 1H, J = 7.8 Hz), 7.73-7.82 (m, 3H), 7.55-
7.60 (m, 2H), 7.32-7.43 (m, 2H), 6.49 (dq, 1H, J = 1.2, 8.1 Hz), 3.92 (s, 2H), 2.62 (d, 3H,  
J = 1.2 Hz)  
13C NMR (75 MHz, CDCl3, 25°C) δ=191.5 (CH), 158.1 (C), 144.1 (C), 144.0 (C), 143.9 
(C), 141.0 (C), 139.0 (C), 127.8 (CH), 127.2 (CH), 127.0 (CH), 125.6 (CH), 125.4 (CH), 
123.1 (CH), 120.6 (CH), 120.2 (CH), 37.2 (CH2), 16.7 (CH3) 
IR (neat) ν 3035, 2922, 2853, 2286, 2071, 1973, 1737, 1652, 1603, 1373, 1228, 828, 750 
cm-1  
HRMS (ESI) for C17H14OLi (M+Li)+: calcd 241.1205, found 241.1190. 
 
O
3-(naphthalen-2-yl)but-2-enal (80):165  Yield: 73% yield, yellow 
solid 
1H NMR (300MHz, CDCl3, 25°C), δ: 10.24 (d, J=7.8 Hz, 1H), 7.99 (d, J=1.5 Hz, 1H), 
7.81-7.88 (m, 3H), 7.61 (dd, J=1.8, 8.7 Hz, 1H), 7.52-7.56 (m, 2H), 6.55 (d, J=1.2, 7.8 
Hz, 1H), 2.60 (d, J=1.2 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ: 191.5 (CH), 157.4 (C), 137.8 (C), 134.3 (C), 133.3 
(C), 129.1 (CH), 128.7 (CH), 127.9 (CH), 127.7 (CH), 127.6 (CH), 127.0 (CH), 126.6 
(CH), 123.7 (CH), 16.5 (CH3) 
IR (neat) ν 3056, 2849, 2769, 1657, 1606, 1379, 1139, 851, 814, 747 cm-1  
HRMS (ESI) for C14H12OLi (M+Li)+: calcd 203.1048, found 203.1098. 
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Synthesis of Self-Condensation Products 
Ring-fused homodimers were generated by self-condensation of α,β-unsaturated 
aldehydes, a modification of Asato et al.3  The generalized approach is illustrated below 
for 6-Methyl-4,6-di-thiophen-2-yl-cyclohexa-1,3-dienecarbaldehyde (32). 
To an oven-dried flask was added 3-Thiophen-2yl-but-2-enal (72) (20 mg, 0.132 mmol) 
dissolved in 10 mL of 200 proof ethanol.  To this solution, was added L-proline (23 mg, 
0.200 mmol).  The mixture was allowed to stir at RT for 24 h prior to quenching the 
reaction with D.I. H20 (30 mL) and extraction with hexanes (3 x 50 mL).  The combined 
organics were washed with brine, dried over MgSO4, and concentrated in vacuo. 
Purification by flash chromatography (5% ethyl acetate/hexanes) afforded 17.7 mg of 32 
as a red oil (47%). 
 
Characterization of Self-Condensation Products 
O
6-Methyl-4,6-bis-[4-methyl-6-(2,6,6-trimethyl-
cyclohex-1-enyl)-hexa-1,3,5-trienyl]-cyclohexa-1,3-dienecarbaldehyde (14):112 
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1H NMR (300MHz, CDCl3, 25°C), δ=9.45 (s, 1H), 6.97 (q, J=7.52, 13.98 Hz, 1H), 6.81 
(d, J=6.10 Hz, 1H), 6.42 (d, J=13.98 Hz, 1H), 6.35 (q, J=10.40, 15.24 Hz, 1H), 6.30 (d, 
J=16.06 Hz, 1H), 6.20 (d, J=7.52 Hz, 1H), 6.16 (d, J=16.06 Hz, 1H), 6.16 (d, J=6.10 Hz, 
1H), 6.08 (d, J=16.31 Hz, 1H), 6.01 (d, J=16.31 Hz, 1H), 6.00 (d, J=10.40 Hz, 1H), 5.85 
(d, J=15.24 Hz, 1H), 2.69 (d, J=16.89 Hz, 1H), 2.42 (d, J=16.89 Hz, 1H), 2.02 (t, J=6.3 
Hz, 2H), 2.00 (s, 3H), 1.99 (t, J=6.3 Hz, 2H), 1.85 (s, 3H), 1.73 (s, 3H), 1.66 (s, 3H), 
1.60-1.64 (m, \4H), 1.48 (s, 3H), 1.45-1.47 (m, 4H), 1.04 (s, 6H), 0.98 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ= 192.0 (CH), 144.1, 144.0, 141.4, 139.5, 138.2, 
137.8, 137.8, 137.7, 137.3, 134.9, 132.6, 130.1, 130.1, 129.7, 129.3, 128.8, 128.6, 126.2, 
123.7, 122.7, 39.5, 39.4, 38.5, 37.9, 34.2, 34.1, 33.1, 32.9, 28.9, 28.5, 24.3, 21.8, 21.6, 
19.2, 12.9, 12.6   
HRMS (ESI) for C40H54OLi (M+Li)+: calcd 550.4175, found  550.4177. 
 
O
6-Methyl-4,6-bis-(4-methyl-pent-3-enyl)-cyclohexa-1,3-
dienecarbaldehyde (15):113 
1H NMR (300MHz, CDCl3, 25°C), δ=9.41 (s, 1H), 6.67 (d, J=5.7 Hz, 1H), 5.92 (d, 
J=6.0 Hz, 1H), 5.04-5.09 (m, 2H), 2.36 (d, J=17.9 Hz, 1H), 2.18 (d, J=3.0 Hz, 4H), 2.02 
(d, J=17.9 Hz, 1H) 1.74-1.94 (m, 3H), 1.69 (s, 3H), 1.65 (s, 3H), 1.62 (s, 3H), 1.55 (s, 
3H),1.31-1.41 (m, 1H) 1.19 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ= 191.6 (CH), 151.1 (C), 146.2 (CH), 141.7 (C), 
132.6 (C), 131.5 (C), 125.0 (CH), 123.5 (CH), 118.2 (CH), 42.1 (CH2), 38.6 (CH2), 38.0 
(CH2), 36.5 (C), 25.9 (CH3), 25.8 (CH3), 25.4 (CH2), 24.1 (CH2), 19.5 (CH3), 18.0 
(CH3), 17.8 (CH3) 
IR (neat) ν 2931, 2968, 1738, 1678, 1448, 1373, 1238, 1044 cm-1  
HRMS (ESI) for C20H30OLi (M+Li)+: calcd 293.2457, found  293.2454. 
 
O
6-Methyl-4,6-bis-[2-(2,6,6-trimethyl-cyclohex-1-enyl)-
vinyl]-cyclohexa-1,3-dienecarbaldehyde (16): 87 
1H NMR (300MHz, CDCl3, 25°C), δ=9.48 (s, 1H), 6.83 (d, J=6.0 Hz, 1H), 6.52 (d, 
J=16.2 Hz, 1H), 6.20 (d, J=16.5 Hz, 1H), 6.09 (dd, J=1.8, 6.0 Hz, 1H), 5.63 (dd, J=1.2, 
16.2 Hz, 1H), 5.33 (d, J=16.2 Hz, 1H), 2.66 (d, J= 16.8 Hz, 1H), 2.37 (dd, J=1.5, 17.1 
Hz, 1H), 2.03 (t, J=6.0 Hz, 2H), 1.89 (t, J=5.4 Hz, 2H), 1.70 (s, 3H), 1.57-1.65 (m, 4H), 
1.55 (s, 3H), 1.52 (s, 3H), 1.44-1.48 (m, 2H), 1.35-1.39 (m, 2H), 1.03 (s, 3H), 1.02 (s, 
3H), 0.87 (s, 3H), 0.86 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.6 (CH), 145.0 (CH), 144.6 (C), 141.8 (C), 
137.7 (C), 137.5 (C), 137.5 (CH), 134.0 (CH), 131.9 (CH), 131.6 (C), 127.9 (C), 124.9 
(CH), 121.9 (CH), 39.8 (CH2), 39.4 (CH2), 38.8 (C), 38.1 (CH2), 34.5 (C), 34.3 (C), 33.4 
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(CH2), 32.7 (CH2), 29.2 (2 x CH3), 28.8 (2 x CH3), 25.3 (CH3), 22.0 (CH3), 21.4 (CH3), 
19.6 (CH2), 19.3 (CH2) 
IR (neat) ν 2956, 2923, 2864, 1675, 1537, 1456, 1375, 1360, 1211, 1076, 967, 909, 733 
cm-1 
HRMS (ESI) for C30H42O (M+H)+: calcd 419.3314, found 419.3379. 
S
O
S
6-Methyl-4,6-di-thiophen-2-yl-cyclohexa-1,3-dienecarbaldehyde 
(32): 
1H NMR (300MHz, CDCl3, 25°C), δ: 9.49 (s, 1H), 7.35-7.40 (m, 1H) 7.28-7.30 (m, 2H), 
7.05-7.14 (m, 3H), 6.93 (d, 1H, J = 6.0 Hz), 6.62 (dd, 1H, J = 0.9, 6.3 Hz,), 3.21 (d, 1H, J 
= 17.4 Hz), 2.93 (dd, 1H, J = 1.5, 17.4 Hz), 1.84 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ: 192.0 (CH), 152.4 (C), 143.7 (CH), 143.6 (C), 142.2 
(C), 141.5 (C), 138.8 (C), 128.6 (CH), 128.6 (CH), 127.9 (CH), 126.6 (CH), 126.2 (CH), 
123.6 (CH), 45.2 (CH2), 29.9 (C), 27.2 (CH3) 
IR (neat) ν 3006, 2928, 2855, 1738, 1455, 1365, 1217, 764 cm-1  
HRMS (ESI) for C16H14OS2Li (M+Li)+: calcd 293.0646, found 293.0654. 
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S
Cl
O
S
Cl
4,6-bis(5-chlorothiophen-2-yl)-6-methylcyclohexa-1,3-
dienecarbaldehyde (33):   
1H NMR (300MHz, CDCl3, 25°C), δ=9.52 (s, 1H), 7.08 (d, J=3.9 Hz, 1H), 6.91-6.98 (m, 
2H), 6.64-6.70 (m, 2H), 6.52 (dd, J=1.8, 6.3 Hz, 1H), 3.06 (d, J=17.4 Hz, 1H), 2.86 (dd, 
J=2.1, 17.4 Hz, 1H), 1.82 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.7 (CH), 149.2 (C), 143.8 (CH), 141.8 (C), 
141.2 (C), 137.8 (C), 132.7 (C), 129.2 (C), 127.7 (CH), 125.8 (CH), 125.6 (CH), 123.0 
(CH), 117.4 (CH), 44.0 (CH2), 39.2 (C), 26.8 (CH3) 
IR (neat) ν 2966, 2927, 2382, 2343, 1672, 1541, 1434, 792 cm-1 
LRMS (APCI) for C16H12Cl2OS2 (M+H)+: calcd 355.0, found 354.9. 
 
O
O
O
6-Methyl-4,6-bis-(5-methyl-furan-2-yl)-cyclohexa-1,3-
dienecarbaldehyde (34):  Yield:  60%; red-yellow solid 
1H NMR (300MHz, CDCl3, 25°C), δ: 9.47 (s, 1H), 7.00 (d, 1H, J = 6.0 Hz), 6.64 (d, 1H, J 
= 6.0 Hz), 6.50 (d, 1H, J = 3.0 Hz), 6.11 (dd, 1H, J = 0.9, 3.3 Hz), 6.00 (d, 1H, J = 3.3 
Hz), 5.89 (m, 1H), 3.17 (d, 1H , J=1.8 Hz), 3.10 (d, 1H, J=1.8 Hz), 2.38 (s, 3H), 2.25 (s, 
3H), 1.57 (s, 3H)  
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13C NMR (75 MHz, CDCl3, 25°C) δ: 191.5 (CH), 157.1 (C), 155.1 (C), 151.9 (C), 151.0 
(C), 143.5 (CH), 139.3 (C), 133.3 (C), 114.1 (CH), 112.3 (CH), 108.9 (CH), 106.1 (CH), 
105.7 (CH), 38.9 (CH2), 37.1 (C), 22.6 (CH3), 14.2 (CH3), 13.8 (CH3) 
IR (neat) ν 3011, 2924, 2854, 1672, 1618, 1535, 1376, 1216, 1077, 1023, 781 cm-1 
HRMS (ESI) for C18H18O3Li (M+Li)+: calcd 289.1416, found 289.1418. 
O
6-methyl-4,6-diphenylcyclohexa-1,3-dienecarbaldehyde (35):  
NMR (300MHz, CDCl3, 25°C), δ=9.52 (s, 1H), 7.16-7.57 (m, 10H), 7.04 (d, J=6.0 Hz, 
1H), 6.63 (dt, J=1.5, 6.0 Hz, 1H), 3.18 (dd, J= 1.5, 17.4 Hz, 1H), 2.85 (dd, J= 1.5, 17.4 
Hz, 1H), 1.72 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.7 (CH), 147.4 (C), 145.0 (C), 144.3 (CH), 
142.8 (C), 139.3 (C), 129.2 (CH), 129.1 (CH), 128.4 (2 x CH), 126.5 (CH), 126.3 (2 x 
CH), 126.1 (CH), 126.0 (2 x CH), 119.1 (CH), 44.9 (CH2), 41.0 (C), 20.4 (CH3) 
IR (neat) ν 3028, 2926, 2813, 2332, 1662, 1550, 1447, 1170, 757, 696 cm-1 
HRMS (ESI) for C20H18Li (M+Li)+: calcd 281.1518, found 281.1528. 
 
O
4,6-Dihexyl-6-methyl-cyclohexa-1,3-dienecarbaldehyde (36):  
Yield:  50%; yellow oil     
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1H NMR (300MHz, CDCl3, 25°C), δ: 9.40 (s, 1H) 6.65 (d, 1H, J = 5.4 Hz), 5.89-5.92 (m, 
1H), 2.32 (d, 1H, J = 18 Hz,), 2.14 (t, 2H, J = 7.2 Hz,), 1.98 (d, 1H, J = 18.3), 1.80-1.89 
(m, 2H), 1.57 (s, 3H), 1.42-1.50 (m, 4H), 1.66-1.39 (m, 18H)  
13C NMR (75 MHz, CDCl3, 25°C) δ= 193.7 (CH), 148.9 (C),  146.2 (CH), 118.0 (CH), 
42.0 (CH2), 38.6 (CH2), 38.0 (CH2), 34.9 (CH2), 31.8 (2 x CH2), 30.3 (CH2), 29.3 (CH2), 
27.2 (CH2), 25.5 (CH2), 25.4 (C), 25.3 (CH2),  22.9 (CH3), 20.9 (CH2), 14.4 (2 x CH3) 
IR (neat) ν 3006, 2956, 2926, 1739, 1679, 1569, 1366 cm-1 
HRMS (ESI) for C20H34O (M+H)+: calcd 291.2688, found 291.2669. 
 
O
4,6,6-trimethylcyclohexa-1,3-dienecarbaldehyde (37): 113 
1H NMR (300MHz, CDCl3, 25°C), δ=9.39(s, 1H), 6.60 (d, J=5.4 Hz, 1H), 5.93-5.97 (m, 
1H), 2.11 (d, J=0.9 Hz, 2H), 1.90 (d, J=0.9 Hz, 3H), 1.19 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=193.5 (CH), 147.4 (C), 145.3 (CH), 142.7 (C), 
118.8 (CH), 46.8 (CH2), 33.0 (C),  26.3 (2 x CH3), 24.3 (CH3) 
IR (neat) ν 2925, 2852, 1675, 1542, 1513, 1457, 1378, 1261, 810 cm-1 
HRMS (ESI) for C10H14OLi (M+Li)+: calcd 157.1205, found 157.1237. 
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O
4,6-bis((E)-4,8-dimethylnona-3,7-dienyl)-6-
methylcyclohexa-1,3-dienecarbaldehyde (38):   
1H NMR (300MHz, CDCl3, 25°C), δ=9.41 (s, 1H), 6.66 (d, J=5.7 Hz, 1H), 5.92 (d, 
J=5.4 Hz, 1H), 5.04-5.09 (m, 4H), 2.36 (d, J=18 Hz, 1H), 2.20 (s, 2H), 2.19 (s, 2H), 
1.77-2.13 (m, 12 H), 1.66 (s, 6H), 1.61 (d, J=0.9 Hz, 3H), 1.59 (s, 6H), 1.54 (d, J=0.9 
Hz, 3H), 1.31-1.41 (m, 1H), 1.19 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=193.6 (CH), 151.1 (C), 146.2 (CH), 141.7 (C), 
136.2 (C), 135.1 (C), 131.6 (C), 131.5 (C), 124.8 (CH), 124.6 (CH), 124.4 (CH), 123.4 
(CH), 118.2 (CH), 42.2 (CH2), 39.9 (CH2), 39.8 (CH2), 38.6 (CH2), 38.0 (CH2), 36.5 (C), 
26.9 (CH2), 26.8 (CH2),  25.9 (2 x CH3), 25.7 (CH2), 25.5 (CH3), 24.0 (CH2), 17.9 
(CH3), 17.9 (CH3), 16.3 (CH3), 16.2 (CH3) 
IR (neat) ν 2965, 2917, 2854, 2710, 1677, 1637, 1568, 1449, 1377, 1170, 831 cm-1 
HRMS (ESI) for C30H46O (M+H)+: calcd 423.3627, found 423.3607. 
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O
4,6-Bis-biphenyl-4-yl-6-methyl-cyclohexa-1,3-
dienecarbaldehyde (39):  Yield: 52%; yellow solid 
1H NMR (300MHz, CDCl3, 25°C), δ: 9.60 (s, 1H), 7.30-7.74 (m, 16H), 7.12 (d, 1H, J = 
6.0 Hz), 6.75 (d, 1H, J = 6.0 Hz), 3.25 (dd, 1H, J = 1.5, 17.7 Hz), 2.92 (dd, 1H, J = 1.2, 
17.4 Hz), 1.56 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ: 192.7 (CH), 159.3 (C), 146.5 (C), 144.5 (C), 144.4 
(CH), 142.8 (C), 142.1 (C), 140.4 (C), 139.3 (C), 138.0 (C), 129.1 (2 x CH), 128.9 (2 x 
CH), 128.0 (CH), 127.6 (2 x CH), 127.5 (CH), 127.3(2 x CH), 127.2 (2 x CH), 127.1 (2 x 
CH), 126.8 (2 x CH), 126.4 (2 x CH), 119.1 (CH), 44.7 (CH2), 40.8 (C), 25.1 (CH3)  
IR (neat) ν 3006, 2970, 2922, 1739, 1678, 1365, 1276, 1261 cm-1  
HRMS (ESI) for C32H26OLi (M+Li)+: calcd 433.2144, found 433.2151. 
 
O
4,6-Bis-(9H-fluoren-2-yl)-6-methyl-cyclohexa-1,3-
dienecarbaldehyde (40):  Yield:  62%; green crystalline solid 
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1H NMR (300MHz, CDCl3, 25°C), δ: 9.55 (s, 1H), 7.67-7.80 (m, 2H), 7.49-7.60 (m, 2H), 
7.17-7.41 (m, 10H), 7.09 (d, 1H, J = 6.0 Hz), 6.71-6.74 (m, 1Hz), 3.91 (s, 2H), 3.85 (s, 
2H), 3.30 (d, 1H, J=18.6 Hz), 2.95 (d, 1H , J = 18.0 Hz,), 1.56 (s, 3H)  
13C NMR (75 MHz, CDCl3, 25°C) δ=192.7 (CH), 150.1 (C), 149.1 (C), 146.5 (2 x C), 
145.0 (C), 144.3 (2 x C), 143.9 (2 x C), 143.6 (2 x C), 142.8 (C), 138.0 (CH), 127.5 
(CH), 127.2 (CH), 126.8 (CH), 126.6 (CH), 125.4 (CH), 125.1 (CH) 125.0 (CH), 124.9 
(CH), 123.1 (CH), 122.6 (CH), 120.4 (CH), 120.2 (CH), 120.0 (CH), 119.8 (CH), 118.7 
(CH), 45.4 (CH2), 37.2 (CH2), 37.1 (CH2), 32.2 (C), 30.0 (CH3) 
IR (neat) ν 2955, 2922, 2853, 2126, 2016, 1976, 1739, 1457, 1375, 1366, 1229, 1217 
cm-1  
HRMS (ESI) for C34H26OLi (M+Li)+: calcd 457.2144, found 457.2136. 
O
6-methyl-4,6-di(naphthalen-2-yl)cyclohexa-1,3-
dienecarbaldehyde (41):   
1H NMR (300MHz, CDCl3, 25°C), δ= 9.57 (s, 1H), 7.40-7.93 (m, 14H), 7.14, J=6.0 Hz, 
1H), 6.82 (d, J=6.0 Hz, 1H), 3.40 (dd, J=1.5, 17.7 Hz, 1H), 3.02 (dd, J=1.5, 17.7 Hz, 
1H), 1.85 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.6 (CH), 144.8 (C), 144.3 (CH), 142.7 (C), 
136.3 (C), 134.0 (C), 133.7 (C), 133.5 (C), 133.1 (C), 132.3 (C), 128.8 (CH), 128.7 
(CH), 128.2 (CH), 127.9 (CH), 127.7 (CH), 127.4 (CH), 127.2 (CH), 127.1 (CH), 126.9 
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(CH), 126.2 (CH), 125.8 (CH), 125.5 (CH), 124.5 (CH), 123.5 (CH), 119.5 (CH), 44.7 
(CH2), 41.3 (C), 24.9 (CH3) 
IR (neat) ν 3056, 2925, 2852, 1675, 1542, 1513, 1457, 1378, 1261, 810 cm-1 
HRMS (ESI) for C28H22O (M+Li)+: calcd 381.1831, found 381.1802. 
 
Determination of Absolute Configuration 
 CD analysis of the menthylhydrazone derivatives of C-30 dimer suggests that the 
major isomer in these instances is in the S-configuration as determined by the quadrant 
rule (chiral excitiation theory).145 
 
 
 
Preparation of Retinal Samples for NMR Analysis 
 A 30 mg/mL solution of all-trans retinal, L-proline, and triethyalmine was 
prepared by dissolving each in CD3OD.  These were stored at -20°C until further use. 
 
NMR Analysis of Retinal Self-Condensation Reaction 
A 5 mm NMR tube was filled with 800 µL of CD3OD and then placed in a 300 
MHz NMR spectrometer.  Once properly shimmed, another tube was filled with 500 µL 
of all-trans retinal (30 mg/mL, 0.05278 mmol) and the instrument reshimmed.  The 
reaction was started by ejecting the all-trans retinal and adding 304 µL, 1.5 equivalents, 
of the L-proline solution (30 mg/mL, 0.07921 mmol), shaking the tube, reinserting the 
tube into the NMR, and immediately acquiring a spectrum that took a total time of 2 
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minutes.  After the initial spectrum, the instrument was periodically reshimmed.  After 3 
hours 30  minutes, all of the all-trans retinal had been consumed and all that existed was 
Schiff base 54 and intermediate 56 at which time the NMR tube was removed and 180 
µL of triethylamine (30 mg/mL, 0.5340 mmol) was added followed by shaking and 
reinsertion of the tube.  After a few minutes, formation of cycloretinal was present.  
After 2 hours 30 minutes, the reaction was complete.  Spectra were acquired over an 8 
hour period at various time points.   
 MS analysis of the reaction was taken at 30, 90, 150, and 270 minutes.  
Intermediates 54 (M + Li = 388.2812 amu) and 56 (M + Li = 654.5181 amu) were both 
observed. 
 
 
NMR Analysis of Citral Self-Condensation Reaction 
A 5 mm NMR tube was filled with 800 µL of CD3OD and was placed in a 300 
MHz NMR for shimming purposes.  Once properly shimmed, another tube was filled 400 
µL of citral (30 mg/mL, 0.07882 mmol) and the instrument was reshimmed.  The reaction 
was started by ejecting the citral and adding 454 µL, 1.5 eq., of the L-proline solution (30 
mg/mL, 0.1183 mmol), shaking the tube, reinserting the tube into the NMR, and 
immediately acquiring a spectrum that took a total time of 2 minutes.  After the initial 
spectrum and periodically throughout the experiment, the instrument was reshimmed.  As 
with all-trans retinal, Schiff base formation initiates immediately just as observed with all-
trans retinal and the reaction proceeds without the use of triethylamine.  Spectra were 
acquired over an eight-hour period at various time points.  However, during this time the 
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reaction did not come to a completion but the data can be paralleled to that of the all-trans 
retinal as intermediate 7 is also formed and can be seen via mass spectroscopy.  Since 
citral is bought as a mixture of cis and trans isomers (see 1H NMR), the overall spectra of 
the reaction are complex just as that of the all-trans retinal limiting our ability to determine 
the structural characteristics of the various intermediates.   
Mass spec also confirmed that seen by NMR analysis, where newly formed peaks 
belonged to that of intermediate 59 (M+H = 384.2803 amu) and to the Schiff base 57 
(M+H = 250.1620 amu, M+Na = 272.1566 amu).   
 
Hydrogen/Deuterium Exchange Experimental Procedure 
100.0 mg (0.6574 mmol) of citral was dissolved in CD3OD followed by the addition of 
115.5 mg (1.0032 mmol) of L-proline.  This was stirred for 10 hours at room temperature 
and was quenched by dilution with hexanes.  The mixture was washed with D2O (3 x 15 
mL), dried and evaporated.  The crude mixture was purified via flash chromatography 
(10% ethyl acetate/hexanes) to yield cyclocitral.  Samples were compared via mass 
spectroscopy (MS) and a NMR study was done to show incorporation which is correlated 
with MS.  Each NMR integral was cut consistently and these were integrated against two 
separate regions, CH3 5’, 6’, 5”, 6” (1.51-1.72 ppm) and as well as the CH at 2 (6.67 ppm) 
which is where exchange does not occur.  Each integral was increased x100 to give extra 
decimal places.   
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Synthesis of the corresponding benzylidene nitrile was synthesized following 
literature protocols and purified by flash column chromatography (10% ethyl 
acetate/hexanes). 102 
 
3-phenylbut-2-enenitrile-β,β,β-d3 (60):  72% yield, colorless oil 
1H NMR (300MHz, CDCl3, 25°C), δ=7.18-7.28 (m, 5H), 5.42 (s, 1H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=138.3 (C), 133.4 (C), 130.6 (CH), 129.1 (2 x CH), 
126.1 (2 x CH), 117.9 (C), 95.8 (CH) 18.8-20.4 (sept, J= 19.55 Hz, CD3) 
HRMS (ESI) for C10H6D3NLi (M+Li)+: calcd 153.1083, found 153.1049. 
  
 Deuterated benzylidene aldehyde 61 was synthesized by DIBAL reduction146 of 
60 followed by hydrolysis with a silica slurry containing 20% deuterium oxide (D2O) in 
ether.147  The reaction was allowed to proceed to 75% completion (3 hours) prior to 
hydrolysis.  After 30 minutes, the organics were filtered, dried over MgSO4, and 
evaporated.  The crude material was subjected to flash chromatography with a gradient 
extending from 2-10% ethyl acetate/hexanes.  Further purification was achieved by 
HPLC employing an isocratic gradient of 10% ethyl acetate/hexanes (the desired all-
trans product, Rt = 14.6 minutes; with the nitrile and cis-aldehyde at Rf = 9.8 and Rf = 
12.3 minutes respectively). 
 
Synthesis of Deuterated Benzylidene Aldehdye
120 
 
O
D D
D
(E)-3-phenylbut-2-enal- β,β,β -d3  (61):  58% yield, colorless oil  
1H NMR (300MHz, CDCl3, 25°C), δ=10.19 (d, J=8.1 Hz, 1H), 7.53-7.58 (m, 2H), 7.41-
7.45 (m, 3H), 6.41 (d, J=7.8 Hz, 1H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=191.7 (CH), 158.1 (C), 142.3 (C), 130.4 (CH), 
129.0 (2 x CH), 126.5 (2 x CH), 117.1 (CH), 15.1-16.5 (sept, J=19.4 Hz, CD3) 
HRMS (ESI) for C10H7D3OLi (M+Li)+: calcd 156.1080, found 156.1076. 
 
Synthesis of 2-isopropyl-5-menthylcyclohexyl Hydrazinecarboxylate 
To synthesize 2-isopropyl-5-methylcyclohexyl hydrazinecarboxylate 81,150 ethyl 
2-isopropyl-5-methylcyclohexyl carbonate was first prepared by reacting 25.0 g (1 
equivalent) of L-menthol with 75 mL of ethyl chloroformate (7.3 equivalents) in the 
presence of pyridine (1 mL).  The reaction was refluxed for 48 hours before the light 
brown product was poured over ice followed by dilution with 20 mL of water.  The 
mixture was then extracted with ethyl ether (5 x 100 mL) with the organic layers 
combined, dried over MgSO4, and concentrated under vacuum.  Assuming 100% 
conversion of the ethyl 2-isopropyl-5-methylcyclohexyl carbonate, 75 mL of 2-ethoxy 
ethanol was used to solubilize the starting material.  Once completely dissolved, a two-
fold excess of hydrazine monohydrate (20 mL) was added and the reaction mixture was  
poured over ice and extracted with ethyl ether (5 x 100 mL).  The organic layers were 
combined, dried over MgSO4, and concentrated under vacuum.  Once the ethyl ether was 
evaporated, 50 mL of hexanes was added and the solution was heated and left at -20°C 
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for 48 h in which white fluffy crystals were formed and were subsequently collected via 
vacuum filtration.  The recrystallization was performed three more times yielding 12.7 g 
(51% yield). 
 
Characterization of 2-isopropyl-5-menthylcyclohexyl Hydrazinecarboxylate 
NH2
H
NO
O
2-isopropyl-5-methylcyclohexyl hydrazinecarboxylate (81):  1H NMR 
(300 MHz, CDCl3, 25°C), δ=6.14 (s, 1H), 4.56 (dt, J=4.5, 21.9 Hz, 1H), 3.74 (s, 2H), 
1.97-2.02 (m, 1H), 1.82-1.92 (m, 1H), 1.61-1.66 (m, 2H), 1.40-1.52 (m, 1H), 1.30 (t, 
J=10.8 Hz, 1H), 1.00-1.10 (m, 1H), 0.91-0.99 (m, 2H), 0.85-0.89 (m, 6H), 0.75 (d, J=6.9 
Hz, 3H)  
13C NMR (75 MHz, CDCl3, 25°C) δ=159.0 (C), 75.7 (CH), 47.5 (CH), 41.6 (CH2), 34.4 
(CH2), 31.6 (CH), 26.4 (CH), 23.7 (CH2), 22.2 (CH3), 21.0 (CH3), 16.6 (CH3) 
HRMS (ESI) for C11H22N2O2 (M+H)+:  calcd 215.1760, found 215.1752. 
 
General Procedure for the Synthesis of the Menthylhydrazones 
Homodimer 36 (0.100 g, 1 equivalent) was dissolved in 200 proof ethanol (20 
mL) with 1.5 equivalents of 2-isopropyl-5-methylcyclohexyl hydrazinecarboxylate 81 at 
room temperature.  After 72 h, the reaction was extracted with 1:1 ethyl acetate/hexanes 
solution (2 x 100 mL), and was washed with brine.  The organic layer was dried over 
magnesium sulfate (MgSO4) and concentrated under vacuum.  The crude material was 
passed thru a silica plug with 10% ethyl acetate/hexanes as the mobile phase.  The 
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mixture was then subjected to high pressure liquid chromatography (HPLC) with a 
mobile phase of 96% ethyl acetate/ 4% hexanes with a flow rate of 1.5 mL/minute.  Two 
fractions were collected corresponding to the R and S stereoisomers respectively. 
 
Characterization of the Menthylhydrazones 
N
H
N O
O
2-isopropyl-5-methylcyclohexyl-2-((4,6-dihexyl-6-
methylcyclohexa-1,3-dienyl)methylene)hydrazinecarboxylate (82):  HRMS (ESI) for 
C31H54N2O2 (M+H)+:  calcd 487.4264, found 487.4238. 
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General Procedure for Conversion of Menthylhydrazones Back to Aldehyde 
Once the R and S stereoisomers were purified, each was dissolved in 20 mL of 
1:1 water/ethanol with 5 mL of 10% sulfuric acid and boiled for 2.5 h in which a color 
change from clear to pink occurred within two hours.  The reaction was removed from 
the heat source and allowed to cool when it was then extracted with ethyl ether (2 x 25 
mL).  The organic layer was then dried with MgSO4 and concentrated under vacuum.  
The crude mixture was then passed through a silica plug with a mobile phase of 10% 
ethyl acetate/hexanes. 
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CHAPTER IV 
SYNTHESIS AND BIOLOGICAL EVALUATION OF HETERODIMERIC 
CYCLOTERPENALS* 
INTRODUCTION 
 The carotenoids are responsible for such processes as the inactivation of free 
radicals.17  The retinoids, for example, the natural and synthetic derivatives of Vitamin 
A, serve as chromophores of the visual transduction system.166  Retinoids also exhibit a 
variety of other biological activities.  They are used extensively in dermatology for a 
variety of conditions, show activity as cancer preventative agents, and are potent 
modulators of growth and differentiation.27-29  In this regard, all-trans retinoic acid 13 
has been shown to differentiate embryonic stem cells into a neuron-like phenotype.30  It 
has also been employed as a cancer chemotherapeutic in treatment of promyelocytic 
leukemia by causing terminal differentiation of the malignant cells.27  Retinoic acid 
analogs TTNPB 83, azulenic compounds 84 and 85 have been shown to possess 
biological activities as cancer chemopreventative agents (Figure 47).166   
 Interestingly, self-condensation of polyene aldehydes has been observed in 
nature resulting in terpenes with cyclodimeric structures.  We defined these molecules  
as cycloterpenals as they are composed of a cyclohexadiene core formed by the 
condensation of two terpene aldehydes.  Cyclocitral 15, for example, was recently 
 
 
* Reprinted with permission from “Synthesis and Cellular Effects of Cycloterpenals:  
Cyclohexadienal-Based Activators of Neurite Outgrowth.” Bench, B. J., Tichy, S. E., 
Perez, L. M., Benson, J., Watanabe, C. M. H., 2008. Bioorganic & Medicinal Chemistry, 
16, 7573-7581, Copyright 2008 by Elsevier Ltd. 
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Figure 47.  Structures of representative retinoid compounds. 
 
isolated from the North Sea bryozoans Flustra foliacea and shown to exhibit antibiotic 
activity.39,88,89  Cycloretinal 14 has been suggested as a contributor of age-related 
macular degeneration.33,34  Furthermore, incubation of the milk whey protein β-
lactoglobulin with β-ionylideneacetaldehyde has been shown to result in a C-30 ring-
fused homodimer cyclo-β-ional 16 (Figure 48).87   
 
 
 
Figure 48.  Structures of cycloretinal, cyclocitral, and C-30 dimer.   
 
13 83 
84 85 
16 15 14 
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On these bases, we broadly speculate that some of these cycloterpenals or their 
structurally and functionally related analogs could be important in developmental 
processes such as neurite outgrowth.  In this chapter, we designed a synthetic library of 
cyclohexadienals and tested the composite library (ring-fused heterodimers) against 
PC12 cells where promising effects were observed on neurite outgrowth.  We also 
screened the library for cytotoxic effects with an array of assays including Jurkats 
(human T-cell leukemia), yeast (Saccharomyces cerevisiae), and two bacterial strains 
(Escherichia coli, Bacillus subtilis).  In some instances, involving aromatic substitutions 
to the central ring, the cyclohexadiene ring system could be aromatized to give 
fluorescent molecules.  In the future, some of these molecules or their respective 
derivatives might find use as fluorescent probes in protein target identification of a 
particular cyclohexadienal.    
 
RESULTS AND DISCUSSION 
Synthesis of Asymmetric Cyclohexadienals 
 The cycloterpenals-based compound library was generated by proline-promoted 
condensation of α,β-unsaturated aldehydes giving mono-, di-, tri-, and tetra-substituted 
cyclohexadienals (Figure 49).  The reaction involves condensation between a donor and 
acceptor aldehyde, where donor molecules require the presence of either a β-methyl or 
β-methylene group.  Acceptor molecules exhibit a wider degree of flexibility, the single 
constraint owing to the presence of an α,β-unsaturated aldehyde.  The reaction proceeds 
by complete conversion of aldehyde to that of the Schiff base followed by a Diels-Alder 
or Michael-like imine addition.31 
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Figure 49.  Substituted heterodimeric cyclohexadienals generated by proline-mediated 
condensation of α,β-unsaturated aldehydes. 
 
Here we detail optimal reaction conditions to favor heterodimer formation over 
competing homodimerization,31 which is inherent to the reaction.  Therefore, the 
reaction is not amendable to a one-pot synthetic strategy, unlike homodimerization, as 
minimal yields are obtained under such conditions.  Moreover, we illustrate the scope of 
the reaction by invoking substrates that vary in function and architecture.   
 
Catalysis Involving a Single Β-methyl Substituted Substrate 
 In order to synthesize this class of tri-substituted heterodimers (Figure 50), we 
first had to optimize the general reaction.  Employing a one-pot strategy, reaction of 3-
thiophen-2-yl-but-2-enal with 4-(dimethyl-amino)-cinnamaldehyde (in a 1:1 mol ratio) 
gave a 5% and 43% yield, respectively, of heterodimer 86 to the thiophene homodimer 
(Table 10).  Likewise, skewing the ratio in favor of the acceptor aldehyde substrate over 
that of the β-methyl substituted aldehyde donor in a one-pot format gave poor yields of 
the heterodimer 86.  Therefore, we implemented this reaction as a model system and 
optimized its conditions in an effort to define a generalizable set of 
OR1
R4
OR2
R3
H
N
COO-
CHO
R1
CHO
R1
R2
CHO
R1
R3R2
CHO
R1
R3R2
R4
+
Donor Acceptor
αβ
128 
 
86 
92 
88
89
90 91 
968
94
101
105
100 
93 
107
99
98
97 
102 103 
106
104
108
110 
109 
111
112 113
Erro 114 
115 116 117 118
95
87 
 
Figure 50.  Chemical structures of heterodimers made with a single β-methyl 
substituted aldehyde. 
 
S
O
S
O
N
S
O
NO2
O
O
O
O
N
O
O
NO2
O
O
N
O
NO2
O O
O
N
O
NO2 O O
N
O
NO2
O O
N
O
NO2
O
S
Cl
O
S
Cl
N
O
O
N
O
NO2
O
O
O
N
O
NO2
O O
N
O O O
N
O
NO2
26
129 
 
reaction conditions to maximize heterodimer yields. 
As α,β-unsaturated aldehydes lacking a β-methyl group fail to self-dimerize 
(confirmed through ESI mass spectroscopy) and the reaction can be envisioned to 
proceed through formation of a Schiff base.31,87  We examined the notion of pre-forming 
the proline Schiff base of the acceptor aldehyde (as monitored by TLC, the Schiff base 
appears at the base-line with concomitant loss of the starting aldehyde) prior to the 
addition of the donor aldehyde.  Intuitively, this should minimize formation of the cyclic  
 
Table 10.  Reactions involving a single β-methyl substituted aldehyde. 
 
aR1 aR2 Comp # bYield (%) cee (%) 
thienyl benzyl 86 48 56 
thienyl dimethylamino-benzyl 87 64 53 
thienyl nitrobenzyl 88 23 49 
CH3furanyl benzyl 89 48 63 
CH3furanyl dimethylamino-benzyl 90 62 72 
CH3furanyl nitrobenzyl 91 22 50 
biphenyl benzyl 92 45 52 
biphenyl dimethylamino-benzyl 93 75 62 
biphenyl nitrobenzyl 94 16 53 
biphenyl H- 95 57 — 
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Table 10 continued. 
fluorenyl benzyl 96 47 43 
fluorenyl dimethylamino-benzyl 97 59 62 
fluorenyl nitrobenzyl 98 22 49 
naphthyl benzyl 99 50 57 
naphthyl dimethylamino-benzyl 100 58 54 
naphthyl nitrobenzyl 101 34 56 
biphenyl benzyl 102 53 64 
biphenyl dimethylamino-benzyl 103 64 54 
biphenyl nitrobenzyl 104 34 51 
2-Cl thienyl benzyl 105 42 36 
2-Cl thienyl dimethylamino-benzyl 106 56 41 
retinyl benzyl 107 55 56 
retinyl dimethylamino-benzyl 108 64 56 
retinyl nitrobenzyl 109 22 50 
retinyl H- 110 51 — 
β-ionyl benzyl 111 47 56 
β-ionyl dimethylamino-benzyl 112 57 59 
β-ionyl nitrobenzyl 113 35 53 
dimethylallyl benzyl 26 12 52 
dimethylallyl dimethylamino-benzyl 114 5 40 
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Table 10 continued. 
farnesenyl benzyl 115 15 62 
methyl benzyl 116 60 56 
methyl dimethylamino-benzyl 117 63 48 
methyl nitrobenzyl 118 47 54 
 
aReaction conditions: 1 (donor) : 1.5 (acceptor) : 3.4 (L-proline); the acceptor was dissolved in 
ethanol, reacted for 2 h to which donor was added and stirred at room temperature for 16-24 h. 
bIsolated yield. cDetermined by Pr(hfc)3 chiral shift reagent. 
 
homodimer, while maximizing heterodimer 87 yields.  To our satisfaction, an overall 
enhancement in reaction yields (from 5% to 64%) was indeed obtained.  Such a strategy 
greatly facilitates reaction yields.  With this method, we were able to limit the formation 
of the homodimer product anywhere from 1% to 14% dependent upon the substrate. 
To illustrate this strategy, we examined Schiff base formation of cinnamaldehyde 
and its derivatives by NMR to rationalize differences observed in reaction yields, i.e. 
while product yields for cinnamaldehyde and 4-dimethylamino-cinnamaldehyde were 
obtained in moderate yields.  The yields for 4-nitro-cinnamaldehyde were considerably 
lower.  Additionally, a difference in color change could also be visualized between that of 
cinnamaldehyde or dimethylamino-cinnamaldehyde and that of the nitro species.  When 
the Schiff base is formed with cinnamaldehyde or the di-methylamino-substituted 
compound (in the presence of excess proline, 1:1.5 molar concentration), the reaction 
progresses from a clear solution to yellow and finally to red.  The reaction is stirred for 
approximately 2 hours before the donor substrate is added (Schiff base formation 
monitored by TLC).  However, when the reaction is performed with 4-
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nitrocinnamaldehyde, the reaction goes from a yellowish hue to a light brown mixture 
with a slight precipitate forming within 20 minutes.  In this case, the donor substrate is 
added and the reaction is stirred for 12-16 hours. 
 A time course analysis was performed by NMR to monitor conversion of the 
three cinnamaldehydes to their corresponding Schiff base products.  Schiff base 
formation between proline and each aldehyde ensues immediately (as detected by NMR 
at 2 minutes).  In Figure 51, cinnamaldehyde and 4-dimethylaminocinnamaldehyde 
Schiff base products are detected by the presence of two doublets, representing their cis 
and trans isomers (α-carbon to the protonated imine), at 8.75 and 8.65 ppm and 8.34 and 
8.29 ppm, respectively.  By 2 h, all of the cinnamaldehyde substrate was converted to 
that of its Schiff base, while it took a total of 4 h for the 4-dimethylamino-cinnaladehyde 
reaction to come to completion.  In contrast, in the case of 4-nitrocinnamaldehyde, 
unknown side reactions began to occur as the desired Schiff base formed (Figure 52).  
Schiff base formation began to form within 2 minutes as exhibited by the presence of the 
pair of cis and trans isomers at 8.85 and 8.74 ppm.  However, at 13 minutes, a small 
singlet begins to appear at 9.74 ppm between the doublet of the 4-nitrocinnamaldehyde 
starting material.  The intensity of the singlet continues to increase while the broad 
singlets at 8.85 and 8.74 ppm decrease over time.  After 2 h and 45 minutes, this 
unknown product is entirely consumed leaving only an unknown product mixture. 
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Figure 51.  Cinnamaldehyde and 4-dimethylaminocinnamaldehyde Schiff base 
formation. 
 
 We also monitored the reaction by utilizing mass spectrometry to evaluate 
intermediate formation along with a time course as the reaction proceeds from Schiff 
base formation to the final product.  The proline-promoted formation of 4-(biphenyl-4-
yl)-6-phenylcyclohexa-1,3-dienecarbaldehyde involving cross-condensation between 
trans-cinnamaldehyde and (E)-3-(biphenyl-4-yl)but-2-enal was examined by LC/MS.  
The reaction is thought to proceed by complete conversion of the aldehyde group to that 
of their corresponding Schiff base (Scheme 16).   
  
134 
 
 
Figure 52.  4-nitrocinnamaldehyde Schiff base formation. 
 
Scheme 16.  Reaction scheme for biphenyl aldehyde and cinnamaldehyde. 
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Cross condensation occurs by deprotonation of the β-methyl group of the donor 
(biphenyl Schiff base), followed by addition to the β-position of the protonated imine of 
the acceptor (cinnamaldehyde Schiff Base), to give intermediate 1.  The reaction can 
then proceed in one of two ways.  Addition of water to the protonated imine would 
result in dissociation of proline and regeneration of the aldehyde group to give 
intermediate 3.  Alternatively, dehydration might occur to give the cyclohexadiene ring 
system as a proline adduct (intermediate 2), where subsequent release of proline would 
yield the final product. 
 To evaluate this reaction, we first incubated cinnamaldehyde with an excess of 
L-proline overnight. (E)-3-(biphenyl-4-yl)but-2-enal was subsequently added and the 
progress of the reaction was monitored over time by LC/MS.  Analysis revealed the 
formation of intermediate 2 but not of intermediate 3 based on their m/z ratios of 
Intermediate 2 and 3, 433.2 and 450.2 respectively.  Unfortunately, we were unable to 
detect the formation of Intermediate 1 as the proline adduct undergoes rapid 
dissociation.   
 Time course analysis of the reaction over a 15 hour period allowed evaluation of 
reaction flux, the build-up and consumption of starting materials, and reaction 
intermediates (Figure ).  As cinnamaldehyde was already in its Schiff base form prior to 
the addition of the biphenyl acceptor aldehyde, as one would expect, biphenyl Schiff 
base formation steadily increases during the first 3 hours.  Once formed, both 
cinnamaldehyde and biphenyl substrates (Figure a and b), Schiff bases decrease over 
time throughout the course of the reaction.  As Figure c reveals, intermediate 2 increases 
during the first 9 hours of the reaction then decreases over time.  Plotting intermediate 2 
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against the final reaction product (Figure d) reveals that as production of intermediate 2 
rises, product formation also increases until intermediate 2 reaches it maximum at 9 
hours. 
Other factors found to influence the cross-condensation reaction included 
substrate (donor to acceptor) ratios and temperature effects.  For instance, varying the 
ratio of donor to that of the acceptor (in a 1:1, 1:1.5, 1:2, and 1:3), at a set catalyst ratio 
(1:1.5 substrate to catalyst ratio, shown to be optimal from previous studies), gave 
surprisingly higher yields at 1:1 (21.4%) and 1:1.5 (64%) molar concentrations.  At 1:2 
and 1:3 molar concentrations, the overall heterodimer yields were 14.0% and 11.2%, 
respectively.  Based upon these findings, we employed 1 (donor): 1.5 (acceptor): 3.8 (L-
proline) molar concentration ratios to effect synthesis of the remainder of the 
heterodimers involving a single β-methylenic substrate. 
Temperature effects on the reaction paralleled that observed with self-
condensation reactions,31 whereby product yields were highest at ambient temperature 
versus -20 to 0 °C or 50 to 100 °C.  In all cases the concentration of catalyst, L-proline, 
in these reactions was held constant at 3.8 equivalents since these amounts were shown 
to give the greatest extents of conversion in homodimer reactions.31  Use of L-proline 
(3.8 equivalents) maintains a substrate to catalyst ratio of 1:1.5, where substrate equals 
donor plus aldehyde. 
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Figure 53.  Time course analysis of proline-promoted formation of biphenyl-
cinnamaldehyde heterodimers. 
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Figure 53 continued. 
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 Utilizing these optimized conditions, we investigated the overall scope of the 
reaction as illustrated in Table 10.  In most cases the heterodimers were generated in 
modest yields.  The lowest yields were obtained with heterodimers bearing 
dimethylallyl-26 and 114 or farnesenyl-115 substituents giving reaction yields in the 5-
15% range, which presumably is attributed to the flexibility of the side chains and 
competing reactions (Figure 54).  Conversely, the highest yields were achieved with 
heterodimers bearing rigid substituents (aromatic or other conjugated systems).  Such 
trends were also observed with homodimerization.31  As expected, in almost all cases the 
cross-condensation reaction was favored by electron donating groups as opposed to 
electron withdrawing substituents.  Homodimer yields ranged from 1% to 14% in each 
instance.   
O O
O O
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Figure 54.  Products resulting from reaction of cinnamaldehyde with citral. 
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Catalysis Between Two Β-methyl Substituted Substrates 
 Proline-promoted synthesis between two β-methylenic substrates would be  
expected to yield a mixture of substituted cyclohexadienals (Figure 55), corresponding 
to two homodimeric and two heterodimeric products ( 
Table 11).  To achieve these cross-condensation reactions, reaction conditions were 
modified slightly.  A 1:1 ratio of each aldehyde substrate and 3 equivalents of L-proline 
were optimal.  Skewing the ration (1:2) only enhanced homodimer formation of the 
more prevalent substrate. 
 Implementing these optimized conditions, we examined the generality of the 
reaction.  Sterics appeared to govern these cross-condensations, as the only heterodimer 
product formed gave the bulkiest substituent at C-4 and the least hindered group at C-6  
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Figure 55.  Chemical structures of heterodimers made with two β-methyl substituted 
aldehydes. 
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with the exception of 119 and 120, in which both heterodimeric products were formed.  
Likewise, reaction of citral and crotonaldehyde gave rise to tri-substituted  
 
Table 11.  Reaction between two β-methyl substituted aldehydes.   
 
aR1 aR2 Comp # bYield (%) cee (%) 
biphenyl methyl 119 49 55 
methyl biphenyl 120 18 57 
biphenyl thienyl 121 14 54 
biphenyl CH3furanyl 122 29 50 
naphthyl H- 123 57 49 
fluorenyl H- 124 67 48 
CH3furanyl methyl 125 40 52 
thienyl H- 126 45 47 
β-ionyl H- 127 39 44 
dimethylallyl CH3furanyl 128 23 46 
dimethylallyl H- 129 59 46 
 
aReaction conditions: 1 (donor) : 1 (acceptor) : 1.5 (L-proline) was dissolved in ethanol and 
stirred at room temperature for 16-24 h.  bIsolated yield. cDetermined by Pr(hfc)3 chiral shift 
reagent. 
 
cyclohexadienal 129, with the dimethylallyl-linkage at C-4.  Reaction yields ranged from 
14% to as high as 67%, with the highest yields arising from condensation with an 
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acceptor aldehyde where R2 is H- or CH3-.  On the contrary, the lowest yields were 
obtained from reactions with an acceptor aldehyde where R2 is thienyl or methylfuranyl.  
While one might expect high level of homodimer to be formed with this one-pot 
strategy, the isolated yields ranged from 3% to 27% in each case.   
 
Catalysis Effected by the Β-methylene Group of the Donor Aldehyde 
Interestingly, catalysis is not limited to reactions with β-methyl substituted 
aldehydes.  A substitution at C-5 of the cyclohexadienal was readily observed as a result 
of deprotonation occurring from the γ-methylene position of the donor aldehyde (Figure 
56).  For instance, use of a β-ethyl substituted donor aldehyde gives methyl-substitution  
 
 
Figure 56.  Chemical structures of heterodimers made with a β-ethyl substituted 
aldehyde. 
 
at C-5 of the tri-substituted cyclohexadienal.  In this regard, reaction of 3-thiophen-2-yl-
pent-2-enal with three different α,β-unsaturated aldehydes resulted in the formation of 
heterodimers shown in Table 12 as the major product with yields ranging from 25% to 
50% and approximately 10% homodimer in each instance.  While it might be 
conceivable to generate the seven membered ring system by proton abstraction of the δ-
130 131 132 
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methyl group, formation was not observed.  Reaction conditions were the same as 
detailed previously and similar yields and ee values were observed. 
 
Table 12.  Reactions with β-ethyl substituted donor aldehydes. 
 
R1 O R2 O
R1
R2
O+ + Homodimer
γ
 
aR1 aR2 Comp # bYield (%) cee (%) 
 thienyl benzyl 130 49 52 
 thienyl dimethylamino benzyl 131 50 50 
 thienyl nitrobenzyl 132 25 51 
aReaction conditions: 1 (donor) : 1.5 (acceptor) : 3.4 (L-proline); the acceptor was dissolved in 
ethanol, reacted for 2 h to which donor was added and stirred at room temperature for 16-24 h.  
bIsolated yield. cDetermined by Pr(hfc)3 chiral shift reagent. 
 
Likewise, reacting cinnamaldehyde with citral gave three heterodimer products (Figure 
54), the expected di-substituted product 26 and two tri-substituted cyclohexadienals, cis 
and trans diastereomers (27 and 28), respectively.  Previous work has actually shown 
that formation of homodimer 15 can be favored (95:5) in the presence of strong base, 
NaH resulting in a mixture of homodimers.111   While we limited the formation of self-
condensation products (15 and 15*) by allowing cinnamaldehyde to go to complete 
Schiff base formation prior to the addition of citral with homodimer 15 still observed in 
9% yield.  Heterodimers 26, 27, 28 were formed in 12%, 25%, and 4% yield respectively 
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(Table 13).  As with previous systems, these reactions favored substituents with electron 
donating groups as opposed to those bearing electron with-drawing substituents.  In this 
regard, reactions involving nitrobenzyl groups gave correspondingly lower yields than 
those involving benzyl or dimethylamino-benzyl substituents.  These β-methylenic 
driven reactions were also demonstrated with farnsenal, β-methyl substituted nonenal in 
combination with acrolein, cinnamaldehyde, and its derivatives.  In most instances only 
the cis product was formed; citral was purchased as a mixture of cis and trans isomers 
while all others were obtained as a single (all-trans) isomeric form.  The compounds 
were assigned on the basis of computation analysis and NMR spectroscopy.   
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Table 13.  Cross-condensation reactions. 
O R2 O
R2
O+
R1R1
 
aR1 & R2 Product Comp # bYield (%) cee 
(%) 
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Table 13 continued.     
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Table 13 continued. 
R1 
farnesenyl 
R2 nitrobenzyl 
 
139 
 
23 
 
55 
     
R1 pentyl 
R2 benzyl 
 
  
140 
 
29 
 
57 
 
R1 pentyl 
R2 dimethyl 
aminobenzyl 
 
  
 
141 
 
 
31 
 
 
55 
aReaction conditions: 1 (donor) : 1.5 (acceptor) : 3.4 (L-proline) the acceptor was dissolved in 
ethanol, reacted for 2 h to which donor was added and stirred at room temperature for 16-24 h.  
bIsolated yield. cDetermined by Pr(hfc)3 chiral shift reagent. 
 
During the structural determination of the products from the 
citral/cinnamaldehyde reaction, we not only isolated the desired 26 compound but also 
two diasteriomers, cis and trans, that occurred during the abstraction of a proton from 
the γ-methylene of citral.  These two diasteriomers gave interesting 1H spectra as the 
proton on C-6 of the carbaldehyde ring (Figure 57).  For the trans diasteriomer 28, a 
doublet (J=9.0 Hz) was observed and a singlet for the cis diasteriomer 27.  We decided 
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to investigate the relationship between these three products by performing B3LYP/6-
31G(d’) geometry optimizations by B3LYP/6-311++G(2d,p) for chemical shift and spin-
spin coupling calculations for each product.  These computational analyses can be used 
to confirm the structural assignment based on the NMR analyses.  
For the β-methyl product 26, we observed a chemical shift of 4.06 ppm giving 
rise to a doublet of doublets (J=1.5, 10.5 Hz) experimentally.  When NMR calculations 
are performed, we also see a chemical shift 4.06 ppm Figure 58.  The bond lengths thru 
space between the C-6 proton and the diastereomeric protons are 2.41 Å and 3.05 Å.  For 
the cis and trans diasteriomers, the comparison between experimental and calculation 
data gives us a difference of -0.47 and +0.34 ppm respectively.  As previously 
mentioned, the cis diasteriomer gives a singlet at 3.93 ppm while the trans diasteriomer 
gives rise to a doublet 3.97 experimentally.  The bond distance between the C-6 proton 
and the C-5 proton for the cis diasteriomer is 3.05 Å.  However, the bond length for the 
trans diasteriomer is 2.38 Å.   
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Figure 57.  1H NMR spectra of the proton on C-6 of the products of the reaction 
between citral and cinnamaldehyde. 
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Figure 58.  NMR predictions. 
Citral with cinnamaldehyde products optimized conformations with an overlay of the cis and 
trans products.  NMR predictions with computational (C) predictions with experimental (E) 
measurement of C-6 proton.   
 
Aromatization and Fluorescence 
 Interestingly, phenyl substituted cyclohexadienals, derived from cinnamaldehyde 
and its substituted analogs, were found to spontaneously aromatize (Figure 59) to give 
fluorescent molecules (over a period of one to several days) in about 5% to 15% 
conversion.  Aromatization could also be invoked directly by reaction with potassium 
permanganate in quantitative yields.167    With further experimentation, some of these 
molecules or their respective derivatives might therefore find use as fluorescent probes 
to identify the protein binding partner of a particular cyclohexadienal.  Quantum 
yields168  
cis  
trans 
desired 
4.06 ppm (C) 
4.06 ppm (E) 
4.40 ppm (C) 
3.93 ppm (E) 
3.63 ppm (C) 
3.97 ppm (E) 
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Figure 59.  Representative set of fluorescing aromatized heterodimers. 
 
were measured in dichloromethane and methanol (Table 14), for a subset of the 
molecules (142-149) including those that were most fluorescent as judged by exposure 
to UV light.  Fluorescence measurements were not obtained for molecules 150-154 
(Figure 60) as they demonstrated a small amount of fluorescence by UV light.  In all 
cases, fluorescence of molecules was quenched in methanol.  The highest quantum 
yields were obtained for compounds 147 and 149 (in dichloromethane), where the 
substituent at C-4 is not conjugated to the central aromatic ring.  While nitro-substituted 
phenyl systems fluoresce mildly, the nitro-group was shown to significantly quench the 
quantum yield.  Also, a crystal structure was obtained for compound 146 (See 
Appendix). 
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Table 14.  Percent conversions and quantum yields of fluorescent cyclohexadienals. 
 
  CH2Cl2 MeOH  
Entry %  Conv. λabs λem φa λabs λem φa 
142 10 368 490 0.025 360 503 0.008 
143 14 368 559 0.016 368 413 0.002 
144 7 368 474 0.042 374 598 0.056 
145 13 374 520 0.112 384 434 0.005 
146 14 368 526 0.046 368  497 0.044 
147 11 363 502 0.699 354 396 0.002 
148 15 368 519 0.088 368 515 0.005 
149 8 368 501 0.312 368 522 0.010 
150 7 -- -- -- -- -- -- 
151 5 -- -- -- -- -- -- 
152 14 -- -- -- -- -- -- 
153 11 -- -- -- -- -- -- 
154 6 -- -- -- -- -- -- 
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Figure 60.  Representative structures of other aromatic compounds.  
 
Effects on Neurite Outgrowth and General Cytotoxicity 
 Given the demonstrated ability of retinoic acid and its analogs to modulate 
growth and cellular differentiation and the ability of a milk whey protein to generate 
cyclo-β-ional, the cycloterpenal-based library of compounds was evaluated for their 
150 151 152 153 154 
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ability to stimulate neurite outgrowth in a PC12 assay.  PC12 cells are a pluripotent cell 
line that was originally cloned in 1976 from a transplantable rat pheochromocytoma and 
exhibits the ability to differentiate into neurons.  The PC12 assay is a widely 
implemented method of identifying compounds that promote neurite outgrowth or 
survival.149 
 The PC12 cells were plated onto collagen Type IV plates at 10,000 cells /well, 
allowed to adhere for 24 hours, followed by the addition of compound at concentrations 
of 100, 10, and 1 μg/mL, respectively.  The cells were monitored over a period of two 
weeks, where the most pronounced effects were observed at about one week of 
exposure.  From our library of cyclohexadienals, two heterodimers (100 and 122) were 
able to successfully stimulate neurite outgrowth (Figure 61).  Therefore, neurite 
outgrowth activity appears to be associated with aromatic substituents.  Intriguingly, 
biphenyl groups have been though to serve as mimics of protein alpha helices.169  
To assess the degree to which stereochemistry dictates phenotype in the neurite 
outgrowth assay, dimers 100 and 122 were derivatized into their corresponding 
menthylhydrazone derivatives150 to allow separation of the stereoisomers by HPLC 
(Scheme 17).  Following HPLC purification, the compounds were each hydrolyzed 
giving each aldehyde in enantiomerically pure form.  Upon reanalysis in the PC12 assay, 
the R-configuration was shown to be responsible for neurite outgrowth activity while the 
S-configuration exhibited no activity (Figure 46).  In the future, it will be interesting to 
establish whether the heterodimers that exhibit activity share the same target as the 
homodimers that possess neurite activity.    
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Figure 61.  Stimulation of neurite outgrowth by cyclohexadienal heterodimers. 
(A) Control, cells treated with absolute ethanol; (B) methylfuran, biphenyl cyclohexadienals, 1 
μg/mL at 6 days; (C) dimethylamino-phenyl, naphthyl-cyclohexadienal; 10 μg/mL at 7 days.  
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Scheme 17.  Isolation of stereoisomers. 
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Figure 62.  Stimulation of neurite outgrowth by heterodimer stereoisomers. 
(A) Control, cells treated with absolute ethanol; (B) R-methylfuran, biphenyl cyclohexadienals, 
10 μg/mL at 6 days; (C) S-methylfuran, biphenyl cyclohexadienals, 10 μg/mL at 6 days;  (D) R-
dimethylamino-phenyl, naphthyl-cyclohexadienal; 10 μg/mL at 6 days; (E) S-dimethylamino-
phenyl, naphthyl-cyclohexadienal; 10 μg/mL at 6 days. 
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 As cyclocitral 15 has been reported to possess antibiotic activity,39,88,151,152 we 
also surveyed our cyclohexadienal library of compounds against bacterial strains 
(Escherichia coli and Bacillus subtilis) and yeast (Saccharomyces cerevisiae).  All 
compounds were tested at three concentrations, 100, 10, and 1 µg/mL.  In most cases, 
moderate to no inhibition was observed, where compounds exhibited MIC values >100 
µg/mL.  Three compounds (121, 135, and 147) were reasonably active against B. subtilis 
with MIC values within the 10-25 µg/mL range.  Against Jurkats, a human T-cell 
Leukemia cell line, the effects were again moderate for the majority of compounds 
tested, a few (94, 98, 106, and 122) demonstrated complete inhibition of growth at 1 
µg/mL.   
 
CONCLUSION 
 The retinoids have achieved prominence for their therapeutic benefits ranging 
from their ability to treat acne and skin blemishes to their ability to differentiate stem 
cells.17,27-30,166  An unusual class of diterpenoid natural products, “cycloterpenals”, have 
been isolated from a variety of organisms including marine sponges and the human 
eye.33,34,39,88,89,151,152  Moreover, incubation of the milk whey protein β-lactoglobulin with 
β-ionylideneacetaldehyde has been shown to give cycl-β-ional.87  As such, it is plausible 
that some of these cycloterpenals or their structurally and functionally related analogs 
could be important in developmental process such as neurite outgrowth. 
 In this chapter, we implemented a proline-promoted condensation reaction that 
enabled diversification of the cycloterpenals skeleton to give a library of molecules with 
varying degrees of substitution.  Specific reaction conditions required to favor cross-
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condensation as opposed to self-condensation were detailed.  In the case of aromatic 
substituents, the cyclohexadiene ring system could be aromatized to give fluorescent 
molecules, which in the long term could lead to used of these molecules as probes in 
protein target identification of a particular cyclohexadienal.   
 The phenotypic effects of these cycloterpenals-based molecules were examined 
in a PC12 assay, where dramatic effects were observed on neurite outgrowth.  These 
results suggest that molecules with this cyclohexadienal motif might have applications in 
neurite regeneration, which plays a significant role in the treatment of neurodegenerative 
diseases or central nervous system injuries. 
 
EXPERIMENTAL 
General 
Fresh THF was dried by passage through an MBRAUN solvent purification 
system and stored over molecular sieves.  All other solvents and reagents were 
purchased and used without further purification.  Chemical shifts for 1H and 13C NMR 
spectra are reported in ppm referenced to TMS (0 ppm) and coupling constants are 
reported in Hertz (Hz).  MS spectra were recorded on an API QSTAR PULSAR (ES) 
apparatus.  IR spectra were recorded with a FT-IR spectrometer.  Chromatographic 
separations were achieved by flash silica chromatography (silica gel 60 mesh, EMD 
Biosciences).  The determination of ee’s were done by Pr(hfc)3 chiral shift reagent.  β-
methylenic aldehydes were synthesized by reduction of their corresponding nitriles,104 
which were derived from their respective methyl-ketone analoges.102  In all cases, the 
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all-trans isomer was utilized except in the case of citral which was purchased as a 
mixture. 
Organisms 
PC12 neuronal cells (CRL 1721) and B. subtilis strain 6633 were obtained from 
the American Type Culture Collection, Rockville, MD. The yeast S. cerevisiae wild-type 
strain [#404; BY4741; MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0] was obtained from Dr. 
Michael Kladde at the Department of Biochemistry, Texas A&M University. The E. coli 
strain DH10B was obtained from Prof. Dennis Gross, Texas A&M University, 
Department of Plant Pathology. 
 
Media Conditions 
• LB (Luria-Bertani) medium contained the following components per liter:  Bacto-
peptone, 10g; Yeast extract, 5g; Sodium chloride, 5g; and deionized water. 
• YPD (Yeast Peptone Dextrose) medium contained the following components per 
liter:  Yeast extract, 5g; Bacto-peptone, 5g; Glucose, 20 g; and deionized water. 
• NB (Nutrient Broth) medium contained the following components per liter:  Beef 
extract, 3g; Peptone, 5g; and deionized water. 
Agar plates of the above media were prepared by adding 20 g/L bacto-agar.  All media 
were autoclaved at 121 °C for 20 minutes. 
 
Neurite Outgrowth Assay 
PC12 cells were maintained in 100 mm Collagen Type IV dishes at 37 ˚C in a 
5% CO2/air temperature.  The cell culture medium consisted of RPMI 1640, with 10% 
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heat-inactivated horse serum and 5% fetal bovine serum.  Cells were removed from the 
culture flasks by flushing with fresh culture medium.  Cells were then transferred to a 15 
mL falcon tube and centrifuged for 15 min. at 1000 rpm.  The medium was removed and 
the cells were resuspended in fresh culture medium.  The cells were counted with a 
hemocytometer and replated in a 96 well Collagen Type IV plate at 10,000 cells/well 
with enough fresh medium to bring the volume to 200 μL.  The cells were allowed to 
adhere for 24 h prior to the addition of compound.  Each cyclohexadienal compound was 
examined at three concentrations in duplicate, to give final concentrations of 100, 10 and 
1 μg/mL respectively.  Each well was visually monitored over a period of 2 weeks for 
neurite outgrowth and intercellular connections.  Fresh medium was added when 
necessary.  Photographs were taken with an Olympus SP-310 camera equipped with a 
modified lens piece that fits over the microscope eyepiece. 
 
Cytotoxicity Assay Against Jurkat Cell LIne 
Jurkat cells were maintained in 75 cm2 culture flasks at 37 ˚C under a 5% CO2 
atmosphere.  The cell culture medium consisted of RPMI 1640 with 10% fetal bovine 
serum.  Cells were harvested by centrifugation (20 min. at 1000 rpm), resuspended in 
fresh culture medium and counted on a hemocytometer.  The cells (1 mL) were arrayed 
(200,000 cells/well) in 48 well plates to which compound was added to give final 
concentrations of 100, 10 and 1 μg/mL respectively.  Cells were incubated for 24 h, 
transferred to 1.5 mL eppendorf tubes and centrifuged for 15 min. at 14,000 rpm.  The 
medium was removed and the cell pellet resuspended in 1 mL of phosphate buffer saline 
(PBS) to wash the cells.  The cells were again centrifuged for 15 min. at 14,000 rpm.  
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The PBS was removed and the cell pellet resuspended in a lysis buffer (CyQuant Cell 
Proliferation Kit).  The stock solution, 20X, should be diluted to a final concentration    
1X with an 80 fold dilution of propidium iodide in order to visualize 200,000 cells/well.   
The lysed cells were then placed in a black 96 well plate and analyzed using a Bio-Tek 
fluorometer to measure relative fluorescence. 
 
Anti-bacterial and Anti-fungal Assays 
Microbes (Saccharomyces cerevisiae, Escherichia coli, and Bacillus subtilis 
6633) were cultured and maintained on agar plates (see supplemental material for media 
conditions).  A single colony was used to inoculate 3 mL of culture medium and allowed 
to grow for 16 h.  The cells (500 μL) were diluted with 50 mL of fresh medium to an 
O.D. of 0.1 and aliquoted into a 96-well plate (100 µL/well).  The assays were set up in 
duplicate and the compounds tested to give final concentrations of 100, 10 and 1 μg/mL.  
Plates were incubated (E. coli and B. subtilis, 37 °C; yeast, 30 °C) and shaken (250 rpm) 
for 16 h and cell density (O.D.) measured with a Bio-Tek microplate reader.   
 
NMR Analysis of Cinnamaldehyde Analogues-Schiff Base Reaction 
A 5 mm NMR tube was filled with 80O µL of CD3OD and was placed in a 300 
MHz NMR for shimming purposes.  Once properly shimmed, another tube was filled 500 
µL of the various cinnamaldehyde derivatives (30 mg/mL) and the instrument was 
reshimmed.  The reaction was started by ejecting the cinnamaldehyde and adding 1.5 eq. 
of the L-proline solution (30 mg/mL), shaking the tube, reinserting the tube into the NMR, 
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and immediately acquiring a spectrum that took a total time of 2 minutes.  After the initial 
spectrum and periodically throughout the experiment, the instrument was reshimmed.   
 
Theoretical Calculations  
The theoretical calculations were performed using the Gaussian 03 suite of 
programs.170  All calculation were performed at the density functional theory (DFT)171 
level with the Becke three-parameter exchange functional (B3)172 and the Lee-Yang-Parr 
correlation functional (LYP)173 (B3LYP).  Pople and co-workers’ double-ζ quality basis 
set (BSI) with a polarization function on the heavy atoms (6-31G(d’))174-176  was used for 
the geometry optimizations.  All structures were fully optimized and frequency 
calculations were performed to guarantee that there were no imaginary modes.  Pople’s 
and co-workers’ triple-ζ quality basis set with a diffuse function on heavy and light 
atoms, a double polarization functions on the heavy atoms and a polarization function on 
the light atoms (6-311++G(2d,p)176,177 was employed for the NMR calculations.  The d 
functions used spherical harmonic representations.  The Gauge-Independent Atomic 
Orbital (GIAO) method178 was used for the NMR calculations.  Spin-spin coupling 
constants179 were also calculated during the NMR calculations.  Calculated proton 
chemical shifts were normalized again the average calculated proton chemical shifts for 
tetramethylsilane (TMS) (δ = 31.77 ppm). 
 
Synthesis of Cross-Condensation Productions 
The following is an example of the synthetic procedure for the synthesis of 4-(5-
Methyl-furan-2-yl)-6-phenyl-cyclohexa-1,3-dienecarbaldehyde (89).  The α,β-
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unsaturated compound cinnamaldehyde (33.0 mg, 1.5 equivalents) was dissolved in 200 
proof ethanol (8 mL) with 3.4 equivalents (72.0 mg) of L-proline.  After approximately 2 
hours, at which point Schiff base formation is complete as monitored via thin layer 
chromatography (TLC), one equivalent of β-methylenic aldehyde 3-(5-methylfuran-2-
yl)-but-2-enal (25 mg, 1 equivalent) was added to the reaction mixture and stirred at 
ambient temperatures for 18 hours.  The reaction was monitored by TLC.  Upon 
completion, the reaction was quenched by the addition of water (20 mL), extracted with 
a 1:1 ethyl acetate/hexanes solution (3 x 50 mL), and was washed with brine.  The 
organic layer was dried over magnesium sulfate (MgSO4) and concentrated under 
vacuum.  The crude product was purified by column chromatography (10% ethyl 
acetate/hexanes) to yield 12.7 mg of the final product (48% yield) as a red oil.   
 
Characterization of Cross Condensation Products 
S
O
6-phenyl-4-(thiophen-2-yl)cyclohexa-1,3-dienecarbaldehyde (86):   
1H NMR (300MHz, CDCl3, 25°C), δ=9.61 (s, 1H), 8.09-8.13 (m, 2H), 7.46 (d, J=9.0 Hz, 
2H), 7.41 (d, J=5.1 Hz, 1H), 7.26-7.30 (m, 2H), 7.17 (d, J=6.0 Hz, 1H), 7.07-7.10 (m, 
1H), 6.74 (dd, J=3.0, 6.0 Hz, 1H), 4.35 (dd, J=1.8, 9.6 Hz, 1H), 3.28 (qd, J=2.5, 9.6, 18.0 
Hz, 1H), 3.12 (dd, J=1.9, 18.0 Hz, 1H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=191.5 (CH), 150.2 (C), 144.1 (CH), 143.5 (C), 
139.0 (C), 137.3 (C), 128.6 (2 x CH), 128.3 (2 x CH), 128.2 (CH), 126.5 (CH), 124.2 (2 
x CH), 118.0 (CH), 34.6 (CH2), 33.9 (CH) 
IR (neat) ν 3020, 2968, 2925, 2853, 2727, 1661, 1540, 1492, 1385, 1180, 844 cm-1 
HRMS (ESI) for C17H14NOSLi (M+Li)+: calcd 273.0925, found 273.0833. 
S
O
N
6-(4-Dimethylamino-phenyl)-4-thiophen-2-yl-cyclohexa-1,3-
dienecarbaldehyde (87):   
1H NMR (300MHz, CDCl3, 25°C), δ=9.55 (s, 1H), 7.33 (d, J=4.5 Hz, 1H), 7.24 (d, J=3.6 
Hz, 1H), 7.17 (d, J=7.8 Hz, 2H), 7.02-7.05 (m, 1H), 6.99 (d, J=6.0 Hz, 1H), 6.58-6.70 
(m, 3H), 6.14 (dd, J=3.9, 7.5 Hz, 1H), 3.12-3.15 (m, 2H), 2.88 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.1 (CH), 145.8 (C), 142.9 (C), 142.0 (C), 139.2 
(CH), 136.8 (C), 133.1 (C), 128.4 (2 x CH), 128.2 (CH), 128.0 (CH), 127.3 (CH), 126.1  
(CH), 118.1 (2 x CH), 34.2 (2 x CH3) 33.6 (CH2), 29.9 (CH) 
IR (neat) ν 2923, 2853, 1664, 1541, 1519, 1456, 1201, 1169, 969, 821, 701 cm-1 
HRMS (ESI) for C19H19NOS (M+H)+: calcd 310.1266, found 310.1237. 
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S
O
NO2
6-(4-Nitro-phenyl)-4-thiophen-2-yl-cyclohexa-1,3-dienecarbaldehyde 
(88):   
1H NMR (300MHz, CDCl3, 25°C), δ=9.57 (s, 1H), 8.07 (d, J=9.0 Hz, 2H), 7.43 (d, J=8.7 
Hz, 2H), 7.37 (dd, J=0.9, 5.1 Hz, 1H), 7.24 (dd, J=1.2, 3.9 Hz, 1H), 7.14 (d, J=6.0 Hz, 
1H), 7.03-7.06 (m, 1H), 6.70 (dd, J=2.4, 6.0 Hz, 1H), 4.31 (dd, J=2.1, 9.6 Hz, 1H), 3.24 
(qd, J=2.7, 9.9, 17.7 Hz, 1H), 3.08 (dd, J=2.1, 18.0 Hz, 1H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.5 (CH), 150.2 (C), 147.2 (C), 144.1 (CH), 
143.4 (C), 139.0 (C), 137.2 (C), 128.6 (CH), 128.3 (2 x CH), 128.1 (CH), 126.5 (CH), 
124.1 (2 x CH), 118.0 (CH), 34.5 (CH), 33.8 (CH2) 
IR (neat) ν 3108, 3075, 2924, 2817, 2717, 1738, 1659, 1539, 1512, 1341, 1168, 1027, 
853, 826, 698 cm-1 
HRMS (ESI) for C17H13NO3S (M+Li)+: calcd 312.0694, found  312.0789. 
 
O
O
4-(5-Methyl-furan-2-yl)-6-phenyl-cyclohexa-1,3-dienecarbaldehyde 
(89):   
1H NMR (300MHz, CDCl3, 25°C), δ= 9.54 (s, 1H), 7.12-7.28 (m, 5H), 7.10 (d, J=6.3 
Hz, 1H), 6.68 (dd, J= 2.6, 6.2 Hz, 1H), 6.45 (d, J=3.3 Hz, 1H), 6.05-6.06 (m, 1H), 4.19 
(dd, J=1.8, 9.3 Hz, 1H), 2.87-3.09 (m, 2H), 2.34 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=191.9 (CH), 155.2 (C), 151.9 (C), 144.1 (CH), 
142.9 (C), 137.9 (C), 134.0 (C), 128.7 (2 x CH), 127.4 (2 x CH), 127.0 (CH), 115.1 
(CH), 112.6 (CH), 108.9 (CH), 34.0 (CH), 31.5 (CH2), 14.2 (CH3) 
IR (neat) ν 3012, 2962, 2941, 2326, 1735, 1431, 1365, 1229, 1211, 1206, 913 cm-1 
HRMS (ESI) for C18H16O2Li (M+Li)+: calcd 271.1310, found  271.1365. 
  
O
O
N
6-(4-Dimethylamino-phenyl)-4-(5-methyl-furan-2-yl)-cyclohexa-1,3-
dienecarbaldehyde (90):  1H NMR (300MHz, CDCl3, 25°C), δ=9.52 (s, 1H), 7.14 (d, 
J=8.7 Hz, 2H), 7.03 (d, J=6.0 Hz, 1H), 6.67 (dd, J=2.1, 6.0 Hz, 1H), 6.61 (d, J=8,7 Hz, 
2H), 6.45 (d, J=3.3 Hz, 1H), 6.04-6.06 (m, 1H), 4.11 (dd, J=2.4, 9.3 Hz, 1H), 2.92-3.05 
(m, 2H), 2.86 (s, 6H), 2.34 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.2 (CH), 155.0 (C), 152.1 (C), 149.9 (C), 143.4 
(CH), 138.5 (C), 134.1 (C), 131.2 (CH), 128.1 (2 x CH), 115.1 (2 x CH), 113.1 (CH), 
112.4 (CH), 108,9 (CH), 41.0 (2 x CH3), 33.1 (CH), 31.5 (CH2), 14.2 (CH3) 
IR (neat) ν 3010, 2983, 2371, 1740, 1730, 1662, 1595, 1536, 1520, 1350, 1220 cm-1 
HRMS (ESI) for C20H21NO2 (M+H)+: calcd 308.1651, found  308.1658. 
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O
O
NO2
4-(5-Methyl-furan-2-yl)-6-(4-nitro-phenyl)-cyclohexa-1,3-
dienecarbaldehyde (91):  1H NMR (300MHz, CDCl3, 25°C), δ=9.56 (s, 1H), 8.09 (d, 
J=8.7 Hz, 2H), 7.44 (d, J=9.0 Hz, 2H), 7.20 (d, J=6.0, 1H), 6.73 (dd, J=2.6, 6.1 Hz, 1H), 
6.50 (d, J=3.3 Hz, 1H), 6.08 (dd, J=0.6, 3.3 Hz, 1H), 4.25-4.30 (m, 1H), 3.08 (qd, J=2.7, 
8.7 Hz, 1H), 2.87 (m, 1H), 2.35 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.5 (CH), 155.8 (C), 151.4 (C), 150.3 (C), 144.7 
(CH), 136.5 (C), 133.7 (C), 133.2 (C), 129.9 (CH), 128.3 (2 x CH), 124.0 (2 x CH), 
115.0 (CH), 113.1 (CH), 34.1 (CH2), 31.2 (CH), 14.2 (CH3) 
IR (neat) ν 3006, 2990, 2925, 1720, 1662, 1538, 1521, 1345, 1276, 1261, 1173, 764, 750 
cm-1  
HRMS (ESI) for C18H15NO4Li (M+Li)+: calcd 316.1161, found 316.1011. 
 
O
4-Biphenyl-4-yl-6-phenyl-cyclohexa-1,3-dienecarbaldehyde (92):  
1H NMR (300MHz, CDCl3, 25°C), δ=9.63 (s, 1H), 7.56-7.66 (m, 5H), 7.29-7.53 (m, 
6H), 7.16-7.25 (m, 3H), 7.14 (d, J=6.0 Hz, 1H), 7.75 (dd, J=2.4, 6.0 Hz, 1H), 4.27 (dd, 
J=2.7, 9.3 Hz, 1H), 3.14-3.32 (m, 2H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.3 (CH), 145.2 (C), 143.7 (CH), 142.7 (C), 
142.0 (C), 140.4 (C), 138.8 (C), 138.3 (C), 129.1 (2 x CH), 128.8 (2 x CH), 128.0 (CH), 
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127.6 (2 x CH), 127.4 (2 x CH), 127.2 (2 x CH), 127.1 (CH), 126.5 (2 x CH), 119.9 
(CH), 34.6 (CH), 34.1 (CH2) 
IR (neat) ν 3028, 2971, 2948, 2131, 1738, 1664, 1448, 1366, 1229, 1217, 1206, 896, 
763, 696 cm-1 
HRMS (ESI) for C25H20OLi (M+Li)+: calcd 343.1674, found 343.1673. 
 
O
N
4-(biphenyl-4-yl)-6-(4-(dimethylamino)phenyl)cyclohexa-1,3-
dienecarbaldehyde (93):  1H NMR (300MHz, CDCl3, 25°C), δ=9.61 (s, 1H), 7.25-7.59 
(m, 9H), 7.20-7.26 (m, 2H), 7.08 (d, J=5.7, 1H), 6.67-6.74 (m, 3H), 4.16-4.20 (m, 1H), 
3.00-3.28 (m, 8H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.6 (CH), 149.6 (C), 145.2 (C), 143.1 (CH), 
141.9 (C), 140.5 (C), 139.4 (C), 138.5 (C), 131.4 (C), 129.1 (2 x CH), 128.1 (2 x CH), 
127.5 (2 x CH), 127.2 (2 x CH), 126.5 (2 x CH), 122.0 (CH), 119.9 (CH), 113.3 (2 x 
CH), 41.1 (2 x CH3), 34.1 (CH2), 36.6 (CH) 
IR (neat) ν 3008, 2971, 2382, 2354, 1739, 1670, 1366, 1275, 1217, 750 cm-1  
HRMS (ESI) for C27H25NO (M+Li)+: calcd 386.2096, found 386.2049. 
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O
NO2
4-Biphenyl-4-yl-6-(4-nitro-phenyl)-cyclohexa-1,3-
dienecarbaldehyde (94): 1H NMR (300MHz, CDCl3, 25°C), δ=9.62 (s, 1H), 8.08 (d 
J=8.7 Hz, 2H), 7.34-7.66 (m, 11H), 7.21 (d, J=6.0 Hz, 1H), 6.78 (dd, J=2.7, 6.0, 1H), 
4.34 (dd, J=1.5, 9.9, 1H), 3.31 (qd, J=2.7, 9.9, 18.0, 1H), 3.13 (dd, J=1.8, 17.9, 1H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.9 (CH), 150.2 (C), 147.2 (C), 145.1 (C), 144.3 
(CH), 142.5 (C), 140.2 (C), 137.7 (C), 137.4 (C), 129.2 (2 x CH), 128.3 (2 x CH), 128.1 
(CH), 127.7 (2 x CH), 127.2 (2 x CH), 126.5 (2 x CH), 124.1 (2 x CH), 119.9 (CH), 34.6 
(CH), 33.7(CH2) 
IR (neat) ν 3029, 2971, 2925, 1738, 1663, 1597, 1516, 1345, 1229, 1217, 1110, 832, 
764, 697 cm-1  
HRMS (ESI) for C25H19NO3Li (M+Li)+: calcd 388.1525, found 388.1575. 
 
O
4-Biphenyl-4-yl-cyclohexa-1,3-dienecarbaldehyde (95): 1H 
NMR (300MHz, CDCl3, 25°C), δ=9.62 (s, 1H), 7.62-7.69 (m, 5H), 7.47-7.52 (m, 2H), 
7.37-7.43 (m, 1H), 6.99 (d, J=5.7 Hz, 1H), 6.70 (d, J=5.7 Hz, 1H), 2.79-2.86 (m, 2H), 
2.62-2.69 (m, 2H) 
170 
 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.7 (CH), 146.6 (C), 143.8 (CH), 141.8 (C), 
140.5 (C), 138.5 (C), 136.7 (C),129.2 (2 x CH), 127.9 (CH), 127.6 (2 x CH), 127.2 (2 x 
CH), 126.4 (2 x CH), 120.4 (CH), 25.9 (CH2), 19.1 (CH2) 
IR (neat) ν  3000, 2993, 2950, 1784, 1765, 1740, 1654, 1383, 1367, 1258, 1056, 832 cm-
1  
HRMS (ESI) for C19H16OLi (M+Li)+: calcd 267.1361, found 267.1423. 
 
O
4-(9H-fluoren-2-yl)-6-phenylcyclohexa-1,3-dienecarbaldehyde 
(96):  1H NMR (300MHz, CDCl3, 25°C), δ=9.62 (s, 1H),7.74-7.80 (m, 2H), 7.67-7.68 
(m, 1H), 7.52- 7.56 (m, 2H), 7.29-7.44 (m, 5H), 7.12-7.26 (m, 3H), 6.74 (dd, J=2.4, 6.0 
Hz, 1H), 4.27 (dd, J=2.7, 9.0 Hz, 1H), 3.90 (s, 2H), 3.22-3.34 (m, 2H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.3 (CH), 146.1 (C), 144.0 (C), 143.9 (CH), 
143.0 (C), 142.9 (C), 141.2 (C), 138.6 (C), 138.5 (C), 138.0 (C), 128.8 (2 x CH), 127.5 
(CH), 127.4 (2 x CH), 127.2 (CH), 127.1 (CH), 125.4 (CH), 125.1 (CH), 122.7 (CH), 
120.4 (CH), 120.2 (CH), 119.6 (CH), 37.1 (CH2), 34.7 (CH), 34.4 (CH2) 
IR (neat) ν 3026, 2971, 2947, 2865, 1738, 1664, 1544, 1366, 1229, 1217, 1206, 1173, 
769 cm-1  
HRMS (ESI) for C26H20O (M+H)+: calcd 355.1674, found 355.1774. 
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O
N
6-(4-Dimethylamino-phenyl)-4-(9H-fluoren-2-yl)-cyclohexa-1,3-
dienecarbaldehyde (97):  1H NMR (300MHz, CDCl3, 25°C), δ=9.63 (s, 1H), 7.73-7.83 
(m, 3H), 7.59 (d, J=8.1 Hz, 1H), 7.33-7.51 (m, 3H), 7.21 (d, J=8.4 Hz, 2H), 7.10 (d, 
J=6.0 Hz, 1H), 6.76 (dd, J=2.1, 6.0 Hz, 1H), 6.72 (d, J=9.0 Hz, 2H), 4.20 (dd, J=3.3, 8.1 
Hz, 1H), 3.93 (s, 2H), 3.26 (dd, J=2.1, 7.5 Hz, 1H), 3.05-3.10 (m, 7H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.6 (CH), 154.3 (C), 152.7 (C), 146.2 (C), 144.0 
(CH), 143.9 (C), 143.3 (C), 142.9 (C), 141.3 (C), 139.2 (C), 138.3 (C), 130.8 (2 x CH), 
127.4 (CH), 127.2 (CH), 125.4 (CH), 125.1 (CH), 124.1 (CH), 122.7 (CH), 120.2 (CH), 
119.6 (CH), 112.0 (2 x CH), 40.4 (2 x CH3), 37.2 (CH2), 34.4 (CH2), 33.7 (CH) 
IR (neat) ν 3049, 2957, 2926, 2891, 2852, 1712, 1672, 1597, 1523, 1456, 1358, 1264, 
1197, 1119, 823, 769, 735 cm-1  
HRMS (ESI) for C28H25NO (M+H)+: calcd 392.2014, found 392.2039. 
 
 
O
NO2
4-(9H-Fluoren-2-yl)-6-(4-nitro-phenyl)-cyclohexa-1,3-
dienecarbaldehyde (98):  1H NMR (300MHz, CDCl3, 25°C), δ=9.66 (s, 1H), 8.11 (d, 
J=8.7 Hz, 2H), 7.79-7.89 (m, 2H), 7.53-7.73 (m, 2H), 7.49 (d, J=8.7 Hz, 2H), 7.31-7.43 
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(m, 3H), 7.25 (d, J=6.3 Hz, 1H), 6.82 (dd, J=2.7, 5.7 Hz, 1H), 4.38 (dd, J=2.4, 10.2 Hz, 
1H), 3.94 (s, 2H), 3.37 (qd, J=2.1, 10.2, 17.7 Hz, 1H), 3.20 (dd, J=2.1, 17.7 Hz, 1H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.9 (CH), 147.2 (C), 146.0 (C), 145.2 (C), 144.5 
(C), 144.1 (CH), 143.9 (C), 143.5 (C), 141.1 (C), 137.4 (C), 137.2 (C), 128.4 (2 x CH), 
127.7 (CH), 127.3 (CH), 125.4 (CH), 125.1 (CH), 124.1 (2 x CH), 123.9 (CH), 122.7 
(CH), 120.6 (CH), 120.4 (CH), 37.2 (CH2), 34.7 (CH2), 34.1 (CH) 
IR (neat) ν 3054, 3030, 2971, 2924, 2853, 1737, 1662, 1594, 1517, 1344, 1108, 854, 
826, 733 cm-1  
HRMS (ESI) for C26H19NO3 (M+H)+: calcd 394.1443, found 394.1412. 
 
O
4-(naphthalen-2-yl)-6-phenylcyclohexa-1,3-dienecarbaldehyde (99):  
1H NMR (300MHz, CDCl3, 25°C), δ=9.63 (s, 1H), 7.79-7.92 (m, 3H), 7.65 (dd, J=1.8, 
8.7 Hz, 2H), 7.46-7.54 (m, 3H), 7.14-7.32 (m, 5H), 6.83 (dd, J=1.8, 6.0 Hz, 1H), 4.29 
(dd, J=4.2, 12.0 Hz, 1H), 3.30 (m, 2H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.4 (CH), 145.4 (C), 143.6 (CH), 142.8 (C), 
138.8 (C), 136.6 (C), 133.7 (C), 133.4 (C), 128.8 (2 x CH), 128.7 (CH), 128.6 (CH), 
127.8 (CH), 127.4 (2 x CH), 127.1 (CH), 127.0 (CH), 126.8 (CH), 125.6 (CH), 123.6 
(CH), 120.4 (CH), 34.6 (CH), 34.0 (CH2) 
IR (neat) ν 3055, 2924, 2810, 2717, 1666, 1547, 1395, 1374, 1169, 842, 814, 749, 699 
cm-1 
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HRMS (ESI) for C23H18O (M+Li)+: calcd 317.1518, found 317.1466. 
 
O
N
6-(4-(dimethylamino)phenyl)-4-(naphthalen-2-yl)cyclohexa-1,3-
dienecarbaldehyde (100):  1H NMR (300MHz, CDCl3, 25°C), δ=9.61 (s, 1H), 7.94 (s, 
1H), 7.82 (m, 3H), 7.67 (dd, J=1.8, 8.7 Hz, 1H), 7.47 (m, 2H), 7.18 (d, J=8.7 Hz, 2H), 
7.07 (d, J=6.0, 1H), 6.81 (d, J=6.0 Hz, 1H), 6.58 (d, J=8.7 Hz, 2H), 4.19 (t, J=6.0 Hz, 
1H), 3.28 (d, J=6.0 Hz, 2H), 2.84 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.6 (CH), 151.6 (C), 145.4 (C), 142.9 (CH), 
140.9 (C), 137.8 (C), 135.7 (C), 134.1 (C), 133.5 (C), 128.7 (CH), 128.5 (CH), 128.1 (2 
x CH), 127.8 (CH), 126.9 (CH), 126.8 (CH), 125.6 (CH), 123.7 (CH), 120.3 (CH), 112.9 
(2 x CH), 40.8 ( 2 x CH3), 34.0 (CH2), 33.7 (CH) 
IR (neat) ν 2932, 2850, 1668, 1547, 1521, 1169, 817 cm-1 
HRMS (ESI) for C25H23NO (M+H)+: calcd 354.1858, found 354.1904. 
 
 
 
O
NO2
4-Naphthalen-2-yl-6-(4-nitro-phenyl)-cyclohexa-1,3-
dienecarbaldehyde (101):   1H NMR (300MHz, CDCl3, 25°C), δ=9.67 (s, 1H), 8.10 (d, 
J=9.0 Hz, 2H), 7.94 (s, 1H), 7.83-7.88 (m, 3H), 7.66 (dd, J=1.8, 8.7 Hz, 1H), 7.48-7.56 
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(m, 4H), 7.26 (d, J=6.0 Hz, 1H), 6.90 (dd, J=2.7, 6.0 Hz, 1H), 4.41 (dd, J=2.1, 9.6 Hz, 
1H), 3.42 (qd, J=2.4, 9.6, 17.7 Hz, 1H), 3.28 (dd, J=2.1, 17.7 Hz, 1H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.0 (CH), 150.2 (C), 147.2 (C), 145.3 (C), 144.3 
(CH), 137.5 (C), 136.0 (C), 133.9 (C), 133.4 (C), 128.9 (CH), 128.8 (CH), 128.4 (2 x 
CH), 127.9 (CH), 127.4 (CH), 127.1 (CH), 125.7 (CH), 124.1 (2 x CH), 123.4 (CH), 
120.4 (CH), 37.7 (CH2), 33.8 (CH) 
IR (neat) ν 3055, 2922, 2851, 1671, 1598, 1544, 1505, 1455, 1373, 1259, 1016, 857, 
814, 788, 747 701 cm-1 
HRMS (ESI) for C235H17NO3 (M+Li)+: calcd 362.1368, found 362.1384. 
 
4,6-diphenylcyclohexa-1,3-dienecarbaldehyde (102):  1H NMR 
(300MHz, CDCl3, 25°C), δ=9.61 (s, 1H), 7.45-7.50 (m, 2H), 7.32-7.41 (m, 3H), 7.28-
7.30 (m, 1H), 7.20-7.24 (m, 2H), 7.17-7.19 (m, 2H), 7.12 (d, J=6.0 Hz, 1H), 6.67 (dd, 
J=2.7, 6.0 Hz, 1H), 4.24 (dd, J=2.1, 9.6 Hz, 1H), 3.08-3.29 (m, 2H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.2 (CH), 144.5 (C), 142.6 (CH), 141.4 (C), 
138.3 (C), 137.5 (C), 128.0 (CH), 127.7 (2 x CH), 127.5 (2 x CH), 126.1 (2 x CH), 125.8 
(CH), 124.8 (2 x CH), 118.8 (CH), 33.3 (CH), 33.0 (CH2) 
IR (neat) ν 3028, 2926, 2813, 2720, 2382, 2332, 2310, 1662, 1551, 1170, 757 cm-1 
HRMS (ESI) for C19H16OLi (M+Li)+: calcd 267.1361, found 267.1368. 
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N
6-(4-(dimethylamino)phenyl)-4-phenylcyclohexa-1,3-
dienecarbaldehyde (103):  1H NMR (300MHz, CDCl3, 25°C), δ=9.60 (s, 1H), 7.44-
7.50 (m, 2H), 7.32-7.41 (m, 5H), 7.18 (d, J=9.0 Hz, 2H), 7.13 (d, J=6.0 Hz, 1H), 6.67-
6.70 (m, 1H), 4.22 (dd, J=1.5, 9.9 Hz, 1H), 3.19-3.30 (m, 1H), 3.08-3.10 (m, 1H), 3.04 
(s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=194.16 (CH), 152.6 (C), 145.8 (C), 143.2 (CH), 
141.2 (C), 139.8 (C), 139.2 (C), 130.8 (2 x CH), 128.9 (CH), 128.2 (CH), 126.1 (CH), 
124.0 (CH), 122.0 (CH), 120.0 (CH), 112.0 (2 x CH), 40.3 (2 x CH3), 34.2 (CH2), 33.7 
(CH) 
IR (neat) ν 2962, 2922. 2382, 2327, 2310, 1665, 1595, 1527, 1369, 1137, 809 cm-1 
LRMS (APCI) for C21H21ON (M+H)+: calcd 304.2, found 304.3. 
 
 
O
NO2
6-(4-Nitro-phenyl)-4-phenyl-cyclohexa-1,3-dienecarbaldehyde (104):  
1H NMR (300MHz, CDCl3, 25°C), δ=9.62 (s, 1H), 8.07 (d, J=8.7 Hz, 2H), 7.34-7.48 (m, 
7H), 7.20 (d, J=6.0 Hz, 1H), 6.71 (dd, J=2.7, 6.0 Hz, 1H), 4.32 (dd, J=1.8, 9.9 Hz, 1H), 
3.29 (qd, J=2.7, 9.9, 17.7 Hz, 1H), 3.08 (dd, J=1.8, 17.7 Hz, 1H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=191.9 (CH), 150.1 (C), 147.2 (C), 145.6 (C), 144.3 
(CH), 139.0 (C), 137.5 (C), 129.7 (CH), 129.1 (2 x CH), 128.3 (2 x CH), 126.0 (2 x CH), 
124.1 (2 x CH), 120.1 (CH), 34.6 (CH), 33.9 (CH2) 
IR (neat) ν 3057, 3029, 2971, 2925, 2854, 2825, 2719, 1739, 1662, 1596, 1551, 1514, 
1343, 1171, 852, 766, 696 cm-1 
HRMS (ESI) for C19H15O3N (M+Li)+: calcd 312.1212, found 312.1198. 
 
S
Cl
O
4-(5-chlorothiophen-2-yl)-6-phenylcyclohexa-1,3-
dienecarbaldehyde (105):  1H NMR (300MHz, CDCl3, 25°C), δ=9.56 (s, 1H), 7.46-
7.50 (m, 1H), 7.14-7.24 (m, 4H), 7.03 (d, J=6.0 Hz, 1H), 6.98 (d, J=3.9 Hz, 1H), 6.84 (d, 
J=3.6 Hz, 1H), 6.53 (dd, J=2.7, 6.3 Hz, 1H), 4.22 (dd, J=2.7, 9.3 Hz, 1H), 2.98-3.16 (m, 
2H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.8 (CH), 142.9 (CH), 142.5 (C), 142.4 (C), 
138.9 (C), 138.1 (C), 132.2 (C), 128.8 (2 x CH), 127.6 (CH), 127.3 (2 x CH), 127.2 
(CH), 125.5 (CH), 118.2 (CH), 34.4 (CH2), 33.4 (CH) 
IR (neat) ν 3095, 3028, 2928, 2868, 2715, 2383, 2343, 2310, 1664, 1542, 1434, 1421, 
1168, 1003, 764, 750 cm-1 
LRMS (APCI) for C17H13ClOS (M+H)+: calcd 301.0, found 301.3. 
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S
Cl
O
N
4-(5-Chloro-thiophen-2-yl)-6-(4-dimethylamino-phenyl)-
cyclohexa-1,3-dienecarbaldehyde (106):  1H NMR (300MHz, CDCl3, 25°C), δ=9.59 (s, 
1H), 7.49-7.52 (m, 2H), 7.29-7.42 (m, 2H), 7.15 (d, J=8.7 Hz, 2H), 7.04 (d, J=6.0 Hz, 
1H), 6.65 (dd, J=2.4, 6.0 Hz, 1H), 4.14 (dd, J=2.4, 9.0 Hz, 1H), 3.05-3.25 (m, 2H), 2.86 
(s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.6 (CH), 145.8 (C), 143.9 (C), 143.0 (CH), 
142.8 (C), 139.8 (C), 139.4 (C), 138.2 (C), 129.1 (CH), 128.9 (2 x CH), 128.7 (CH), 
128.0 (CH), 120.0 (CH), 113.1 (2 x CH), 41.0 (2 x CH3), 34.3 (CH2), 33.6 (CH) 
IR (neat) ν 2981, 2890, 1674, 1473, 1463, 1382, 1275, 1261, 1151, 1073, 954, 764 cm-1 
LRMS (APCI) for C19H18ClNOS (M+H)+: calcd 344.1, found 344.2. 
 
O
4-[4-Methyl-6-(2,6,6-trimethyl-cyclohex-1-enyl)-hexa-
1,3,5-trienyl]-6-phenyl-cyclohexa-1,3-dienecarbaldehyde (107):  1H NMR (300MHz, 
CDCl3, 25°C), δ=9.51 (s, 1H), 7.13-7.27 (m, 5H), 6.99 (d, J=6.3 Hz, 1H), 6.89 (dd, 
J=11.7, 15.0 Hz, 1H), 6.41 (d, J=15.6 Hz, 1H), 6.24-6.32 (m, 2H), 6.10-6.18 (m, 2H), 
4.19 (dd, J=2.1, 9.3 Hz, 1H), 3.01 (dd, J=2.4, 17.4 Hz, 1H), 2.84-2.94 (m, 1H), 2.02 (t, 
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J=6.2 Hz, 2H), 1.96 (s, 3H), 1.71 (s, 3H), 1.58-1.65 (m, 2H), 1.44-1.48 (m, 2H), 1.02 (s, 
6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.8 (CH), 144.9 (C), 143.8 (CH), 143.4 (C), 
139.9 (C), 139.1 (C), 138.0 (C), 137.5 (CH), 133.0 (CH), 130.4 (C), 130.3 (CH), 129.7 
(CH), 129.0 (CH), 128.7 (2 x CH), 127.4 (2 x CH), 127.0 (CH), 123.6 (CH), 39.8 (CH2), 
34.5 (C), 34.4 (CH), 33.4 (CH2), 30.9 (CH2), 29.2 (2 x CH3), 22.0 (CH3), 19.4 (CH2), 
13.2 (CH3) 
IR (neat) ν 3007, 2971, 1739, 1664, 1514, 1366, 1275, 1261, 1217, 765, 750 cm-1 
HRMS (ESI) for C29H34O (M+Li)+: calcd 405.2770, found 405.2816. 
 
O
N
6-(4-(dimethylamino)phenyl)-4-((1E,3E,5E)-4-methyl-6-
(2,6,6-trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl)cyclohexa-1,3-dienecarbaldehyde 
(108):  1H NMR (300MHz, CDCl3, 25°C), δ=9.49 (s, 1H), 7.15 (d, J=8.4 Hz, 2H), 6.94 
(d, J=6.0 Hz, 1H), 6.85-6.89 (m, 1H), 6.59-6.66 (m, 2H), 6.41 (d, J=15.0 Hz, 1H), 6.10-
6.29 (m, 4H), 4.06-4.16 (m, 1H), 2.96-3.09 (m, 2H), 2.88 (s, 6H), 1.96-2.05 (m, 5H), 
1.60 (m, 4H), 1.71 (s, 3H), 1.02 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.1 (CH), 145.0 (C), 143.3 (C), 139.9 (C), 138.0 
(C), 137.6 (2 x CH), 136.8 (C), 133.3 (C), 133.2 (CH), 130.8 (C), 130.4 (2 x CH), 129.6 
(CH), 128.9 (CH), 128.2 (CH), 123.6 (2 x CH), 39.8 (2 x CH3), 34.5 (CH), 33.5 (CH2), 
33.4 (CH2), 30.8 (CH2), 29.9 (C), 29.2 (2 x CH3), 22.0 (CH3), 19.4 (CH2), 13.2 (CH3) 
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IR (neat) ν 3010, 2958, 2888, 2820, 2383, 2326, 2300, 1661, 1596, 1527, 1371, 1135, 
972, 812 cm-1 
HRMS (ESI) for C31H39NO (M+H)+: calcd 442.3110, found  442.3122. 
  
O
NO2
4-((1E,3E,5E)-4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hexa-
1,3,5-trienyl)-6-(4-nitrophenyl)cyclohexa-1,3-dienecarbaldehyde (109):  1H NMR 
(300MHz, CDCl3, 25°C), δ=9.51 (s, 1H), 8.08 (d, J=9.0 Hz, 2H), 7.40 (d, J=8.4 Hz, 2H), 
7.07 (d, J=6.3 Hz, 1H), 6.88 (dd, J=11.5, 15.0 Hz, 1H), 6.41 (d, J=15.3 Hz, 1H),  6.10-
6.31 (m, 4H), 4.28 (t, J=5.7 Hz, 1H), 2.95 (d, J=5.7 Hz, 2H), 1.96 (s, 3H), 1.94 (t, J=6.9 
Hz, 2H),  1.70 (s, 3H), 1.57-1.65 (m, 2H), 1.43-1.47 (m, 2H), 1.01 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.4 (CH), 150.7 (C), 144.7 (C), 144.5 (CH), 
140.7 (C), 137.9 (C), 137.6 (C), 137.4 (CH), 135.0 (C), 132.5 (CH), 130.7 (C), 130.3 
(CH), 130.1 (CH), 129.6 (CH), 128.3 (2 x CH), 124. 1 (2 x CH), 123.3 (CH), 39.8 
(CH2), 34.5 (C), 34.4 (CH), 33.4 (CH2), 30.6 (CH2), 29.2 (2 x CH3), 22.0 (CH3), 19.4 
(CH2), 13.2 (CH3) 
IR (neat) ν 3008, 2968, 1720, 1666, 1589, 1361, 978, 810 cm-1 
HRMS (ESI) for C29H33NO3Li (M+Li)+: calcd 450.2620, found  450.2625. 
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O
4-[4-Methyl-6-(2,6,6-trimethyl-cyclohex-1-enyl)-hexa-
1,3,5-trienyl]-cyclohexa-1,3-dienecarbaldehyde (110):  1H NMR (300MHz, CDCl3, 
25°C), δ=9.50 (s, 1H), 6.86-6.95 (m, 2H), 6.39 (d, J=15.3 Hz, 1H), 6.28 (d, J=15.9 Hz, 
1H), 6.12-6.19 (m, 3H), 2.55 (s, 4H), 2.00-2.04 (m, 5H), 1.72 (s, 3H), 1.58-1.66 (m, 2H), 
1.41-1.49 (m, 2H), 1.03 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.2 (CH), 146.3 (C), 144.1 (CH), 140.0 (2 x C), 
138.0 (C), 137.5 (CH), 136.9 (C), 133.0 (CH), 130.3 (CH), 129.3 (CH), 128.8 (CH), 
124.0 (CH), 39.4 (CH2), 34.5 (C), 33.4 (CH2), 29.2 (2 x CH3), 22.9 (CH2), 22.0 (CH3), 
19.4 (CH2), 18.9 (CH2), 13.1 (CH3) 
IR (neat) ν 2954, 2926, 1717, 1664, 1514, 1400, 1221, 1082, 966, 866 cm-1 
HRMS (ESI) for C23H30O (M+Li)+: calcd 329.24567, found  329.2466. 
 
O
6-Phenyl-4-[2-(2,6,6-trimethyl-cyclohex-1-enyl)-vinyl]-cyclohexa-
1,3-dienecarbaldehyde (111):  1H NMR (300MHz, CDCl3, 25°C), δ=9.52 (s, 1H), 7.14-
7.29 (m, 5H), 6.97 (d, J=5.7 Hz, 1H), 6.49 (d, J=16.2 Hz, 1H), 6.26 (d, J=16.2 Hz, 1H), 
6.17 (dd, J=2.4, 6.0 Hz, 1H), 4.19 (dd, J=1.8, 9.6 Hz, 1H), 3.01 (dd, J=2.1, 17.7 Hz, 1H), 
2.85 (qd, J=2.1, 9.6, 17.7 Hz, 1H), 2.03 (t, J=6.3 Hz, 2H), 1.72 (s, 3H), 1.56-1.65 (m, 
2H), 1.43-1.48 (m, 2H), 1.02 (s, 3H), 1.01 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=192.1 (CH), 145.2 (C), 144.1 (CH), 143.5 (C), 
139.2 (C), 137.7 (C), 133.9 (CH), 132.5 (C), 128.7 (2 x CH), 127.4 (3 x CH), 126.9 
(CH), 122.5 (CH), 39.9 (CH2), 34.5 (CH2), 34.3 (C), 33.6 (CH), 30.3 (CH2), 29.2 (2 x 
CH3), 22.1 (CH3), 19.3 (CH2) 
IR (neat) ν 2925, 2866, 1667, 1536, 1453, 1275, 1163, 1077, 751, 699 cm-1 
HRMS (ESI) for C24H28O (M+Li)+: calcd 339.2300, found  339.2358. 
 
O
N
6-(4-Dimethylamino-phenyl)-4-[2-(2,6,6-trimethyl-cyclohex-1-
enyl)-vinyl]-cyclohexa-1,3-dienecarbaldehyde (112):  1H NMR (300MHz, CDCl3, 
25°C), δ=9.50 (s, 1H), 7.14 (d, J=9.0 Hz, 2H), 6.90 (d, J=6.3 Hz, 1H), 6.61 (d, J=8.7 Hz, 
2H), 6.52 (d, J=16.2 Hz, 1H), 6.26 (d, J=16.2 Hz, 1H), 6.15 (dd, J=2.4, 6.0 Hz, 1H), 4.09 
(dd, J=1.5, 9.6 Hz, 1H), 3.00 (dd, J=1.8, 17.7 Hz, 1H), 2.89 (s, 6H), 2.74-2.86 (m, 1H), 
2.04 (t, J=5.7 Hz, 2H), 1.73 (s, 3H), 1.57-1.65 (m, 2H), 1.43-1.48 (m, 2H), 1.03 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.3 (CH), 149.9 (C), 145.3 (C), 143.3 (CH), 
139.9 (C), 137.7 (C), 134.0 (CH), 132.1 (C), 132.1 (CH), 128.0 (2 x CH), 128.0 (C), 
122.4 (CH), 113.0 (2 x CH), 41.0 (2 x CH3), 39.9 (CH2), 34.5 (C), 33.5 (CH2), 33.3 
(CH), 30.3 (CH2), 29.2 (2 x CH3), 22.1 (CH3), 19.3 (CH2) 
IR (neat) ν 3005, 2926, 2863, 2806, 2713, 1738, 1663, 1613, 1519, 1444, 1356, 1275, 
1200, 1160, 965, 819, 765, 750 cm-1 
HRMS (ESI) for C26H33NO (M+Li)+: calcd 382.2722, found  382.2784. 
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O
NO2
6-(4-Nitro-phenyl)-4-[2-(2,6,6-trimethyl-cyclohex-1-enyl)-vinyl]-
cyclohexa-1,3-dienecarbaldehyde (113):  1H NMR (300MHz, CDCl3, 25°C), δ=9.53 (s, 
1H), 8.04-8.10 (m, 2H), 7.41 (d, J=9.3 Hz, 1H), 7.31 (d, J=8.7 Hz, 1H), 7.06 (d, J=5.7 
Hz, 1H), 6.50 (d, J=16.5 Hz, 1H), 6.32 (dd, J=2.7, 6.0 Hz, 1H), 6.27 (d, J=16.2 Hz, 1H), 
4.27 (dd, J=3.3, 8.1 Hz, 1H), 3.04 (d, J=17.1 Hz, 1H), 2.84-2.95 (m, 1H), 2.17-2.35 (m, 
2H), 1.71 (s, 3H), 1.57-1.66 (m, 2H), 1.40-1.48 (m, 2H), 1.01 (s, 3H), 1.00 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.5 (CH), 147.1 (C), 144.9 (C), 144.7 (CH), 
137.8 (C), 137.5 (C), 133.4 (C), 133.1 (CH), 130.3 (C), 128.4 (CH), 128.3 (2 x CH), 
124.0 (2 x CH), 122.3 (CH), 39.8 (CH2), 34.5 (C), 34.3 (CH), 33.6 (CH), 32.2 (CH2), 
29.9 (2 x CH3), 22.1 (CH3), 19.2 (CH2) 
HRMS (ESI) for C24H27NO3 (M+Li)+: calcd 384.2151, found 384.2158. 
 
O
4-(4-Methyl-pent-3-enyl)-6-phenyl-cyclohexa-1,3-
dienecarbaldhehyde (26):  1H NMR (300MHz, CDCl3, 25°C), δ= 9.52 (s, 1H), 7.10-
7.24 (m, 5H), 6.96 (d, J=5.4 Hz, 1H), 6.03-6.07 (m, 1H), 4.94-5.00 (m, 1H), 4.06 (dd, 
J=1.5, 10.5 Hz, 1H), 2.79-2.89 (m, 1H), 2.48 (dd, J= 1.5, 18.0 Hz, 1H), 2.03-2.20 (m, 
4H), 1.64 (s, 3H), 1.55 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=192.4 (CH), 151.1 (C), 144.5 (CH), 143.0 (C), 
132.7 (C), 128.6 (2 x CH), 127.3 (2 x CH), 126.9 (CH), 123.3 (CH), 119.1 (CH), 38.1 
(CH2), 36.2 (CH2), 34.4 (CH2), 30.8 (C), 25.9 (CH3), 25.7 (CH2), 17.9 (CH3) 
IR (neat) ν 3026, 2971, 2926, 2144, 1738, 1670, 1574, 1449, 1366, 1228, 1217, 1205, 
698 cm-1 
HRMS (ESI) for C19H22OLi (M+Li)+: calcd 273.1831, found 273.1839 . 
 
O
N
6-(4-Dimethylamino-phenyl)-4-(4-methyl-pent-3-enyl)-cyclohexa-
1,3-dienecarbaldehyde (114):  1H NMR (300MHz, CDCl3, 25°C), δ=9.43 (s, 1H), 7.13 
(d, J=9.0 Hz, 2H), 6.77 (d, J=5.4 Hz, 1H), 6.60 (d, J=8.7 Hz, 2H), 6.07-6.12 (m, 1H), 
5.12-5.20 (m, 1H), 3.89 (d, J=8.4 Hz, 1H), 2.88 (s, 6H), 2.24-2.37 (m, 2H), 1.99-2.20 
(m, 4H), 1.89 (d, J=1.2 Hz, 3H), 1.71 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=193.1 (CH), 151.8 (C), 142.7 (CH), 141.6 (C), 
137.0 (C), 135.2 (C), 133.1 (C), 129.9 (2 x CH), 121.5 (CH), 119.1 (CH), 112.6 (2 x 
CH), 41.0 (2 x CH3), 38.2 (CH2), 37.6 (CH), 30.8 (CH2), 26.4 (CH2), 26.1 (CH3), 18.3 
(CH3) 
IR (neat) ν 2966, 2912, 2852, 2802, 2709, 2368, 1739, 1669, 1640, 1612, 1574, 1518, 
1480, 1444, 1348, 1195, 1163, 947, 814 cm-1 
HRMS (ESI) for C21H27NOLi (M+Li)+: calcd 316.2253, found 316.2250. 
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O
4-(4,8-dimethylnona-3,7-dienyl)-6-phenylcyclohexa-1,3-
dienecarbaldehyde (115):  1H NMR (300MHz, CDCl3, 25°C), δ=9.51 (s, 1H), 7.13-
7.24 (m, 5H), 6.96 (d, J=5.4 Hz, 1H), 6.04-6.07 (m, 1H), 4.96-5.09 (m, 2H), 4.06 (dd, 
J=1.5, 10.5 Hz, 1H), 2.78-2.90 (m, 1H), 2.49 (dd, J=1.5, 17.7 Hz, 1H), 1.88-2.26 (m, 
8H), 1.68 (s, 3H), 1.60 (s, 3H), 1.54 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.4 (CH), 151.1 (C), 144.5 (CH), 142.9 (C), 
137.8 (C), 136.3 (C), 131.7 (C), 128.6 (2 x CH), 127.3 (2 x CH), 126.9 (CH), 124.4 
(CH), 123.2 (CH), 119.1 (CH), 39.8 (CH2), 38.2 (CH2), 36.2 (CH2), 34.4 (CH), 26.8 
(CH2), 26.0 (CH2), 25.5 (CH3), 17.9 (CH3), 16.2 (CH3) 
IR (neat) ν 2967, 2923, 2851, 2371, 2366, 2328, 1673, 1575, 1182 cm-1 
HRMS (ESI) for C24H30O (M+H)+: calcd 341.2457, found 341.2485. 
 
O
4-methyl-6-phenylcyclohexa-1,3-dienecarbaldehyde (116):  1H NMR 
(300MHz, CDCl3, 25°C), δ=9.50 (s, 1H), 7.15-7.26 (m, 5H), 6.93 (d, J=5.4 Hz, 1H), 
6.04-6.07 (m, 1H), 4.06 (d, J=10.5 Hz, 1H), 2.81-2.91 (dd, J=10.5, 18.3 Hz, 1H), 2.46 (d, 
J=18.3 Hz, 1H), 1.89 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.4 (CH), 147.6 (C), 144.5 (CH), 143.4 (C), 
137.6 (C), 128.7 (2 x CH), 127.2 (2 x CH), 126.9 (CH), 119.7 (CH), 37.3 (CH2), 34.4 
(CH), 24.4 (CH3) 
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IR (neat) ν 3028, 2971, 2926, 2383, 2343, 2309, 1738, 1669, 1575, 1375, 1196, 756 cm-1 
HRMS (ESI) for C14H14OLi (M+Li)+: calcd 205.1205, found 205.1236. 
 
O
N
6-(4-(dimethylamino)phenyl)-4-methylcyclohexa-1,3-dienecarbaldehyde 
(117):  1H NMR (300MHz, CDCl3, 25°C), δ=9.48 (s, 1H), 7.11 (d, J=9.0 Hz, 2H), 6.86 
(d, J=5.7 Hz, 1H), 6.61-6.72 (m, 2H), 6.01- 6.04 (m, 1H), 3.97 (d, J=9.6 Hz, 1H), 3.07 
(d, J=11.1 Hz,1H), 2.89 (s, 6H), 2.44 (d, J=18.6 Hz, 1H), 1.89 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.7 (CH), 149.7 (C), 147.6 (C), 143.8 (CH), 
138.2 (C), 131.8 (C), 127.9 (2 x CH), 119.6 (CH), 113. (2 x CH), 41.0 (2 x CH3), 37.3 
(CH2), 33.5 (CH), 24.5 (CH3)  
IR (neat) ν 2923, 2851, 2382, 2342, 2327, 1670, 1612, 1596, 1577, 1520, 1253, 1165, 
817, 736 cm-1 
HRMS (ESI) for C16H19ONLi (M+Li)+: calcd 248.1627, found 248.1653. 
 
O
NO2
4-Methyl-6-(4-nitro-phenyl)-cyclohexa-1,3-dienecarbaldehyde (118):  1H 
NMR (300MHz, CDCl3, 25°C), δ=9.53 (s, 1H), 8.11 (d J=8.7 Hz, 2H), 7.41 (d, J=8.4 
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Hz, 2H), 7.05 (d, J=5.7 Hz, 1H), 6.12-6.15 (m, 1H), 4.17 (d, J=8.7 Hz, 1H), 2.88-2.99 
(m, 1H), 2.44 (dd, J=1.5, 18.3 Hz, 1H), 1.93 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.0 (CH), 150.9 (C), 147.5 (C), 147.1 (C), 145.0 
(CH), 136.3 (C), 128.3 (2 x CH), 124.0 (2 x CH), 119.9 (CH), 36.9 (CH), 34.6 (CH2), 
24.3 (CH3) 
IR (neat) ν 2971, 2925, 2819, 2717, 1738, 1666, 1575, 1514, 1342, 1195, 1155, 852, 
827, 697 cm-1 
HRMS (ESI) for C14H13O3NLi (M+Li)+: calcd 250.1055, found 250.1017. 
 
Synthesis of Heterodimers Utilizing Two β-methyl Substituted Substrates 
The following is an example of the synthetic procedure for the synthesis of 4-
(9H-fluoren-2-yl)-6-methylcyclohexa-1,3-dienecarbaldehyde (124).  In a dried 100 mL 
flask, 3-(9H-Fluoren-2-yl)-but-2-enal (100mg, 1 equivalent) and crotonaldehyde (30 mg, 
1 equivalent) were dissolved in 15 mL of 200 proof ethanol.  L-proline (300 mg, 3 
equivalents) was added to facilitate the reaction.  The reaction was stirred for 16 hours at 
room temperature before being quenched by the addition of 20 mL of water.  The 
reaction mixture was extracted with a 1:1 ethyl acetate/hexanes solution (3 x 50 mL) and 
was washed with brine.  The organic layer was dried over magnesium sulfate (MgSO4) 
and concentrated under vacuum.  The crude product was purified by column 
chromatography (10% ethyl acetate/hexanes) to yield 57.6 mg of the final product (67% 
yield) as a green solid.   
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Characterization of Heterodimers Utilizing Two β-methyl Substrates 
O
4-(biphenyl-4-yl)-6,6-dimethylcyclohexa-1,3-
dienecarbaldehyde (119): 1H NMR (300MHz, CDCl3, 25°C), δ=9.53 (s, 1H), 7.60-7.63 
(m, 5H), 7.43-7.49 (m, 2H), 7.34-7.40 (m, 2H), 6.83 (d, J=6.0 Hz, 1H), 6.65 (dt, J=1.2, 
6.0 Hz, 1H), 2.66 (d, J=1.2 Hz, 2H), 1.31 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=193.3 (CH), 144.9 (C), 144.3 (CH), 144.1 (C), 
141.8 (C), 140.5 (C), 138.6 (C), 129.1 (2 x CH), 127.9 (CH), 127.5 (2 x CH), 127.2 (2 x 
CH), 126.4 (2 x CH), 119.1 (CH), 43.5 (CH2), 33.4 (C), 26.1 (2 x CH3) 
IR (neat) ν 3030, 2924, 1678, 1596, 1487, 1262, 1184, 1135, 1006, 837, 765, 697 cm-1 
HRMS (ESI) for C21H20OLi (M+Li)+: calcd 295.1674, found 295.1749. 
 
O
6-(biphenyl-4-yl)-4,6-dimethylcyclohexa-1,3-dienecarbaldehyde 
(120): 1H NMR (300MHz, CDCl3, 25°C), δ=9.45 (s, 1H), 7.54-7.58 (m, 2H), 7.48-7.51 
(m, 2H), 7.30-7.43 (m, 5H), 6.87 (d, J=5.4 Hz, 1H), 6.03 (dq, J=1.5, 5.4 Hz, 1H), 2.69 
(d, J=18.0 Hz, 1H), 2.40 (d, J=18.0 Hz, 1H), 1.91 (d, J=1.2 Hz, 3H), 1.67 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.7 (CH), 146.9 (C), 145.2 (CH), 141.5 (C), 
141.1 (C), 140.0 (C), 139.1 (C), 128.9 (2 x CH), 127.2 (3 x CH), 127.1 (2 x CH), 126.6 
(2 x CH), 119.0 (CH), 48.1 (CH2), 40.4 (C), 25.3 (CH3), 24.1 (CH3) 
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IR (neat) ν 3051, 2923, 2854, 1655, 1602, 1455, 1422, 1253, 1163, 1142, 1124, 827, 
769, 734 cm-1  
HRMS (ESI) for C21H20OLi (M+Li)+: calcd 295.1674, found 295.1682.  
 
O
S
4-Biphenyl-4-yl-6-methyl-6-thiophen-2-yl-cyclohexa-1,3-
dienecarbaldehyde (121):  1H NMR (300MHz, CDCl3, 25°C), δ=9.56 (s, 1H), 7.28-
7.63 (m, 10H), 7.09 (d, J=6.3 Hz, 1H), 7.00-7.06 (m, 2H), 6.72 (d, J=6.3 Hz, 1H), 3.20 
(d, J=17.4 Hz, 1H), 2.92 (d, J=17.4 Hz, 1H), 1.77 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.3 (CH), 153.9 (C), 144.5 (CH), 143.8 (C), 
142.8 (C), 141.1 (C), 139.4 (C), 138.5 (C), 129.1 (2 x CH), 128.9 (2 x CH), 128.0 (CH), 
127.6 (2 x CH), 127.2 (2 x CH), 126.8 (2 x CH), 126.4 (CH), 117.3 (CH), 44.7 (CH2), 
40.8 (C), 25.1 (CH3) 
IR (neat) ν 3110, 2958, 2925, 2854, 1728, 1682, 1597, 1425, 1257, 1071, 701 cm-1 
HRMS (ESI) for C24H20OSLi (M+Li)+: calcd 363.1395, found  363.1360. 
 
O
O
4-Biphenyl-4-yl-6-methyl-6-(5-methyl-furan-2-yl)-cyclohexa-1,3-
dienecarbaldehyde (122):  1H NMR (300MHz, CDCl3, 25°C), δ=9.49 (s, 1H), 7.30-7-
71 (m, 9H), 6.97 (d, J=6.0 Hz, 1H), 6.60 (d, J=5.7 Hz, 1H), 6.07-6.08 (m, 1H), 5.85-5.87 
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(m, 1H), 2.60 (dd, J=1.35, 17.1 Hz, 1H), 2.48 (d, J=17.1 Hz, 1H), 2.32 (s, 3H), 1.72 (s, 
3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=191.6 (CH), 146.5 (C), 145.4 (C), 145.1 (C), 144.5 
(CH), 143.6 (C), 143.1 (C), 142.1 (C), 139.3 (C), 131.2 (CH), 129.1 (2 x CH), 128.9 
(CH), 127.6 (CH), 127.3 (2 x CH), 126.8 (CH), 126.4 (CH), 119.1 (CH), 108.9 (CH), 
106.1 (CH), 44.7 (CH2), 31.8 (C), 22.6 (CH3), 14.4 (CH3) 
IR (neat) ν 2960, 2924,2875, 2854, 1728, 1695, 1600, 1487, 1456, 1262, 1120, 766 cm-1 
HRMS (ESI) for C25H22O2 (M+Li)+: calcd 361.1780, found  361.1745. 
O
6-methyl-4-(naphthalen-2-yl)cyclohexa-1,3-dienecarbaldehyde 
(123):  1H NMR (300MHz, CDCl3, 25°C), δ=9.58 (s, 1H), 8.01-8.05 (m, 2H), 7.96-7.99 
(m, 1H), 7.63-7.71 (m, 4H), 6.92 (d, J=6.0 Hz, 1H), 6.75 (dd, J=2.7, 6.0 Hz, 1H), 3.73-
3.77 (m, 1H), 2.95-3.18 (m, 2H), 1.05 (d, J=6.9 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.7 (CH), 145.0 (C), 142.5 (CH), 141.9 (C), 
137.3 (C), 133.6 (C), 133.4 (C), 128.5 (CH), 128.0 (CH), 127.4 (2 x CH), 126.8 (CH), 
125.4 (CH), 123.7 (CH), 119.9 (CH), 33.6 (CH2), 24.4 (CH), 18.1 (CH3) 
IR (neat) ν  3053, 2926, 1665, 1548, 1177, 818, 749 cm-1 
HRMS (ESI) for C18H16O (M+Li)+: calcd 255.1361, found 255.1411.  
 
O
4-(9H-fluoren-2-yl)-6-methylcyclohexa-1,3-dienecarbaldehyde 
(124):  1H NMR (300MHz, CDCl3, 25°C), δ=9.56 (s, 1H), 7.77-7.90 (m, 2H), 7.55-7.59 
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(m, 2H), 7.25-7.44 (m, 3H), 6.90 (d, J=6.0 Hz, 1H), 6.65 (dd, J=2.7, 6.0 Hz, 1H), 3.93 (s, 
2H), 3.05-3.15 (m, 1H), 2.95 (dq, J=2.7, 8.4 Hz, 1H), 2.76-2.78 (m, 1H), 1.04 (d, J=7.2 
Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.6 (CH), 145.7 (C), 143.9 (C), 143.8 (C), 142.8 
(C), 142.7 (CH), 141.6 (C), 141.3 (C), 138.7 (C), 127.4 (CH), 127.2 (CH), 125.4 (CH), 
125.0 (CH), 122.6 (CH), 120.4 (CH), 120.2 (CH), 119.1 (CH), 37.2 (CH2), 33.9 (CH2), 
24.4 (CH), 18.1 (CH3) 
IR (neat) ν 3053, 2962, 2925, 2868, 1733, 1663, 1546, 1423, 1265, 1183, 1046, 825, 
733, 703 cm-1  
HRMS (ESI) for C21H18O (M+H)+: calcd 287.1436, found 287.1436. 
 
O
O
6,6-dimethyl-4-(5-methylfuran-2-yl)cyclohexa-1,3-
dienecarbaldehyde (125):  1H NMR (300MHz, CDCl3, 25°C), δ=9.44 (s, 1H), 6.81 (d, 
J=6.0 Hz, 1H), 6.58 (d, J=6.0 Hz, 1H), 6.48 (d, J=3.6 Hz, 1H), 6.07-6.10 (m, 1H), 2.41 
(d, J=1.2, 2H), 2.36 (s, 3H), 1.26 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=193.0 (CH), 150.1 (C), 144.9 (C), 141.2 (C), 137.7 
(CH), 136.4 (C), 126.6 (CH), 114.7 (CH), 109.1 (CH), 41.0 (CH2), 26.1 (2 x CH3), 23.0 
(C), 14.2 (CH3) 
IR (neat) ν 3012, 2983, 1730, 1665, 1585, 1540, 1334, 1213 cm-1 
HRMS (ESI) for C14H16O2 (M+Li)+: calcd 223.1310, found 223.1319. 
 
191 
 
S
O
6-Methyl-4-thiophen-2-yl-cyclohexa-1,3-dienecarbaldehyde (126):  
1H NMR (300MHz, CDCl3, 25°C), δ=9.52 (s, 1H), 7.35 (d, J=5.1 Hz, 1H), 7.28 (d, J= 
5.4 Hz, 1H), 7.07-7.09 (m, 1H), 6.85 (d, J=6.0 Hz, 1H), 6.60 (dd, J=2.4, 5.7 Hz, 1H), 
3.02-3.12 (m, 1H), 2.81-2.91 (m, 1H), 2.65-2.72 (m 1H), 1.01 (d, J=7.2 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.2 (CH), 144.8 (C), 142.3 (C), 141.7 (C), 138.8 
(C), 128.4 (CH), 127.2 (CH), 125.8 (CH), 117.6 (CH), 33.9 (CH2), 24.4 (CH), 18.3 (CH-
3) 
IR (neat) ν 3083, 3048, 3022, 2979, 2961, 1765, 1732, 1222, 1210, 764 cm-1 
HRMS (ESI) for C12H12OS (M+H)+: calcd 211.0769, found  211.0732. 
 
O
6-Methyl-4-[2-(2,6,6-trimethyl-cyclohex-1-enyl)-vinyl]-cyclohexa-
1,3-dienecarbaldehyde (127):  1H NMR (300MHz, CDCl3, 25°C), δ=9.47 (s, 1H), 6.79 
(d, J=5.7 Hz, 1H), 6.50 (d, J=16.2 Hz, 1H), 6.26 (d, J=16.2 Hz, 1H), 6.09 (d, J=6.0 Hz, 
1H), 2.96-3.07 (m, 1H), 2.52 (d, J=4.8 Hz, 2H), 1.74 (s, 3H), 1.60-1.66 (m, 2H), 1.45-
1.50 (m, 4H), 1.05 (s, 6H), 0.96 (d, J=6.9 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.3 (CH), 144.6 (C), 143.1 (CH), 137.7 (C), 
134.6 (CH), 131.9 (C), 131.7 (CH), 129.2 (C), 121.9 (CH), 39.9 (CH2), 34.5 (CH2), 33.5 
(CH2), 30.4 (CH), 30.0 (C), 29.2 (2 x CH3), 24.1 (CH3), 19.3 (CH3), 18.4 (CH2) 
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IR (neat) ν 3006, 2970, 2957, 2925, 2864, 1738, 1664, 1536, 1375, 1365, 1275, 1261, 
1062, 764 cm-1 
HRMS (ESI) for C19H26OLi (M+Li)+: calcd 277.2144, found  277.2134. 
 
O
O
6-methyl-6-(5-methylfuran-2-yl)-4-(4-methylpent-3-enyl)cyclohexa-
1,3-dienecarbaldehyde (128):  1H NMR (300MHz, CDCl3, 25°C), δ=9.45 (s, 1H), 6.85 
(d, J=6.0 Hz, 1H), 6.56 (d, J=6.0 Hz, 1H), 6.48 (d, J=3.3 Hz, 1H), 6.07-6.09 (m, 1H), 
5.01-5.08 (m, 1H),  2.64 (dd, J=1.2, 17.1 Hz, 1H), 2.35 (s, 3H), 2.30 (dd, J=1.4, 17.3 Hz, 
1H), 1.81-1.98 (m, 4H), 1.63 (s, 3H), 1.58 (s, 3H), 1.53 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=193.1 (CH), 155.2 (C), 152.0 (C), 151.0 (C), 145.9 
(CH), 141.9 (C), 132.4 (C), 124.9 (CH), 114.5 (CH), 112.0 (CH), 108.8 (CH), 43.7 
(CH2), 38.4 (CH2), 37.7 (CH2), 32.2 (C), 24.0 (CH3), 23.0 (CH3), 21.3 (CH3), 14.4 (CH3) 
IR (neat) ν 2920, 2851, 2171, 1737, 1541, 1454, 1375, 1265, 1049, 707, 703 cm-1 
HRMS (ESI) for C19H24O2Li (M+Li)+: calcd 291.1936, found  291.1957. 
 
O
4,6-Dimethyl-5-(3-methyl-but-2-enyl)-cyclohexa-1,3-
dienecarbaldehyde (129): 1H NMR (300MHz, CDCl3, 25°C), δ=9.47 (s, 1 H), 6.66 (d, 
J=5.4 Hz, 1H), 5.93 (dq, J=1.5, 5.4 Hz, 1H), 5.02-5.09 (m, 1H), 2.78 (q, J=6.9 Hz, 1H), 
1.83-1.96 (m, 6H), 1.69 (s, 3H), 1.48 (s, 3H), 0.97 (d, J=6.6 Hz, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C), δ=192.9 (CH), 151.5 (C), 142.1 (CH), 139.3 (C), 
134.3 (C), 121.5 (CH), 118.0 (CH), 47.1 (CH), 31.9 (CH2), 27.5 (CH), 25.8 (CH3), 23.6 
(CH3), 22.7 (CH3), 17.8 (CH3) 
IR (neat) ν 2981, 2970, 1754, 1672, 1458, 1363, 1228, 1045 cm-1 
HRMS (ESI) for C14H20O (M+Li)+: calcd 211.1674, found 211.1680. 
 
Synthesis of Heterodimers with β-ethyl Substituted Substrates 
 The same synthetic procedure was utilized in the production of the tri-substituted 
cyclohexadienals that was used for the synthesis of the cross condensation products.   
 
Characterization of Heterodimers Derived From β-ethyl Substrates 
S
O
5-methyl-6-phenyl-4-(thiophen-2-yl)cyclohexa-1,3-dienecarbaldehyde 
(130): 1H NMR (300MHz, CDCl3, 25°C), δ=9.62 (s, 1H), 7.11-7.28 (m, 6H), 7.02-7.16 
(m, 2H), 6.62 (d, J=6.0 Hz, 1H), 3.94 (s, 1H), 3.19 (q, J=7.2 Hz, 1H), 1.22 (d, J=7.2 Hz, 
3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.6 (CH), 145.4 (C), 143.6 (C), 142.3 (CH), 
142.2 (C), 137.2 (C), 128.8 (2 x CH2), 128.5 (CH), 127.5 (CH), 127.3 (2 x CH), 127.1 
(CH), 126.0 (CH), 116.7 (CH), 42.3 (CH), 40.0 (CH), 20.7 (CH3) 
IR (neat) ν 3028, 2963. 2925, 2852, 2717, 1663, 1540, 1492, 1395, 1170, 845, 698 cm-1 
HRMS (ESI) for C18H16OS (M+Li)+: calcd 287.1082, found 287.1063. 
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S
O
N
6-(4-Dimethylamino-phenyl)-5-methyl-4-thiophen-2-yl-cyclohexa-
1,3-dienecarbaldehyde (131): 1H NMR (300MHz, CDCl3, 25°C), δ=9.60 (s, 1H), 7.76 
(d, J=5.4 Hz, 1H), 7.32 (dd, J=0.6, 5.1 Hz, 1H), 7.23 (dd, J=0.9, 3.9 Hz, 1H), 7.03 (d, 
J=9.0 Hz, 2H), 7.00 (d, J=6.0 Hz, 1H), 6.70 (d, J=9.0 Hz, 2H), 6.61 (d, J=6.0 Hz, 1H), 
3.86 (s, 1H), 3.16 (q, J=7.5 Hz, 1H), 3.09 (s, 6H), 1.23 (d, J=7.5 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.7 (CH), 149.5 (C), 149.2 (C), 147.3 (C), 145.4 
(CH), 141.9 (C), 136.9 (C), 132.2 (CH), 128.5 (2 x CH), 127.5 (CH), 126.0 (CH),166.6 
(CH), 111.2 (2 x CH), 41.5 (CH), 40.3 (2 x CH3), 39.6 (CH), 20.6 (CH3) 
IR (neat) ν 3004, 2970, 2924, 2805, 2736, 1738, 1663, 1597, 1540, 1372, 1167, 765, 750 
cm-1 
HRMS (ESI) for C20H21ONS (M+H)+: calcd 324.1422, found 324.1452. 
 
 
S
O
NO2
5-Methyl-6-(4-nitro-phenyl)-4-thiophen-2-yl-cyclohexa-1,3-
dienecarbaldehyde (132): 1H NMR (300MHz, CDCl3, 25°C), δ=9.66 (s, 1H), 8.07 (m, 
2H), 7.55-7.60 (m, 1H), 7.39-7.46 (m, 2H), 7.26 (d, J=3.6 Hz, 1H), 7.18 (d, J=6.3 Hz, 
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1H), 7.04-7.10 (m, 1H), 6.69 (d, J=6.0 Hz, 1H), 4.06 (s, 1H), 3.18 (q, J=7.2 Hz, 1H), 
1.22 (d, J=7.2 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.2 (CH), 149.7 (C), 147.2 (C), 145.3 (C), 143.0 
(CH), 143.0 (C), 135.8 (C), 133.3 (CH), 129.9 (2 x CH), 128.7 (CH), 128.2 (CH) 124.1 
(2 x CH), 116.6 (CH), 42.2 (CH), 39.6 (CH), 20.7 (CH3) 
IR (neat) ν 3074, 2963, 2927, 2855, 1717, 1663, 1602, 1539, 1517, 1345, 1273, 1171, 
852, 712 cm-1 
HRMS (ESI) for C18H15O3NS (M+H)+: calcd 326.0851, found 326.0887. 
 
Synthesis of Heterodimers Effected by β-methylene Group 
 The same synthetic procedure was utilized in the production of the tri-substituted 
cyclohexadienals that was used for the synthesis of the cross condensation products.   
 
Characterization of Heterodimers Effected by β-methylene Group 
O
H
H
(5R,6R)-4-methyl-5-(3-methylbut-2-enyl)-6-phenylcyclohexa-1,3-
dienecarbaldehyde (27):  1H NMR (300MHz, CDCl3, 25°C), δ=9.54 (s, 1H), 7.11-7.24 
(m, 5H), 6.94 (d, J=5.7 Hz, 1H), 6.02-6.05 (m, 1H), 5.15-5.21 (m, 1H), 3.93 (s, 1H), 2.25 
(dd, J=4.5, 12.6 Hz, 1H), 1.98-2.16 (m, 2H), 1.88 (s, 3H), 1.77 (s, 3H), 1.55 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ= 192.9 (CH), 152.0 (C), 143.6 (CH), 142.7 (C), 
136.4 (C), 135.6 (C), 128.7 (2 x CH), 127.3 (2 x CH), 126.8 (CH), 121.3 (CH), 119.2 
(CH), 48.4 (CH), 38.2 (CH), 30.8 (CH2), 26.2 (CH3), 23.6 (CH3), 17.9 (CH3) 
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IR (neat) ν 3029, 2969, 2916, 2850, 2806, 2715, 2160, 1670, 1641, 1575, 1442, 1201, 
1182 cm-1 
HRMS (ESI) for C19H22OLi (M+Li)+: calcd 273.1831, found  273.1832. 
 
O
HH
(5S,6R)-4-methyl-5-(3-methylbut-2-enyl)-6-phenylcyclohexa-1,3-
dienecarbaldehyde (28):  1H NMR (300MHz, CDCl3, 25°C), δ= 9.43 (s, 1H), 7.13-7.29 
(m, 5H). 6.81 (d, J=5.7 Hz, 1H), 6.10-6.14 (m, 1H), 5.10-5.15 (m, 1H), 3.97 (d, J=9.0 
Hz, 1H), 2.87-2.95 (m, 1H), 2.25-2.35 (m, 1H), 2.09-2.16 (m, 1H), 1.96 (s, 3H), 1.70 (s, 
3H), 1.29 (s, 3H)  
13C NMR (75 MHz, CDCl3, 25°C) δ=192.3 (CH), 151.9 (C), 143.2 (CH), 141.1 (C), 
138.9 (C), 133.4 (C), 129.2 (2 x CH), 128.2 (2 x CH), 127.0 (CH), 123.0 (CH), 121.6 
(CH), 43.7 (CH), 38.5 (CH), 26.5 (CH2), 26.1 (CH3), 22.4 (CH3), 18.1 (CH3) 
IR (neat) ν 3029, 2917, 2852, 2713, 2165, 1670, 1571, 1452, 1169, 698 cm-1 
HRMS (ESI) for C19H22OLi (M+Li)+: calcd 273.1831, found 273.1832. 
 
O O
H
H
HH
N N
6-(4-Dimethylamino-phenyl)-4-methyl-5-(3-methyl-but-2-
enyl)-cyclohexa-1,3-dienecarbaldehyde(133 & 134):  1H NMR (300MHz, CDCl3, 
25°C), trans product δ=9.53 (s, 1H), 7.04 (d, J=8.7 Hz, 2H), 6.87 (d, J=5.7 Hz, 1H), 6.61 
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(d, J=8.7 Hz, 2H), 6.00-6.06 (m, 1H), 5.15-5.21 (m, 1H), 3.85 (s, 1H), 2.88 (s, 6H), 2.27 
(dd, J=4.5, 9.9 Hz, 1H), 1.96-2.22 (m, 2H), 1.90 (s, 3H), 1.76 (s, 3H), 1.67 (s, 3H) 
cis product δ=9.50 (s, 1H), 7.10 (d, J=9.0 Hz, 2H), 6.87 (d, J=5.7 Hz, 1H), 6.61 (d, J=8.7 
Hz, 2H), 6.00-6.06 (m, 1H), 5.15-5.21 (m, 1H), 4.99-5.04 (m, 1H), 3.98 (d, J=9.3 Hz, 
1H), 2.88 (s, 6H), 2.47 (dd, J=1.2, 18Hz, 1H), 1.96-2.22 (m, 2H), 1.90 (s, 3H), 1.76 (s, 
3H), 1.67 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) trans product δ=193.1 (CH), 152.0 (C), 149.7 (C), 
143.0 (CH), 137.1 (C), 135.2 (C), 131.1 (C), 128.0 (2 x CH), 121.6 (CH), 119.1 (CH), 
113.0 (2 x CH), 48.4 (CH), 41.0 (2 x CH3), 37.4 (CH), 30.8 (CH2), 26.2 (CH3), 23.6 
(CH3), 18.0 (CH3) 
cis product δ=192.6 (CH), 151.1 (C), 149.6 (C), 143.8 (CH), 138.4 (C), 132.6 (C), 131.4 
(C), 127.9 (2 x CH), 123.5 (CH), 119.0 (CH), 113.0 (2 x CH), 48.4 (CH), 41.0 (2 x 
CH3), 33.5 (CH), 30.8 (CH2), 26.0 (CH3), 23.6 (CH3), 18.0 (CH3) 
IR (neat) ν 2966, 2909, 2805, 2715, 1672, 1641, 1614, 1576, 1519, 1444, 1349, 1196, 
1162, 815 cm-1 
HRMS (ESI) for C21H27NOLi (M+Li)+: calcd 316.2253, found 316.2273. 
 
O
NO2
4-methyl-5-(3-methylbut-2-enyl)-6-(4-nitrophenyl)cyclohexa-1,3-
dienecarbaldehyde (135):  1H NMR (300MHz, CDCl3, 25°C), δ=9.55 (s, 1H), 8.07 (d, 
J=8.7 Hz, 2H), 7.27 (d, J=8.7 Hz, 2H), 7.03 (d, J=5.4 Hz, 1H), 6.08 (dd, J= 1.5, 5.7 Hz, 
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1H), 5.17-5.20 (m, 1H), 4.02 (s, 1H), 2.12-2.22 (m, 3H), 1.88 (s, 3H), 1.79 (s, 3H), 1.54 
(s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.4 (CH), 151.8 (C), 150.3 (C), 145.8 (C), 144.1 
(CH), 136.4 (C), 135.1 (C), 128.3 (2 x CH), 124.0 (2 x CH), 120.1 (CH), 119.3 (CH), 
48.4 (CH), 38.1 (CH), 30.7 (CH2), 26.2 (CH3), 23.5 (CH3), 17.9 (CH3) 
IR (neat) ν 2967, 2928, 2382, 2327, 2335, 1673, 1576, 1520, 1346, 1110, 837 cm-1 
HRMS (ESI) for C19H21NO3 (M+H)+: calcd 318.1681, found 318.1741. 
 
 
O
4-Methyl-5-(3-methyl-but-2-enyl)-cyclohexa-1,3-
dienecarbaldehyde (136):  1H NMR (300MHz, CDCl3, 25°C), δ=9.49 (s, 1H), 6.72 (dd, 
J=2.1, 5.4 Hz, 1H), 5.95 (dd, J=1.2, 5.4 Hz, 1H), 5.02-5.08 (m, 1H), 2.62 (dd, J=3.3, 
17.1 Hz, 1H), 2.11-2.37 (m, 4H), 1.95 (s, 3H), 1.70 (s, 3H), 1.51 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=193.2 (CH), 153.2 (C), 132.7 (CH), 134.5 (C), 
134.3 (C), 121.7 (CH), 119.7 (CH), 38.9 (CH), 29.9 (CH2), 29.3 (CH2), 26.1 (CH3) 23.0 
(CH3), 17.8 (CH3) 
IR (neat) ν 2926, 2855, 1686, 1670, 1575, 1442, 1266, 735 cm-1 
HRMS (ESI) for C13H18O (M+H)+: calcd 191.1436, found 191.1447. 
 
O
5-(3,7-dimethylocta-2,6-dienyl)-4-methyl-6-phenylcyclohexa-
1,3-dienecarbaldehyde (137):  1H NMR (300MHz, CDCl3, 25°C), δ=9.54 (s, 1H), 7.12-
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7.24 (m, 5H), 6.94 (d, J=5.7, 1H), 6.04 (dq, J=1.5, 5.7 Hz, 1H), 5.04-5.23 (m, 2H), 3.93 
(s, 1H), 2.46 (t, J=6.9 Hz, 1H), 2.23-2.30 (m, 1H), 1.95-2.17 (m, 5H), 1.88 (d, J=1.2 Hz, 
3H), 1.70 (d, J=1.2 Hz, 3H), 1.63 (s, 3H), 1.58 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.8 (CH), 151.9 (C), 143.6 (CH), 142.8 (C), 
139.2 (C), 136.4 (C), 131.8 (C), 128.7 (2 x CH), 127.3 (2 x CH), 126.8 (CH), 124.4 
(CH), 121.1 (CH), 119.2 (CH), 48.5 (CH), 40.2 (CH2), 38.3 (CH), 30.8 (CH2), 26.9 
(CH2), 26.0 (CH3), 23.6 (CH3), 18.0 (CH3), 16.3 (CH3) 
IR (neat) ν 2972, 2924, 2851, 2370, 2328, 2318, 1702, 1674, 1578, 1261, 1077, 764, 699 
cm-1 
HRMS (ESI) for C24H30O (M+H)+: calcd 341.2457, found 341.2456. 
 
O
N
6-(4-Dimethylamino-phenyl)-5-(3,7-dimethyl-octa-2,6-
dienyl)-4-methyl-cyclohexa-1,3-dienecarbaldehyde (138):  1H NMR (300MHz, 
CDCl3, 25°C), δ=9.52 (s, 1H), 7.03 (d, J=9.0 Hz, 2H), 6.87 (d, J=5.4 Hz, 1H), 6.60 (d, 
J=8.7 Hz, 2H), 6.01 (dd, J=1.5, 5.7 Hz, 1H), 5.12-5.22 (m, 2H), 3.84 (s, 1H), 2.88 (s, 
6H), 2.85 (dd, J=4.5, 9.1 Hz, 1H), 1.95-2.18 (m, 6H), 1.90 (s, 3H), 1.71 (s, 3H), 1.63 (s, 
3H), 1.55 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=191.7 (CH), 150.6 (C), 148.4 (C), 141.6 (CH), 
137.6 (C), 135.8 (C), 130.5 (C), 129.8 (C), 126.7 (2 x CH), 123.2 (CH), 120.3 (CH), 
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117.8 (CH), 111.7 (2 x CH), 47.2 (CH), 39.7 (2 x CH3), 38.9 (CH2), 36.2 (CH), 29.6 
(CH2), 25.7 (CH2), 24.7 (CH3), 22.4 (CH3), 16.7 (CH3), 15.0 (CH3) 
IR (neat) ν 2926, 2865, 2823, 2720, 1735, 1664, 1613, 1519, 1357, 1200, 1160, 966, 820 
cm-1 
HRMS (ESI) for C26H35NO (M+H)+: calcd 378.2797, found 378.2626. 
 
O
NO2
5-(3,7-Dimethyl-octa-2,6-dienyl)-4-methyl-6-(4-nitro-phenyl)-
cyclohexa-1,3-dienecarbaldehyde (139): 1H NMR (300MHz, CDCl3, 25°C), δ=9.55 (s, 
1H), 8.07 (d, J=8.7 Hz, 2H), 7.26 (d, J=8.7 Hz, 2H), 7.03 (d, J=5.4 Hz, 1H), 6.08 (d, 
J=5.4 Hz, 1H), 5.11-5.20 (m, 2H), 4.02 (s, 1H), 2.05-2.27 (m, 7H), 1.88 (s, 3H), 1.70 (s, 
3H), 1.63 (s, 3H), 1.54 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.3 (CH), 151.7 (C), 150.4 (C), 147.0 (C), 144.0 
(CH), 140.1 (C), 135.2 (C), 132.0 (C), 128.3 (2 x CH), 124.2 (CH), 124.0 (2 x CH), 
120.6 (CH), 119.3 (CH), 48.5 (CH), 40.1 (CH2), 38.2 (CH), 30.7 (CH2), 26.9 (CH2), 26.0 
(CH3), 23.5 (CH3), 18.0 (CH3), 16.3 (CH3) 
IR (neat) ν 2968, 2914, 2853, 2716, 1670, 1576, 1517, 1440, 1344, 1183, 837 cm-1 
HRMS (ESI) for C24H29NO3 (M+Li)+: calcd 386.2307, found 386.2387. 
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O
4-Methyl-5-pentyl-6-phenyl-cyclohexa-1,3-dienecarbaldehyde 
(140): 1H NMR (300MHz, CDCl3, 25°C), δ=9.55 (s, 1H), 7.06-7.27 (m, 5H), 6.96 (d, 
J=5.7 Hz, 1H), 5.98-6.03 (m, 1H), 3.86 (s, 1H), 2.14 (t, J=7.2 Hz, 1H), 1.90 (s, 3H), 
1.20-1.42 (m, 8H), 0.84-0.90 (m, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.4 (CH), 152.3 (C), 143.6 (C), 143.8 (CH), 
142.9 (C), 128.6 (2 x CH), 127.3 (2 x CH), 126.9 (CH), 119.0 (CH), 38.9 (CH2), 38.0 
(CH), 32.2 (CH), 31.9 (CH2), 26.9 (CH2), 23.6 (CH3), 22.8 (CH2), 14.3 (CH3) 
IR (neat) ν 2955, 2926, 2856, 1725, 1674, 1577, 1453, 1378, 1274, 1181, 1031, 763, 698 
cm-1 
HRMS (ESI) for C19H24O (M+Li)+: calcd 275.1987, found 275.2025. 
 
O
N
6-(4-Dimethylamino-phenyl)-4-methyl-5-pentyl-cyclohexa-1,3-
dienecarbaldehyde (141): 1H NMR (300MHz, CDCl3, 25°C), δ=9.51 (s, 1H), 7.05-7.10 
(m, 2H), 6.84 (d, J=5.4 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H), 5.98-6.03 (m, 1H), 3.86 (s, 1H), 
2.88 (s, 6H), 2.14 (t, J=7.2 Hz, 1H), 1.88 (s, 3H), 1.19-1.42 (m, 8H), 0.84-0.91 (m, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=193.1 (CH), 152.3 (C), 143.9 (C), 143.1 (CH), 
137.2 (C), 131.2 (C), 127.9 (2 x CH), 118.9 (CH), 113.0 (2 x CH), 40.9 (2 x CH3), 38.2 
(CH2), 37.9 (CH), 33.5 (CH), 32.1 (CH2), 26.6 (CH2), 23.6 (CH3), 22.8 (CH2), 14.3 
(CH3) 
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HRMS (ESI) for C21H29NO (M+H)+: calcd 312.2327, found 312.2356. 
 
Characterization of Aromatic Heterodimers 
O
N
 4''-Dimethylamino-[1,1';3',1'']terphenyl-4'-carbaldehyde (142):  1H 
NMR (300MHz, CDCl3, 25°C), δ=10.06 (1H), 8.07 (d, J=8.4 Hz, 1H), 7.65-7.69 (m, 
2H), 7.30-7.52 (m, 7H), 6.83 (d, J=8.7 Hz, 2H), 3.04 (6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=193.1 (CH), 150.6 (C), 147.5 (C), 144.5 (C), 142.4 
(C), 140.2 (C), 134.7 (C), 132.7 (CH), 131.4 (2 x CH), 129.6 (CH), 129.2 (2 x CH), 
128.5 (CH), 127.6 (2 x CH), 125.7 (CH), 112.3 (2 x CH), 40.7 (2 x CH3) 
IR (neat) ν 3063, 2957, 2919, 2850, 2382, 2366, 2330, 2326, 2310, 1682, 1600, 1396, 
1263, 840 cm-1  
LRMS (APCI) for C21H19NO (M+H)+: calcd 302.2 , found 302.2. 
O
NO2
5-Methyl-4'-nitro-biphenyl-2-carbaldehyde (143):  1H NMR (300MHz, 
CDCl3, 25°C), δ=10.38 (s, 1H), 8.37 (d, J=9.0 Hz, 2H), 7.97 (d, J=8.1 Hz, 1H), 7.81 (d, 
J=9.0 Hz, 2H), 7.65 (d, J=8.1 Hz, 1H), 7.56 (s, 1H), 2.81 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.4 (CH), 148.0 (C), 146.4 (C), 143.8 (C), 141.7 
(C), 134.3 (C), 133.0 (CH), 131.1 (CH), 128.4 (2 x CH), 125.6 (CH), 124.5 (2 x CH), 
20.0 (CH3) 
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IR (neat) ν 3082, 2971, 2925, 2852, 2744, 1738, 1694, 1596, 1563, 1509, 1342, 1218, 
1203, 1108, 851, 823, 753 cm-1 
HRMS (ESI) for C14H11O3NLi (M+Li)+: calcd 248.0899, found 248.0993. 
 
O
5-[4-Methyl-6-(2,6,6-trimethyl-cyclohex-1-enyl)-hexa-1,3,5-
trienyl]-biphenyl-2-carbaldehyde (144): 1H NMR (300MHz, CDCl3, 25°C), δ=9.91 (s, 
1H), 7.99 (d, J=8.4 Hz, 1H), 7.39-7.55 (m, 7H), 7.35 (d, J=3.6 Hz, 1H), 6.60 (d, J=15.3 
Hz, 1H), 6.14-6.32 (m, 3H), 2.05 (s, 3H), 2.03 (t, J=6.9 Hz, 2H), 1.73 (s, 3H), 1.58-1.66 
(m, 2H), 1.46-1.49 (m, 2H), 1.04 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=191.9 (CH), 146.8 (C), 143.4 (C), 139.4 (C), 138.2 
(C), 138.0 (C), 137.5 (CH), 137.4 (C), 132.4 (C), 130.5 (CH), 130.2 (2 x CH), 129.8 
(CH), 129.3 (CH), 128.8 (CH), 128.4 (2 x CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 
125.6 (CH), 39.8 (CH2), 34.5 (C), 33.3 (CH2), 29.2 (2 x CH3), 22.0 (CH3), 19.5 (CH2), 
13.2 (CH3) 
IR (neat) ν 3028. 2958, 2925, 2859, 1738, 1683, 1583, 1445, 1361, 1258, 1208, 1118, 
967, 806, 767, 702 cm-1 
HRMS (ESI) for C29H32O (M+H)+: calcd 403.2613, found 403.2653. 
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O
N
4'-Dimethylamino-5-naphthalen-2-yl-biphenyl-2-carbaldehyde 
(145):   1H NMR (300MHz, CDCl3, 25°C), δ=10.08 (s, 1H), 8.10-8.14 (m, 2H), 7.86-
7.96 (m, 3H), 7.75-7.82 (m, 3H), 7.49-7.58 (m, 2H), 7.35 (d, J=9.0 Hz, 2H), 8.84 (d, 
J=9.0 Hz, 2H), 3.04 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.0 (CH), 149.5 (C), 146.1 (C), 145.1 (C), 136.3 
(C), 132.7 (C), 132.2 (C), 131.5 (C), 130.3 (C), 130.2 (2 x CH), 128.7 (CH), 127.8 (CH), 
127.5 (2 x CH), 127.4 (CH), 126.8 (CH), 125.7 (2 x CH), 124.8 (CH), 124.3 (CH), 111.2 
(2 x CH), 39.5 (2 x CH3) 
IR (neat) ν 2919, 2850, 1683, 1598, 1525, 1360, 1196, 816, 749 cm-1 
HRMS (ESI) for C25H21NO (M+H)+: calcd 352.1701, found 352.1747. 
 
O
N
4'-Dimethylamino-5-(9H-fluoren-2-yl)-biphenyl-2-carbaldehyde 
(146):  1H NMR (300MHz, CDCl3, 25°C), δ=10.01 (s, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.77-
7.89 (m, 4H), 7.68-7.70 (m, 2H), 7.57 (d, J=7.2 Hz, 1H), 7.50 (d, J=7.8 Hz, 2H), 7.32-
7.43 (m, 4H), 3.98 (s, 2H), 3.16 (s, 6H); 13C NMR (75 MHz, CDCl3, 25°C) δ=193.1 
(CH), 153.0 (C), 149.1 (C), 148.5 (C), 145.7 (C), 144.3 (C), 143.8 (C), 141.2 (C), 134.9 
(C), 132.5 (C), 131.4 (2 x CH), 129.5 (CH), 128.4 (CH), 127.3 (2 x CH), 127.2 (CH), 
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126.5 (CH), 125.7 (CH), 125.4 (CH), 124.3 (CH), 120.5 (CH), 120.4 (CH), 112.5 (2 x 
CH), 40.8 (2 x CH3), 34.5 (CH2); IR (neat) ν 3046, 2985, 2954, 1677, 1589, 1458, 1265, 
1119, 825, 771 cm-1 HRMS (ESI) for C28H23NO (M+H)+: calcd 390.1858, found 
390.1853. 
 
O
N
4'-(dimethylamino)-5-methylbiphenyl-2-carbaldehyde (147):  1H NMR 
(300MHz, CDCl3, 25°C), δ=9.98 (s, 1H), 7.90 (d, J=7.8 Hz, 1H), 7.57 (d, J=9.0 Hz, 1H), 
7.24-7.28 (m, 3H), 6.80 (d, J=8.7 Hz, 2H), 3.02 (s, 6H), 2.44 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=193.1 (CH), 155.1 (C), 150.5 (C), 146.7 (C), 144.6 
(CH), 141.3 (C), 133.1 (C), 131.5 (CH), 131.3 (2 x CH), 127.9 (CH), 112.3 (2 x CH), 
40.7 (2 x CH3), 22.1 (CH3) 
IR (neat) ν 2925, 2853, 2383, 2327, 2310, 1678, 1602, 1524, 1357, 1198, 817 cm-1 
HRMS (ESI) for C16H17ONLi (M+Li)+: calcd 246.1470, found 246.1485. 
 
O
N
4'''-Dimethylamino-[1,1';4',1'';3'',1''']quaterphenyl-4''-
carbaldehyde (148):  1H NMR (300MHz, CDCl3, 25°C), δ=10.10 (s, 1H), 8.12 (d, J=8.4 
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Hz, 1H), 7.68-7.81 (m, 8H), 7.48-7.53 (m, 2H), 7.41-7.44 (m, 1H), 7.38 (d, J=9.0 Hz 
2H), 6.87 (d, J=8.7 Hz, 2H), 3.08 (s, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ= 193.0 (CH), 150.7 (C), 147.2 (C), 145.8 (C), 141.5 
(C), 140.7 (C), 139.0 (C), 132.7 (C), 131.4 (2 x CH), 129.4 (CH), 129.1 (2 x CH), 128.6 
(CH), 128.0 (2 x CH), 127.9 (2 x CH), 127.8 (CH), 127.3 (2 x CH), 125.6 (CH), 125.5 
(C), 112.4 (2 x CH), 20.7 (2 x CH3) 
IR (neat) ν 3039, 2924, 2342, 2213, 1685, 1601, 1487, 1446, 1264, 1003, 817, 740, 734, 
692 cm-1  
HRMS (ESI) for C27H23NO (M+H)+: calcd 378.1858, found 378.1868. 
 
O
N
4'-Dimethylamino-5-(4-methyl-pent-3-enyl)-biphenyl-2-
carbaldehyde (149):  1H NMR (300MHz, CDCl3, 25°C), δ=10.24 (s, 1H), 7.85 (d, J=8.1 
Hz, 1H), 7.53-7.60 (m, 3H), 7.45 (s, 1H), 6.81 (d, J=9.0 Hz, 2 H), 5.19-5.25 (m, 1H), 
3.09 (t, J=7.2 Hz, 2H), 3.03 (s, 6H), 2.29-2.39 (m, 2H), 1.68 (s, 3H), 1.49 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=191.8 (CH), 145.7 (C), 133.4 (C), 133.3 (C), 132.2 
(CH), 131.7 (C), 129.9 (C), 128.6 (CH), 128.2 (2 x CH), 127.4 (C), 124.1 (CH), 123.3 
(CH), 112.7 (2 x CH), 40.6 (2 x CH3), 33.0 (CH2), 30.8 (CH2), 25.9 (CH3), 17.8 (CH3) 
IR (neat) ν 2968, 2918, 2850, 2350, 1736, 1667, 1594, 1515, 1457, 1345 cm-1 
HRMS (ESI) for C21H25NO (M+Li)+: calcd 314.2096, found 314.2093.    
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O
5-(4-methylpent-3-enyl)biphenyl-2-carbaldehyde (150):  1H NMR 
(300MHz, CDCl3, 25°C), δ=9.94 (s, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.20-7.50 (m, 7H), 
5.13-5.19 (m, 1H), 2.74 (t, J=7.7 Hz, 2H), 2.31-2.41 (m, 2H), 1.69 (s, 3H), 1.55 (d, J=1.8 
Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.5 (CH), 149.1 (C), 146.3 (C), 138.3 (C), 133.1 
(C), 131.9 (C), 131.1 (CH), 130.3 (2 x CH), 128.6 (2 x CH), 128.3 (CH), 128.2 (CH), 
127.9 (CH), 123.2 (CH), 36.5 (CH2), 29.8 (CH2), 25.9 (CH3), 17.9 (CH3) 
IR (neat) ν 2966, 2923, 2856, 2371, 2343, 2318, 1687, 1602, 1445, 1258, 1075, 831, 
797, 768, 702 cm-1 
HRMS (ESI) for C19H20O (M+H)+: calcd 265.1592, found 265.0790. 
 
O
NO2
5-(4-Methyl-pent-3-enyl)-4'-nitro-biphenyl-2-carbaldehyde (151):  
1H NMR (300MHz, CDCl3, 25°C), δ=9.71 (s, 1H), 8.33 (d, J=9.0 Hz, 1H), 8.17 (d, J=8.7 
Hz, 1H), 7.57 (d, J=9.0 Hz, 1H), 7.53 (s, 1H), 7.42 (d, J=9.0 Hz, 1H), 6.95 (d, J=16.8 
Hz, 1H), 6.81 (d, J=16.5 Hz, 1H), 4.37 (t, J=7.6 Hz, 1H), 3.28 (t, J=7.7 Hz, 2H), 2.69-
2.79 (m, 2H), 1.71 (s, 3H), 1.58 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=185.2 (CH). 149.2 (C), 146.9 (C), 143.7 (C), 140.5 
(C), 139.1 (C), 134.0 (C), 131.6 (CH), 126.5 (2 x CH), 124.5 (2 x CH), 124.0 (2 x CH), 
120.9 (CH), 30.0 (CH2), 26.9 (CH2), 25.3 (CH3), 18.03 (CH3) 
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IR (neat) ν 2928, 2850, 2324, 2218, 2027, 1995, 1734, 1667, 1592, 1515, 1458, 1343, 
1109, 859 cm-1 
HRMS (ESI) for C19H19NO3 (M+H)+: calcd 310.1443, found 310.1437. 
 
 
O
NO2
4''-Nitro-[1,1';3',1'']terphenyl-4'-carbaldehyde (152):  1H NMR 
(300MHz, CDCl3, 25°C), δ=9.71 (s, 1H), 8.33 (d, J=8.7 Hz, 2H), 8.17 (d, J=9.0 Hz, 2H), 
8.02-8.08 (m, 1H), 7.57 (d, J=8.7 Hz, 2H), 7.48-7.55 (m, 1H), 7.43 (d, J=9.0 Hz, 2H), 
6.78-6.98 (m, 2H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=185.3 (CH), 149.2 (C), 143.7 (C), 140.5 (C), 131.7 
(3 x CH), 131.2 (C), 129.9 (C), 126.5 (3 x CH), 124.5 (3 x CH), 124.0 (3 x CH), 120.9 
(CH) 
IR (neat) ν 2924, 2856, 1718, 1654, 1626, 1587, 1514, 1343, 1272, 1107, 941, 861 cm-1 
HRMS (ESI) for C19H13NO3 (M+H)+: calcd 304.0974 , found 304.1138. 
 
 
O
O
N
4'-(dimethylamino)-5-(5-methylfuran-2-yl)biphenyl-2-carbaldehyde 
(153):  1H NMR (300MHz, CDCl3, 25°C), δ=9.78 (s, 1H), 7.99 (d, J=8.4 Hz, 1H), 7.63-
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7.67 (m, 2H), 7.32 (d, J=8.4 Hz, 2H), 6.79-6.87 (m, 2H), 6.73 (d, J=3.3 Hz, 1H), 6.11-
6.13 (m, 1H), 3.04 (s, 6H), 2.39 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=192.6 (CH), 153.9 (C), 151.5 (C), 150.7 (C), 145.8 
(C), 140.4 (C), 135.6 (C), 131.3 (2 x CH), 129.0 (C), 128.5 (CH), 125.1 (CH), 121.6 
(CH), 112.3 (2 x CH), 109.3 (CH), 108.6 (CH), 29.9 (CH3), 14.1 (CH3) 
IR (neat) ν 3063, 3013, 2979, 2371, 2362, 2318, 1739, 1436, 1365, 1266, 1216, 1201, 
860 cm-1 
HRMS (ESI) for C20H19NO2 (M+H)+: calcd 306.1416, found  306.1431.  
 
O
5-methylbiphenyl-2-carbaldehyde (154):  1H NMR (300MHz, CDCl3, 
25°C), δ=10.3 (s, 1H), 7.88 (d, J=8.1 Hz, 1H), 7.57-7.65 (m, 2H), 7.36-7.51 (m, 5H), 
2.17 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C), δ=192.6 (CH), 153.7 (C), 146.5 (C), 141.3 (C), 140.0 
(C), 132.9 (CH), 130.7 (CH), 129.2 (2 x CH), 128.6 (CH), 127.6 (2 x CH), 125.3 (CH), 
20.1 (CH3) 
IR (neat) ν 3027, 2963, 2384, 2363, 2324, 1698, 1605, 1448, 1261, 1093, 1053 800 cm-1 
HRMS (ESI) for C14H12OLi (M+Li)+: calcd 203.1048, found 203.1058. 
 
Determination of Quantum Yields 
Relative quantum yields168 were obtained with a photon counting 
spectrofluorometer equipped with a photomultiplier tube, which is sensitive up to 850-
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900 nm.  The slit width was 0.5 nm for both excitation and emission sources.  The 
quantum yield was calculated with the following equation: 
 
φx=φst(Ix/Ist)(Ast/Ax)(ηx2/ηst2) 
 
where the x subscript denotes unknown, st denotes standard,  φst is the reported quantum 
yield of the standard, I is the integrated emission spectra, A is the absorbance at the 
excitation wavelength and η is the refractive index of the solvent used.  Quinine sulfate 
(φ = 0.55 in 0.1 M H2SO4) was used as the standard. 
Synthesis of 2-isopropyl-5-menthylcyclohexyl Hydrazinecarboxylate 
To synthesize 2-isopropyl-5-methylcyclohexyl hydrazinecarboxylate 81,150 ethyl 2-
isopropyl-5-methylcyclohexyl carbonate was first prepared by reacting 25.0 g (1 
equivalent) of L-menthol with 75 mL of ethyl chloroformate (7.3 equivalents) in the 
presence of pyridine (1 mL).  The reaction was refluxed for 48 hours before the light 
brown product was poured over ice followed by dilution with 20 mL of water.  The 
mixture was then extracted with ethyl ether (5 x 100 mL) with the organic layers 
combined, dried over MgSO4, and concentrated under vacuum.  Assuming 100% 
conversion of the ethyl 2-isopropyl-5-methylcyclohexyl carbonate, 75 mL of 2-ethoxy 
ethanol was used to solubilize the starting material.  Once completely dissolved, a two-
fold excess of hydrazine monohydrate (20 mL) being added and then the reaction 
mixture was  poured over ice and extracted with ethyl ether (5 x 100 mL) with the 
organic layers combined, dried over MgSO4, and concentrated under vacuum.  Once the 
ethyl ether was evaporated, 50 mL of hexanes was added and the solution was heated 
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and left at -20°C for 48 h in which white fluffy crystals were formed and were 
subsequently collected via vacuum filtration.  The recrystallization was performed three 
more times yielding 12.7 g (51% yield). 
 
Characterization of 2-isopropyl-5-menthylcyclohexyl Hydrazinecarboxylate 
NH2
H
NO
O
2-isopropyl-5-methylcyclohexyl hydrazinecarboxylate (81):  1H NMR 
(300 MHz, CDCl3, 25°C), δ=6.14 (s, 1H), 4.56 (dt, J=4.5, 21.9 Hz, 1H), 3.74 (s, 2H), 
1.97-2.02 (m, 1H), 1.82-1.92 (m, 1H), 1.61-1.66 (m, 2H), 1.40-1.52 (m, 1H), 1.30 (t, 
J=10.8 Hz, 1H), 1.00-1.10 (m, 1H), 0.91-0.99 (m, 2H), 0.85-0.89 (m, 6H), 0.75 (d, J=6.9 
Hz, 3H)  
13C NMR (75 MHz, CDCl3, 25°C) δ=159.0 (C), 75.7 (CH), 47.5 (CH), 41.6 (CH2), 34.4 
(CH2), 31.6 (CH), 26.4 (CH), 23.7 (CH2), 22.2 (CH3), 21.0 (CH3), 16.6 (CH3) 
HRMS (ESI) for C11H22N2O2 (M+H)+:  calcd 215.1760, found 215.1752. 
 
General Procedure for the Synthesis of the Menthylhydrazones 
Heterodimer 4-Biphenyl-4-yl-6-methyl-6-(5-methyl-furan-2-yl)-cyclohexa-1,3-
dienecarbaldehyde 122 (0.100 g, 1 equivalent) was dissolved in 200 proof ethanol (20 
mL) with 1.5 equivalents of 2-isopropyl-5-methylcyclohexyl hydrazinecarboxylate 81 at 
room temperature.  After 72 h, the reaction was extracted with 1:1 ethyl acetate/hexanes 
solution (2 x 100 mL), and was washed with brine.  The organic layer was dried over 
magnesium sulfate (MgSO4) and concentrated under vacuum.  The crude material was 
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passed thru a silica plug with 10% ethyl acetate/hexanes as the mobile phase.  The 
mixture was then subjected to high pressure liquid chromatography (HPLC) with a 
mobile phase of 96% ethyl acetate/ 4% hexanes with a flow rate of 1.5 mL/minute.  Two 
fractions were collected corresponding to the R and S stereoisomers respectively. 
 
Characterization of the Menthylhydrazones 
N
H
N O
O
N
2-isopropyl-5-methylcyclohexyl-2-((6-(4-
(dimethylamino)phenyl)-4-(naphthalen-2-yl)cyclohexa-1,3 
dienyl)methylene)hydrazinecarboxylate (155):  HRMS (ESI) for C36H43N3O2 (M+H)+:  
calcd 550.3434, found 550.3424. 
 
N
H
N O
O
O
 2-isopropyl-5-methylcyclohexyl 2-((4-(biphenyl-4-yl)-6-
methyl-6-(5-methylfuran-2-yl)cyclohexa-1,3-
dienyl)methylene)hydrazinecarboxylate (156):  HRMS (ESI) for C36H42N2O3 (M+H)+:  
calcd 551.3274, found 551.3269. 
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General Procedure for Conversion of Menthylhydrazones Back to Aldehyde 
Once the R and S stereoisomers were purified, each was dissolved in 20 mL of 
1:1 water/ethanol with 5 mL of 10% sulfuric acid and boiled for 2.5 h in which a color 
change from clear to pink occurred within two hours.  The reaction was removed from 
the heat source and allowed to cool when it was then extracted with ethyl ether (2 x 25 
mL).  The organic layer was then dried with MgSO4 and concentrated under vacuum.  
The crude mixture was then passed through a silica plug with a mobile phase of 10% 
ethyl acetate/hexanes. 
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CHAPTER V 
 SYNTHESIS OF CYCLOHEXADIENE ENAMINONITRILES AND 
QUINAZOLINES* 
INTRODUCTION 
Enaminonitriles 
Enaminonitriles (Figure 63) are useful scaffolds in the synthesis of a wide 
variety of heterocyclic systems with purposes ranging from pharmaceuticals, fungicides, 
and to solvatochromatic dyes, which are dyes that change in position and sometimes 
intensity of an electronic absorption or emission band, accompanying a change in the 
polarity of the medium.180-184 
 
 
 
Figure 63.  General enaminonitrile scaffolds. 
 
An example of the pharmaceutical potential of this class of compounds comes from the 
recent advances toward an effective therapy for transmissible spongiform 
encephalopathies (TSEs) or prions diseases.  These neurodegenerative diseases can be 
 
 
*Reprinted with permission from “An Efficient One-Pot Synthesis of Tethered 
Cyclohexadiene Enaminonitriles from Methyl-Ketones:  An Effective Route to 
Quinazolines.” Bench, B.J., Suarez, V. H. Watanabe, C. M. H., 2008. Bioorganic & 
Medicinal Chemistry Letters, 18, 3126-3130, Copyright 2008 by Elsevier Ltd. 
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characterized by spongiform changes within the large vacuoles in the cortex, cerebellum, 
astrocytosis, neuronal death, and deposits of the pathological protein PrPSc (the “scrapie 
form” of PrP).  While this is mainly seen within the brain, it can also occur in other 
organs and tissues.  In this category of diseases, one finds scrapie in sheep and goats, 
bovine spongiform encephalopathy (Mad Cow) in cattle, chronic wasting disease in deer, 
and Creutzfeldt-Jacob disease in humans, 185 which is attributed to  the consumption of 
contaminated beef products.186-188  To date though, there are currently no effective 
treatments for the prevention of infection or even disease progression.189  However, 
enaminonitriles based on a pyridine dicarbonitrile scaffold (Figure 64) have been shown 
to bind to cell-surface glycosylphosphatidylinositol anchored protein PrPC which inhibits 
the posttranslation conversion of the anchor protein into its protease-resistant isoform 
PrPSc.190  This abnormal protein folding is quite rapid and leads to rapid progression of 
the disease.189  Enaminonitriles, such as 157 and its analogs 158-160  (Figure 64) have 
shown biological activity (157, 18 μM; 158, 35 μM; 159, 19 μM; 160, 16 μM) against 
scrapie-infected mouse neuroblastoma cells (ScN2a) inhibiting PrPSc.190 
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Figure 64.  Enaminonitriles active against mice ScN2a cells.190 
 
 
The self-dimerization of α,β-unsaturated nitriles to cyclic enaminonitriles 
(Figure 65) has been previously performed utilizing lithium diisopropylamide (LDA)191 
as well as other strong bases (ethanolic KOH or piperidine) with moderate yields.192,193  
To date, only a small number of substituted cyclohexadiene enaminonitriles have been 
synthesized with no report on their biological activities.191,194   
 
 
 
Figure 65.  Known cyclohexadiene enaminonitriles. 
 
  
 
157 158 159 160 
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Quinazolines 
In addition to inducing many biological effects, enaminonitriles are also 
important intermediaries in the synthesis of quinazolines.  Quinazolines are used as dyes, 
antibiotics, and pharmaceuticals with many possessing biological activities.195-197  The 
quinazolines (Figure 66), for example, have been employed in the treatments of 
hypertension and hyperplasia.  Doxazosin 161, known as Cardura®, is an alpha blocker 
used to treat high blood pressure by inhibiting the binding of norepinephrine to alpha 
receptors in the autonomic nervous system leading to the relaxation of the smooth 
vascular muscles.198  Prazosin 162, trade names Minipress® and Hypovase®, acts as an 
 
 
 
Figure 66.  Quinazolines used as therapeutic agents. 
 
 
161 162 
163 
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adrenergic alpha-1 antagonist used in the treatment of heart failure hypertension, 
pheochromocytoma (tumor of the adrenal gland), prostatic hypertrophy, and urinary 
retention.199  Alfuzosin 163, known as Uroxatral®, is used in the treatment of benign 
prostatic hyperplasia by relaxing the muscles in the prostate and the bladder neck 
making it easier to urinate.  It employs the same mechanism just as 161 and 162 by 
blocking norepinephrine binding to alpha receptors.200 
 Naturally occurring quinozoline antibiotics are produced by various species of 
streptomycetes and are distributed throughout nature.201,202  Echinomycin 164 and 
triostin A 165 are two examples of the family of molecules that exhibit potent 
antibacterial, anticancer, and antiviral activities.203  This class of antibiotics contains two 
quinoxaline-2-carboxyl moieties that are linked to a cross-bridge cyclic octapeptide 
dilactone core (Figure 67).204  Echinomycin 164 is reported to be a strong inhibitor of 
DNA transcription205 and synthesis.206  164 binds to double stranded DNA sandwiching 
two base pairs within its U-shaped conformation.207-210 
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Figure 67.  Structures of quinozoline antibiotics. 
 
 
Discovery of New Self-Condensation Reaction 
In previous studies, we successfully synthesized a library of functionalized 
cyclohexadienals that have shown biological activities ranging from antimicrobial to 
neurite outgrowth activities against PC12 cells.211,212  To construct our library of 
substituted cyclohexadienals, we utilized β-methylenic aldehyde starting materials, 
which were formed via the reduction of their corresponding α,β-unsaturated nitriles.  To 
synthesize these nitrile intermediates, we performed a Horner-Wadsworth Emmons 
164 
165 
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reaction by treating methyl-ketone substrates with a ylide solution generated by 
treatment with diethyl (cyanomethyl)-phosphonate (C6H12NO3P) and sodium hydride 
(NaH) (Scheme 18) consisting of one equivalent of each of the three components.102   
 
Scheme 18.  Horner Wadsworth Emmons reaction. 
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However, when this reaction was treated with excess NaH, we discovered that the nitrile 
itself underwent a self-dimerization resulting in complex enaminonitriles.  This was first 
discovered during the production of 3-(thiophen-2-yl)but-2-enenitrile (72) from the 
treatment of 4-acetyl-biphenyl with C6H12NO3P.  During the setup of this reaction, 
excess NaH was added and upon review of the crude 1H-NMR, new peaks were 
observed within the spectrum.  What was noticeable was the fact that there were peaks 
similar to that of the cyclohexadienals32,211 that were mentioned in previous chapters.  As 
you can see in the example spectrum (Figure 68) of 3-(biphenyl-4-yl)but-2-enenitrile 
(78), the peaks that first caught our attention were that of the diasteriomer protons of the 
cyclohexadiene ring (2.9 and 3.3 ppm).  This led us to believe that this might be a self-
dimerization product due to the deprotonation of methyl group of the α,β-unsaturated 
nitrile causing a self-dimerization with that of another α,β-unsaturated nitrile.  From 
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these results, we began to investigate this new reaction and developed a one-pot 
synthetic strategy towards the development of these new self-dimerizization products. 
 
 
 
Figure 68.  1H-NMR depicting the mixture of α,β-unsaturated nitrile with self-
dimerization product.   
The α,β-unsaturated nitrile peaks are shown in blue while the self-dimerization product peaks are 
shown in red.  
  
In this chapter, we describe a new one-pot strategy for the synthesis of tethered 
cyclohexadiene enaminonitriles via the reduction of the intermediate nitrile with excess 
NaH.  We compare this synthetic methodology with that reported previously, where self-
dimerization of the α,β-unsaturated nitriles ensues upon LDA191 treatment or other 
strong bases.192,193  Additionally, we synthesized the quinazoline191 derivatives (Scheme 
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19) of each enaminonitriles by heating the enaminonitrile with formic acid and 
formamide only to discover that the synthetic procedure described within the literature 
did not work as described.  Here we provide new reaction conditions that produce the 
compounds in moderate yields.  We additionally report on the biological activities of this 
library of compounds including their cytotoxic effects against bacteria (E. coli and B. 
subtilis 6633), yeast, and human T-cell leukemia (Jurkat). 
 
Scheme 19.  Quinazolines derived from a cyclohexadiene enaminonitrile scaffold. 
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RESULTS AND DISCUSSION 
Enaminonitrile Reaction Optimazation  
 As previously mentioned, enaminonitriles can be generated in a one-pot format 
by implementation of a Horner-Wadsworth Emmons reaction where the methyl-ketone 
is treated with a ylide solution produced by the treatment of diethyl (cyanomethyl)-
phosphonate with excess NaH.102  To optimize the synthesis of our library of 
enaminonitriles, we employed a thiophene substrate as a model for the production of  
166, where we discovered that an excess of six equivalents of NaH were required to 
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facilitate the deprotonation of the nitriles (Scheme 19).  This thiophene substrate was 
used because we first discovered the conversion of nitriles into enaminonitriles while 
synthesizing our library of cyclohexadienals212 and it was high yielding.  It was found 
that after four days a yield of 89% was obtained for 166.  Four days was required to 
reach 100 percent conversion of the α,β-unsaturated nitrile into the corresponding 
enaminonitrile product.  An analysis of the conversion of nitrile to enaminonitrile by 1H- 
NMR, after one day a conversion of 74.5% was observed while 81.5% and 91.5% of the 
nitrile was converted after two and three days respectively. When fewer equivalents of 
NaH were used to facilitate the reaction, yields were drastically diminished (Table 15).  
When 0.5, 1.0, 1.25 and 2.0 equivalents were used to perform the reaction, no yield was 
observed as there was only total conversion of the methyl-ketone into the thiophene 
nitrile product intermediate.  However, we began to see a small conversion of the nitrile 
into the product at 3.0 equivalents, but with a meager yield of 7%.  An increase in yield 
began to occur at 4.0 equivalents giving an isolated yield of 43%.  When we increased 
the amount of NaH over 7.0 equivalents, i.e. 8.0 and 10.0 equivalents, yields began to 
dramatically decrease to 41% and 10% respectively in comparison to the 89% yield 
observed with the optimum 7.0 equivalents. 
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Table 15.  Percent yields using NaH. 
This table represents the overall yields based on the equivalents of NaH used to facilitate the 
reaction. 
 
Equivalent
Percent 
Yield 
0.5 0 
1.0 0 
1.25 0 
2.0 0 
3.0 7 
4.0 43 
7.0 89 
8.0 41 
10.0 10 
 
  
Enaminonitrile Reaction Mechanism 
To form enaminonitriles, deprotonation of the nitriles β-methyl has to occur 
leading to the formation of an allylic anion which can tautomerize making it capable of 
attacking another β-methyl nitrile in a Michael type reaction (Scheme 20).  This would 
lead to an intermediate which undergoes a Thorpe-Ziegler cyclization forming an imine 
which then tautomerizes to give the final enaminonitrile product. 
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Scheme 20.  Proposed reaction mechanism of enaminonitrile synthesis. 
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Synthesis of Enaminonitriles Utilizing NAH 
With these optimized conditions in hand, various substrates (Figure 69) were 
analyzed to investigate the scope of the reaction as shown in Table 16.  We were able 
obtain moderate yields ranging from the lowest, 79%, and the highest, 96%.  The 
substrates that were employed for this study ranged from small and large bulky 
aromatics to aliphatic alkyl containing substrates.  However, the trend for this NaH 
mediated reaction indicated that the small and large aromatic substrates were capable of 
undergoing deprotonation forming the enaminonitrile product while the aliphatic alkyl 
chain substrates gave no yield.  We first looked at the previously mentioned thiophene 
166 and a bromo-substituted thiophene 167 which gave high yields of 89 % and 96 % 
respectively.  The next set of compounds we evaluated was the unsubstituted phenyl, 
fluoro, and bromo substituted substrates.  The un-substituted phenyl 168 and the 4-fluoro 
phenyl 169 substrates both gave yields of 88 % while the 4-bromo phenyl 170 starting 
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material gave a lower yield in comparison of 79%.  With these results, we were skeptical 
of the bulkier biphenyl 171 and naphthalene 172 substrate’s yields as we would expect 
diminished yields. However, they produced higher yields in comparison to the other 
small aromatic thiophene and phenyl substituted compounds other than the bromo-
thiophene 167 substrate with yields of 93% and 90% respectively.  
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Figure 69.  Enaminonitrile compounds synthesized. 
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A limitation of this one-pot strategy is that it does not facilitate the dimerization 
of aliphatic alkyl substrates (Table 16).  When we tested the β-ionone 173 and 2-
octanone 174 substrates, we found that no enaminonitrile product was formed in the 
crude 1H-NMR.  The only compound present in the spectrum was the nitrile intermediate 
itself.  To evaluate if this was simply an equivalency issue, we employed higher NaH 
equivalents of 8.0, 10.0, and 12.0 but the result was still the same as on nitrile 
intermediate was present..  This could be attributed to the reduced stabilization of the 
resulting β-methyl anion after deprotonation requiring a much stronger base for the 
reaction to proceed to form the enaminonitrile product.   
 
Synthesis of Substituted Enaminonitriles Using LDA 
We compared our new NaH catalyzed reaction to the LDA reaction that was 
reported by Tucker in 1981.  Tucker’s work focused on treating small aliphatic nitriles 
with LDA in tetrahydrofuran (THF) resulting in the self-dimerization enaminonitriles.191  
For this set of experiments, we generated the corresponding nitriles from their methyl-
ketones, purified them by flash chromatography, and subsequently reacted them with 
LDA in THF, thus producing their enaminonitrile product in two steps (Scheme 21).   
 
Scheme 21.  Synthesis of enaminonitriles using LDA.  
Reagents and conditions:  (i) 1.1 equivs. C6H12NO3P, 1.1 equiv NaH; (ii) LDA. 
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Table 16.  Substrate effects with excess NaH.   
 
R Group Compound Yield (%) 
 
 
 
166 89 
 
 
 
167 96 
 
 
 
168 88 
 
 
 
169 88 
 
 
 
170 79 
 
 
 
171 93 
 
 
 
172 90 
 
 
 
173 --- 
 
 
 
174 --- 
 
 
S
SBr
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Surprisingly we observed an inverse correlation with LDA compared to the trend with 
the NaH catalyzed reaction (Table 17).  The NaH reaction readily self-dimerizes small 
and large aromatics in high yields, while LDA gives minimal yields.    These results 
could be attributed to steric effects with LDA resulting in the lack of full dissociation of 
the catalyst prior to self-condensation.  Conversely, reactions catalyzed with LDA 
seemed to favor long chain alkyl substrates while NaH failed to convert them into their 
enaminonitrile products.  Previous reports by Tucker demonstrated the LDA method 
with alkylidene malononitriles with included 3-methyl-2-butenenitrile and 3-methyl-2-
pentenenitrile which gave high to moderate yields of 90 % and 60 %, respectively.191 
 As mentioned, we observed lower yields with LDA (Table 17) in comparison to 
that of the NaH catalyzed reactions.  For the small and large aromatics, we observed 
yields ranging from 12 % to 28 % for the LDA catalyzed reactions while the NaH 
catalyzed reactions gave us yields ranging from 79 % to 96 %.  However, while we 
observed no conversion of the aliphatic nitriles with NaH, we did see a yield of 36 % for 
the C-15 nitrile 173 and 31 % for the 3-methyl-non-2-enenitrile 174 substrate.  For 
thiophene 166, we saw a yield of 28 % while the bromo-substituted thiophene 167 gave 
an overall yield of 24 % in comparison to 89 % and 96 % respectively using NaH in a 
one-pot fashion.  The phenyl-substrates yields were even lower than the thiophene 
substrates as 168 gave a yield of 18% while the fluoro 169 and bromo 170 substituted 
phenyls demonstrated yields of 20% each.  For the bulkier biphenyl 171 and naphthalene 
172 substrates, the yields were diminished additionally with isolated yields of 12% and 
13% respectively.   
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Table 17.  Substrate effects with LDA.   
 
R Group Compound Yield (%) 
 
 
 
166 28 
 
 
 
167 24 
 
 
 
168 18 
 
 
 
169 20 
 
 
 
170 20 
 
 
 
171 12 
 
 
 
172 13 
 
 
173 36 
 
 
174 31 
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Synthesis of Quinazolines 
 The interesting aspect of the enaminonitriles is the 1,2-relationship of the amino 
and nitrile groups.  This can be exploited in the synthesis of the class of compounds 
known as quinazolines (Figure 70).  From literature, these compounds can be 
synthesized via the heating in the presence of formic acid and formamide at 200°C 
(Scheme 22).  While it was previously reported by Tucker that the reaction took one 
hour to go to completion, we were unable to isolate any quinazoline product under these 
conditions.191   
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Figure 70.  Quinazoline compounds synthesized. 
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We decided to optimize this reaction as the reported conditions offered little or no 
product formation based on crude 1H-NMR’s on the various substrates we examined.  
With formic acid having a low boiling point, we implemented a reflux set-up which was 
not used in Tucker’s work.  This may explain why we were seeing little product 
formation as the formic acid evaporates upon heating.  By using the thiophene 
enaminonitrile 166 as a model substrate, we still observed a small trace of product 
formation after one hour according to the crude 1H-NMR.  At 12 hours, approximately 
half of the starting material was converted into quinazoline and upon isolation and 
purification, a 37% yield was obtained.  According to the crude 1H-NMR, the complete 
conversion of the enaminonitrile to the quinazoline was observed after 24 hours while 
affording a 73% isolated yield. 
 
Scheme 22.  Synthesis of quinazolines.  
Reagents and conditions:  (i) CHOOH, H2NCHO, 200°C, 24 h. 
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 With conditions optimized, we synthesized our small library of quinazolines 
(Table 18) from our enaminonitriles utilizing our one-pot synthetic strategy with the 
exception of the aliphatic substrates 173 and 174 in which employed LDA to produce 
their enaminonitrile products.  Overall yields for the quinazoline synthesis were 
moderate with a range from 54% to 78%.  The alkyl aliphatics gave the lowest yields 
while the unsubstituted aromatic possessed a higher isolated yield when compared to the 
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fluoro or bromo-substituted substrates.  For the thiophene 175, a yield of 73% was 
observed while its bromo 176 analogue was at 60%.  As for the phenyl substrates, the 
unsubstituted 177 substrate offered a yield of 74% while the fluoro 178 and bromo 179 
substrates yields were 67% and 70% respectively.  For this reaction, the bulkier 
substrates offered the highest yields in which the isolated yields for the biphenyl 180 and 
naphthalene 181 quinazolines were 78% and 74% respectively.  As mentioned, the 
lowest yields for our scope were the aliphatic substrates and the isolated yields for 182 
and 183 were 54% and 57% respectively.   
 
Biological Evaluation of Compounds 
 The biological activities of the synthesized enaminonitriles (166-174) and their 
quinazoline (175-183) derivatives were screened against an array of assays.  We looked 
at their ability to inhibit the growth of Jurkats (a leukemic T-cell line) as well as 
bacterial strains (E. coli and B. subtilis) and yeast (S. cerevisiae).  The most pronounced 
effects that we observed were against the Jurkats cell line, where in all cases the 
quinazolines were more active than their corresponding enaminonitriles.  The most 
effective compounds which exhibited IC50 values in the low micromolar range were 
quinazolines 178 (3.24 μM), 181 (9.37 μM), and 176 (9.51 μM) were heterocyclic and in 
many instances, halogenated (Table 19).  With the anti-microbial assays, we did not see 
much of an effect as all of the compounds displayed moderate activities.  Minimal 
inhibition concentration (MIC) values were ≥163 μM in B. subtilis, ≥189 μM in E. coli, 
and ≥197 μM against S. cerevisiae which can be seen in Table 20.  
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Table 18.  Quinazoline product yields. 
 
R Group Compound Yield (%) 
 
 
 
175 73 
 
 
 
176 60 
 
 
 
177 74 
 
 
 
178 67 
 
 
 
179 70 
 
 
 
180 78 
 
 
 
181 74 
 
 
 
182 54 
 
 
 
183 57 
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Table 19.  Cytotoxic activities against Jurkats. 
 
Compound
IC50 
(μg/ml) 
μM 
166 51.485 172.15 
167 6.424 13.93 
168 4.342 15.13 
169 6.257 19.37 
170 9.213 20.52 
171 8.478 19.31 
172 7.35 18.99 
173 5.452 12.65 
174 14.166 46.75 
175 5.008 15.36 
176 4.586 9.51 
177 5.522 17.59 
178 1.133 3.24 
179 5.962 12.69 
180 4.848 10.4 
181 3.881 9.37 
182 5.849 12.8 
183 4.148 12.61 
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Table 20.  Anti-microbial activities of library. 
 
B. Subtilis 6633  E. coli  Yeast  
Compound 
IC50 
(μg/ml) μM 
IC50 
(μg/ml) μM 
IC50 
(μg/ml) μM 
166 62.33 208.4 57.37 191.8 64.24 214.8 
167 75.02 162.8 89.33 193.8 91.24 198 
168 56.32 196.1 58.39 203.3 58.37 203.3 
169 65.23 201.9 69.36 214.6 68.59 212.3 
170 76.33 170 87.39 194.6 90.24 201 
171 78.25 178.2 85.64 195 87.75 199.8 
172 80.23 207.2 79.64 205.7 78.26 202.1 
173 82.37 191 81.57 189.1 85.27 197.7 
174 74.56 245.9 70.37 232 68.26 225.1 
175 74.66 229 71.24 218.5 69.26 212.4 
176 80.24 166.5 92.37 191.7 95.26 197.7 
177 75.64 240.8 60.37 192.1 66.53 211.8 
178 80.23 229.1 70.24 200.6 71.29 203.6 
179 79.64 169.4 90.24 192 95.26 202.7 
180 80.26 172.1 91.26 195.7 94.7 203.1 
181 79.64 192.3 78.69 190 81.57 196.9 
182 77.99 170.1 87.37 190.6 90.98 198.5 
183 78.65 238.1 70.79 214.3 74.57 225.8 
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CONCLUSION 
 These findings represent a new one-pot synthetic strategy in the preparation of 
cyclohexadiene enaminonitriles.  The reaction is high yielding with small aromatics and 
other bulky substrates thus complementing that of previously reported syntheses using 
LDA.  The only instance to where the one-pot synthetic strategy cannot be implemented 
is with alkyl substrates.  The cyclohexadiene enaminonitrile were additionally 
implemented as precursors in the synthesis of quinazolines, a scaffold with demonstrated 
therapeutic activities.  In this regard, we optimized reaction conditions reported in the 
literature which generated each quinazoline in moderate yields. 
 In cell-based assays, the quinazolines gave the most promising effects where IC50 
values in the low micromolar range were measured against a human leukemic cell-line.  
The identification of the cellular targets of these lead compounds might direct the 
synthesis of functionally and structurally related analogs with more potent biological 
activities.   
 
EXPERIMENTAL 
General 
Fresh THF was dried by passage through an MBRAUN solvent purification system and 
stored over molecular sieves.  All other solvents and reagents were purchased and used 
without further purification.  1H (300 MHz) and 13C (75 MHz) spectra were recorded on 
a 300 MHz spectrometer.  Chemical shifts for 1H and 13C NMR spectra are reported in 
ppm referenced to TMS (0 ppm) and coupling constants are reported in Hertz (Hz).  MS 
spectra were recorded on an API QSTAR PULSAR (ES) apparatus.  Infrared (IR) 
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spectra were recorded with a FT-IR spectrometer.  Chromatographic separations were 
achieved by flash silica chromatography (silica gel 60 mesh, EMD Biosciences).   
 
General Procedure for NaH Catalyzed Formation of Enaminonitriles 
To an oven dried flask, 7.1 equivalents of NaH was added and immediately 
flushed with pure nitrogen gas.  Enough THF was added to dissolve the NaH and this 
solution was allowed to stir for five min. before 1.1 equivalents of diethyl 
(cyanomethyl)-phosphonate was added to create the ylide solution.  After approximately 
ten minutes, 1 equivalent of methyl-ketone substrate was added and this reaction mixture 
was allowed to stir at room temperature for 4 days.  After 4 days, the reaction mixture 
was quenched by the addition of water and extracted with ethyl ether and washed with 
ammonium sulfate, water, and brine before being dried over magnesium sulfate and 
evaporated under vacuum.  The crude product was subsequently purified via flash 
chromatography with 100% dichloromethane. 
 
Characterization of Enaminonitriles 
NH2
CN
S
S
2-Amino-6-methyl-4,6-di(thiophen-2-yl)cyclohexa-1,3-
dienecarbonitrile (166):  1H NMR (300MHz, CDCl3, 25°C), δ=7.33 (d, J=3.0 Hz, 1H), 
7.22 (d, J=3.9 Hz, 1H), 7.10-7.12 (m, 1H), 7.03-7.06 (m, 1H), 6.86-6.92 (m, 2H), 6.19 
(d, J=2.1 Hz, 1H), 4.51 (s, 2H), 3.18 (d, J=16.8 Hz, 1H), 2.86 (dd, J=2.1, 16.8 Hz, 1H), 
1.74 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=152.6 (C), 142.9 (C), 142.7 (C), 138.8 (C), 128.4 
(CH), 127.3 (CH), 126.8 (CH), 126.2 (CH), 123.8 (CH), 123.5 (CH), 120.0 (C), 115.3 
(CH), 81.4 (C), 43.5 (CH2), 38.1 (C), 30.3 (CH3) 
IR (neat) ν 3466, 3352, 3234, 3100, 2968, 2925, 2863, 2169, 1635, 1552, 1407, 853, 
827, 701 cm-1  
HRMS (ESI) for C16H14N2S2 (M+H)+: calcd 299.0677, found 299.0662. 
 
NH2
CN
S
S
Br
Br
2-Amino-4,6-bis(5-bromothiophen-2-yl)-6-methylcyclohexa-
1,3-dienecarbo-nitrile (167):  1H NMR (300MHz, CDCl3, 25°C), δ=6.98 (d, J=3.9 Hz, 
1H), 6.92 (d, J=3.9 Hz, 1H), 6.79 (d, J=3.6 Hz, 1H), 6.62 (d, J=3.9 Hz, 1H), 6.10 (d, 
J=2.1 Hz, 1H), 4.69 (s, 2H), 2.96 (d, J=16.8 Hz, 1H), 2.75 (dd, J=2.4, 16.8 Hz, 1H), 1.68 
(s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=153.9 (C), 152.9 (C), 144.0 (C), 137.7 (C), 131.4 
(CH), 129.7 (CH), 126.6 (CH), 123.9 (CH), 119.7 (C), 115.7 (CH), 114.9 (C), 110.1 (C), 
80.1 (C), 42.6 (CH2), 38.4 (C), 30.0 (CH3) 
IR (neat) ν 3466, 3348, 3236, 3095, 2968, 2931, 2866, 2169, 1635, 1552, 1435, 1408, 
1216, 966, 792 cm-1 
 HRMS (ESI) for C16H12N2Br2S2 (M+Li)+: calcd 460.8969, found 460.8918. 
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NH2
CN
2-Amino-6-methyl-4,6-diphenylcyclohexa-1,3-dienecarbonitrile 
(168):  1H NMR (300MHz, CDCl3, 25°C), δ=7.25-7.41 (m, 9H), 7.15-7.21 (m, 1H), 6.13 
(d, J=2.1 Hz, 1H), 4.61 (s, 2H), 3.18 (d, J=16.8 Hz, 1H), 2.82 (dd, J=2.1, 16.8 Hz, 1H), 
1.67 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=153.3 (C), 147.1 (C), 145.7 (C), 139.1 (C), 129.2 
(CH), 129.0 (2 x CH), 128.5 (2 x CH), 126.7 (CH), 126.2 (2 x CH), 125.9 (2 x CH), 
121.9 (C), 118.0 (CH), 80.5 (C), 42.3 (CH2), 39.4 (C), 29.1 (CH3) 
IR (neat) ν 3477, 3355, 3036, 2961, 2165, 1637,1556, 1496, 1401, 1265, 871, 763, 699 
cm-1 
HRMS (ESI) for C20H18N2  (M+H)+: calcd 287.1548, found 287.1574. 
 
2-Amino-4,6-bis(4-fluorophenyl)-6-methylcyclohexa-1,3-
dienecarbonitrile (169):  1H NMR (300MHz, CDCl3, 25°C), δ=7.30-7.38 (m, 4H), 6.92-
7.09 (m, 4H), 6.09 (d, J=2.4 Hz, 1H), 4.63 (s, 2H), 3.07 (d, J=16.8 Hz, 1H), 2.80 (dd, 
J=2.1, 16.8 Hz, 1H), 1.65 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=165.0 (C), 163.3 (C), 161.7 (C), 153.2 (C), 144.6 
(C), 129.4 (d, J=8.0 Hz, C), 127.8 (CH), 127.8 (CH), 127.7 (CH), 127.7 (CH), 120.6 (C), 
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117.7 (CH), 116.2 (CH), 115.9 (CH), 115.4 (CH), 115.1 (CH), 80.2 (C), 42.7 (CH2), 
39.1 (C), 29.1 (CH3) 
IR (neat) ν 3455, 3347, 3232, 3017, 2971, 2948, 2170, 1738, 1641, 1556, 1506, 1366, 
1229, 1217, 1160, 908, 828, 729 cm-1 
HRMS (ESI) for C20H16N2F2 (M+H)+: calcd 323.1360, found 323.1370. 
 
2-Amino-4,6-bis(4-bromophenyl)-6-methylcyclohexa-1,3-
dienecarbonitrile (170):  1H NMR (300MHz, CDCl3, 25°C), δ=7.21-7.48 (m, 8H), 6.15 
(s, 1H), 4.71 (s, 2H), 3.04 (d, J=16.8 Hz, 1H), 2.79 (d, J=16.8 Hz, 1H), 1.63 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=153.3 (C), 146.0 (C), 144.4 (C), 137.7 (C), 132.2 
(2 x CH), 131.6 (2 x CH), 128.0 (2 x CH), 127.4 (2 x CH), 123.5 (C), 120.8 (C), 120.6 
(C), 118.4 (CH), 79.9 (C), 42.1 (CH2), 39.3 (C), 29.0 (CH3) 
IR (neat) ν 3468, 3346, 3234, 2965, 2929, 2870, 21731642, 1557, 1488, 1393, 1078, 
1007, 817 cm-1 
HRMS (ESI) for C20H16N2Br2 (M+Li)+: calcd 448.9840, found 448.9805. 
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2-Amino-4,6-di(biphenyl-4-yl)-6-methylcyclohexa-1,3-
dienecarbonitrile (171):  1H NMR (300MHz, CDCl3, 25°C), δ=7.31-7.70 (m, 18 H), 
6.22 (d, J=1.8 Hz, 1H), 4.64 (s, 2H), 3.27 (d, J=16.8 Hz, 1H), 2.88 (dd, J=1.8, 16.8 Hz, 
1H), 1.75 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=153.3 (C), 146.3 (C), 145.1 (C), 142.0 (C), 140.9 
(C), 140.4 (C), 139.5 (C), 137.8 (C), 129.2 (2 x CH), 129.0 (2 x CH), 128.0 (CH), 127.6 
(2 x CH), 127.5 (2 x CH), 127.3 (5 x CH), 126.7 (2 x CH), 126.4 (2 x CH), 121.0 (C), 
117.8 (CH), 80.6 (C), 42.1 (CH2), 39.6 (C), 29.2 (CH3) 
IR (neat) ν 3462, 3347, 3057, 3028, 2965, 2928, 2872, 2170, 1638, 1551, 1486, 1396, 
1274, 1006, 832, 763, 730, 696 cm-1 
HRMS (ESI) for C32H26N2  (M+H)+: calcd 439.2174, found 439.2163. 
 
2-Amino-6-methyl-4,6-di-naphthalen-2-yl-cyclohexa-1,3-
dienecarbonitrile (172):  1H NMR (300MHz, CDCl3, 25°C), δ=7.88 (d, J=1.2 Hz, 1H), 
7.71-7.85 (m, 7H), 7.65 (dd, J=1.8, 8.4 Hz, 1H), 7.54 (d, J=2.1 Hz, 1H), 7.47-7.52 (m, 
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2H), 7.39-7.44 (m, 2H), 6.27 (d, J=1.8 Hz, 1H), 3.46 (d, J=17.4 Hz, 1H), 3.01 (dd, 
J=2.1, 16.8 Hz, 1H), 1.81 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=153.0 (C), 145.6 (C), 144.3 (C), 136.2 (C), 133.7 
(C), 133.5 (C), 133.4 (C), 132.4 (C), 128.7 (CH), 126.6 (CH), 128.4 (CH), 128.3 (CH), 
127.9 (CH), 127.6 (CH), 127.0 (CH), 126.9 (CH), 126.2 (CH), 125.9 (CH), 125.4 (CH), 
125.0 (CH), 124.5 (CH), 123.4 (CH), 120.5 (C), 118.2 (CH), 81.3 (C), 42.1 (CH2), 39.7 
(C), 29.0 (CH3) 
IR (neat) ν 3472, 3346, 3229, 3054, 2963, 2168, 1638, 1554, 1505, 1404, 1275, 850, 
815, 746 cm-1 
 HRMS (ESI) for C28H22N2  (M+H)+: calcd 387.1861, found 387.1830. 
 
2-Amino-6-methyl-4,6-bis-2-(2,6,6-trimethylcyclohex-1-
enyl)vinyl)cyclohexa-1,3-dienecarbonitrile (173)213:  1H NMR (300MHz, CDCl3, 
25°C), δ=6.43 (d, J=16.2 Hz, 1H), 6.10 (d, J=16.2 Hz, 1Hz), 5.75 (dd, J=1.2, 16.2 Hz, 
1H), 5.70 (s, 1H), 5.20 (d, J=15.9 Hz, 1H), 4.33 (s, 2H), 2.59 (d, J=16.5 Hz, 1H), 2.29 
(dd, J=1.8, 16.5 Hz, 1H), 1.89-2.03 (m, 4H), 1.67 (s, 3H), 1.52-1.62 (m, 9H), 1.40-1.47 
(m, 2H), 1.39 (s, 3H), 1.00 (s, 3H), 0.99 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=153.0 (C), 144.0 (C), 138.6 (CH), 137.6 (C), 137.5 
(C), 133.5 (CH), 131.8 (CH), 131.2 (C), 127.9 (C), 125.2 (CH), 120.4 (C), 119.1 (CH), 
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79.9 (C), 39.7 (CH2), 39.4 (CH2), 37.3 (C), 36.8 (CH2), 34.4 (C), 34.2 (C), 33.3 (CH2), 
32.7 (CH2), 29.1 (CH3), 29.1 (CH3), 28.9 (2 x CH3), 28.3 (CH3), 21.9 (CH3), 21.5 (CH3), 
19.5 (CH2), 19.3 (CH2) 
IR (neat) ν 3474, 3359, 3233, 2958, 2926, 2865, 2171, 1738, 1636, 1553, 1456, 1361, 
1217, 969 cm-1 
HRMS (ESI) for C30H42N2  (M+H)+: calcd 431.3426, found 431.3394. 
 
  2-Amino-4,6-dihexyl-6-methylcyclohexa-1,3-
dienecarbonitrile (174):  1H NMR (300MHz, CDCl3, 25°C), δ=5.52 (s, 1H), 4.25 (s, 
2H), 2.06-2.16 (m, 3H), 1.96 (d, J=17.1 Hz, 1H), 1.20-1.42 (m, 18H), 1.09 (s, 3H), 0.83-
0.87 (m, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=152.4 (C), 150.4 (C), 120.9 (C), 116.2 (CH), 79.4 
(C), 41.0 (CH2), 40.5 (CH2), 37.8 (CH2), 34.4 (C), 32.1 (CH2), 31.9 (CH2), 30.2 (CH2), 
29.2 (CH2), 27.0 (CH3), 26.8 (CH2), 24.7 (CH2), 22.9 (CH2), 22.8 (CH2), 14.3 (CH3), 
14.3 (CH3) 
IR (neat) ν 3470, 3360, 3234, 2956, 2927, 2857, 2169, 1658, 1568, 1457, 1417, 1378, 
911, 733 cm-1 
HRMS (ESI) for C20H34N2  (M+H)+: calcd 303.2800, found 303.2803. 
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Synthesis of Α,Β-Unsaturated Nitriles102 
Nitriles 62-70 for LDA reactions were prepared following literature protocols 
and purified by flash column chromatography (gradient of 2-10% ethyl acetate/hexanes).  
Starting material 62-70 are found in Chapter III while 184 was synthesized for 
compounds of this chapter. 
 
Characterization of Α,Β-Unsaturated Nitriles 
3-(5-bromothiophen-2-yl)but-2-enenitrile (184):  1H NMR 
(300MHz, CDCl3, 25°C), δ=6.98 (d, J=3.3 Hz, 2H), 5.43 (q, J=0.9 Hz, 1H), 2.34 (d, 
J=0.9 Hz, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=151.2 (C), 143.3 (C), 131.6 (CH), 128.4 (CH), 
117.4 (C), 116.2 (C), 93.6 (CH), 19.67 (CH3) 
IR (neat) ν 3095, 3050, 2995, 2925, 2852, 2210, 1660, 1593, 1411, 1269, 969, 790 cm-1 
HRMS (ESI) for C8H6NBrS  (M+H)+: calcd 227.9483, found 227.9463. 
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General Procedure for LDA Self-Dimerizations191 
A solution of α,β-unsaturated nitrile in THF was added to a stirred solution of 
lithium diisopropylamide (2.0 M) in THF that was cooled to -20°C.  The reaction 
mixture was warmed to room temperature and stirred until the starting material was 
consumed (monitored via thin layered chromatography).  The reaction was then 
quenched by the addition of water.  The mixture was extracted with ethyl ether.  The 
organic layer was washed with ammonium sulfate, water, and brine before being dried 
over magnesium sulfate and evaporated under vacuum.  The crude product was purified 
via flash chromatography with 100% dichloromethane. 
 
General Procedure for Quinazolines191 
Enaminonitrile was dried over vacuum and dissolved with 2.0 equivalents of 
formic acid and 2.0 equivalents of formamide.  This mixture was refluxed for 24 h at 
200°C.  Upon completion, the reaction mixture was brought back to room temperature 
and extracted with 100 mL (2 x 50 mL) of ethyl ether.  The combined ether layers were 
washed with water and a concentrated brine solution before being dried over magnesium 
sulfate and concentrated in vacuo.  The crude product was purified via flash 
chromatography with a gradient of 100% dichloromethane to 90% dichloromethane/10% 
methanol. 
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Characterization of Quinazolines 
5-Methyl-5,7-di(thiophen-2-yl)-5,6-dihydroquinazolin-4-amine 
(175):  1H NMR (300MHz, CDCl3, 25°C), δ=8.39 (s, 1H), 7.34-7.37 (m, 2H), 7.24 (dd, 
J=1.2, 3.6 Hz, 1H), 7.15 (dd, J=0.9, 3.6 Hz, 1H), 7.02-7.06 (m, 2H), 6.92 (d, J=2.4 Hz, 
1H), 4.86 (s, 2H), 3.30 (dd, J=2.4, 16.8 Hz, 1H), 2.91 (d, J=16.8 Hz, 1H), 1.70 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=165.7 (C), 160.0 (C), 153.2 (CH), 151.4 (C), 142.4 
(C), 140.1 (C), 128.6 (CH), 128.6 (CH), 127.5 (CH), 126.9 (CH), 126.8 (CH), 125.5 
(CH), 124.7 (C), 117.3 (CH), 46.5 (CH2), 39.4 (C), 22.3 (CH3) 
IR (neat) ν 3469, 3342, 3183, 3106, 3073, 3037, 2923, 2886, 1688, 1613, 1556, 1448, 
1420, 1183, 1047, 852, 700 cm-1 
HRMS (ESI) for C17H15N3S2 (M+H)+: calcd 326.0786, found 326.0707. 
 
5,7-Bis(5-bromothiophen-2-yl)-5-methyl-5,6-
dihydroquinazolin-4-aminE (176):  1H NMR (300MHz, CDCl3, 25°C), δ=8.43 (s, 1H), 
6.91-7.04 (m, 5H), 4.82 (s, 2H), 3.22 (dd, J=1.5, 17.1 Hz, 1H), 2.91 (d, J=17.1 Hz, 1H), 
1.79 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=159.9 (C), 157.4 (CH), 154.9 (C), 143.2 (C), 136.8 
(C), 135.8 (C), 129.8 (CH), 128.2 (CH), 127.3 (CH), 125.3 (CH), 121.9 (2 x C), 121.5 
(CH), 112.9 (C), 45.9 (CH2), 40. 7 (C), 22.2 (CH3) 
IR (neat) ν 3469, 3388, 3294, 3159, 2967, 2927, 2854, 1618, 1554, 1421, 1049, 961, 
797, 730, 703 cm-1 
HRMS (ESI) for C17H13Br2N3S2  (M+H)+: calcd 481.8996, found 481.8980. 
 
5-Methyl-5,7-diphenyl-5,6-dihydroquinazolin-4-amine (177):  1H 
NMR (300MHz, CDCl3, 25°C), δ=8.20 (s, 1H), 7.30-7.72 (m, 10H), 6.84 (s, 1H), 4.60 
(s, 2H), 3.22 (dd, J=1.5, 17.7 Hz, 1H), 2.95 (dd, J=1.2, 17.7 Hz, 1H), 1.90 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=158.0 (C), 153.0 (C), 150.6 (CH), 146.9 (C), 145.8 
(C), 139.1 (C), 129.2 (CH), 129.0 (2 x CH), 128.5 (2 x CH), 126.7 (CH), 126.1 (2 x CH), 
125.9 (2 x CH), 121.0 (C), 117.8 (CH), 42.3 (CH2), 39.4 (C), 29.1 (CH3) 
IR (neat) ν 3469, 3352, 3233, 3083, 3059, 3033, 2966, 2924, 1654, 1588, 1487, 1417, 
1006, 832, 764, 697 cm-1 
HRMS (ESI) for C21H19N3 (M+H)+: calcd 314.1657, found 314.1613. 
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5,7-Bis(4-fluorophenyl)-5-methyl-5,6-dihydroquinazolin-4-
amine (178):  1H NMR (300MHz, CDCl3, 25°C), δ=8.18 (s, 1H), 7.28-7.51 (m, 3H), 
6.88-7.19 (m, 7H), 6.70 (s, 1H), 5.80 (s, 2H), 3.07 (dd, J=1.5, 17.4 Hz, 1H), 2.85 (d, 
J=17.4 Hz, 1H), 1.83 (S, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ= 165.1 (C), 163.1 (C), 159.2 (C), 157.9 (C), 147.6 
(CH), 146.7 (C), 144.1 (C), 134.9 (C), 127.8 (CH), 127.7 (CH), 127.5 (CH), 127.4 (CH), 
123.7 (C), 122.6 (CH), 116.1 (CH), 115.8 (CH), 115.3 (CH), 115.0 (CH), 44.8 (CH2), 
40.9 (C), 25.1 (CH3) 
IR (neat) ν 3465, 3389, 3320, 3171, 3055, 2928, 2967, 1652, 1585, 1508, 1421, 1229, 
1161, 1013, 828, 734 cm-1 
HRMS (ESI) for C21H17F2N2 (M+H)+: calcd 350.1469, found 350.1488. 
 
5,7-Bis(4-bromophenyl)-5-methyl-5,6-dihydroquinazolin-4-
amine (179):  1H NMR (300MHz, CDCl3, 25°C), δ=8.42 (s, 1H), 7.45-7.52 (m, 2H), 
7.32-7.40 (m, 4H), 7.17-7.25 (m, 2H), 6.75 (s, 1H), 4.50 (s, 2H), 3.06 (dd, J=1.5, 17.7 
Hz, 1H), 2.83 (dd, J=1.5, 17.7 Hz, 1H), 1.80 (s, 3H) 
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13C NMR (75 MHz, CDCl3, 25°C) δ=162.1 (C), 157.8 (C), 147.6 (CH), 147.2 (C), 143.9 
(C), 137.6 (C), 132.2 (2 x CH), 131.5 (2 x CH), 127.8 (2 x CH), 127.4 (2 x CH), 123.7 
(C), 123.6 (C), 123.1 (CH), 120.3 (C), 44.3 (CH2), 41.1 (C), 24.6 (CH3) 
IR (neat) ν 3469, 3387, 3294, 3158, 3104, 2927, 2854, 1618, 1554, 1439, 1421, 1049, 
961, 797, 730 cm-1 
HRMS (ESI) for C21H17N3Br2 (M+H)+: calcd 469.9867, found 469.9860. 
 
5,7-Di(biphenyl-4-yl)-5-methyl-5,6-dihydroquinazolin-4-
amine (180):  1H NMR (300MHz, CDCl3, 25°C), δ=8.40 (s, 1H), 7.51-7.70 (m, 8H), 
7.29-7.49 (m, 10H), 7.15 (d, J=2.4 Hz, 1H), 4.76 (s, 2H), 3.31 (dd, J=2.4, 17.1 Hz, 1H), 
2.92 (d, J=17.1 Hz, 1H), 1.71 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=160.0 (C), 157.6 (C), 157.0 (2 x C), 153.1 (CH), 
143.4 (2 x C), 140.6 (C), 137.0 (2 x C), 129.2 (CH), 129.1 (CH), 128.2 (2 x CH), 127.9 
(CH), 127.6 (CH), 127.4 (CH), 127.3 (3 x CH), 127.2 (5 x CH), 126.3 (CH), 125.5 (CH), 
125.0 (CH), 124.5 (C), 121.4 (CH), 46.7 (CH2), 40.3 (C), 22.6 (CH3) 
IR (neat) ν 3462, 3380, 3298, 3031, 2958, 2925, 2856, 1600, 1556, 1487, 1264, 832, 
765, 697 cm-1 
HRMS (ESI) for C33H27N3  (M+H)+: calcd 466.2283, found 466.2229. 
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5-Methyl-5,7-di(naphthalen-2-yl)-5,6-dihydroquinazolin-4-
amine (181):  1H NMR (300MHz, CDCl3, 25°C), δ=8.48 (s, 1H), 8.05 (s, 1H), 7.76-7.93 
(m, 8H), 7.67 (dd, J=1.8, 8.4 Hz, 1H), 7.54-7.62 (m, 2H), 7.40-7.53 (m, 4H), 7.11 (d, 
J=2.7 Hz, 1H), 4.39 (s, 2H), 3.47 (dd, J=2.7, 17.1 Hz, 1H), 2.97 (d, J=17.1 Hz, 1H), 1.85 
(s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=160.0 (C), 158.5 (C), 157.2 (C), 145.1 (CH), 142.9 
(C), 136.2 (C), 133.7 (C), 133.6 (C), 133.4 (C), 132.7 (C), 129.7 (CH), 128.6 (3 x CH), 
128.3 (CH), 128.0 (CH), 127.9 (CH), 127.1 (CH), 126.9 (CH), 126.9 (CH), 126.8 (CH), 
126.1 (CH), 125.2 (CH), 124.4 (CH), 123.8 (C), 123.6 (CH), 45.5 (CH2), 42.5 (C), 21.1 
(CH3) 
IR (neat) ν 3471, 3387, 3308, 3177, 3054, 2961, 2927, 2854, 1671, 1598, 1557, 1449, 
1376, 1274, 1046, 854, 817, 747 cm-1 
HRMS (ESI) for C29H23N3 (M+H)+: calcd 414.1970, found 414.1938. 
 
5-methyl-5,7-bis((E)-2-(2,6,6-trimethylcyclohex-1-
enyl)vinyl)-5,6-dihydro-quinazolin-4-amine (182):  1H NMR (300MHz, CDCl3, 
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25°C), δ=8.20, (s, 1H), 6.75 (d, J=16.2 Hz, 1H), 6.60 (s, 1H), 6.35 (d, J=16.2 Hz, 1Hz), 
6.00 (dd, J=1.2, 16.2 Hz, 1H), 5.30 (d, J=15.9 Hz, 1H), 4.40 (s, 2H), 2.58 (d, J=16.5 Hz, 
1H), 2.18-2.20 (m, 1H), 1.88-2.03 (m, 4H), 1.67 (s, 3H), 1.52-1.62 (m, 9H), 1.40-1.47 
(m, 2H), 1.39 (s, 3H), 1.00 (s, 3H), 0.99 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=161.8 (C), 159.8 (C), 151.8 (CH), 146.2 (C), 139.4 
(CH), 138.4 (C), 138.3 (C), 134.3 (CH), 132.6 (CH), 132.0 (C), 128.7 (C), 126.0 (CH), 
119.4 (C), 118.5 (CH), 40.4 (CH2), 40.1 (CH2), 37.9 (C), 37.5 (CH2), 35.1 (C), 34.9 (C), 
34.0 (CH2), 33.4 (CH2), 29.8 (CH3), 29.6 (CH3), 29.6 (2 x CH3), 30.0 (CH3), 22.0 (CH3), 
21.5 (CH3), 20.2 (CH2), 20.0 (CH2) 
IR (neat) ν 3472, 3360, 3243, 2958, 2928, 2866, 1704, 1636, 1555, 1345, 1217, 707 cm-1 
HRMS (ESI) for C31H43N3 (M+H)+: calcd 458.3535, found 458.3543. 
 
5,7-dihexyl-5-methyl-5,6-dihydroquinazolin-4-amine 
(183):  1H NMR (300MHz, CDCl3, 25°C), δ=8.2 (s, 1H), 6.08 (s, 1H), 5.18 (s, 2H), 
1.96-2.27 (m, 4H), 1.49-1.54 (m, 2H), 1.16-1.42 (m, 19H), 0.88-1.02 (m, 6H) 
13C NMR (75 MHz, CDCl3, 25°C) δ=162.9 (C), 158.2 (C), 151.7 (CH), 146.7 (C), 122.9 
(CH), 121.6 (C), 41.5 (CH2), 40.3 (CH2), 38.5 (CH2), 37.7 (CH2), 31.1 (CH2), 31.9 
(CH2), 30.4 (CH2), 29.3 (CH2), 27.0 (CH3), 25.9 (CH2), 25.4 (CH2), 23.2 (CH2), 22.9 
(CH2), 14.3 (2 x CH3) 
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IR (neat) ν 3470, 3360, 3234, 2956, 2927, 2857, 1655, 1578, 1457, 1378, 911 cm-1 
HRMS (ESI) for C21H35N3  (M+H)+: calcd 330.2909, found 330.2920. 
 
Organisms and Cell Lines 
Jurkats (TIB-152) and B. subtilis strain 6633 were obtained from the American 
Type Culture Collection, Rockville, MD. The yeast S. cerevisiae wild-type strain [#404; 
BY4741; MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0] was obtained from Dr. Michael 
Kladde at the Department of Biochemistry, Texas A&M University. The E. coli strain 
DH10B was obtained from Prof. Dennis Gross, Texas A&M University, Department of 
Plant Pathology. 
 
Cytotoxicity Assay Against the Human T-cell Leukemia, Jurkat Cell Line 
Jurkat cells were maintained in 75 cm2 culture flasks at 37 ˚C under a 5% CO2 
atmosphere.  The cell culture medium consisted of RPMI 1640 with 10% fetal bovine 
serum.  Cells were harvested by centrifugation (20 min. at 1000 rpm), resuspended in 
fresh culture medium and counted on a hemocytometer.  The cells (1 mL) were arrayed 
(200,000 cells/well) in 48 well plates to which compound was added to give final 
concentrations of 100, 10 and 1 μg/mL respectively.  Cells were incubated for 24 h, 
transferred to 1.5 mL eppendorf tubes and centrifuged for 15 min. at 14,000 rpm.  The 
medium was removed and the cell pellet resuspended in 1 mL of phosphate buffer saline 
(PBS) to wash the cells.  The cells were again centrifuged for 15 min. at 14,000 rpm.  
The PBS was removed and the cell pellet resuspended in a lysis buffer. The lysed cells 
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were placed in a black 96 well plate and analyzed using a Bio-Tek fluorometer to 
measure relative fluorescence. 
 
Anti-bacterial and Anti-fungal Assays  
Microbes (Saccharomyces cerevisiae, Escherichia coli, and Bacillus subtilis 
6633) were cultured and maintained on agar plates (see supplemental material for media 
conditions).  A single colony was used to inoculate 3 mL of culture medium and allowed 
to grow for 16 h.  The cells (500 μL) were diluted with 50 mL of fresh medium to an 
O.D. of 0.1 and aliquoted into a 96-well plate (100 μL/well).  The assays were set up in 
duplicate and the compounds tested to give final concentrations of 100, 10 and 1 μg/mL.  
Plates were incubated (E. coli and B. subtilis, 37 °C; yeast, 30 °C) and shaken (250 rpm) 
for 16 h and cell density (O.D.) measured with a Bio-Tek microplate reader.   
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CHAPTER VI 
CONCLUSION 
 In recent years, the advancements in the field of natural products have grown 
tremendously.  The discovery of new drugs occurs on a daily basis with many of these 
possessing biological activities.  Along with new drug discovery comes the discovery of 
new and unique molecular scaffolds.  An example of this is the understudied class of 
compounds known as the cycloterpenals.  The cycloterpenals possess a cyclohexadienal 
structural core and two have been isolated in nature thus far.  The formation of 
cyclocitral has been suspected since the late 1890’s and it was not until 1932 that the 
cyclohexadienal structure was ascribed.35,36  Cyclocitral was recently isolated from the 
North Sea bryozoans Flustra foliacea and exhibited antibacterial activity against two 
bacterial strains.38,39  Interestingly, cycloretinal was isolated from the human eye.  This 
product is formed from the dimerization of the vision chromophore all-trans-retinal.  
This molecule, along with other bisretinoids that have been characterized in the eye, is 
believed to act as a contributor of age-related macular degeneration, the leading cause of 
blindness in the elderly.33,34   
 In the early 1990’s, the formation of cyclo-β-ional from β-
ionylideneacetaldehyde was observed when the substrate was incubated with the milk 
protein β-lactoglobulin (β-LG).  β-LG is the major whey protein in dairy milk 
constituting 50-55% of the protein volume.43  The only function ascribed to β-LG after 
70 years of extensive research is that it is involved as a carrier of essential nutrients such 
as fatty acids, retinoids, and steroids.  Humans do not possess a homolog to β-LG so the 
only source of the protein in the human body is through the consumption of dairy 
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products.  However, humans have a receptor in the small intestines where β-LG is 
absorbed into the blood stream.  This protein is quite robust as it is able to survive the 
milk pasteurization process and the highly acidic environment within the stomach.  
Protein analysis of blood samples reveal that levels of β-LG in the blood stream are on 
average between 0.7 to 1.2 g/dL.  In our investigations, we have revealed that β-LG can 
mediated the dimerization of natural and unnatural β-methyl aldehydes.  Since β-LG is 
the principal whey protein in dairy milk, we set out to demonstrate that the protein in 
store bought milks could perform the reaction in vitro.  To our amazement, the milk that 
we drink daily was able to facilitate the reaction of converting citral to cyclocitral.  To 
demonstrate that the protein can mediate this reaction in vivo, we fed eight rabbits skim 
milk along with a β-LG solution.  We fed the rabbits retinal along with these solutions 
only to discover that indeed cycloretinal was formed within the blood streams of the 
rabbits.  These in vivo results help demonstrate how the slow accumulation of 
cycloretinal in the human eyes may be occurring as recent proteomic studies of various 
regions of the eyes has shown that β-LG is present.81   
 The reasons why β-methyl aldehydes can be dimerized by β-LG is not fully 
understood.  Do these cycloterpenals possess other functionalities within the body?  We 
hypothesized that since β-LG is the major whey protein in milk that these molecules may 
be involved in developmental processes such as cellular differentiation or neuronal 
development.  The cycloterpenals are an understudied class of molecules so we set out to 
build a library of these molecules based on the cyclohexadienal scaffold.  We 
incorporated various substituents in hopes of getting a glimpse into harnessing the power 
of these molecules.  To do this, we developed a synthetic strategy that mimicked the 
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protein mediated reaction carried out by β-LG.  By using L-proline, we were able to 
successfully synthesize over 100 cycloterpenals and screen for their biological activities.  
We established cell-based assays where we screened for antifungal/antimicrobial 
activities as well as a PC12 assay to screen for neurite outgrowth.  Dramatic effects were 
observed with the PC12 assay where three molecules from our library stimulated neurite 
outgrowth and cell survival.  The molecules possessing this activity contained aromatic 
substituents and long aliphatic chains.  Biphenyl groups have been thought to serve as 
mimics of protein alpha helices while long aliphatic chains are capable of inserting into 
lipid bilayers.169  In the case of the aromatic substituted cycloterpenals, the 
cyclohexadiene ring system could be aromatized to give fluorescent molecules.  In the 
long term, these molecules could lead to protein target identification for a certain 
cycloterpenal.   
 During the synthesis of our β-methyl starting materials, we noticed the formation 
of a side product due to increased concentration of sodium hydride (NaH) that was 
utilized in a Horner-Wadsworth-Emmons reaction in the preparation of α,β-unsaturated-
nitriles.  A characteristic of this side product was that it possessed diastereomeric 
protons similar to that of our cyclohexadienals.  We isolated and characterized this side 
product to discover that the β-methyl-nitrile had self-condensated into a cyclohexadiene 
enaminonitrile.  Optimization of this reaction was pursued as this new synthetic strategy 
utilizing excess NaH gave yields from 80-96% in comparison to previous literature 
protocols which used lithium diisopropylamide (LDA).  The yields for the LDA 
reactions were a meager 12-36% dependent upon substrate.  These new cyclohexadiene 
enaminonitriles were taken on step further to produce substituted quinazolines.  This 
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class of molecules are important as antibacterial agents.  We screened this library of 18 
compounds against our cell-based screens where we saw CC50 values in the low 
micromolar range.  The identification of the cellular targets of these compounds might 
direct the synthesis of functionally and structurally related analogues with more potent 
biological activities.   
 With our studies of substituted cyclohexadienes, we have established a direct link 
between β-LG and age-related macular degeneration.  These findings could aid in the 
development of new therapeutics for the treatment of age-related macular degeneration.  
We have also discovered that the class of molecules known as cycloterpenals have 
therapeutic potential as they can be further developed in the treatment of 
neurodegenerative diseases or central nervous system injuries.  This is only the tip of the 
iceberg as only two cycloterpenals have been isolated in nature with the growing 
possibility of others in the near future.  These molecules may serve a purpose that we are 
uncertain at the present as the principal whey protein in dairy milk may play a larger role 
in living systems as it mediates the dimerization of natural aldehydes.     
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APPENDIX A 
 
 
 
 
 
A-1.  1H-NMR spectra of natural cyclocitral (top) and deuterated cyclocitral. 
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A-2.  Full 1H-NMR spectra at various time points for all-trans retinal self-condensation. 
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A-2.  Continued. 
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A-2.  Continued. 
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A-3.  H,H-COSY spectra of retinal reaction.   
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Full spectra on top with blow up of region of interest on bottom. 
30 minutes 
 
 
 
A-4.  Mass spectra correlating to NMR results for Schiff base formation and 
intermediate for all-trans retinal. 
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1 hour 30 minutes 
 
 
A-4.  Continued. 
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A-4.  Continued. 
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2 hours 30 minutes 
 
 
 
A-4.  Continued. 
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4 hours 30 minutes 
 
 
A-4.  Continued. 
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A-4.  Continued. 
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A-5.  Full 1H-NMR spectra at various time points for citral self-condensation.   
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A-5.  Continued. 
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A-5.  Continued. 
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A-6.  Mass spectra correlating to NMR results for Schiff base 57 and intermediate 59 for 
formation of cyclocitral from citral. 
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A-7.  Spectra of 14. 
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A-8.  Spectra of 15. 
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A-9.  Spectra of 32. 
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A-10.  Spectra of 33. 
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A-11.  Spectra of 34. 
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A-12.  Spectra of 35. 
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A-13.  Spectra of 36. 
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A-14.  Spectra of 37. 
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A-15.  Spectra of 38. 
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A-16.  Spectra of 39. 
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A-17.  Spectra of 40. 
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A-18.  Spectra of 41. 
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A-19.  Spectra of 60. 
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A-20.  Spectra of 61. 
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A-21.  Spectra of 62. 
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A-22.  Spectra of 63. 
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A-23.  Spectra of 64. 
 
304 
 
 
 
A-24.  Spectra of 65. 
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A-25.  Spectra of 66. 
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A-26.  Spectra of 67. 
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A-27.  Spectra of 68. 
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A-28.  Spectra of 69.   
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A-29.  Spectra of 70. 
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A-30.  Spectra of 71. 
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A-31.  Spectra of 72. 
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A-32.  Spectra of 73. 
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A-33.  Spectra of 74. 
314 
 
 
 
A-34.  Spectra of 75. 
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A-35.  Spectra of 76. 
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A-36.  Spectra of 77. 
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A-37.  Spectra of 78.   
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A-38.  Spectra of 79. 
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A-39.  Spectra of 80.   
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A-40.  Spectra of 81. 
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APPENDIX B
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B-1.  Full 1H spectra at various time points for cinnamaldehyde Schiff base. 
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B-2.  Full 1H Spectra at various time points for 4-dimethylamino-cinnamaldehyde 
Schiff base. 
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B-3.  Full 1H Spectra at Various Time Points for 4-Nitro-Cinnamaldehyde Schiff 
Base. 
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B-4.  Numbering scheme for β-methyl product. 
 
 
B-5.  Numbering scheme for γ-methylene cis and trans products. 
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B-6.  Table of bond distance between desired atoms thru space. 
 Distances between atoms 
 Atoms Distance  
 H(21)-H(22) 3.0424 
cis H(22)-H(31) 3.0474 
 H(22)-H(30) 2.5894 
 H(39)-H(38) 2.5022 
   
   
 H(22)-H(21) 2.3793 
trans H(31)-H(21) 2.4651 
 H(30)-H(21) 3.0566 
 H(39)-H(38) 2.5199 
   
 H(42)-H(37) 2.4055 
 H(42)-H(38) 3.0544 
 H(38)-H(32) 3.4743 
Desired H(38)-H(31) 3.9748 
 H(37)-H(32) 2.5532 
 H(37)-H(31) 3.7381 
 H(36)-H(35) 2.5131 
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B-7.  Table of NMR predictions of citral plus cinnamaldehyde products. 
 
 
 NMR predictions  
cis-isomer_cit+  desired_cit+cin  trans-isomer_ci  
C  1     0.00 C  1     0.00 C  1     0.00 
C  2     0.00 C  2     0.00 C  2     0.00 
C  3     0.00 C  3     0.00 C  3     0.00 
C  4     0.00 C  4     0.00 C  4     0.00 
C  5     0.00 C  5     0.00 C  5     0.00 
C  6     0.00 C  6     0.00 C  6     0.00 
C  7     0.00 C  7     0.00 C  7     0.00 
C  8     0.00 C  8     0.00 C  8     0.00 
O  9     0.00 C  9     0.00 O  9     0.00 
C  10    0.00 C  10    0.00 C  10    0.00 
C  11    0.00 C  11    0.00 C  11    0.00 
C  12    0.00 C  12    0.00 C  12    0.00 
C  13    0.00 C  13    0.00 C  13    0.00 
C  14    0.00 O  14    0.00 C  14    0.00 
C  15    0.00 C  15    0.00 C  15    0.00 
C  16    0.00 C  16    0.00 C  16    0.00 
C  17    0.00 C  17    0.00 C  17    0.00 
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C  18    0.00 C  18    0.00 C  18    0.00 
C  19    0.00 C  19    0.00 C  19    0.00 
C  20    0.00 C  20    0.00 C  20    0.00 
H  21    1.78 H  21    2.08 H  21    3.63 
H  22    4.40 H  22    1.32 H  22    2.71 
H  23    1.07 H  23    1.33 H  23    0.76 
H  24    1.12 H  24    1.67 H  24    0.59 
H  25    1.44 H  25    1.57 H  25    0.81 
H  26    1.68 H  26    1.81 H  26    1.62 
H  27    1.66 H  27    5.48 H  27    1.64 
H  28    1.61 H  28    2.62 H  28    1.53 
H  29    5.34 H  29    1.59 H  29    5.74 
H  30    2.15 H  30    9.56 H  30    2.45 
H  31    2.12 H  31    2.28 H  31    1.83 
H  32    9.83 H  32    2.15 H  32    9.23 
H  33    2.17 H  33    7.59 H  33    2.06 
H  34    2.04 H  34    7.49 H  34    2.19 
H  35    1.89 H  35    7.52 H  35    1.90 
H  36    7.63 H  36    6.25 H  36    7.65 
H  37    7.50 H  37    2.25 H  37    7.52 
H  38    7.53 H  38    2.77 H  38    7.36 
H  39    6.39 H  39    7.58 H  39    6.01 
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H  40    7.58 H  40    7.70 H  40    7.58 
H  41    7.68 H  41    7.40 H  41    7.61 
H  42    7.54 H  42    4.06 H  42    7.53 
 
B-8.  Table of dihedral Angles and J-values of Selected Bonds. 
 Dihedral Angles   
    
 Bonds Dihedrals J-value 
    
 H(29)-C(17)-C(16)-H(30) -147.65 9.98 
 H(29)-C(17)-C(16)-H(31) -32.446 8.28 
 H(30)-C(16)-C(7)-H(22) -81.237 2.08 
 H(31)-C(16)-C(7)-H(22) 165.21 12.31 
Trans 
product H(41)-C(15)-C(14)-H(36) 0.3983 11 
 H(36)-C(14)-C(13)-H(37) 0.2499 11 
 H(37)-C(13)-C(12)-H(40) 0.0839 11 
 H(40)-C(12)-C(11)-H(42) -0.2413 11 
 H(22)-C(7)-C(6)-H(21) 160.2 11.79 
 H(38)-C(4)-C(3)-H(39) 6.3471 10.88 
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 H(29)-C(17)-C(16)-H(31) 157.1 11.41 
 H(29)-C(17)-C(16)-H(30) 40.64 7 
 H(31)-C(16)-C(7)-H(21) 61.883 3.75 
 H(30)-C(16)-C(7)-H(21) 176.59 12.96 
Cis 
product H(41)-C(15)-C(14)-H(36) 0.11 11 
 H(37)-C(13)-C(12)-H(40) -0.1052 11 
 H(40)-C(12)-C(11)-H(42) 0.0087 11 
 H(21)-C(7)-C(6)-H(22) 55.602 4.63 
 H(38)-C(4)-C(3)-H(39) 11.676 10.61 
    
    
 H(35)-C(9)-C(8)-H(36) 9.3054 10.75 
 H(32)-C(6)-C(5)-H(29) 178.09 12.99 
 H(32)-C(6)-C(5)-H(28) 62.709 3.64 
Desired H(31)-C(6)-C(5)-H(29) -66.222 3.22 
 H(31)-C(6)-C(5)-H(28) 178.4 12.99 
 H(29)-C(5)-C(3)-H(27) 56.755 4.48 
 H(28)-C(5)-C(3)-H(27) 174.02 12.89 
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B-9.  Table of total Nuclear Spin-Spin Couplings for Cis Product. 
Cis Product     
      
Total nuclear spin-spin coupling J(Hz)    
 1 2 3 4 5 
1 0.000000     
2 41.862800 0.000000    
3 2.612210 71.893900 0.000000   
4 5.136900 -2.937690 53.219600 0.000000  
5 -1.208270 7.516430 -2.825330 70.385500 0.000000 
6 2.183560 -2.246380 5.249840 0.129298 41.589400 
7 1.676650 38.531300 0.040648 4.804590 -2.557860 
8 0.693838 -1.858610 4.903180 0.658931 54.475000 
9 0.166942 -2.068580 1.160440 -6.593110 1.688840 
10 0.106285 3.633080 -0.451467 2.556150 -1.203260 
11 0.054285 -0.095191 0.102004 0.345540 2.790520 
12 -0.025429 -0.014007 0.004850 0.117538 0.271804 
13 0.021175 0.041142 -0.038651 0.031568 0.167495 
14 -0.036791 0.067195 -0.004024 -0.032640 -0.158761 
15 -0.006239 0.170241 -0.022400 -0.100456 1.221040 
16 0.636831 -2.435420 2.140770 -1.407760 2.490880 
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17 0.142680 0.896143 -0.069963 0.015173 -0.148480 
18 0.385495 -0.146360 0.058912 -0.036266 0.091555 
19 -0.153877 0.033133 -0.009640 -0.000947 -0.010167 
20 -0.129436 0.039566 0.009145 -0.015354 0.010791 
21 3.770460 -5.034930 4.295770 -0.793500 6.779000 
22 -1.189920 4.765760 -3.479080 5.035080 -8.022380 
23 0.405810 -0.016263 -0.010704 -0.023084 -0.018845 
24 0.343816 -0.124683 0.019370 -0.050681 0.014804 
25 -0.002197 0.001021 -0.014732 -0.018641 0.000963 
26 0.261355 -0.107005 0.019666 -0.034553 -0.007111 
27 0.044085 -0.008361 0.025626 -0.017544 0.002785 
28 0.217588 -0.093787 0.012423 -0.019760 0.008306 
29 1.344940 -0.114493 0.223788 -0.068768 0.095023 
30 -0.208177 1.972950 -0.196544 0.272156 -0.047372 
31 0.016065 7.040730 0.242549 -0.242776 0.031247 
32 -0.009953 0.006962 1.257720 2.760480 22.268600 
33 120.956000 -8.009170 7.137510 -2.354040 2.255700 
34 119.509000 -8.294150 6.099510 -3.244080 2.783100 
35 120.464000 -3.600730 5.771890 0.138248 -0.025408 
36 -0.004624 0.022976 -0.038940 0.013119 0.024014 
37 -0.048813 -0.041598 -0.044680 -0.020489 -0.192522 
38 0.156911 7.386420 2.309190 154.020000 -1.991150 
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39 5.983860 -0.645620 150.797000 2.626490 5.812110 
40 0.006893 0.014816 -0.017420 0.026241 0.173843 
41 -0.056723 0.073608 -0.107725 0.180322 -0.204997 
42 -0.019076 -0.038329 -0.000619 -0.002593 -0.129723 
 6.00 7.00 8.00 9.00 10.00 
6 0.000000     
7 32.283100 0.000000    
8 4.244610 1.987000 0.000000   
9 -0.210710 0.307581 34.989500 0.000000  
10 43.919500 -1.798860 2.102250 0.127505 0.000000 
11 3.703460 1.186870 -0.222416 0.051622 59.983900 
12 3.723640 -0.937777 0.037020 0.009595 -1.693050 
13 -0.758126 0.907480 -0.012039 0.027450 9.154140 
14 2.974890 -0.906011 0.037888 0.000332 -1.744370 
15 1.669250 0.878206 0.507589 -0.000481 58.130300 
16 -0.951551 31.709000 -0.551637 -0.325896 1.426180 
17 3.783570 -2.083750 0.112478 0.001097 -0.084204 
18 0.003548 2.607100 -0.020573 -0.034197 -0.010468 
19 0.195802 -0.889258 0.006247 0.001931 -0.003675 
20 -0.023357 -0.814940 -0.001580 0.000932 0.015821 
21 -2.453040 128.223000 0.909011 -0.143036 1.002520 
22 118.336000 -6.794620 1.832650 1.071560 -6.480860 
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23 0.026554 1.607630 -0.013356 0.014654 0.018892 
24 -0.013213 1.496120 -0.023304 -0.001986 0.025246 
25 0.028397 0.095135 -0.000026 0.015586 0.090962 
26 0.132689 2.645490 -0.016492 0.003477 0.001556 
27 0.000089 0.062361 -0.007423 -0.002501 -0.003767 
28 -0.040197 2.059730 -0.016611 -0.003233 -0.002362 
29 -0.092959 0.807794 -0.014090 -0.057526 0.099028 
30 2.181890 -5.148880 0.159571 -0.054320 -0.250075 
31 1.435820 -3.931040 -0.043387 -0.004310 0.140554 
32 -0.077705 -0.157623 162.583000 -4.176310 0.138306 
33 -1.576620 3.144520 -1.271590 -0.496692 0.295734 
34 -1.791010 2.250810 -1.574620 -0.606709 0.216340 
35 0.697796 7.157510 -0.077945 0.023629 0.187045 
36 0.594056 0.243879 -0.028885 0.011271 6.767750 
37 0.530886 -0.694656 0.006607 0.036197 -1.356680 
38 6.466750 -1.265690 5.325740 -0.104002 0.137673 
39 -1.152300 5.828710 -0.027341 -0.071419 -0.033038 
40 0.379792 0.322239 -0.082333 0.050663 6.706050 
41 2.709250 -0.737425 0.532786 -0.119920 0.330187 
42 4.574030 -0.765870 -0.018125 0.113844 0.197976 
 11 12 13 14 15 
11 0.000000     
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12 59.304600 0.000000    
13 -2.163410 58.898800 0.000000   
14 9.065780 -1.672300 58.987500 0.000000  
15 -0.412134 8.932370 -2.185450 59.340300 0.000000 
16 -0.161650 0.098384 -0.046934 0.080722 0.510308 
17 -0.004732 0.009109 -0.012176 0.022971 0.103076 
18 0.000400 -0.007858 -0.001467 -0.006346 0.012322 
19 -0.001451 0.001283 -0.001745 0.002111 0.000411 
20 0.012083 0.007072 0.007155 0.009846 0.000157 
21 -0.115367 0.075995 -0.069526 0.040837 -0.064903 
22 5.805440 0.095648 0.168905 0.421870 5.587560 
23 0.022447 0.018809 0.012870 0.009066 0.036199 
24 0.012252 0.008932 0.015016 0.024111 0.032733 
25 0.073225 0.055784 0.052716 0.073087 0.082378 
26 0.004940 -0.004477 -0.000604 -0.005065 0.009550 
27 -0.005589 -0.009523 -0.009760 -0.005257 -0.001178 
28 -0.003192 -0.006323 -0.001418 0.002773 0.032441 
29 -0.024343 -0.010344 -0.031015 0.001028 0.118706 
30 0.043672 -0.062940 -0.008284 0.034715 0.112228 
31 0.069209 0.033807 -0.026137 0.208630 0.511960 
32 0.165363 0.009719 -0.005209 0.159548 0.621782 
33 -0.039049 0.000346 0.001647 -0.006325 0.021080 
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34 -0.038578 0.006056 -0.000789 -0.006622 0.056732 
35 -0.003456 -0.024675 -0.006630 -0.033159 -0.011548 
36 -1.252050 7.204800 1.237250 148.899000 1.426680 
37 6.981790 1.329230 149.626000 1.472750 7.027740 
38 0.368389 0.054860 -0.035127 -0.050114 0.027899 
39 -0.053179 -0.024561 -0.031081 -0.029335 -0.022027 
40 1.359680 148.262000 1.082440 7.075810 -1.252210 
41 6.270240 -1.055180 6.797330 0.830806 148.241000 
42 146.614000 1.007490 6.803660 -0.920210 5.704800 
 16 17 18 19 20 
16 0.000000     
17 44.397200 0.000000    
18 0.765667 79.710900 0.000000   
19 4.430460 3.730160 42.255100 0.000000  
20 3.489760 2.397180 41.726600 4.554290 0.000000 
21 -4.237940 1.734450 -0.166763 0.112481 0.056737 
22 9.920080 0.116135 0.274737 -0.042638 -0.064738 
23 -1.006370 5.233390 -6.157350 2.255100 117.764000 
24 -1.066240 4.968870 -6.379290 2.114260 117.842000 
25 0.369370 3.456150 -3.194530 8.639030 120.053000 
26 -0.667640 5.607770 -6.118790 117.287000 1.986670 
27 0.165368 5.780000 -3.481970 120.050000 7.934250 
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28 -1.025940 5.354670 -6.235540 117.886000 2.202750 
29 3.860720 143.412000 -0.584974 7.525340 7.385940 
30 122.046000 -5.754340 6.433780 -0.853525 -0.525116 
31 120.951000 -5.037460 4.605070 -0.617888 0.117319 
32 -0.051504 -0.008396 -0.023907 -0.009802 -0.005413 
33 -1.667670 0.241448 0.354217 -0.001505 0.000177 
34 -1.871750 0.254673 0.066289 -0.007003 -0.013540 
35 -0.205017 -0.108688 0.074955 -0.036673 -0.041350 
36 -0.051439 -0.030552 -0.017271 -0.007375 0.003533 
37 0.040201 -0.014838 -0.024778 -0.008304 0.001235 
38 0.450852 -0.037273 -0.012234 -0.017773 -0.020048 
39 -1.533930 0.076593 -0.039798 -0.004340 -0.030120 
40 -0.112828 -0.036732 -0.018592 -0.010506 0.000546 
41 0.757721 0.125701 -0.027842 -0.000655 0.003341 
42 0.042567 0.000211 -0.022985 -0.006771 0.003625 
 21 22 23 24 25 
21 0.000000     
22 6.934080 0.000000    
23 0.018433 0.131631 0.000000   
24 -0.184064 0.158631 -17.432800 0.000000  
25 0.226299 -0.004193 -12.502100 -12.474200 0.000000 
26 -0.152877 0.232675 -1.507150 -1.737080 -0.318410 
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27 -0.035506 -0.043638 -0.278958 -0.314821 2.725150 
28 -0.214825 0.066208 -1.694110 -1.601630 -0.375354 
29 -0.316401 -0.013797 -2.582500 -2.342780 -0.636441 
30 10.511400 -1.070440 1.779910 1.309130 -0.062297 
31 4.211070 -0.521701 0.288089 0.599402 -0.082441 
32 -0.174358 0.029779 -0.043800 -0.040453 0.004064 
33 -0.560510 2.881380 0.070208 -0.094316 0.010163 
34 -0.667508 3.355130 0.030907 -0.115990 -0.008331 
35 0.197758 0.047876 -0.039227 -0.052572 -0.079336 
36 -0.131977 0.115770 -0.045468 0.008399 0.046820 
37 -0.031841 -0.382851 -0.030433 -0.016621 0.016515 
38 -0.087213 -4.168710 -0.083026 -0.059057 -0.061486 
39 -0.168470 1.141450 -0.077963 -0.113196 -0.078998 
40 -0.042111 0.121063 -0.004740 -0.039621 0.018352 
41 0.033345 -0.577010 -0.043232 0.006179 0.087714 
42 0.265718 -0.135026 0.011653 -0.052712 0.049678 
 26 27 28 29 30 
26 0.000000     
27 -12.004200 0.000000    
28 -16.803300 -12.488700 0.000000   
29 -2.309130 -0.018469 -2.426640 0.000000  
30 1.300030 0.024880 2.301770 6.328950 0.000000 
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31 0.593404 -0.113051 0.525603 9.495170 -12.377900 
32 -0.049743 -0.046056 -0.046822 -0.072539 -0.022796 
33 0.120913 0.174192 -0.041082 0.374684 0.190997 
34 -0.012828 -0.020382 -0.096062 0.016970 0.121169 
35 0.015055 0.026754 -0.022146 0.053542 -0.108337 
36 -0.042572 -0.041641 -0.019363 -0.075951 0.014527 
37 -0.041518 -0.053574 -0.034626 -0.082333 -0.085911 
38 -0.060348 -0.033953 -0.056579 -0.032181 -0.062214 
39 -0.073870 -0.003065 -0.078704 0.015092 0.092166 
40 -0.027266 -0.052231 -0.042066 -0.096057 -0.097528 
41 -0.039815 -0.016490 -0.006628 0.055803 0.280346 
42 -0.019059 -0.040065 -0.049117 -0.069406 -0.094614 
 31 32 33 34 35 
31 0.000000     
32 -0.003985 0.000000    
33 -0.609595 -0.139333 0.000000   
34 -0.481941 -0.139538 -20.643200 0.000000  
35 -0.037365 -0.082964 -11.748800 -12.739900 0.000000 
36 0.029556 -0.006436 -0.049673 -0.060974 -0.065816 
37 -0.031751 -0.050241 -0.037789 -0.031831 -0.084936 
38 -0.046955 -0.259110 1.496610 1.272460 -0.010976 
39 -0.045924 0.697035 -2.803240 -3.022560 -0.089471 
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40 -0.091664 -0.064831 -0.045110 -0.018212 -0.052821 
41 0.467426 0.650222 0.018187 0.025113 -0.068174 
42 -0.012896 0.012836 -0.001279 0.092147 -0.051668 
 36 37 38 39 40 
36 0.000000     
37 6.509510 0.000000    
38 -0.072232 -0.121959 0.000000   
39 -0.088267 -0.078440 5.418680 0.000000  
40 0.993945 6.593980 -0.051401 -0.086072 0.000000 
41 6.984630 0.778221 -0.079963 -0.054194 0.513859 
42 0.451278 0.806012 -0.080215 -0.063650 6.808880 
 41 42    
41 0.000000     
42 1.482740 0.000000    
 
B-10.  Table of total Nuclear Spin-Spin Couplings for Desired Product. 
Desired product     
      
Total nuclear spin-spin coupling J(Hz)    
 1 2 3 4 5 
1 0.000000     
2 42.304200 0.000000    
3 3.715680 81.086700 0.000000   
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4 4.614660 42.156700 2.460630 0.000000  
5 4.430720 0.353378 43.987300 3.606950 0.000000 
6 -1.033460 3.496870 -1.629490 -0.906829 31.562200 
7 0.122472 0.317023 5.081840 -0.086201 -3.001990 
8 -0.008534 0.115621 -0.001583 -0.016499 3.234180 
9 -0.008226 -0.047432 0.099212 -0.013737 -1.755950 
10 0.001844 0.046288 0.009776 0.000679 1.571570 
11 -0.006499 -0.009238 -0.066466 -0.003355 -0.910864 
12 0.009009 0.008362 -0.101604 0.022858 1.997660 
13 -0.005069 -0.029299 -0.019110 -0.003154 -0.804358 
14 0.002409 -0.010580 0.010473 0.002625 -0.420337 
15 0.000312 0.002969 0.005035 0.004133 0.266075 
16 -0.000746 -0.001155 -0.001446 0.002034 -0.015178 
17 -0.000964 -0.002267 -0.002078 0.001289 0.001702 
18 -0.001314 -0.001375 -0.002362 0.000919 0.006975 
19 -0.000715 -0.002539 -0.001167 0.001908 -0.001909 
20 -0.000411 -0.001092 -0.000749 0.002993 0.009540 
21 8.572300 -3.225190 3.385510 119.315000 0.442919 
22 2.260340 -6.158250 5.200250 118.053000 -0.992646 
23 2.089010 -6.335050 4.917760 118.352000 -0.956512 
24 117.578000 -6.104250 5.554010 2.076020 -0.642503 
25 120.509000 -3.468370 5.881390 8.034230 0.189339 
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26 117.710000 -6.206270 5.323140 2.119690 -0.946514 
27 7.605580 -0.714848 142.698000 7.166930 4.038160 
28 -0.426348 4.147260 -4.105040 0.278144 119.556000 
29 -1.290720 5.827430 -6.053910 -0.972711 122.286000 
30 -0.007979 -0.013826 -0.008950 -0.005777 -0.052955 
31 0.050592 -0.200547 2.773100 0.153128 -3.678220 
32 0.102881 -0.127601 1.724610 0.068203 -6.124090 
33 -0.005492 -0.009798 -0.008235 -0.000110 0.001016 
34 -0.006775 -0.011047 -0.011863 -0.002586 -0.004630 
35 -0.004145 0.029853 0.088156 -0.016488 0.932272 
36 -0.017930 -0.060266 -0.011181 -0.021715 -1.679960 
37 -0.002514 -0.012617 0.012944 0.024681 -0.543074 
38 -0.004875 -0.123377 0.102277 0.007024 -2.291790 
39 -0.006133 -0.009144 -0.010999 -0.001741 -0.009441 
40 -0.002653 -0.010471 0.001076 0.004936 0.027584 
41 -0.003858 -0.006574 -0.006073 0.001905 -0.006358 
42 -0.003344 0.049686 0.000872 0.001898 1.467130 
 6.00 7.00 8.00 9.00 10.00 
6 0.000000     
7 41.618200 0.000000    
8 2.433200 72.891400 0.000000   
9 4.761060 -3.244530 54.239600 0.000000  
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10 -1.180950 8.093060 -2.979760 71.979100 0.000000 
11 2.275470 -2.379450 5.180780 0.146365 41.223600 
12 2.490510 38.133000 0.211353 5.570800 -2.364220 
13 0.686604 -1.848980 4.841930 0.899026 55.277800 
14 0.161376 -2.472700 1.307690 -6.755820 1.607260 
15 0.003194 4.159400 -0.764201 2.473880 -2.085070 
16 0.094301 0.013459 0.084306 0.303319 2.317380 
17 -0.018405 -0.024733 0.000549 0.082094 -0.029305 
18 0.022440 0.106111 -0.036240 0.039945 0.327216 
19 -0.031922 -0.082003 0.006764 -0.036108 -0.338523 
20 0.020729 -0.031104 0.011619 -0.078319 1.175440 
21 0.040398 0.029002 -0.002514 -0.011111 -0.009287 
22 1.880140 0.182900 0.024195 -0.008032 -0.011927 
23 1.927140 0.096198 0.044760 -0.013736 -0.000201 
24 2.800200 0.272788 0.087760 -0.004291 0.004457 
25 0.074643 0.010401 -0.011123 -0.004257 -0.013995 
26 2.236590 0.047311 0.033241 -0.000263 -0.012991 
27 2.446980 -0.174430 -0.019224 0.006403 -0.038758 
28 -3.242210 1.661340 -0.308310 0.072902 -0.098027 
29 -5.170160 1.949920 -0.161458 0.100695 -0.058156 
30 -0.000363 -0.057617 1.318890 2.773290 22.229600 
31 122.653000 -3.787800 5.835510 0.115889 0.002560 
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32 123.062000 -6.793020 5.928820 -1.902490 1.884540 
33 -0.004245 0.047949 -0.039241 0.026884 0.072856 
34 -0.040162 -0.098567 -0.030953 -0.038880 -0.288138 
35 0.142773 7.182940 2.229620 153.065000 -2.092200 
36 5.590100 -0.232925 150.484000 2.915650 5.585970 
37 3.387120 -5.062410 4.768580 -0.831964 7.743320 
38 1.433070 -7.673080 5.005450 -3.735360 3.976230 
39 0.006664 0.044540 -0.023028 0.021507 0.175362 
40 -0.027708 -0.064431 -0.049346 0.233226 -0.277147 
41 -0.019070 -0.085867 -0.017905 0.002138 -0.239264 
42 -1.163860 3.587920 -3.404630 4.704850 -7.309180 
 11 12 13 14 15 
11 0.000000     
12 33.618300 0.000000    
13 4.957670 2.323940 0.000000   
14 -0.225818 0.300335 35.014600 0.000000  
15 43.494900 -1.934610 2.306040 0.176736 0.000000 
16 3.767620 1.554590 -0.110758 0.038928 60.500000 
17 3.696750 -0.764550 -0.030924 0.024566 -1.726970 
18 -0.731976 0.880305 0.030786 0.009838 9.059440 
19 3.197050 -0.920799 -0.025008 0.004549 -1.693750 
20 2.091750 1.683470 0.144967 0.019255 59.151300 
351 
 
21 0.013534 0.022611 0.001748 0.013927 0.023820 
22 -0.003373 -0.000297 -0.008258 0.014521 0.005583 
23 -0.013072 -0.006514 -0.013202 0.007199 0.003705 
24 -0.016897 -0.009372 -0.017190 0.006814 -0.000682 
25 -0.006599 -0.007048 -0.006534 0.011457 -0.004836 
26 -0.006987 -0.010484 -0.007554 0.009282 -0.004459 
27 0.075918 0.247144 -0.002762 0.026361 -0.013600 
28 0.143595 0.156787 0.064529 0.031079 0.007815 
29 0.084925 -0.161795 0.050544 -0.003510 -0.023611 
30 0.124880 -0.170397 161.850000 -4.093030 0.080995 
31 0.560711 6.745880 -0.093848 0.030831 0.339833 
32 -1.086440 2.528620 -1.102640 -0.383575 0.301062 
33 0.544672 0.271506 0.008389 0.002658 6.674400 
34 0.539031 -0.671552 -0.027475 0.033690 -1.347330 
35 6.486560 -1.231550 5.323280 -0.119023 -0.188218 
36 -0.911063 6.117330 -0.022026 -0.050691 0.143559 
37 -2.701830 125.428000 0.761937 -0.152377 0.735672 
38 -6.027710 119.762000 -1.546730 -0.511089 5.039670 
39 0.411277 0.301445 -0.022559 0.057001 6.775330 
40 3.174100 -0.515649 0.134391 -0.028431 -0.195236 
41 4.559260 -0.745660 -0.060904 0.124910 0.281710 
42 119.675000 -6.059240 1.549850 1.019420 -5.790570 
352 
 
 16 17 18 19 20 
16 0.000000     
17 59.179400 0.000000    
18 -2.163890 59.335900 0.000000   
19 8.921580 -1.669420 59.065300 0.000000  
20 -0.239325 8.909600 -2.155740 60.028600 0.000000 
21 0.018780 0.011915 0.010270 0.016515 0.022857 
22 0.006198 0.003567 0.000582 0.000921 0.003778 
23 0.000484 -0.000813 0.000019 0.002995 0.004042 
24 -0.001203 -0.002655 -0.004376 -0.004069 -0.002711 
25 -0.004526 -0.006280 -0.007402 -0.005264 -0.004125 
26 -0.003834 -0.004819 -0.004687 -0.002907 -0.002387 
27 -0.006565 -0.011407 -0.011715 -0.009040 -0.007323 
28 0.018070 0.002344 0.002013 0.017049 0.023740 
29 -0.003790 -0.013353 -0.012379 0.002420 0.003093 
30 0.319026 0.011096 0.042283 0.056775 0.382317 
31 0.017384 -0.019073 -0.003732 -0.032568 -0.004515 
32 -0.022626 -0.003145 0.000485 -0.019575 -0.003436 
33 -1.253730 7.159920 1.292450 148.511000 1.428330 
34 7.008630 1.350480 149.419000 1.462090 7.066110 
35 0.307735 0.016727 -0.017858 -0.054904 0.036527 
36 -0.052249 -0.034445 -0.023866 -0.035792 -0.074247 
353 
 
37 -0.105293 0.028456 -0.020169 0.023534 -0.020896 
38 -0.169583 -0.004321 0.016501 0.047135 0.092983 
39 1.354100 148.266000 1.089390 7.104160 -1.256080 
40 6.148050 -1.035230 6.873540 0.755469 147.210000 
41 147.089000 1.127520 6.727920 -0.941009 5.717100 
42 5.870820 0.269376 -0.030482 0.680796 4.808790 
 21 22 23 24 25 
21 0.000000     
22 -12.346000 0.000000    
23 -12.594000 -17.296100 0.000000   
24 -0.360513 -1.479910 -1.726630 0.000000  
25 2.714330 -0.265094 -0.324623 -12.255400 0.000000 
26 -0.357888 -1.656540 -1.567780 -16.652100 -12.345400 
27 -0.702640 -2.469670 -2.526720 -2.313910 -0.035365 
28 -0.179822 -0.019375 0.045284 0.030266 -0.152754 
29 -0.040923 2.422890 2.073590 2.272940 0.043487 
30 -0.007224 -0.027654 -0.033419 -0.031165 -0.031623 
31 -0.089620 0.015211 -0.229137 -0.140458 0.028094 
32 0.096547 -0.060236 -0.216541 -0.141083 -0.023555 
33 0.018146 -0.021900 -0.008954 -0.025679 -0.027203 
34 0.000722 -0.019990 -0.019996 -0.025279 -0.032945 
35 -0.043353 -0.045154 -0.038286 -0.014013 -0.025010 
354 
 
36 -0.035412 -0.053979 -0.064243 -0.043786 0.005629 
37 0.197922 0.064726 -0.003842 0.004952 -0.025204 
38 0.146951 -0.010960 -0.012345 -0.055286 -0.029049 
39 0.005383 -0.007886 -0.024096 -0.017612 -0.030021 
40 0.053793 -0.014627 -0.000449 -0.020861 -0.015895 
41 0.030750 0.008339 -0.022635 -0.006672 -0.019972 
42 0.021672 0.002574 -0.021005 0.007285 -0.025026 
 26 27 28 29 30 
26 0.000000     
27 -2.374010 0.000000    
28 0.014363 9.899620 0.000000   
29 3.401610 4.443640 -12.722600 0.000000  
30 -0.034172 -0.046210 -0.028763 -0.046422 0.000000 
31 -0.169503 0.033504 11.759200 3.585760 -0.074537 
32 -0.213763 -0.291109 4.342220 11.407200 -0.123625 
33 -0.018812 -0.038731 0.015746 -0.005568 -0.019129 
34 -0.025427 -0.048451 -0.016057 -0.042350 -0.055998 
35 -0.035226 -0.027894 -0.166405 -0.091074 -0.199647 
36 -0.033110 0.068594 -0.014818 0.208257 0.607447 
37 -0.024188 -0.037418 0.272900 -0.011919 -0.178378 
38 -0.027374 0.003325 0.725867 0.336848 -0.151487 
39 -0.026594 -0.045408 -0.016827 -0.051473 -0.027598 
355 
 
40 -0.013365 -0.021013 0.095321 0.068546 0.271530 
41 -0.024509 -0.033852 0.015109 -0.043126 0.100755 
42 -0.033860 -0.049818 -0.114120 -0.179200 0.054390 
 31 32 33 34 35 
31 0.000000     
32 -12.058900 0.000000    
33 -0.058155 -0.047456 0.000000   
34 -0.081671 -0.046955 6.463250 0.000000  
35 0.059301 0.792271 -0.061999 -0.124383 0.000000 
36 -0.098532 -2.016030 -0.075008 -0.087150 5.509320 
37 -0.232211 -0.670265 -0.096903 -0.034420 -0.066961 
38 -0.987392 -2.764380 0.041329 -0.043688 1.316630 
39 -0.050927 -0.026144 0.960827 6.593690 -0.054990 
40 -0.065796 -0.024387 7.013800 0.786700 -0.047034 
41 -0.054897 0.039486 0.456780 0.797750 -0.091155 
42 0.111416 2.164090 0.109868 -0.200427 -3.835470 
 36 37 38 39 40 
36 0.000000     
37 -0.520195 0.000000    
38 -3.690340 -17.341700 0.000000   
39 -0.086301 -0.058219 -0.109903 0.000000  
40 -0.091721 0.005198 0.246469 0.505476 0.000000 
356 
 
41 -0.084545 0.164314 -0.085279 6.706110 1.482990 
42 0.962861 8.535670 19.353300 0.032708 -0.484783 
 41 42    
41 0.000000     
42 0.005386 0.000000    
 
B-11.  Table of total Nuclear Spin-Spin Couplings for Trans Product. 
trans product     
      
Total nuclear spin-spin coupling J(Hz)    
 1 2 3 4 5 
1 0.000000     
2 41.768200 0.000000    
3 2.775880 72.878600 0.000000   
4 5.170370 -3.236780 54.438400 0.000000  
5 -1.285520 8.507780 -2.847080 71.415000 0.000000 
6 2.423270 -1.774130 4.898170 0.095340 40.901900 
7 1.976600 39.315300 0.201101 4.727510 -1.854660 
8 0.698849 -1.904320 5.008490 0.928840 55.832800 
9 0.170761 -2.687270 1.370900 -6.690110 1.616710 
10 0.001183 3.634260 -0.845491 2.545350 -2.390090 
11 0.120866 0.197256 0.035867 0.264950 2.056160 
12 -0.016792 0.086878 0.001175 0.053823 -0.157006 
357 
 
13 0.025284 0.030020 -0.033559 0.042099 0.384814 
14 -0.034434 -0.041094 0.009963 -0.037188 -0.398900 
15 0.024002 -0.076874 0.007267 -0.057736 1.279610 
16 1.330800 -1.268680 2.313800 -0.847086 3.498690 
17 0.847858 0.066596 -0.090079 -0.024487 0.516678 
18 0.161019 -0.136483 0.071534 -0.020222 0.054741 
19 -0.019220 0.029726 -0.029586 -0.008828 0.024970 
20 0.060687 0.021878 -0.012472 -0.011076 -0.011018 
21 -1.237930 3.242110 -3.414080 4.761650 -7.591970 
22 1.530700 -7.759510 4.827690 -3.577740 3.032640 
23 0.217499 -0.079126 0.022733 -0.011253 0.042134 
24 -0.011200 0.002076 -0.021343 -0.020177 0.004505 
25 0.035829 -0.114792 0.008219 -0.020516 0.016465 
26 0.061097 -0.104462 0.041731 -0.003467 0.063782 
27 0.072283 -0.092073 0.029138 -0.009290 -0.000121 
28 0.012155 -0.004791 -0.007039 -0.016939 -0.018397 
29 1.550470 -0.171942 -0.011471 -0.026500 0.049167 
30 -0.207178 8.178730 0.785014 -0.014088 0.275489 
31 0.051146 4.220690 -0.192034 0.037047 -0.300281 
32 0.005694 -0.064387 1.294350 2.641880 21.888900 
33 120.737000 -7.770750 7.146620 -2.484370 2.395280 
34 119.919000 -8.085420 6.227100 -2.962720 2.606770 
358 
 
35 120.673000 -3.646460 6.539460 0.352552 -0.008983 
36 -0.003257 0.018217 -0.036477 0.033025 0.091337 
37 -0.044007 -0.063664 -0.021936 -0.053948 -0.317360 
38 -0.022145 7.166890 2.323290 153.197000 -2.021730 
39 6.646370 -0.534765 149.831000 2.561470 5.870030 
40 0.005816 0.018133 -0.026055 0.016437 0.162886 
41 -0.024421 0.000776 -0.027828 0.250087 -0.284932 
42 -0.030308 0.037416 -0.031429 -0.005589 -0.282977 
 6.00 7.00 8.00 9.00 10.00 
6 0.000000     
7 33.349200 0.000000    
8 4.842260 2.287080 0.000000   
9 -0.171599 0.301307 34.997900 0.000000  
10 43.271600 -1.693100 2.396520 0.212437 0.000000 
11 3.017220 1.860390 -0.021600 0.027642 59.614200 
12 3.426530 -0.418831 -0.063129 0.025244 -1.711700 
13 -0.715101 0.653020 0.049099 0.004517 8.989790 
14 3.209210 -0.690943 -0.040982 0.002124 -1.634010 
15 2.166520 1.610080 0.101070 0.011988 59.095200 
16 0.716011 34.969700 0.323964 -0.093314 0.397766 
17 4.300470 -2.588900 0.333216 -0.007498 -0.106795 
18 -0.085680 2.555850 0.000347 0.003463 0.040015 
359 
 
19 0.201778 -0.997391 -0.001670 0.004014 0.005191 
20 -0.032507 -0.907325 -0.001174 0.006336 0.102786 
21 119.792000 -6.108140 1.623920 1.030690 -6.043650 
22 -5.736800 122.799000 -1.509950 -0.488637 5.807680 
23 0.020244 1.855020 0.015460 0.016412 0.044708 
24 0.023270 0.133058 -0.003506 0.042230 0.215173 
25 -0.009209 1.640150 0.019886 0.024453 0.039948 
26 0.110465 2.861670 0.032134 0.010151 -0.004491 
27 -0.051846 2.308800 0.002247 0.018355 -0.001518 
28 0.005376 0.080534 -0.004257 0.018755 0.003868 
29 0.021360 1.041770 0.013510 0.039180 0.082472 
30 4.464170 -4.434450 0.168048 0.091135 -0.022267 
31 0.634979 -4.462260 -0.007661 0.084000 -0.109722 
32 0.097193 -0.173166 161.381000 -4.099390 0.069243 
33 -1.384000 2.804570 -1.388180 -0.521365 0.686514 
34 -1.414280 1.751550 -1.493260 -0.555883 0.576304 
35 0.736873 6.316630 -0.079365 0.039300 0.254464 
36 0.524185 0.195830 0.017259 -0.003749 6.621440 
37 0.517233 -0.506522 -0.044509 0.032068 -1.344040 
38 6.505830 -1.037770 5.293870 -0.145208 -0.443818 
39 -0.830194 6.211990 0.093638 -0.034595 0.165527 
40 0.413945 0.212347 -0.000605 0.058428 6.731780 
360 
 
41 3.121420 -0.273272 0.063058 -0.016737 -0.363718 
42 4.023980 -0.466123 -0.087401 0.129680 0.236871 
 11 12 13 14 15 
11 0.000000     
12 58.084200 0.000000    
13 -2.099500 58.609400 0.000000   
14 8.924510 -1.569280 58.417300 0.000000  
15 -0.143063 8.861700 -2.122760 59.330900 0.000000 
16 0.015206 -0.006633 -0.021690 0.025669 -0.081488 
17 0.038287 -0.001398 -0.008372 -0.007563 0.004532 
18 0.013432 -0.004197 0.003011 0.007873 0.000194 
19 0.000658 0.004182 0.001008 0.007862 0.008893 
20 0.027517 0.016853 0.003191 0.040532 0.127131 
21 5.984300 0.272376 -0.045503 0.754042 4.795810 
22 -0.191497 -0.003022 0.032403 0.040320 0.159307 
23 0.037899 0.019842 0.036407 0.072078 0.043959 
24 0.172957 0.116257 0.103232 0.170014 0.239289 
25 0.018419 0.045322 0.026465 0.041151 0.039539 
26 0.001055 -0.004970 0.005211 0.007715 0.012585 
27 0.011959 0.001853 0.005533 0.000909 0.011557 
28 0.000772 -0.006120 -0.006638 -0.002328 0.004294 
29 0.078315 -0.013603 -0.022477 -0.010295 -0.013298 
361 
 
30 0.432589 0.108631 -0.000900 -0.010294 0.126472 
31 -0.011283 -0.017263 -0.013927 -0.016795 0.167888 
32 0.451238 0.032391 0.063657 0.018387 0.354067 
33 -0.032942 -0.008873 0.001296 -0.013100 0.010907 
34 -0.041536 -0.014559 0.000468 -0.030688 -0.003547 
35 0.025562 -0.022700 -0.006197 -0.032410 -0.009151 
36 -1.252840 7.153100 1.275500 148.730000 1.452480 
37 6.996100 1.331080 149.881000 1.436940 7.036950 
38 0.263829 -0.001048 -0.007805 -0.054920 0.044015 
39 -0.048423 -0.032319 -0.029117 -0.027991 -0.076000 
40 1.385150 148.545000 1.094750 7.102380 -1.253510 
41 6.167580 -1.008530 6.909690 0.714482 148.144000 
42 148.337000 1.168380 6.736530 -0.934315 5.759350 
 16 17 18 19 20 
16 0.000000     
17 43.858100 0.000000    
18 0.558311 79.673300 0.000000   
19 4.604260 3.877170 42.202700 0.000000  
20 3.273270 2.271350 41.213900 4.386240 0.000000 
21 7.190170 0.050788 0.026621 0.015533 0.055596 
22 -5.363020 3.508450 -0.080402 0.159398 0.054637 
23 -1.114570 5.152000 -6.289390 2.087570 117.449000 
362 
 
24 0.275073 3.413130 -3.017740 8.821260 120.580000 
25 -1.057800 5.126450 -6.431630 2.372950 117.642000 
26 -0.682840 5.580890 -6.208760 117.507000 2.006800 
27 -1.027510 5.487900 -6.140800 117.732000 2.183040 
28 0.152843 5.866730 -3.458870 119.957000 7.778330 
29 4.393490 144.152000 -0.798962 7.554250 7.540500 
30 120.470000 -5.829770 4.787290 -0.830116 -0.075488 
31 119.743000 -4.701120 6.587830 -0.503543 -0.235248 
32 -0.060049 -0.026615 -0.024584 -0.009178 0.008543 
33 -0.679011 0.628915 0.286697 -0.057185 -0.037842 
34 -0.746009 1.097750 0.098563 -0.000805 0.010392 
35 0.168831 0.907359 0.202639 -0.060493 -0.025112 
36 -0.047662 -0.028610 -0.011843 -0.008100 -0.007472 
37 -0.016101 -0.027772 -0.019384 -0.008643 0.003681 
38 0.277842 -0.024562 -0.018691 -0.012663 -0.010082 
39 -0.324281 -0.008632 -0.033101 -0.014962 -0.025951 
40 -0.020702 -0.029168 -0.023620 -0.009130 0.003047 
41 0.015858 -0.005809 -0.012572 -0.006000 -0.014654 
42 0.132201 0.008698 -0.034208 -0.011228 -0.003391 
 21 22 23 24 25 
21 0.000000     
22 17.063000 0.000000    
363 
 
23 -0.091223 0.046233 0.000000   
24 0.035862 0.262579 -12.844600 0.000000  
25 -0.047791 -0.184746 -17.725100 -12.349300 0.000000 
26 -0.079130 -0.030311 -1.598040 -0.298760 -1.703010 
27 -0.080556 -0.183655 -1.763890 -0.362974 -1.511910 
28 -0.043690 -0.010769 -0.334831 2.805030 -0.246580 
29 -0.006645 -0.306005 -2.692830 -0.591918 -2.278680 
30 0.051884 1.791810 0.763146 0.048944 1.115180 
31 -0.142070 8.865430 1.123830 -0.063332 0.664207 
32 0.090941 -0.135447 -0.026396 0.021700 -0.036618 
33 2.632370 -3.945910 0.169702 -0.002578 0.035894 
34 2.917730 -4.048230 -0.038552 -0.032075 -0.085915 
35 -0.064101 -0.745506 0.093499 -0.072025 -0.034893 
36 0.113851 0.061077 0.071154 0.020618 -0.042360 
37 -0.167779 -0.044196 -0.015370 0.001508 -0.001717 
38 -3.732060 1.264180 -0.067434 -0.060205 -0.086672 
39 0.923129 -3.417940 -0.067143 -0.068760 -0.098829 
40 0.030500 -0.088510 -0.068659 0.019092 -0.005148 
41 -0.427517 0.199838 0.090554 0.102002 -0.051291 
42 0.052246 -0.092888 -0.072408 0.069880 -0.015044 
 26 27 28 29 30 
26 0.000000     
364 
 
27 -16.794100 0.000000    
28 -12.177800 -12.310900 0.000000   
29 -2.406360 -2.409260 -0.016319 0.000000  
30 1.146040 1.054000 -0.085115 8.510900 0.000000 
31 0.611513 1.376680 -0.025441 6.889320 -13.464800 
32 -0.039454 -0.040844 -0.044575 -0.068339 0.001052 
33 0.179361 0.057936 0.140635 0.658931 -0.045617 
34 -0.037714 -0.043438 0.079072 0.241827 0.106700 
35 0.048196 0.021746 -0.011749 0.454742 -0.302843 
36 -0.001700 -0.034154 -0.053224 -0.092574 -0.081749 
37 -0.033622 -0.030112 -0.061051 -0.092833 -0.042475 
38 -0.063888 -0.080151 -0.058842 -0.098619 -0.127393 
39 -0.045048 -0.068977 -0.034662 -0.062927 0.393990 
40 -0.048849 -0.026090 -0.056586 -0.088333 0.024903 
41 0.011171 -0.045194 -0.033555 -0.065827 -0.009964 
42 -0.054037 -0.027223 -0.042878 -0.027295 0.314124 
 31 32 33 34 35 
31 0.000000     
32 -0.031617 0.000000    
33 0.053767 -0.138541 0.000000   
34 0.297255 -0.158959 -19.820200 0.000000  
35 -0.099789 -0.083717 -12.260600 -12.492900 0.000000 
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36 -0.107761 -0.027147 -0.020655 -0.060722 -0.054234 
37 -0.098347 -0.055090 -0.056633 -0.072128 -0.086267 
38 -0.198282 -0.167117 1.471640 1.169160 0.041181 
39 0.188045 0.590085 -2.862350 -2.660220 -0.047118 
40 -0.035408 0.001452 -0.060596 -0.052081 -0.061578 
41 -0.078342 0.129804 0.045485 -0.048620 -0.051027 
42 0.087468 0.187156 -0.059607 -0.015660 -0.075022 
 36 37 38 39 40 
36 0.000000     
37 6.483990 0.000000    
38 -0.053049 -0.122318 0.000000   
39 -0.074686 -0.088898 5.706080 0.000000  
40 0.999817 6.608710 -0.059562 -0.094000 0.000000 
41 7.072020 0.810039 -0.030935 -0.078705 0.491120 
42 0.458035 0.824012 -0.096538 -0.087256 6.715570 
 41 42    
41 0.000000     
42 1.494660 0.000000    
 
 
 
 
 
366 
 
 
B-12.  X-ray crystal determination of 146. 
 
Table 21.  Crystal data and structure refinement for cw02a. 
Identification code  cw02a 
Empirical formula  C28 H23 N O 
Formula weight  389.47 
Temperature  90(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.116(5) Å = 90.844(6)°. 
 b = 10.160(5) Å = 97.738(6)°. 
 c = 21.595(10) Å  = 110.128(6)°. 
Volume 2060.5(17) Å3 
Z 4 
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Density (calculated) 1.256 Mg/m3 
Absorption coefficient 0.075 mm-1 
F(000) 824 
Crystal size 0.50 x 0.04 x 0.04 mm3 
Theta range for data collection 1.91 to 25.00°. 
Index ranges -11<=h<=12, -12<=k<=12, -25<=l<=25 
Reflections collected 16109 
Independent reflections 7096 [R(int) = 0.0533] 
Completeness to theta = 25.00° 98.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9970 and 0.9633 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7096 / 0 / 545 
Goodness-of-fit on F2 1.003 
Final R indices [I>2sigma(I)] R1 = 0.0530, wR2 = 0.1048 
R indices (all data) R1 = 0.1127, wR2 = 0.1295 
Largest diff. peak and hole 0.368 and -0.199 e.Å-3 
 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for cw02a.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
_______________________________________________________________  
 x y z U(eq) 
________________________________________________________________  
O(1A) 2551(2) 1103(2) 1336(1) 45(1) 
N(1A) 8261(2) 7471(2) 592(1) 41(1) 
C(1A) 4513(3) 2256(3) 2127(1) 32(1) 
C(2A) 5868(3) 3330(2) 2285(1) 29(1) 
C(3A) 6584(3) 3418(2) 2886(1) 29(1) 
C(4A) 6027(3) 2528(2) 3345(1) 28(1) 
C(5A) 4662(3) 1518(3) 3186(1) 33(1) 
C(6A) 3937(3) 1386(3) 2586(1) 35(1) 
C(7A) 3751(3) 1929(3) 1481(1) 39(1) 
C(8A) 6478(3) 4399(2) 1841(1) 29(1) 
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C(9A) 5678(3) 5070(3) 1482(1) 32(1) 
C(10A) 6247(3) 6084(3) 1083(1) 34(1) 
C(11A) 7692(3) 6510(3) 1017(1) 33(1) 
C(12A) 8529(3) 5880(3) 1394(1) 33(1) 
C(13A) 7930(3) 4863(3) 1792(1) 34(1) 
C(14A) 7373(3) 8114(3) 224(1) 50(1) 
C(15A) 9786(3) 8134(3) 638(2) 67(1) 
C(16A) 6824(3) 2649(2) 3984(1) 28(1) 
C(17A) 8317(3) 3147(2) 4086(1) 32(1) 
C(18A) 9097(3) 3257(2) 4670(1) 31(1) 
C(19A) 8387(3) 2862(2) 5183(1) 27(1) 
C(20A) 8901(3) 2773(2) 5841(1) 27(1) 
C(21A) 10280(3) 3095(2) 6164(1) 33(1) 
C(22A) 10462(3) 2833(3) 6789(1) 36(1) 
C(23A) 9296(3) 2293(3) 7099(1) 37(1) 
C(24A) 7926(3) 2000(3) 6786(1) 34(1) 
C(25A) 7736(3) 2235(2) 6158(1) 27(1) 
C(26A) 6372(3) 1973(3) 5712(1) 31(1) 
C(27A) 6893(3) 2372(2) 5096(1) 25(1) 
N(1B) 3251(3) 7268(2) 522(1) 44(1) 
O(1B) -2442(2) 785(2) 1233(1) 75(1) 
C(1B) -418(3) 1885(3) 2005(1) 40(1) 
C(2B) 856(3) 3047(3) 2177(1) 33(1) 
C(3B) 1556(3) 3159(3) 2792(1) 33(1) 
C(4B) 1078(3) 2185(3) 3233(1) 35(1) 
C(5B) -135(3) 1008(3) 3031(1) 43(1) 
C(6B) -859(3) 861(3) 2435(1) 45(1) 
C(7B) -1386(3) 1794(3) 1418(1) 50(1) 
C(8B) 1456(3) 4128(3) 1740(1) 32(1) 
C(9B) 2059(3) 5551(3) 1942(1) 33(1) 
C(10B) 2640(3) 6587(3) 1550(1) 34(1) 
C(11B) 2658(3) 6253(3) 919(1) 33(1) 
C(12B) 2065(3) 4815(3) 708(1) 36(1) 
C(13B) 1496(3) 3808(3) 1110(1) 35(1) 
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C(14B) 3118(3) 6902(3) -140(1) 55(1) 
C(15B) 3855(3) 8740(3) 739(1) 55(1) 
C(16B) 1791(3) 2436(3) 3899(1) 33(1) 
C(17B) 2493(3) 3804(3) 4167(1) 37(1) 
C(18B) 3097(3) 4089(3) 4800(1) 39(1) 
C(19B) 2970(3) 2970(3) 5165(1) 35(1) 
C(20B) 3456(3) 2929(3) 5839(1) 33(1) 
C(21B) 4218(3) 3999(3) 6305(1) 34(1) 
C(22B) 4553(3) 3609(3) 6900(1) 38(1) 
C(23B) 4174(3) 2231(3) 7042(1) 43(1) 
C(24B) 3422(3) 1178(3) 6590(1) 41(1) 
C(25B) 3050(3) 1500(3) 5997(1) 33(1) 
C(26B) 2263(3) 561(3) 5411(1) 41(1) 
C(27B) 2286(3) 1591(3) 4920(1) 30(1) 
C(28B) 1693(3) 1309(3) 4282(1) 40(1) 
C(28A) 6122(3) 2281(2) 4504(1) 28(1) 
_____________________________________________________ 
 
Bond lengths [Å] and angles [°] for  cw02a. 
_____________________________________________________  
O(1A)-C(7A)  1.210(3) 
N(1A)-C(11A)  1.381(3) 
N(1A)-C(14A)  1.446(3) 
N(1A)-C(15A)  1.445(4) 
C(1A)-C(6A)  1.389(3) 
C(1A)-C(2A)  1.421(3) 
C(1A)-C(7A)  1.472(3) 
C(2A)-C(3A)  1.383(3) 
C(2A)-C(8A)  1.486(3) 
C(3A)-C(4A)  1.395(3) 
C(4A)-C(5A)  1.402(3) 
C(4A)-C(16A)  1.482(3) 
C(5A)-C(6A)  1.382(3) 
C(8A)-C(9A)  1.396(3) 
370 
 
C(8A)-C(13A)  1.399(4) 
C(9A)-C(10A)  1.374(3) 
C(10A)-C(11A)  1.402(4) 
C(11A)-C(12A)  1.411(4) 
C(12A)-C(13A)  1.382(3) 
C(16A)-C(28A)  1.397(3) 
C(16A)-C(17A)  1.402(4) 
C(17A)-C(18A)  1.377(3) 
C(18A)-C(19A)  1.391(3) 
C(19A)-C(27A)  1.404(3) 
C(19A)-C(20A)  1.462(3) 
C(20A)-C(25A)  1.393(3) 
C(20A)-C(21A)  1.399(3) 
C(21A)-C(22A)  1.378(3) 
C(22A)-C(23A)  1.385(4) 
C(23A)-C(24A)  1.387(4) 
C(24A)-C(25A)  1.380(3) 
C(25A)-C(26A)  1.511(3) 
C(26A)-C(27A)  1.506(3) 
C(27A)-C(28A)  1.389(3) 
N(1B)-C(11B)  1.378(3) 
N(1B)-C(14B)  1.447(3) 
N(1B)-C(15B)  1.450(3) 
O(1B)-C(7B)  1.212(3) 
C(1B)-C(6B)  1.402(4) 
C(1B)-C(2B)  1.416(3) 
C(1B)-C(7B)  1.475(4) 
C(2B)-C(3B)  1.402(3) 
C(2B)-C(8B)  1.480(4) 
C(3B)-C(4B)  1.394(3) 
C(4B)-C(5B)  1.399(4) 
C(4B)-C(16B)  1.496(4) 
C(5B)-C(6B)  1.370(4) 
C(8B)-C(9B)  1.399(3) 
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C(8B)-C(13B)  1.403(3) 
C(9B)-C(10B)  1.379(3) 
C(10B)-C(11B)  1.404(3) 
C(11B)-C(12B)  1.416(3) 
C(12B)-C(13B)  1.373(3) 
C(16B)-C(17B)  1.400(3) 
C(16B)-C(28B)  1.406(4) 
C(17B)-C(18B)  1.402(4) 
C(18B)-C(19B)  1.373(4) 
C(19B)-C(27B)  1.391(3) 
C(19B)-C(20B)  1.478(4) 
C(20B)-C(21B)  1.404(3) 
C(20B)-C(25B)  1.427(4) 
C(21B)-C(22B)  1.381(4) 
C(22B)-C(23B)  1.370(4) 
C(23B)-C(24B)  1.373(4) 
C(24B)-C(25B)  1.363(4) 
C(25B)-C(26B)  1.522(3) 
C(26B)-C(27B)  1.498(3) 
C(27B)-C(28B)  1.409(4) 
 
C(11A)-N(1A)-C(14A) 119.8(2) 
C(11A)-N(1A)-C(15A) 119.9(2) 
C(14A)-N(1A)-C(15A) 117.9(2) 
C(6A)-C(1A)-C(2A) 118.9(2) 
C(6A)-C(1A)-C(7A) 118.0(2) 
C(2A)-C(1A)-C(7A) 122.8(2) 
C(3A)-C(2A)-C(1A) 118.1(2) 
C(3A)-C(2A)-C(8A) 119.8(2) 
C(1A)-C(2A)-C(8A) 121.9(2) 
C(2A)-C(3A)-C(4A) 123.3(2) 
C(3A)-C(4A)-C(5A) 117.6(2) 
C(3A)-C(4A)-C(16A) 121.9(2) 
C(5A)-C(4A)-C(16A) 120.5(2) 
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C(6A)-C(5A)-C(4A) 120.3(2) 
C(5A)-C(6A)-C(1A) 121.7(2) 
O(1A)-C(7A)-C(1A) 124.5(3) 
C(9A)-C(8A)-C(13A) 115.7(2) 
C(9A)-C(8A)-C(2A) 122.9(2) 
C(13A)-C(8A)-C(2A) 121.3(2) 
C(10A)-C(9A)-C(8A) 123.0(3) 
C(9A)-C(10A)-C(11A) 121.1(3) 
N(1A)-C(11A)-C(10A) 121.7(3) 
N(1A)-C(11A)-C(12A) 121.6(3) 
C(10A)-C(11A)-C(12A) 116.8(2) 
C(13A)-C(12A)-C(11A) 121.0(3) 
C(12A)-C(13A)-C(8A) 122.4(3) 
C(28A)-C(16A)-C(17A) 117.8(2) 
C(28A)-C(16A)-C(4A) 121.5(2) 
C(17A)-C(16A)-C(4A) 120.8(2) 
C(18A)-C(17A)-C(16A) 122.6(2) 
C(17A)-C(18A)-C(19A) 119.1(2) 
C(18A)-C(19A)-C(27A) 119.5(2) 
C(18A)-C(19A)-C(20A) 131.8(2) 
C(27A)-C(19A)-C(20A) 108.6(2) 
C(25A)-C(20A)-C(21A) 119.8(2) 
C(25A)-C(20A)-C(19A) 108.9(2) 
C(21A)-C(20A)-C(19A) 131.4(2) 
C(22A)-C(21A)-C(20A) 119.3(2) 
C(21A)-C(22A)-C(23A) 120.5(3) 
C(22A)-C(23A)-C(24A) 120.6(3) 
C(25A)-C(24A)-C(23A) 119.1(3) 
C(24A)-C(25A)-C(20A) 120.7(2) 
C(24A)-C(25A)-C(26A) 129.5(2) 
C(20A)-C(25A)-C(26A) 109.8(2) 
C(27A)-C(26A)-C(25A) 102.9(2) 
C(28A)-C(27A)-C(19A) 120.6(2) 
C(28A)-C(27A)-C(26A) 129.6(2) 
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C(19A)-C(27A)-C(26A) 109.7(2) 
C(11B)-N(1B)-C(14B) 120.2(2) 
C(11B)-N(1B)-C(15B) 120.8(2) 
C(14B)-N(1B)-C(15B) 118.5(2) 
C(6B)-C(1B)-C(2B) 119.1(3) 
C(6B)-C(1B)-C(7B) 118.4(3) 
C(2B)-C(1B)-C(7B) 122.1(3) 
C(3B)-C(2B)-C(1B) 117.3(2) 
C(3B)-C(2B)-C(8B) 119.7(2) 
C(1B)-C(2B)-C(8B) 123.0(2) 
C(4B)-C(3B)-C(2B) 123.7(2) 
C(3B)-C(4B)-C(5B) 116.9(3) 
C(3B)-C(4B)-C(16B) 121.1(2) 
C(5B)-C(4B)-C(16B) 121.9(2) 
C(6B)-C(5B)-C(4B) 121.3(3) 
C(5B)-C(6B)-C(1B) 121.4(3) 
O(1B)-C(7B)-C(1B) 124.5(3) 
C(9B)-C(8B)-C(13B) 115.7(2) 
C(9B)-C(8B)-C(2B) 121.0(2) 
C(13B)-C(8B)-C(2B) 123.3(2) 
C(10B)-C(9B)-C(8B) 122.7(2) 
C(9B)-C(10B)-C(11B) 121.0(2) 
N(1B)-C(11B)-C(10B) 121.9(2) 
N(1B)-C(11B)-C(12B) 120.9(2) 
C(10B)-C(11B)-C(12B) 117.1(2) 
C(13B)-C(12B)-C(11B) 120.6(2) 
C(12B)-C(13B)-C(8B) 123.0(2) 
C(17B)-C(16B)-C(28B) 118.3(3) 
C(17B)-C(16B)-C(4B) 120.7(2) 
C(28B)-C(16B)-C(4B) 120.9(2) 
C(18B)-C(17B)-C(16B) 122.6(3) 
C(19B)-C(18B)-C(17B) 117.9(3) 
C(18B)-C(19B)-C(27B) 121.7(3) 
C(18B)-C(19B)-C(20B) 130.6(2) 
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C(27B)-C(19B)-C(20B) 107.7(2) 
C(21B)-C(20B)-C(25B) 119.2(2) 
C(21B)-C(20B)-C(19B) 131.9(2) 
C(25B)-C(20B)-C(19B) 108.9(2) 
C(22B)-C(21B)-C(20B) 117.9(2) 
C(23B)-C(22B)-C(21B) 122.3(3) 
C(24B)-C(23B)-C(22B) 120.2(3) 
C(25B)-C(24B)-C(23B) 120.1(3) 
C(24B)-C(25B)-C(20B) 120.3(2) 
C(24B)-C(25B)-C(26B) 131.0(2) 
C(20B)-C(25B)-C(26B) 108.6(2) 
C(27B)-C(26B)-C(25B) 103.0(2) 
C(19B)-C(27B)-C(28B) 120.2(2) 
C(19B)-C(27B)-C(26B) 111.7(2) 
C(28B)-C(27B)-C(26B) 128.0(2) 
C(16B)-C(28B)-C(27B) 119.3(2) 
C(27A)-C(28A)-C(16A) 120.3(2) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
 
Anisotropic displacement parameters  (Å2x 103) for cw02a.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 
] 
__________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________ 
O(1A) 43(1)  37(1) 44(1)  -4(1) -10(1)  6(1) 
N(1A) 38(2)  40(1) 39(1)  11(1) 4(1)  5(1) 
C(1A) 33(2)  29(1) 32(2)  0(1) -1(1)  11(1) 
C(2A) 31(2)  26(1) 32(2)  -3(1) 2(1)  13(1) 
C(3A) 29(2)  23(1) 33(2)  -3(1) 1(1)  5(1) 
C(4A) 29(2)  25(1) 32(2)  0(1) 1(1)  12(1) 
C(5A) 35(2)  28(1) 34(2)  4(1) 3(1)  8(1) 
C(6A) 29(2)  26(1) 44(2)  0(1) -2(1)  4(1) 
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C(7A) 43(2)  32(2) 36(2)  0(1) -1(1)  10(2) 
C(8A) 29(2)  27(1) 29(2)  -2(1) -1(1)  7(1) 
C(9A) 27(2)  36(2) 30(2)  1(1) 0(1)  8(1) 
C(10A) 36(2)  35(2) 32(2)  4(1) 1(1)  13(1) 
C(11A) 35(2)  30(1) 25(2)  -2(1) 1(1)  3(1) 
C(12A) 28(2)  39(2) 28(2)  2(1) -1(1)  7(1) 
C(13A) 33(2)  36(2) 31(2)  0(1) -1(1)  12(1) 
C(14A) 60(2)  54(2) 39(2)  16(2) 9(2)  21(2) 
C(15A) 46(2)  67(2) 65(2)  25(2) 2(2)  -9(2) 
C(16A) 32(2)  18(1) 31(2)  -2(1) -1(1)  7(1) 
C(17A) 32(2)  28(1) 33(2)  2(1) 4(1)  9(1) 
C(18A) 24(2)  27(1) 40(2)  -1(1) 4(1)  6(1) 
C(19A) 21(2)  21(1) 37(2)  -1(1) 3(1)  7(1) 
C(20A) 27(2)  19(1) 33(2)  -5(1) 0(1)  6(1) 
C(21A) 26(2)  30(1) 40(2)  -3(1) 6(1)  8(1) 
C(22A) 28(2)  38(2) 38(2)  -1(1) -5(1)  12(1) 
C(23A) 44(2)  33(2) 31(2)  -2(1) 0(1)  11(1) 
C(24A) 31(2)  34(2) 36(2)  -2(1) 9(1)  7(1) 
C(25A) 24(2)  19(1) 36(2)  -3(1) 2(1)  6(1) 
C(26A) 26(2)  30(1) 34(2)  -3(1) 5(1)  7(1) 
C(27A) 25(2)  15(1) 35(2)  0(1) 6(1)  6(1) 
N(1B) 56(2)  33(1) 38(2)  3(1) 5(1)  12(1) 
O(1B) 59(2)  57(1) 73(2)  -6(1) -19(1)  -14(1) 
C(1B) 37(2)  33(2) 44(2)  -3(1) 1(2)  7(1) 
C(2B) 31(2)  32(1) 36(2)  -2(1) 1(1)  12(1) 
C(3B) 27(2)  31(1) 38(2)  0(1) 5(1)  9(1) 
C(4B) 28(2)  32(2) 46(2)  5(1) 11(1)  11(1) 
C(5B) 40(2)  38(2) 51(2)  5(1) 8(2)  11(2) 
C(6B) 37(2)  34(2) 54(2)  -3(2) 1(2)  0(1) 
C(7B) 41(2)  45(2) 51(2)  -8(2) -3(2)  3(2) 
C(8B) 30(2)  32(1) 32(2)  -3(1) -4(1)  11(1) 
C(9B) 30(2)  34(2) 34(2)  -3(1) 1(1)  11(1) 
C(10B) 31(2)  30(1) 38(2)  -5(1) 0(1)  8(1) 
C(11B) 33(2)  33(2) 32(2)  1(1) -1(1)  12(1) 
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C(12B) 39(2)  41(2) 29(2)  -4(1) -3(1)  16(1) 
C(13B) 36(2)  27(1) 38(2)  -2(1) -3(1)  9(1) 
C(14B) 62(2)  61(2) 33(2)  9(2) 6(2)  11(2) 
C(15B) 61(2)  37(2) 61(2)  2(2) 17(2)  8(2) 
C(16B) 25(2)  40(2) 40(2)  13(1) 12(1)  14(1) 
C(17B) 33(2)  40(2) 39(2)  5(1) 9(1)  13(1) 
C(18B) 31(2)  32(2) 55(2)  7(1) 13(2)  10(1) 
C(19B) 21(2)  28(1) 55(2)  -5(1) 12(1)  7(1) 
C(20B) 19(2)  52(2) 33(2)  2(1) 6(1)  18(1) 
C(21B) 27(2)  30(1) 48(2)  0(1) 8(1)  12(1) 
C(22B) 28(2)  47(2) 35(2)  -6(1) 3(1)  9(1) 
C(23B) 30(2)  53(2) 47(2)  8(2) 6(1)  15(2) 
C(24B) 33(2)  40(2) 54(2)  11(2) 11(2)  13(1) 
C(25B) 19(2)  31(1) 45(2)  -10(1) 5(1)  4(1) 
C(26B) 37(2)  31(2) 53(2)  0(1) 5(2)  10(1) 
C(27B) 26(2)  32(1) 37(2)  9(1) 10(1)  12(1) 
C(28B) 27(2)  39(2) 53(2)  -1(1) 11(1)  7(1) 
C(28A) 25(2)  22(1) 35(2)  1(1) 2(1)  8(1) 
 
Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for cw02a. 
____________________________________________________________________ 
 x  y  z  U(eq) 
____________________________________________________________________ 
  
H(3A) 7500 4119 2990 35 
H(5A) 4232 923 3493 40 
H(6A) 3022 681 2484 42 
H(7A) 4235 2400 1156 46 
H(9A) 4695 4814 1514 39 
H(10A) 5653 6504 847 41 
H(12A) 9519 6159 1373 40 
H(13A) 8525 4464 2041 40 
H(14A) 6525 7380 2 76 
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H(14B) 7909 8694 -80 76 
H(14C) 7083 8703 502 76 
H(15A) 10171 8639 1049 101 
H(15B) 10009 8797 309 101 
H(15C) 10214 7415 586 101 
H(17A) 8809 3419 3737 38 
H(18A) 10108 3599 4722 37 
H(21A) 11082 3489 5956 39 
H(22A) 11394 3024 7008 43 
H(23A) 9437 2123 7530 45 
H(24A) 7129 1641 7001 41 
H(26A) 5749 973 5690 37 
H(26B) 5845 2567 5838 37 
H(3B) 2404 3942 2915 39 
H(5B) -462 296 3312 52 
H(6B) -1676 47 2311 55 
H(7B) -1167 2579 1167 60 
H(9B) 2068 5816 2367 40 
H(10B) 3033 7540 1710 41 
H(12B) 2060 4545 284 44 
H(13B) 1113 2852 954 42 
H(14D) 3655 6282 -199 82 
H(14E) 3496 7758 -360 82 
H(14F) 2112 6418 -309 82 
H(15D) 3124 9029 895 82 
H(15E) 4201 9307 392 82 
H(15F) 4649 8878 1078 82 
H(17B) 2564 4570 3911 44 
H(18B) 3579 5027 4970 47 
H(21B) 4495 4961 6215 41 
H(22B) 5064 4321 7220 46 
H(23B) 4433 2003 7455 52 
H(24B) 3160 224 6691 50 
H(26C) 2759 -79 5304 49 
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H(26D) 1274 -3 5465 49 
H(28B) 1232 368 4113 48 
H(28A) 5112 1967 4453 34 
 
 
B-13.  Cytotoxicity data for microbes. 
Compound 
B. subtilis 
6633 
E. coli Yeast Jurkats 
Control 0.382 1.067 1.34 1352.5 
86A 0.0945 1.2715 1.0585 1142.8 
86B 0.242 1.2805 1.0815 1219.8 
86C 0.289 1.3255 1.1465 1416.6 
87A 0.2105 1.0755 1.07 661.84 
87B 0.2225 1.268 1.19 1197.7 
87C 0.265 1.335 1.2185 1408.7 
88A 0.0905 1.145 1.043 459.03 
88B 0.248 1.3505 1.1815 796.19 
88C 0.28 1.3805 1.85 1099.9 
89A 0.156 0.7 1.607 180.61 
89B 0.1875 0.7455 1.746 544.36 
89C 0.5535 0.89 1.764 935.13 
90A 0.126 0.7925 1.536 199.45 
90B 0.5315 0.811 1.715 248.05 
90C 0.5415 0.8185 1.771 1181 
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91A 0.047 1.1945 1.1075 926.01 
91B 0.297 1.2075 1.166 1360.1 
91C 0.3455 1.3035 1.1705 1413.4 
92A 0.1795 0.889 1.238 228.05 
92B 0.27 1.013 1.29 324.4 
92C 0.32 1.155 1.4155 410.67 
93A 0.4765 0.7715 1.828 574.25 
93B 0.523 0.8365 1.872 1211.5 
93C 0.537 0.849 1.902 1391.4 
94A 0.1805 0.959 1.276 109.025 
94B 0.2495 0.971 1.264 275.045 
94C 0.346 1.061 1.3755 312.05 
95A 0.335 0.876 1.2825 668.885 
95B 0.4375 0.9385 1.3285 712.825 
95C 0.6705 1.0575 1.4785 867.21 
96A 0.1535 1.295 1.1 971.36 
96B 0.268 1.0385 1.162 1201.7 
96C 0.3325 1.341 1.1795 1523.1 
97A 0.3505 0.9865 1.3165 151.93 
97B 0.3545 1.049 1.3435 2615.85 
97C 0.4375 1.0815 1.369 2799.1 
98A 0.216 1.013 1.271 55.5 
380 
 
98B 0.2205 1.072 1.319 126.722 
98C 0.251 1.083 1.357 213.175 
99A 0.1145 0.5805 1.478 119.79 
99B 0.183 0.941 1.833 375.32 
99C 0.704 0.947 1.862 1577 
100A 0.6095 0.707 1.759 787.17 
100B 0.6435 0.7495 1.796 1543.3 
100C 0.689 0.783 1.844 1660.1 
101A 0.017 1.0905 1.0645 1063 
101B 0.197 1.293 1.2045 1330.3 
101C 0.224 1.3375 1.259 1351.8 
102A 0.2015 1.2545 0.6295 775.14 
102B 0.2705 1.3425 1.031 808.445 
102C 0.2895 1.413 1.035 1077.62 
103A 0.1675 1.176 0.808 927.85 
103B 0.246 1.3115 1.016 1295.05 
103C 0.3375 1.38 1.0245 1824.1 
104A 0.3485 0.935 1.337 476.675 
104B 0.363 0.9345 1.349 925.455 
104C 0.385 1.0245 1.389 793.995 
105A 0.141 1.245 0.7245 526.79 
105B 0.1755 1.134 1.128 702.42 
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105C 0.303 1.355 1.13 1319.6 
106A 0.18 1.019 1.2415 63.7075 
106B 0.2945 1.038 1.334 166.115 
106C 0.3205 1.251 1.484 315.35 
107A 0.3385 0.9345 1.3265 624.28 
107B 0.351 0.9765 1.3715 1153 
107C 0.5745 1.194 1.4075 1184.9 
108A 0.104 1.027 1.388 995.515 
108B 0.2385 1.0465 1.392 1182.1 
108C 0.2915 1.157 1.524 1300.7 
109A 0.205 1.0065 1.346 262.315 
109B 0.2505 1.0215 1.352 318.73 
109C 0.375 1.141 1.479 856.985 
110A 0.27 1.023 1.335 291.72 
110B 0.2905 1.0285 1.354 1131.5 
110C 0.345 1.211 1.508 1523.3 
111A 0.1045 0.73 1.709 348.72 
111B 0.506 0.754 1.808 1065.9 
111C 0.554 0.864 1.845 1454.2 
112A 0.302 0.9595 1.343 29.9465 
112B 0.3385 1.03 1.3665 729.675 
112C 0.386 1.2255 1.6095 898.63 
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113A 0.1285 1.347 1.066 693.29 
113B 0.1755 1.407 1.133 735.37 
113C 0.1885 1.486 1.1815 956.85 
26A 0.1325 0.995 1.344 47.7535 
26B 0.45 1.037 1.045 446.6 
26C 0.5145 1.139 1.438 516.2 
114A 0.1055 0.7925 1.536 199.45 
114B 0.5425 0.811 1.715 248.05 
114C 0.5875 0.8185 1.771 1181 
115A 0.096 1.1845 1 655.13 
115B 0.2735 1.3445 1.1105 885.45 
115C 0.2925 1.387 1.1835 1107.4 
116A 0.0356 1.2515 0.9995 1318.2 
116B 0.0985 1.355 1.028 1459.6 
116C 0.1775 1.376 1.0325 1478 
117A 0.2645 0.939 1.2405 99.0895 
117B 0.272 1.002 1.2855 232.865 
117C 0.2915 1.146 1.3775 715.45 
118A 0.087 1.151 1.019 734.525 
118B 0.1825 1.2765 1.025 1680.2 
118C 0.2205 1.504 1.063 1715.45 
119A 0.3745 0.9745 1.3445 603.33 
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119B 0.3835 1.021 1.447 605.64 
119C 0.5085 1.0465 1.4675 638.36 
120A 0.021 0.9205 1.324 499.145 
120B 0.069 1.0615 1.3245 756.75 
120C 0.378 1.106 1.4375 958.04 
121A 0.1385 1.039 1.301 558.81 
121B 0.1815 1.054 1.311 1051.4 
121C 0.3185 1.066 1.427 1188.73 
122A 0.0565 1.029 1.2475 59.7755 
122B 0.249 1.052 1.403 244.86 
122C 0.344 1.058 1.4325 257.55 
123A 0.435 0.5575 1.459 938.53 
123B 0.5855 0.824 1.691 1305.6 
123C 0.5915 0.9025 1.812 1566.2 
124A 0.1665 1.374 0.9595 718.03 
124B 0.247 1.384 1.0995 1245.7 
124C 0.3465 1.369 1.1715 1296.7 
125A 0.3715 0.961 1.275 872.96 
125B 0.402 1.1165 1.286 880.355 
125C 0.4125 1.1525 1.313 1076.85 
126A 0.1815 1.4615 0.7915 359.593 
126B 0.197 1.4635 1.016 470.015 
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126C 0.2295 1.474 1.0285 1443.05 
127A 0.3265 0.991 1.3465 691.315 
127B 0.356 0.9915 1.391 761.965 
127C 0.372 1.0185 1.438 1007.865 
128A 0.104 1.027 1.388 558.81 
128B 0.2385 1.0465 1.92 1015.4 
128C 0.2915 1.157 1.524 1188.73 
129A 0.2005 0.9995 1.298 420.065 
129B 0.273 0.977 1.326 668.42 
129C 0.2725 1.03 1.35 752.02 
130A 0.1615 1.0585 0.5925 285.24 
130B 0.235 1.07 0.977 312.065 
130C 0.2825 1.148 1.0495 808.91 
131A 0.168 0.968 1.185 60.125 
131B 0.178 0.991 1.2825 125.915 
131C 0.182 1.026 1.369 719.6 
132A 0.3335 1.003 1.2555 653.74 
132B 0.3455 1.0945 1.3245 789.945 
132C 0.368 1.2395 1.33 854.43 
27A 0.223 1.191 0.6805 501.92 
27B 0.3135 1.466 1.068 623.935 
27C 0.3465 1.5585 1.0715 1379.85 
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28A 0.1955 1.034 1.095 131.772 
28B 0.2655 1.049 1.286 321.3 
28C 0.281 1.19 1.3535 489.9 
133A 0.1685 0.7905 1.522 525.05 
133B 0.3605 0.876 1.694 814.23 
133C 0.3825 0.928 1.74 1741.3 
134A 0.1685 0.7905 1.522 525.05 
134B 0.3605 0.876 1.694 814.23 
134C 0.3825 0.928 1.74 1741.3 
135A 0.038 1.067 0.783 610.73 
135B 0.1035 1.396 1.174 673.98 
135C 0.213 1.373 1.2 1081.4 
136A 0.1105 1.019 1.3465 450.585 
136B 0.347 1.029 1.373 830.41 
136C 0.3565 1.084 1.5285 1251.45 
137A 0.2585 1.301 0.998 656.75 
137B 0.2896 1.333 1.0435 1079.7 
137C 0.347 1.342 1.1625 1568.4 
138A 0.332 0.9955 1.321 110.65 
138B 0.3375 1.038 1.351 370.58 
138C 0.459 1.0695 1.353 483.41 
139A 0.364 0.996 1.213 1968 
386 
 
139B 0.3745 0.9955 1.3205 2311.5 
139C 0.5055 1.0435 1.353 2650.2 
140A 0.312 0.9625 1.3 553.955 
140B 0.321 0.951 1.35 673.625 
140C 0.3355 0.991 1.361 675.48 
141A 0.325 0.929 1.323 241.88 
141B 0.365 0.978 1.375 420.755 
141C 0.3705 0.9335 1.377 663.42 
142A 0.2185 1.403 0.4755 670.39 
142B 0.248 1.6365 1.05 817.695 
142C 0.3645 1.595 1.109 966.04 
143A 0.182 0.992 1.231 345.45 
143B 0.247 1.04 1.299 375.4 
143C 0.4335 1.149 1.3185 417.035 
144A 0.2545 1.056 1.299 494.525 
144B 0.281 1.127 1.339 1053.91 
144C 0.33 1.2715 1.446 1789.6 
145A 0.2605 1.066 1.27 802.78 
145B 0.307 1.075 1.305 831.34 
145C 0.506 1.133 1.444 1013.03 
146A 0.2555 1.026 0.467 370.46 
146B 0.269 1.054 1.324 631.655 
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146C 0.409 1.0605 1.398 939.52 
147A 0.0535 1.2355 0.606 1433 
147B 0.115 1.43 1.01 1563.9 
147C 0.2535 1.568 1.03 1541.5 
148A 0.1385 1.038 0.8515 624.485 
148B 0.152 1.438 1.0305 1044.89 
148C 0.316 1.542 1.046 1209.85 
149A 0.3235 1.066 1.282 669.1 
149B 0.3535 1.0775 1.337 869.12 
149C 0.6065 1.2095 1.348 992.495 
150A 0.1145 1.1675 0.981 348.49 
150B 0.207 1.385 1.197 673.74 
150C 0.352 1.379 1.2145 846.95 
151A 0.0495 1.215 0.9935 391.965 
151B 0.2315 1.3715 1.0335 901.74 
151C 0.237 1.64 1.074 1225.93 
152A 0.2885 1.014 1.361 638.705 
152B 0.294 1.056 1.368 684.64 
152C 0.416 1.074 1.48 1015.3 
153A 0.2575 1.036 1.32 314.845 
153B 0.2865 1.076 1.335 399.595 
153C 0.378 1.08 1.341 414.5 
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154A 0.0195 1.2265 1 890.5 
154B 0.2105 1.573 1.0345 1350.65 
154C 0.3655 1.5475 1.0495 1827.5 
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B-14.  Spectra of 86. 
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B-15.  Spectra of 87. 
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B-16.  Spectra of 88. 
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B-17.  Spectra of 89. 
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B-18.  Spectra of 90. 
 
394 
 
 
B-19.  Spectra of 91. 
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B-20.  Spectra of 92. 
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B-21.  Spectra of 93. 
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B-22.  Spectra of 94. 
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B-23.  Spectra of 95. 
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B-24.  Spectra of 96. 
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B-25.  Spectra of 97. 
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B-26.  Spectra of 98. 
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B-27.  Spectra of 99.   
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B-28.  Spectra of 100.  
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B-29.  Spectra of 101. 
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B-30.  Spectra of 102. 
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B-31.  Spectra of 103.   
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B-32.  Spectra of 104. 
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B-33.  Spectra of 105. 
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B-34.  Spectra of 106. 
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B-35.  Spectra of 107. 
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B-36.  Spectra of 108. 
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B-37.  Spectra of 109. 
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B-38.  Spectra of 110. 
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B-39.  Spectra of 111. 
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B-40.  Spectra of 112. 
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B-41.  Spectra of 113. 
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B-42.  Spectra of Error! Bookmark not defined. 
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B-43.  Spectra of 114.   
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B-44.  Spectra of 115. 
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B-45.  Spectra of 116.   
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B-46.  Spectra of 117. 
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B-47.  Spectra of 118. 
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B-48.  Spectra of 119. 
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B-49.  Spectra of 120. 
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B-50.  Spectra of 121. 
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B-51.  Spectra of 122. 
427 
 
 
 
B-52.  Spectra of 123. 
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B-53.  Spectra of 124. 
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B-54.  Spectra of 125. 
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B-55.  Spectra of 126. 
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B-56.  Spectra of 127. 
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B-57.  Spectra of 128. 
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B-58.  Spectra of 129. 
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B-59.  Spectra of 130. 
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B-60.  Spectra of 131. 
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B-61.  Spectra of 132. 
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B-62.  Spectra of 27. 
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B-63.  Spectra of 28. 
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B-64.  Spectra of 133 and 134. 
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B-65.  Spectra of 135. 
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B-66.  Spectra of 136. 
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B-67.  Spectra of 137.  
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B-68.  Spectra of 138.   
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B-69.  Spectra of 139. 
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B-70.  Spectra of 140. 
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B-71.  Spectra of 141. 
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B-72.  Spectra of 142. 
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B-73.  Spectra of 143. 
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B-74.  Spectra of 144. 
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B-75.  Spectra of 145. 
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B-76.  Spectra of 146. 
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B-77.  Spectra of 147. 
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B-78.  Spectra of 148. 
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B-79.  Spectra of 149.
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B-80.  Spectra of 150.   
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B-81.  Spectra of 151. 
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B-82.  Spectra of 152. 
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B-83.  Spectra of 153.   
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B-84.  Spectra of 154. 
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B-85.  Spectra of 81. 
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APPENDIX C 
 
 
 
 
 
C-1.  Spectra of 166. 
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C-2.  Spectra of 167. 
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C-3. Spectra of 168.  
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C-4.  Spectra of 169.  
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C-5.  Spectra of 170. 
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C-6.  Spectra of 171. 
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C-7.  Spectra of 172. 
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C-8.  Spectra of 173. 
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C-9.  Spectra of 174. 
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C-10.  Spectra of 175. 
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C-11.  Spectra of 176. 
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C-12.  Spectra of 177. 
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C-13.  Spectra of 178. 
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C-14.  Spectra of 179. 
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C-15.  Spectra of 180. 
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C-16.  Spectra of 181. 
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C-17.  Spectra of 182. 
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C-18.  Spectra of 183.  
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